[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "llama-2-7b-chat-hf_response": "Acrokeratosis paraneoplastica is a rare skin condition that is characterized by the growth of keratinous lesions on the skin, often in association with certain types of cancer. Here are some synonyms for Acrokeratosis paraneoplastica:\n1. Acrokeratosis paraneoplastic syndrome: This term is used to describe the combination of acrokeratosis and paraneoplastic syndrome, which refers to a group of conditions that are associated with cancer.\n2. Keratosis paraneoplastica: This term refers specifically to the growth of keratinous lesions on the skin in association with cancer.\n3. Paraneoplastic keratosis: This term is used to describe the growth of keratinous lesions on the skin in association with cancer, without specifying the exact location of the lesions.\n4. Cutaneous paraneoplastic syndrome: This term refers to a group of conditions that are associated with cancer and affect the skin, including acrokeratosis paraneoplastica.\n5. Secondary acrokeratosis: This term is used to describe the growth of keratinous lesions on the skin in response to an underlying medical condition, such as cancer.\n6. Acrokeratosis of cancer: This term is used to describe the growth of keratinous lesions on the skin in association with cancer.\n7. Cancer-associated acrokeratosis: This term is used to describe the growth of keratinous lesions on the skin in association with cancer.\n8. Paraneoplastic acrokeratosis: This term is used to describe the growth of keratinous lesions on the skin in association with cancer, without specifying the exact location of the lesions.\n9. Keratosis of malignancy: This term is used to describe the growth of keratinous lesions on the skin in association with cancer.\n10. Cutaneous malignancy-related acrokeratosis: This term is used to describe the growth of keratinous lesions on the skin in association with cancer.\nIt is important to note that these terms are not interchangeable, and each term has its own specific meaning and context. If you have any further questions or concerns, please feel free to ask.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "llama-2-7b-chat-hf_response": "Weaver syndrome and Sotos syndrome are both rare genetic disorders that affect brain development and can cause a range of cognitive, physical, and behavioral symptoms. While they share some similarities, they are distinct conditions with different genetic causes and clinical features.\nWeaver syndrome, also known as 22q11.2 deletion syndrome, is caused by a deletion or duplication of genetic material on chromosome 22, specifically at the q11.2 location. This genetic change can lead to a range of symptoms, including:\n1. Intellectual disability: Weaver syndrome can cause mild to severe intellectual disability, which can range from difficulty with learning new information to significant cognitive impairment.\n2. Speech and language difficulties: Individuals with Weaver syndrome may experience difficulty with speech and language development, including stuttering, slurred speech, and difficulty with word retrieval.\n3. Autism spectrum disorder: Weaver syndrome can increase the risk of developing autism spectrum disorder (ASD), which can cause social interaction and communication challenges.\n4. Behavioral problems: Weaver syndrome can also lead to behavioral problems, such as anxiety, hyperactivity, and difficulty with impulse control.\n5. Physical features: Weaver syndrome can also cause a range of physical features, including short stature, small head size, and distinctive facial features, such as a flat nose bridge and small ears.\nSotos syndrome, on the other hand, is caused by a mutation in the NSD1 gene, which is located on chromosome 5. Sotos syndrome is characterized by:\n1. Delayed growth and development: Children with Sotos syndrome typically experience delayed growth and development, including delayed reaching of milestones such as sitting, standing, and walking.\n2. Intellectual disability: Sotos syndrome can cause mild to severe intellectual disability, which can impact daily functioning and independence.\n3. Distinctive facial features: Individuals with Sotos syndrome may have distinctive facial features, including a large head, prominent eyes, and a small nose.\n4. Speech and language difficulties: Sotos syndrome can cause difficulty with speech and language development, including stuttering and slurred",
    "llama-2-7b-chat-hf_fact_raw": "1. Weaver syndrome is also known as 22q11.2 deletion syndrome and is caused by a deletion or duplication of genetic material on chromosome 22.\n2. Weaver syndrome can cause symptoms such as intellectual disability, speech and language difficulties, autism spectrum disorder, behavioral problems, and distinctive physical features.\n3. Sotos syndrome is caused by a mutation in the NSD1 gene on chromosome 5.\n4. Sotos syndrome is characterized by delayed growth and development, intellectual disability, distinctive facial features, and speech and language difficulties.\n5. Both Weaver syndrome and Sotos syndrome are rare genetic disorders that affect brain development and can cause cognitive, physical, and behavioral symptoms.",
    "llama-2-7b-chat-hf_fact": [
      "Weaver syndrome is also known as 22q11.2 deletion syndrome and is caused by a deletion or duplication of genetic material on chromosome 22.",
      "Weaver syndrome can cause symptoms such as intellectual disability, speech and language difficulties, autism spectrum disorder, behavioral problems, and distinctive physical features.",
      "Sotos syndrome is caused by a mutation in the NSD1 gene on chromosome 5.",
      "Sotos syndrome is characterized by delayed growth and development, intellectual disability, distinctive facial features, and speech and language difficulties.",
      "Both Weaver syndrome and Sotos syndrome are rare genetic disorders that affect brain development and can cause cognitive, physical, and behavioral symptoms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Weaver syndrome is not the same as 22q11.2 deletion syndrome; they are two separate genetic disorders.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "llama-2-7b-chat-hf_response": "JASPAR (Joint Analysis of Sequence and Pathway Annotation) is a widely used database of protein-DNA interaction (PDIs) and protein-protein interaction (PPIs) data. Here are the releases of the JASPAR database:\n1. JASPAR Release 1.0 (2003): This was the first release of the JASPAR database, which contained 140,000 PDIs and 130,000 PPIs from 11 organisms.\n2. JASPAR Release 2.0 (2006): This release added 100,000 new PDIs and 100,000 new PPIs, bringing the total number of interactions to 240,000.\n3. JASPAR Release 3.0 (2010): This release included 300,000 new PDIs and 300,000 new PPIs, as well as updated annotations and improved integration with other databases.\n4. JASPAR Release 4.0 (2013): This release added 400,000 new PDIs and 400,000 new PPIs, bringing the total number of interactions to 740,000.\n5. JASPAR Release 5.0 (2016): This release included 600,000 new PDIs and 600,000 new PPIs, as well as improved computational methods for predicting PDIs and PPIs.\n6. JASPAR Release 6.0 (2019): This release added 800,000 new PDIs and 800,000 new PPIs, bringing the total number of interactions to 1.6 million.\n7. JASPAR Release 7.0 (2022): This is the latest release of the JASPAR database, which contains over 1.8 million PDIs and PPIs, as well as improved annotations and computational methods for predicting interactions.\nIt's worth noting that the JASPAR database is updated regularly, with new releases appearing approximately every 2-3 years. Each release includes new",
    "llama-2-7b-chat-hf_fact_raw": "1. JASPAR Release 1.0 was released in 2003 and contained 140,000 PDIs and 130,000 PPIs from 11 organisms.\n2. JASPAR Release 2.0 was released in 2006 and added 100,000 new PDIs and 100,000 new PPIs.\n3. JASPAR Release 3.0 was released in 2010 and included 300,000 new PDIs and 300,000 new PPIs.\n4. JASPAR Release 4.0 was released in 2013 and added 400,000 new PDIs and 400,000 new PPIs.\n5. JASPAR Release 5.0 was released in 2016 and included 600,000 new PDIs and 600,000 new PPIs.",
    "llama-2-7b-chat-hf_fact": [
      "JASPAR Release 1.0 was released in 2003 and contained 140,000 PDIs and 130,000 PPIs from 11 organisms.",
      "JASPAR Release 2.0 was released in 2006 and added 100,000 new PDIs and 100,000 new PPIs.",
      "JASPAR Release 3.0 was released in 2010 and included 300,000 new PDIs and 300,000 new PPIs.",
      "JASPAR Release 4.0 was released in 2013 and added 400,000 new PDIs and 400,000 new PPIs.",
      "JASPAR Release 5.0 was released in 2016 and included 600,000 new PDIs and 600,000 new PPIs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: Without additional context or access to the specific database release notes/history for JASPAR, it's not possible to accurately verify the given statements about the number of PDIs (Protein-DNA Interactions) and PPIs (Protein-Protein Interactions) included in each release.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "llama-2-7b-chat-hf_response": "The KP4 protein is a viral protein that is encoded by the KP4 virus, which is a member of the Parvoviridae family. The KP4 protein is one of the most well-studied viral proteins and has been found to play a crucial role in the replication and pathogenesis of the virus. Here are some of the key functions of the KP4 protein:\n1. Nucleocapsid protein: The KP4 protein is the main component of the nucleocapsid, which is a protein-DNA complex that surrounds the viral genome. The KP4 protein helps to protect the genome from host cellular defense mechanisms and also plays a role in the assembly of new virus particles.\n2. Replication initiation: The KP4 protein is involved in the initiation of viral replication by binding to specific DNA sequences near the viral origin of replication. This binding event recruits other viral proteins that are necessary for replication to occur.\n3. Transcriptional regulation: The KP4 protein can bind to specific DNA sequences and regulate the transcription of viral genes. This is achieved through the formation of a protein-DNA complex that inhibits the activity of transcription factors.\n4. Cell-cell fusion: The KP4 protein has been shown to play a role in the fusion of infected cells with uninfected cells. This process is thought to be mediated by the KP4 protein's ability to interact with the plasma membrane of infected cells.\n5. Induction of apoptosis: The KP4 protein has been shown to induce apoptosis (programmed cell death) in infected cells. This can occur through the activation of caspases, which are enzymes that play a role in the execution of apoptosis.\n6. Inhibition of interferon signaling: The KP4 protein has been shown to inhibit the production of interferon, a protein that is produced by infected cells in response to viral infection. This can prevent the host from mounting a robust antiviral response.\n7. Modulation of the immune response: The KP4 protein has been shown to modulate the immune response by interacting with immune cells and suppressing their activity. This can prevent the",
    "llama-2-7b-chat-hf_fact_raw": "1. The KP4 protein is encoded by the KP4 virus, a member of the Parvoviridae family.\n2. The KP4 protein is the main component of the nucleocapsid in the KP4 virus.\n3. The KP4 protein is involved in initiating viral replication by binding to specific DNA sequences.\n4. The KP4 protein can regulate the transcription of viral genes by binding to specific DNA sequences.\n5. The KP4 protein has been shown to induce apoptosis in infected cells.",
    "llama-2-7b-chat-hf_fact": [
      "The KP4 protein is encoded by the KP4 virus, a member of the Parvoviridae family.",
      "The KP4 protein is the main component of the nucleocapsid in the KP4 virus.",
      "The KP4 protein is involved in initiating viral replication by binding to specific DNA sequences.",
      "The KP4 protein can regulate the transcription of viral genes by binding to specific DNA sequences.",
      "The KP4 protein has been shown to induce apoptosis in infected cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: It is unclear which virus encodes the KP4 protein without further information, but Parvoviridae is a family of viruses and KP4 is not commonly associated with it.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-2-7b-chat-hf_response": "DITPA, also known as 3,5-dinitrophenyl-2-hydroxy-benzamide, is a synthetic compound that has been used as a thyroid hormone analog in experimental and clinical studies. It is a reversible inhibitor of thyroid hormone synthesis and action, meaning that it can bind to and inhibit the activity of thyroid hormone receptors in the body.\nDITPA has been used in a variety of studies to investigate the role of thyroid hormones in various physiological processes, including metabolism, growth, and development. For example, DITPA has been used to study the effects of thyroid hormone deficiency on metabolism, growth, and development in animals. It has also been used to investigate the effects of thyroid hormone excess on these processes.\nIn clinical studies, DITPA has been used to treat hypothyroidism, a condition in which the thyroid gland does not produce enough thyroid hormones. DITPA has been shown to increase the levels of thyroid hormones in the blood and improve symptoms such as fatigue, weight gain, and cold intolerance. However, it is important to note that DITPA is not a replacement for natural thyroid hormones and should only be used under the close supervision of a healthcare provider.\nIt is also worth noting that DITPA has been shown to have potential side effects, including gastrointestinal disturbances, muscle weakness, and changes in heart rate. As with any medication, it is important to carefully weigh the potential benefits and risks of using DITPA in clinical studies.\nIn summary, DITPA is a thyroid hormone analog that has been used in experimental and clinical studies to investigate the role of thyroid hormones in various physiological processes and to treat hypothyroidism. While it has shown promise in these studies, it is important to carefully consider the potential benefits and risks of using DITPA and to only use it under the close supervision of a healthcare provider.",
    "llama-2-7b-chat-hf_fact_raw": "1. DITPA stands for 3,5-dinitrophenyl-2-hydroxy-benzamide.\n2. It is used as a synthetic thyroid hormone analog in experimental and clinical studies.\n3. DITPA is a reversible inhibitor of thyroid hormone synthesis and action.\n4. It has been used in studies to investigate the role of thyroid hormones in metabolism, growth, and development.\n5. DITPA has been used to treat hypothyroidism in clinical studies.",
    "llama-2-7b-chat-hf_fact": [
      "DITPA stands for 3,5-dinitrophenyl-2-hydroxy-benzamide.",
      "It is used as a synthetic thyroid hormone analog in experimental and clinical studies.",
      "DITPA is a reversible inhibitor of thyroid hormone synthesis and action.",
      "It has been used in studies to investigate the role of thyroid hormones in metabolism, growth, and development.",
      "DITPA has been used to treat hypothyroidism in clinical studies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: DITPA stands for 3,5-diiodothyropropionic acid.\n2. TRUE\n3. FALSE [correction]: DITPA is not a reversible inhibitor of thyroid hormone synthesis and action; it is a thyroid hormone analog.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "llama-2-7b-chat-hf_response": "Great, I'm glad you asked! The COUGER tool is a fantastic resource for anyone looking to improve their mental health and well-being. COUGER stands for \"Cognitive, Occupational, and Behavioral Functioning Assessment Tool,\" and it's a comprehensive evaluation system designed to assess an individual's cognitive, occupational, and behavioral functioning.\nThe COUGER tool is used by mental health professionals to assess an individual's strengths, weaknesses, and areas of concern in the following areas:\n1. Cognitive Functioning: This includes assessing an individual's ability to process information, pay attention, remember things, and solve problems.\n2. Occupational Functioning: This involves evaluating an individual's ability to perform daily tasks and activities, such as managing their finances, maintaining their home, and interacting with others.\n3. Behavioral Functioning: This assessment looks at an individual's ability to regulate their emotions, manage their behavior, and interact with others in a socially appropriate manner.\nThe COUGER tool is a valuable resource for mental health professionals because it provides a comprehensive and structured approach to evaluating an individual's mental health functioning. It can help identify areas of strength and weakness, inform treatment plans, and monitor progress over time.\nIn addition, the COUGER tool can be used in a variety of settings, including clinical settings, schools, and workplaces. It's a versatile and widely recognized tool that can help mental health professionals better understand an individual's mental health needs and develop effective treatment plans.\nOverall, the COUGER tool is a valuable resource for anyone looking to improve their mental health and well-being. It provides a comprehensive and structured approach to evaluating an individual's cognitive, occupational, and behavioral functioning, and can help inform treatment plans and monitor progress over time.",
    "llama-2-7b-chat-hf_fact_raw": "1. COUGER stands for \"Cognitive, Occupational, and Behavioral Functioning Assessment Tool.\"\n2. The COUGER tool is designed to assess an individual's cognitive, occupational, and behavioral functioning.\n3. Mental health professionals use the COUGER tool to evaluate an individual's strengths, weaknesses, and areas of concern.\n4. The COUGER tool includes assessments of cognitive functioning such as information processing, attention, memory, and problem-solving.\n5. The COUGER tool is used in clinical settings, schools, and workplaces.",
    "llama-2-7b-chat-hf_fact": [
      "COUGER stands for \"Cognitive, Occupational, and Behavioral Functioning Assessment Tool.\"",
      "The COUGER tool is designed to assess an individual's cognitive, occupational, and behavioral functioning.",
      "Mental health professionals use the COUGER tool to evaluate an individual's strengths, weaknesses, and areas of concern.",
      "The COUGER tool includes assessments of cognitive functioning such as information processing, attention, memory, and problem-solving.",
      "The COUGER tool is used in clinical settings, schools, and workplaces."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: COUGER does not stand for \"Cognitive, Occupational, and Behavioral Functioning Assessment Tool.\" The correct acronym and expansion are unknown.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "llama-2-7b-chat-hf_response": "Yes, there are drugs available to treat tick-borne encephalitis (TBE), a viral infection caused by the TBE virus. The most common drugs used to treat TBE are:\n1. Antiviral medications: There are several antiviral medications that have been shown to be effective in treating TBE, including ribavirin, oseltamivir, and zanamivir. These medications work by reducing the replication of the virus in the body and can help alleviate symptoms such as fever, headache, and muscle pain.\n2. Corticosteroids: Corticosteroids, such as prednisone, may be prescribed to reduce inflammation in the brain and spinal cord, which can occur in some cases of TBE.\n3. Immunoglobulins: Immunoglobulins, such as intravenous immunoglobulin (IVIG), may be used to treat severe cases of TBE, particularly in cases where the infection has spread to the central nervous system. IVIG contains antibodies that can help neutralize the virus and reduce inflammation.\n4. Supportive care: In addition to medication, supportive care is important in managing TBE. This may include rest, hydration, and pain management. In severe cases, hospitalization may be necessary to provide more intensive care.\nIt's important to note that the most effective treatment for TBE is early diagnosis and treatment, as the virus can cause significant damage to the brain and nervous system if left untreated. If you suspect you or someone you know may have TBE, it's important to seek medical attention immediately.\nIt's also worth noting that there are several vaccines available to protect against TBE, particularly for people who live in or visit areas where the virus is common. These vaccines are typically given in a series of shots over several months, and can provide long-term protection against TBE.",
    "llama-2-7b-chat-hf_fact_raw": "1. Tick-borne encephalitis (TBE) is a viral infection caused by the TBE virus.\n2. Antiviral medications such as ribavirin, oseltamivir, and zanamivir are used to treat TBE.\n3. Corticosteroids like prednisone may be prescribed to reduce inflammation in the brain and spinal cord caused by TBE.\n4. Immunoglobulins, like intravenous immunoglobulin (IVIG), may be used in severe cases of TBE.\n5. There are vaccines available to protect against TBE, typically given in a series of shots over several months.",
    "llama-2-7b-chat-hf_fact": [
      "Tick-borne encephalitis (TBE) is a viral infection caused by the TBE virus.",
      "Antiviral medications such as ribavirin, oseltamivir, and zanamivir are used to treat TBE.",
      "Corticosteroids like prednisone may be prescribed to reduce inflammation in the brain and spinal cord caused by TBE.",
      "Immunoglobulins, like intravenous immunoglobulin (IVIG), may be used in severe cases of TBE.",
      "There are vaccines available to protect against TBE, typically given in a series of shots over several months."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: There are no specific antiviral medications for the treatment of TBE.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I'm glad you asked! There are several genome browser databases available for DNA shape annotations, each with its own unique features and capabilities. Here are some of the most popular ones:\n1. UCSC Genome Browser: The UCSC Genome Browser is one of the most widely used genome browsers, and it provides DNA shape annotations for a wide range of organisms, including humans, mice, and worms. The browser allows users to visualize and explore genomic sequences, as well as view annotations such as gene locations, regulatory elements, and chromatin structure.\n2. Ensembl Genome Browser: Ensembl is another popular genome browser that provides DNA shape annotations for a wide range of organisms, including humans, mice, and worms. Ensembl's annotations include information on gene structure, gene expression, and regulatory elements, as well as 3D chromatin structure.\n3. ChromHMM: ChromHMM is a genome browser that focuses specifically on the 3D structure of chromatin. It provides detailed annotations of chromatin structure, including histone modification patterns and chromatin interactions. ChromHMM also allows users to explore the genomic locations of specific genes and regulatory elements.\n4. HiC-Pro: HiC-Pro is a genome browser that provides 3D chromatin structure annotations for a wide range of organisms. It uses high-throughput chromosome conformation capture (Hi-C) data to generate maps of chromatin interactions, which can be used to infer the 3D organization of chromosomes.\n5. 4D-Nucleosome: 4D-Nucleosome is a genome browser that provides 3D chromatin structure annotations for a wide range of organisms. It uses a combination of Hi-C data and other high-throughput techniques to generate detailed maps of chromatin interactions, including information on nucleosome positioning and dynamics.\n6. Chromatin Map Viewer: Chromatin Map Viewer is a genome browser that provides 3D chromatin structure annotations for a wide range of organisms. It uses a combination of Hi-C data and other high-throughput techniques to generate detailed maps of chromatin interactions, including information on nucleosome positioning and dynamics.\n7. Genome Graph: Genome Graph",
    "llama-2-7b-chat-hf_fact_raw": "1. UCSC Genome Browser provides DNA shape annotations and allows users to visualize genomic sequences and view annotations.\n2. Ensembl Genome Browser provides DNA shape annotations, including information on gene structure and expression.\n3. ChromHMM focuses on the 3D structure of chromatin and provides detailed annotations of chromatin structure.\n4. HiC-Pro uses high-throughput chromosome conformation capture data to generate maps of chromatin interactions.\n5. 4D-Nucleosome and Chromatin Map Viewer use a combination of Hi-C data and other high-throughput techniques to generate detailed maps of chromatin interactions.",
    "llama-2-7b-chat-hf_fact": [
      "UCSC Genome Browser provides DNA shape annotations and allows users to visualize genomic sequences and view annotations.",
      "Ensembl Genome Browser provides DNA shape annotations, including information on gene structure and expression.",
      "ChromHMM focuses on the 3D structure of chromatin and provides detailed annotations of chromatin structure.",
      "HiC-Pro uses high-throughput chromosome conformation capture data to generate maps of chromatin interactions.",
      "4D-Nucleosome and Chromatin Map Viewer use a combination of Hi-C data and other high-throughput techniques to generate detailed maps of chromatin interactions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Ensembl Genome Browser provides information on gene structure and expression, but does not focus on DNA shape annotations.\n3. FALSE [correction]: ChromHMM is a software tool for learning chromatin states, but it does not focus on the 3D structure of chromatin.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-2-7b-chat-hf_response": "The EZH2 gene encodes for the enzyme Enhancer of Zeste 2 (EZH2), which is a histone methyltransferase that plays a crucial role in regulating gene expression by modifying histone proteins. Mutations in the EZH2 gene have been associated with several syndromes, including:\n1. EZH2-related syndrome: This is a rare genetic disorder characterized by developmental delays, intellectual disability, and distinctive facial features, such as a flat nasal bridge, widely spaced eyes, and a small jaw. Other features may include heart defects, kidney problems, and delayed growth and development.\n2. Beckwith-Wiedemann syndrome: This is a genetic disorder that can affect various organs and systems in the body, including the brain, abdominal organs, and limbs. The syndrome is characterized by delayed growth and development, and may cause intellectual disability, delayed speech and language development, and distinctive physical features such as a large abdomen, wide neck, and small head.\n3. Silver-Russell syndrome: This is a rare genetic disorder characterized by short stature, delayed growth and development, and intellectual disability. Other features may include distinctive facial features, such as a small head, widely spaced eyes, and a short nose, as well as heart defects, kidney problems, and delayed speech and language development.\n4. Mowat-Wilson syndrome: This is a rare genetic disorder that can affect various organs and systems in the body, including the brain, digestive system, and limbs. The syndrome is characterized by distinctive facial features, such as a small head, widely spaced eyes, and a short nose, as well as intellectual disability, delayed speech and language development, and other health problems.\n5. Neurofibromatosis type 1 (NF1): This is a genetic disorder that can affect various organs and systems in the body, including the brain, nerves, and skin. The syndrome is characterized by distinctive facial features, such as a large head, widely spaced eyes, and a small nose, as well as neurological problems, such as seizures, and skin abnormalities, such as",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the EZH2 gene have been associated with EZH2-related syndrome, which includes developmental delays and distinctive facial features.\n2. Beckwith-Wiedemann syndrome, which affects various organs and is characterized by delayed growth and distinctive physical features, has been associated with mutations in the EZH2 gene.\n3. Silver-Russell syndrome, associated with mutations in the EZH2 gene, is characterized by short stature, delayed growth, and intellectual disability.\n4. Mowat-Wilson syndrome, which can affect various organs and is characterized by distinctive facial features and delayed development, has been linked to mutations in the EZH2 gene.\n5. Neurofibromatosis type 1 (NF1), a genetic disorder with symptoms affecting the brain, nerves, and skin, is associated with mutations in the EZH2 gene.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the EZH2 gene have been associated with EZH2-related syndrome, which includes developmental delays and distinctive facial features.",
      "Beckwith-Wiedemann syndrome, which affects various organs and is characterized by delayed growth and distinctive physical features, has been associated with mutations in the EZH2 gene.",
      "Silver-Russell syndrome, associated with mutations in the EZH2 gene, is characterized by short stature, delayed growth, and intellectual disability.",
      "Mowat-Wilson syndrome, which can affect various organs and is characterized by distinctive facial features and delayed development, has been linked to mutations in the EZH2 gene.",
      "Neurofibromatosis type 1 (NF1), a genetic disorder with symptoms affecting the brain, nerves, and skin, is associated with mutations in the EZH2 gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Beckwith-Wiedemann syndrome has been associated with changes in the imprinting of genes on chromosome 11p15.5, not specifically mutations in the EZH2 gene.\n3. FALSE [correction]: Silver-Russell syndrome is associated with changes on chromosome 7 or chromosome 11, not specifically mutations in the EZH2 gene.\n4. FALSE [correction]: Mowat-Wilson syndrome has been linked to mutations in the ZEB2 gene, not the EZH2 gene.\n5. FALSE [correction]: Neurofibromatosis type 1 (NF1) is associated with mutations in the NF1 gene, not the EZH2 gene.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I'm happy to provide you with a list of human proteins that are known to undergo a dimer-to-tetramer transition. This type of transition involves the conversion of a protein dimer (a molecule composed of two identical subunits) into a tetramer (a molecule composed of four identical subunits). Here are some examples of human proteins that exhibit this type of transition:\n1. Hemoglobin: Hemoglobin is a protein in red blood cells that carries oxygen from the lungs to the body's tissues. It undergoes a dimer-to-tetramer transition in response to changes in oxygen availability, allowing it to adapt to different oxygen demands.\n2. Myoglobin: Myoglobin is a protein found in muscle cells that stores oxygen for use during exercise. It also undergoes a dimer-to-tetramer transition in response to changes in oxygen availability.\n3. Alcohol dehydrogenase: Alcohol dehydrogenase is an enzyme that breaks down alcohols in the body. It undergoes a dimer-to-tetramer transition in response to changes in the concentration of NAD+, a coenzyme that plays a critical role in energy metabolism.\n4. Acetylcholinesterase: Acetylcholinesterase is an enzyme that breaks down the neurotransmitter acetylcholine in the nervous system. It undergoes a dimer-to-tetramer transition in response to changes in the concentration of choline, the precursor to acetylcholine.\n5. Carbonic anhydrase: Carbonic anhydrase is an enzyme that helps regulate the pH of body fluids by catalyzing the reversible reaction between carbon dioxide and water. It undergoes a dimer-to-tetramer transition in response to changes in the concentration of bicarbonate ions.\n6. Lactate dehydrogenase: Lactate dehydrogenase is an enzyme that plays a role in glycolysis, the breakdown of glucose for energy production. It under",
    "llama-2-7b-chat-hf_fact_raw": "1. Hemoglobin undergoes a dimer-to-tetramer transition in response to changes in oxygen availability.\n2. Myoglobin, found in muscle cells, also undergoes a dimer-to-tetramer transition in response to changes in oxygen availability.\n3. Alcohol dehydrogenase undergoes a dimer-to-tetramer transition in response to changes in the concentration of NAD+.\n4. Acetylcholinesterase undergoes a dimer-to-tetramer transition in response to changes in the concentration of choline.\n5. Carbonic anhydrase undergoes a dimer-to-tetramer transition in response to changes in the concentration of bicarbonate ions.",
    "llama-2-7b-chat-hf_fact": [
      "Hemoglobin undergoes a dimer-to-tetramer transition in response to changes in oxygen availability.",
      "Myoglobin, found in muscle cells, also undergoes a dimer-to-tetramer transition in response to changes in oxygen availability.",
      "Alcohol dehydrogenase undergoes a dimer-to-tetramer transition in response to changes in the concentration of NAD+.",
      "Acetylcholinesterase undergoes a dimer-to-tetramer transition in response to changes in the concentration of choline.",
      "Carbonic anhydrase undergoes a dimer-to-tetramer transition in response to changes in the concentration of bicarbonate ions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Myoglobin, found in muscle cells, does not undergo a dimer-to-tetramer transition; it functions as a monomer.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-2-7b-chat-hf_response": "Phospholamban (PLN) is a protein that plays a crucial role in the regulation of the cardiac sodium pump (Na+/K+-ATPase) and is involved in various cellular processes, including cell survival and apoptosis. Several proteins have been found to interact with PLN and are also anti-apoptotic, meaning they inhibit or prevent programmed cell death. Here are some examples:\n1. Bcl-2: Bcl-2 (B-cell lymphoma 2) is a family of proteins that regulate mitochondrial outer membrane permeabilization, which can lead to apoptosis. Bcl-2 protein can interact with PLN and inhibit its pro-apoptotic function, thereby protecting cells from undergoing apoptosis.\n2. Bcl-xL: Similar to Bcl-2, Bcl-xL (B-cell lymphoma 2 extra large) is another anti-apoptotic protein that can interact with PLN. Bcl-xL can inhibit the pro-apoptotic function of PLN and protect cells from undergoing apoptosis.\n3. Mcl-1: Myeloid cell leukemia 1 (Mcl-1) is another anti-apoptotic protein that can interact with PLN. Mcl-1 can inhibit the pro-apoptotic function of PLN and protect cells from undergoing apoptosis.\n4. AKT: The protein kinase B (AKT) signaling pathway is involved in cell survival and can interact with PLN. Activation of AKT can inhibit the pro-apoptotic function of PLN and protect cells from undergoing apoptosis.\n5. FOXO1: The forkhead box O (FOXO) transcription factors, such as FOXO1, can also interact with PLN and regulate its pro-apoptotic function. FOXO1 can inhibit the pro-apoptotic function of PLN and protect cells from undergoing apoptosis.\nIn summary, several proteins have been found to interact with PLN and are also anti-apoptotic, including Bcl-2, Bcl-xL, Mcl-1, AKT, and FOX",
    "llama-2-7b-chat-hf_fact_raw": "1. Bcl-2 is a protein that can interact with phospholamban (PLN) and inhibit its pro-apoptotic function.\n2. Bcl-xL is an anti-apoptotic protein that can interact with PLN.\n3. Myeloid cell leukemia 1 (Mcl-1) is another anti-apoptotic protein that can interact with PLN.\n4. The protein kinase B (AKT) signaling pathway can interact with PLN and inhibit its pro-apoptotic function.\n5. The forkhead box O (FOXO) transcription factors, such as FOXO1, can interact with PLN and regulate its pro-apoptotic function.",
    "llama-2-7b-chat-hf_fact": [
      "Bcl-2 is a protein that can interact with phospholamban (PLN) and inhibit its pro-apoptotic function.",
      "Bcl-xL is an anti-apoptotic protein that can interact with PLN.",
      "Myeloid cell leukemia 1 (Mcl-1) is another anti-apoptotic protein that can interact with PLN.",
      "The protein kinase B (AKT) signaling pathway can interact with PLN and inhibit its pro-apoptotic function.",
      "The forkhead box O (FOXO) transcription factors, such as FOXO1, can interact with PLN and regulate its pro-apoptotic function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: The provided statements require specific scientific knowledge about protein interactions that is not commonly known, and no passage is provided to verify the statements.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-2-7b-chat-hf_response": "Yes, there is evidence to suggest that vitamin D supplementation can reduce the incidence of falls in older people in clinical trials.\nVitamin D is an essential nutrient that plays a role in maintaining muscle strength, balance, and bone health, all of which are important factors in preventing falls. Many older adults have low levels of vitamin D, which can increase their risk of falling.\nNumerous clinical trials have investigated the effect of vitamin D supplementation on fall incidence in older adults. Here are some key findings from these trials:\n1. A 2014 meta-analysis published in the Journal of the American Geriatrics Society pooled data from 17 randomized controlled trials involving over 10,000 older adults. The analysis found that vitamin D supplementation was associated with a significant reduction in fall incidence (relative risk = 0.75, 95% CI = 0.63-0.89).\n2. A 2017 Cochrane review updated the evidence on vitamin D supplementation and fall prevention in older adults. The review included 16 randomized controlled trials involving over 7,000 participants. The authors found that vitamin D supplementation significantly reduced the risk of falls in older adults (risk ratio = 0.73, 95% CI = 0.59-0.91).\n3. A 2019 study published in the Journal of Bone and Mineral Research found that vitamin D supplementation improved balance and reduced the risk of falls in older adults with low vitamin D levels. The study involved 160 older adults who were randomized to receive either vitamin D supplements or a placebo for 12 months.\n4. A 2020 study published in the American Journal of Clinical Nutrition found that vitamin D supplementation reduced the risk of falls in older adults with osteoporosis. The study involved 240 older adults who were randomized to receive either vitamin D supplements or a placebo for 12 months.\nWhile the evidence is promising, it's important to note that not all studies have found a significant",
    "llama-2-7b-chat-hf_fact_raw": "1. A 2014 meta-analysis in the Journal of the American Geriatrics Society found that vitamin D supplementation was associated with a significant reduction in fall incidence among older adults.\n2. A 2017 Cochrane review found that vitamin D supplementation significantly reduced the risk of falls in older adults.\n3. A 2019 study in the Journal of Bone and Mineral Research showed that vitamin D supplementation improved balance and reduced the risk of falls in older adults with low vitamin D levels.\n4. A 2020 study in the American Journal of Clinical Nutrition found that vitamin D supplementation reduced the risk of falls in older adults with osteoporosis.",
    "llama-2-7b-chat-hf_fact": [
      "A 2014 meta-analysis in the Journal of the American Geriatrics Society found that vitamin D supplementation was associated with a significant reduction in fall incidence among older adults.",
      "A 2017 Cochrane review found that vitamin D supplementation significantly reduced the risk of falls in older adults.",
      "A 2019 study in the Journal of Bone and Mineral Research showed that vitamin D supplementation improved balance and reduced the risk of falls in older adults with low vitamin D levels.",
      "A 2020 study in the American Journal of Clinical Nutrition found that vitamin D supplementation reduced the risk of falls in older adults with osteoporosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-2-7b-chat-hf_response": "Yes, there is an association between Jarid2 and miR-155 in Th17 cells.\nJarid2 (Jumonji AT-rich DNA-binding protein 2) is a histone-modifying enzyme that plays a crucial role in regulating gene expression by modifying histone H3 lysine 9 (H3K9) dimethylation. H3K9 dimethylation is a repressive chromatin mark that can lead to the silencing of gene transcription.\nMiR-155 (microRNA-155) is a small non-coding RNA molecule that plays a crucial role in the regulation of Th17 cell differentiation and inflammation. Th17 cells are a subtype of T cells that are involved in the immune response to extracellular bacteria and fungi.\nStudies have shown that Jarid2 and miR-155 are co-regulated in Th17 cells. Specifically, Jarid2 has been shown to be a direct target of miR-155, and miR-155 has been shown to regulate Jarid2 expression.\nOne study published in the journal Nature Communications in 2017 found that miR-155 regulates Jarid2 expression in Th17 cells by binding to the 3' untranslated region (UTR) of the Jarid2 mRNA. The study showed that overexpression of miR-155 leads to decreased Jarid2 expression, while inhibition of miR-155 leads to increased Jarid2 expression.\nAnother study published in the journal Immunity in 2018 found that Jarid2 is required for the proper differentiation of Th17 cells and that miR-155 regulates Jarid2 expression by modulating the expression of genes involved in histone modification.\nThese studies suggest that there is a complex interplay between Jarid2 and miR-155 in the regulation of Th17 cell differentiation and inflammation. Further research is needed to fully understand the mechanisms underlying this association and its implications for immune function and disease.\nIn summary, there is a direct association between Jarid2 and miR-155 in",
    "llama-2-7b-chat-hf_fact_raw": "1. Jarid2 is a histone-modifying enzyme that regulates gene expression by modifying histone H3 lysine 9 (H3K9) dimethylation.\n2. MiR-155 is a non-coding RNA molecule that plays a role in Th17 cell differentiation and inflammation.\n3. Studies have shown that Jarid2 is a direct target of miR-155 in Th17 cells.\n4. A study published in Nature Communications in 2017 reported that miR-155 regulates Jarid2 expression in Th17 cells by binding to the 3' UTR of Jarid2 mRNA.\n5. Research published in Immunity in 2018 found that Jarid2 is required for proper differentiation of Th17 cells, and miR-155 modulates its expression.",
    "llama-2-7b-chat-hf_fact": [
      "Jarid2 is a histone-modifying enzyme that regulates gene expression by modifying histone H3 lysine 9 (H3K9) dimethylation.",
      "MiR-155 is a non-coding RNA molecule that plays a role in Th17 cell differentiation and inflammation.",
      "Studies have shown that Jarid2 is a direct target of miR-155 in Th17 cells.",
      "A study published in Nature Communications in 2017 reported that miR-155 regulates Jarid2 expression in Th17 cells by binding to the 3' UTR of Jarid2 mRNA.",
      "Research published in Immunity in 2018 found that Jarid2 is required for proper differentiation of Th17 cells, and miR-155 modulates its expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Jarid2 is not a histone-modifying enzyme but a protein that is part of the Polycomb Repressive Complex 2 (PRC2) that regulates gene expression by modifying histone H3 lysine 27 (H3K27) methylation.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "llama-2-7b-chat-hf_response": "The human HoxD cluster contains 8 genes, which are located on chromosomes 2, 6, and 12. These genes are involved in the regulation of embryonic development and patterning, particularly in the formation of the vertebral column, limbs, and brain. The HoxD genes are named Hoxd1-Hoxd8 and are numbered according to their location along the chromosome.\nHere is a list of the genes in the human HoxD cluster:\n1. Hoxd1 - located on chromosome 2\n2. Hoxd2 - located on chromosome 2\n3. Hoxd3 - located on chromosome 6\n4. Hoxd4 - located on chromosome 6\n5. Hoxd5 - located on chromosome 12\n6. Hoxd6 - located on chromosome 12\n7. Hoxd7 - located on chromosome 2\n8. Hoxd8 - located on chromosome 12\nEach of these genes contains a specific DNA sequence that is responsible for encoding a protein product, which plays a crucial role in the development and function of various tissues in the body. Mutations in these genes can lead to a range of developmental disorders and birth defects, including spinal cord abnormalities, limb abnormalities, and brain defects.\nIt's worth noting that the HoxD cluster is one of several clusters of genes that are involved in the regulation of embryonic development and patterning in vertebrates. Other clusters include the HoxA and HoxB clusters, which are located on different chromosomes and have distinct functions. Understanding the function of these genes and their role in development and disease is an active area of research in developmental biology and genetics.",
    "llama-2-7b-chat-hf_fact_raw": "1. The human HoxD cluster contains 8 genes.\n2. These genes are located on chromosomes 2, 6, and 12.\n3. The HoxD genes are involved in the regulation of embryonic development and patterning.\n4. The genes in the HoxD cluster are named Hoxd1-Hoxd8.\n5. Mutations in HoxD genes can lead to developmental disorders and birth defects.",
    "llama-2-7b-chat-hf_fact": [
      "The human HoxD cluster contains 8 genes.",
      "These genes are located on chromosomes 2, 6, and 12.",
      "The HoxD genes are involved in the regulation of embryonic development and patterning.",
      "The genes in the HoxD cluster are named Hoxd1-Hoxd8.",
      "Mutations in HoxD genes can lead to developmental disorders and birth defects."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The human HoxD cluster contains 9 genes.\n2. FALSE [correction]: These genes are located on chromosome 2.\n3. TRUE\n4. FALSE [correction]: The genes in the HoxD cluster are named HoxD1-HoxD13, not all numbers are used.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-2-7b-chat-hf_response": "Casein Kinase 1 (CK1) is a serine/threonine protein kinase that plays a crucial role in various cellular processes, including cell signaling, metabolism, and gene expression. Phosphorylation of CK1 by other kinases can activate or inhibit its activity, leading to changes in downstream signaling pathways. Here are some common phosphorylation consensus motifs found in CK1:\n1. Thr-Gly-Thr (TGT) motif: This is a common consensus motif for CK1 phosphorylation sites, found in the activation loop of the enzyme. Thr-Gly-Thr motifs are recognized by the catalytic subunit of protein kinase A (PKA), which phosphorylates CK1 at this site.\n2. Ser-Gly-X-X-Ser (SGS) motif: This motif is found in the substrate binding site of CK1 and is recognized by the catalytic subunit of protein kinase C (PKC). PKC phosphorylates CK1 at this site, leading to changes in its activity.\n3. Thr-X-Tyr-X-Ser (TXS) motif: This motif is found in the activation loop of CK1 and is recognized by the catalytic subunit of protein kinase M (PKM). PKM phosphorylates CK1 at this site, leading to changes in its activity.\n4. Ser-X-X-Ser (SXS) motif: This motif is found in the substrate binding site of CK1 and is recognized by the catalytic subunit of protein kinase A (PKA). PKA phosphorylates CK1 at this site, leading to changes in its activity.\n5. Thr-Gly-X-X-Ser (TGXS) motif: This motif is found in the activation loop of CK1 and is recognized by the catalytic subunit of protein kinase C (PKC). PKC phosphorylates CK1 at this site, leading to changes in its activity.\n6. Ser-Gly-X-X-Thr (SGXT) motif: This motif",
    "llama-2-7b-chat-hf_fact_raw": "1. CK1 is a serine/threonine protein kinase involved in cell signaling, metabolism, and gene expression.\n2. The Thr-Gly-Thr (TGT) motif is a common consensus motif for CK1 phosphorylation, found in the activation loop of the enzyme.\n3. The Ser-Gly-X-X-Ser (SGS) motif is recognized by the catalytic subunit of protein kinase C (PKC) for CK1 phosphorylation.\n4. The Thr-X-Tyr-X-Ser (TXS) motif in the activation loop of CK1 is recognized by the catalytic subunit of protein kinase M (PKM).\n5. The Ser-X-X-Ser (SXS) and Thr-Gly-X-X-Ser (TGXS) motifs are found in CK1 and are recognized by the catalytic subunits of protein kinases A (PKA) and C (PKC) respectively.",
    "llama-2-7b-chat-hf_fact": [
      "CK1 is a serine/threonine protein kinase involved in cell signaling, metabolism, and gene expression.",
      "The Thr-Gly-Thr (TGT) motif is a common consensus motif for CK1 phosphorylation, found in the activation loop of the enzyme.",
      "The Ser-Gly-X-X-Ser (SGS) motif is recognized by the catalytic subunit of protein kinase C (PKC) for CK1 phosphorylation.",
      "The Thr-X-Tyr-X-Ser (TXS) motif in the activation loop of CK1 is recognized by the catalytic subunit of protein kinase M (PKM).",
      "The Ser-X-X-Ser (SXS) and Thr-Gly-X-X-Ser (TGXS) motifs are found in CK1 and are recognized by the catalytic subunits of protein kinases A (PKA) and C (PKC) respectively."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The Ser-Gly-X-X-Ser (SGS) motif is a common consensus motif for CK1 phosphorylation, found in substrates of the enzyme, not the activation loop.\n3. FALSE [correction]: The Ser-Gly-X-X-Ser (SGS) motif is not specifically recognized by protein kinase C (PKC) for CK1 phosphorylation; it is a motif recognized by CK1 itself.\n4. UNKNOWN\n5. FALSE [correction]: The Ser-X-X-Ser (SXS) motif is recognized by the catalytic subunits of protein kinase A (PKA), but there is no evidence that the Thr-Gly-X-X-Ser (TGXS) motif is specifically recognized by protein kinase C (PKC) for CK1 phosphorylation; it could be a substrate motif for CK1.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-2-7b-chat-hf_response": "The ASPH (aspartate beta-hydroxylase) gene in humans encodes several different proteins/isoforms, including:\n1. Aspartate beta-hydroxylase (ASPH): This is the primary isoform encoded by the ASPH gene, and it plays a critical role in the biosynthesis of the neurotransmitters serotonin and dopamine. Aspartate beta-hydroxylase is a rate-limiting enzyme in the synthesis of these neurotransmitters, and mutations in the ASPH gene have been associated with various neurological disorders, including epilepsy and intellectual disability.\n2. Tissue inhibitor of metalloproteinases 1 (TIMP1): The ASPH gene also encodes a protein called TIMP1, which is a tissue inhibitor of metalloproteinases. TIMP1 is a negative regulator of matrix metalloproteinases (MMPs), a family of enzymes involved in the breakdown of the extracellular matrix. MMPs are involved in various physiological processes, including tissue development, remodeling, and inflammation.\n3. Neprilysin (NEP): The ASPH gene also encodes a protein called neprilysin (NEP), which is a protease that plays a role in the degradation of various proteins, including amyloid-beta, a protein that accumulates in the brain in Alzheimer's disease. NEP is also involved in the clearance of catecholamines, such as dopamine and norepinephrine, and mutations in the ASPH gene have been associated with various neurological disorders, including Parkinson's disease.\n4. Prothrombin (F2): The ASPH gene also encodes a protein called prothrombin (F2), which is involved in the coagulation cascade. Prothrombin is converted to thrombin, which is essential for blood clotting. Mutations in the ASPH gene have been associated with bleeding disorders, such as hemophilia A.\n5. Glycoprotein VI (GPVI): The ASPH gene also encodes a protein called glycoprotein VI (GPVI",
    "llama-2-7b-chat-hf_fact_raw": "1. The ASPH gene encodes the primary isoform aspartate beta-hydroxylase, which is involved in the biosynthesis of serotonin and dopamine.\n2. The ASPH gene encodes TIMP1, a tissue inhibitor of metalloproteinases.\n3. The ASPH gene also encodes neprilysin, a protease involved in the degradation of amyloid-beta and clearance of catecholamines.\n4. Prothrombin, involved in the coagulation cascade, is encoded by the ASPH gene.\n5. The ASPH gene encodes the protein glycoprotein VI.",
    "llama-2-7b-chat-hf_fact": [
      "The ASPH gene encodes the primary isoform aspartate beta-hydroxylase, which is involved in the biosynthesis of serotonin and dopamine.",
      "The ASPH gene encodes TIMP1, a tissue inhibitor of metalloproteinases.",
      "The ASPH gene also encodes neprilysin, a protease involved in the degradation of amyloid-beta and clearance of catecholamines.",
      "Prothrombin, involved in the coagulation cascade, is encoded by the ASPH gene.",
      "The ASPH gene encodes the protein glycoprotein VI."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The ASPH gene does not encode aspartate beta-hydroxylase; it actually encodes Aspartate Hydroxylase, which is involved in the post-translational hydroxylation of certain aspartyl and asparaginyl residues in proteins.\n2. FALSE [correction]: The ASPH gene does not encode TIMP1; it encodes Aspartate Hydroxylase.\n3. FALSE [correction]: The ASPH gene does not encode neprilysin; it encodes Aspartate Hydroxylase.\n4. FALSE [correction]: The ASPH gene does not encode prothrombin; the F2 gene encodes prothrombin.\n5. FALSE [correction]: The ASPH gene does not encode glycoprotein VI; the GP6 gene encodes glycoprotein VI.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "llama-2-7b-chat-hf_response": "Empagliflozin, also known as Jardiance, is a medication used to treat type 2 diabetes. It was approved by the US Food and Drug Administration (FDA) in 2014.\nEmpagliflozin was approved on July 8, 2014, by the FDA for the treatment of adults with type 2 diabetes to improve glycemic control, along with diet and exercise. The drug was approved based on the results of clinical trials that demonstrated its safety and effectiveness in lowering blood sugar levels and improving glycemic control in people with type 2 diabetes.\nSince its approval, empagliflozin has become a widely used medication for the treatment of type 2 diabetes, and it is available in a variety of formulations, including tablets, oral suspension, and injection. It is important to note that empagliflozin is not approved for the treatment of type 1 diabetes or diabetic ketoacidosis, and it should only be used under the guidance of a healthcare provider.",
    "llama-2-7b-chat-hf_fact_raw": "1. Empagliflozin, also known as Jardiance, is used to treat type 2 diabetes.\n2. The FDA approved Empagliflozin in 2014.\n3. Empagliflozin was approved specifically to improve glycemic control in adults with type 2 diabetes, alongside diet and exercise.\n4. The approval of Empagliflozin by the FDA was based on the results of clinical trials showing its safety and effectiveness.\n5. Empagliflozin is not approved for the treatment of type 1 diabetes or diabetic ketoacidosis.",
    "llama-2-7b-chat-hf_fact": [
      "Empagliflozin, also known as Jardiance, is used to treat type 2 diabetes.",
      "The FDA approved Empagliflozin in 2014.",
      "Empagliflozin was approved specifically to improve glycemic control in adults with type 2 diabetes, alongside diet and exercise.",
      "The approval of Empagliflozin by the FDA was based on the results of clinical trials showing its safety and effectiveness.",
      "Empagliflozin is not approved for the treatment of type 1 diabetes or diabetic ketoacidosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-2-7b-chat-hf_response": "Lon1 is a protein that plays a crucial role in the DNA damage response pathway in plants. In the model plant Arabidopsis thaliana, loss of the Lon1 gene has been shown to have several interesting consequences. Here are some of the key results:\n1. Increased sensitivity to DNA-damaging agents: Lon1 is involved in the repair of DNA double-strand breaks (DSBs) and interstrand cross-links (ICLs). Mutants lacking Lon1 are more sensitive to DNA-damaging agents such as ionizing radiation and certain chemotherapeutic drugs.\n2. Enhanced tolerance to oxidative stress: Lon1 has been shown to play a role in the response to oxidative stress, which can result from exposure to environmental factors such as UV light, heat, and drought. Lon1-deficient mutants are more tolerant to oxidative stress, suggesting that Lon1 may play a role in the regulation of antioxidant defense pathways.\n3. Altered cell cycle regulation: Lon1 regulates the G1/S checkpoint and the G2/M checkpoint, which are critical for ensuring proper cell cycle progression. Lon1-deficient mutants exhibit altered cell cycle regulation, leading to changes in cell number and tissue organization.\n4. Changes in gene expression: Lon1 regulates the expression of a large number of genes involved in various cellular processes, including DNA repair, cell cycle regulation, and stress response. Lon1-deficient mutants exhibit changes in gene expression patterns, suggesting that Lon1 plays a role in regulating the transcriptional landscape of the cell.\n5. Altered root development: Lon1 is expressed in the root meristem, and mutants lacking Lon1 exhibit altered root development, including changes in root length, diameter, and branching patterns.\n6. Delayed flowering time: Lon1-deficient mutants exhibit a delay in flowering time, suggesting that Lon1 may play a role in the regulation of floral induction.\n7. Increased susceptibility to pathogens: Lon1 has been shown to play a role in the immune response, and Lon1-",
    "llama-2-7b-chat-hf_fact_raw": "1. Lon1 is involved in the repair of DNA double-strand breaks and interstrand cross-links in Arabidopsis thaliana.\n2. Mutants lacking Lon1 in Arabidopsis thaliana are more sensitive to DNA-damaging agents.\n3. Lon1-deficient mutants in Arabidopsis thaliana are more tolerant to oxidative stress.\n4. Lon1 regulates the G1/S checkpoint and G2/M checkpoint in Arabidopsis thaliana cell cycle regulation.\n5. Loss of Lon1 in Arabidopsis thaliana leads to altered root development, including changes in root length, diameter, and branching.",
    "llama-2-7b-chat-hf_fact": [
      "Lon1 is involved in the repair of DNA double-strand breaks and interstrand cross-links in Arabidopsis thaliana.",
      "Mutants lacking Lon1 in Arabidopsis thaliana are more sensitive to DNA-damaging agents.",
      "Lon1-deficient mutants in Arabidopsis thaliana are more tolerant to oxidative stress.",
      "Lon1 regulates the G1/S checkpoint and G2/M checkpoint in Arabidopsis thaliana cell cycle regulation.",
      "Loss of Lon1 in Arabidopsis thaliana leads to altered root development, including changes in root length, diameter, and branching."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Lon1-deficient mutants in Arabidopsis thaliana are less tolerant to oxidative stress.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I can confirm that there is no direct evidence of a linker histone in the yeast genome. Histones are small, positively charged proteins that are the primary components of chromatin, the complex of DNA and proteins that make up the chromosomes in eukaryotic cells. In eukaryotes, histones are highly modified and play a crucial role in regulating chromatin structure and gene expression.\nThe yeast genome, specifically Saccharomyces cerevisiae, does contain histones, but they are not linker histones. Histones in yeast are similar in structure and function to those found in other eukaryotes, including humans. However, there are some differences in the types of histones present in yeast compared to other eukaryotes. For example, yeast histones are generally shorter than those found in other eukaryotes, and they have a more open chromatin structure.\nLinker histones are a specific type of histone that are found in some eukaryotes, including humans, and are characterized by the presence of a long, unstructured N-terminal tail. These tails are thought to play a role in the formation of higher-order chromatin structures, such as chromatin loops and domain interactions. While linker histones have been identified in some organisms, such as Drosophila and mammals, there is no direct evidence of their presence in the yeast genome.\nIn summary, while histones are present in the yeast genome, there is no direct evidence of linker histones in this organism. The histones found in yeast are similar to those found in other eukaryotes, but they have some distinct differences in structure and function.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is no direct evidence of a linker histone in the yeast genome.\n2. Histones are the primary components of chromatin in eukaryotic cells.\n3. The yeast genome does contain histones but not linker histones.\n4. Yeast histones are similar to those found in other eukaryotes but are generally shorter and have a more open chromatin structure.\n5. Linker histones, characterized by a long unstructured N-terminal tail, have been identified in some eukaryotes such as Drosophila and mammals but not in yeast.",
    "llama-2-7b-chat-hf_fact": [
      "There is no direct evidence of a linker histone in the yeast genome.",
      "Histones are the primary components of chromatin in eukaryotic cells.",
      "The yeast genome does contain histones but not linker histones.",
      "Yeast histones are similar to those found in other eukaryotes but are generally shorter and have a more open chromatin structure.",
      "Linker histones, characterized by a long unstructured N-terminal tail, have been identified in some eukaryotes such as Drosophila and mammals but not in yeast."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-2-7b-chat-hf_response": "Yes, there is evidence to suggest that tomato juice can help lower cholesterol levels. Tomatoes are rich in a powerful antioxidant called lycopene, which has been shown to have a positive impact on cholesterol levels.\nSeveral studies have investigated the effect of tomato juice on cholesterol levels, and the results are promising. For example, a 2011 study published in the Journal of Nutrition found that drinking 8 ounces of tomato juice daily for 12 weeks lowered total cholesterol levels by 10% in healthy adults. Another study published in the American Journal of Clinical Nutrition in 2015 found that drinking 1 cup of tomato juice daily for 12 weeks lowered LDL (\"bad\") cholesterol levels by 12% in adults with mild hypercholesterolemia.\nThe exact mechanism by which tomato juice lowers cholesterol levels is not fully understood, but it is thought to involve several factors. Lycopene in tomato juice may help reduce the amount of \"bad\" cholesterol in the blood by inhibiting the production of cholesterol in the liver. Additionally, tomato juice contains other nutrients like fiber, vitamins, and minerals that can help improve overall cardiovascular health.\nIt's important to note that while tomato juice may help lower cholesterol levels, it is not a substitute for a healthy diet and lifestyle. A diet rich in fruits, vegetables, whole grains, and lean protein sources, along with regular physical activity and a healthy weight, can help lower cholesterol levels and reduce the risk of heart disease.\nIn summary, there is evidence to suggest that tomato juice can help lower cholesterol levels, but it is important to consume it as part of a balanced diet and lifestyle.",
    "llama-2-7b-chat-hf_fact_raw": "1. Tomatoes contain an antioxidant called lycopene, which can impact cholesterol levels positively.\n2. A study published in the Journal of Nutrition in 2011 found that drinking 8 ounces of tomato juice daily for 12 weeks lowered total cholesterol levels by 10% in healthy adults.\n3. A study published in the American Journal of Clinical Nutrition in 2015 showed that drinking 1 cup of tomato juice daily for 12 weeks lowered LDL cholesterol levels by 12% in adults with mild hypercholesterolemia.\n4. Lycopene in tomato juice may reduce the amount of \"bad\" cholesterol by inhibiting cholesterol production in the liver.\n5. Tomato juice contains nutrients like fiber, vitamins, and minerals that can improve cardiovascular health.",
    "llama-2-7b-chat-hf_fact": [
      "Tomatoes contain an antioxidant called lycopene, which can impact cholesterol levels positively.",
      "A study published in the Journal of Nutrition in 2011 found that drinking 8 ounces of tomato juice daily for 12 weeks lowered total cholesterol levels by 10% in healthy adults.",
      "A study published in the American Journal of Clinical Nutrition in 2015 showed that drinking 1 cup of tomato juice daily for 12 weeks lowered LDL cholesterol levels by 12% in adults with mild hypercholesterolemia.",
      "Lycopene in tomato juice may reduce the amount of \"bad\" cholesterol by inhibiting cholesterol production in the liver.",
      "Tomato juice contains nutrients like fiber, vitamins, and minerals that can improve cardiovascular health."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Tomato juice does not contain fiber, but it does contain vitamins and minerals that can improve cardiovascular health.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-2-7b-chat-hf_response": "Hsp70 and Hsp110 are two heat shock proteins that play important roles in regulating mRNA stability in eukaryotic cells. These proteins are part of the heat shock response (HSR), a cellular stress response that helps protect cells against various types of stress, including heat stress, oxidative stress, and protein misfolding.\nHsp70 and Hsp110 are both involved in mRNA stability through different mechanisms:\n1. Hsp70: Hsp70 is a chaperone protein that helps to protect mRNA from degradation by binding to the 3' untranslated region (UTR) of the mRNA and preventing it from being degraded by the RNA exosome complex. The RNA exosome complex is a large complex of ribonucleases that degrade RNA molecules in the cell. By binding to the 3' UTR of mRNA, Hsp70 can prevent the RNA exosome complex from accessing and degrading the mRNA, leading to increased mRNA stability.\n2. Hsp110: Hsp110 is also a chaperone protein that helps to protect mRNA from degradation by binding to the 5' UTR of the mRNA and preventing it from being degraded by the RNA exosome complex. In addition to its role in protecting mRNA from degradation, Hsp110 can also help to stabilize mRNA by preventing the formation of RNA-RNA interactions that can lead to mRNA degradation.\nBoth Hsp70 and Hsp110 can also play a role in regulating mRNA translation by modulating the activity of ribosomes, the cellular machines responsible for translating mRNA into protein. By binding to mRNA, Hsp70 and Hsp110 can influence the recruitment and activity of ribosomes, leading to changes in mRNA translation rates.\nIn addition to their roles in mRNA stability and translation, Hsp70 and Hsp110 have been implicated in other cellular processes, including protein folding, protein degradation, and cellular stress response pathways.\nIn summary, Hsp70",
    "llama-2-7b-chat-hf_fact_raw": "1. Hsp70 and Hsp110 are heat shock proteins that help regulate mRNA stability in eukaryotic cells.\n2. Hsp70 prevents mRNA degradation by binding to the 3' untranslated region of the mRNA.\n3. The RNA exosome complex is responsible for degrading RNA molecules in the cell.\n4. Hsp110 helps protect mRNA from degradation by binding to the 5' untranslated region of the mRNA.\n5. Hsp70 and Hsp110 can influence the recruitment and activity of ribosomes involved in translating mRNA into protein.",
    "llama-2-7b-chat-hf_fact": [
      "Hsp70 and Hsp110 are heat shock proteins that help regulate mRNA stability in eukaryotic cells.",
      "Hsp70 prevents mRNA degradation by binding to the 3' untranslated region of the mRNA.",
      "The RNA exosome complex is responsible for degrading RNA molecules in the cell.",
      "Hsp110 helps protect mRNA from degradation by binding to the 5' untranslated region of the mRNA.",
      "Hsp70 and Hsp110 can influence the recruitment and activity of ribosomes involved in translating mRNA into protein."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Hsp70 prevents mRNA degradation by binding to the 5' untranslated region of the mRNA.\n3. TRUE\n4. FALSE [correction]: Hsp110 helps protect mRNA from degradation by acting as a nucleotide exchange factor for Hsp70.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "llama-2-7b-chat-hf_response": "Deiodinases are enzymes that play a crucial role in the regulation of thyroid hormone metabolism in various tissues, including skeletal muscle. There are three isoforms of deiodinases found in skeletal muscle:\n1. Type 1 deiodinase (D1): This is the most abundant form of deiodinase in skeletal muscle, accounting for approximately 70% of total deiodinase activity. D1 is responsible for converting T4 to T3 in the muscle, which is then released into the circulation. T3 is the active form of thyroid hormone that regulates metabolism, growth, and development.\n2. Type 2 deiodinase (D2): D2 is less abundant than D1 in skeletal muscle but still plays a significant role in the regulation of thyroid hormone metabolism. D2 is responsible for converting both T4 and T3 to reverse T3 (rT3), which is inactive and can inhibit the activity of T3.\n3. Type 3 deiodinase (D3): D3 is the least abundant form of deiodinase in skeletal muscle, but it has been shown to play a role in the regulation of thyroid hormone metabolism in certain tissues, including muscle. D3 is responsible for converting T4 to T3 in the muscle, but it is less efficient than D1.\nThe expression of these deiodinases in skeletal muscle is regulated by various factors, including thyroid hormone levels, nutrient availability, and exercise. For example, thyroid hormone stimulates the expression of D1 and D2 in skeletal muscle, while fasting or low-nutrient conditions can downregulate deiodinase expression. Exercise has been shown to increase D1 expression in skeletal muscle, which can enhance the conversion of T4 to T3 and improve muscle function.\nIn summary, the three deiodinases present in skeletal muscle are D1, D2, and D3. These enzymes play critical roles in regulating thyroid hormone metabolism in muscle, and their expression is regulated by various factors",
    "llama-2-7b-chat-hf_fact_raw": "1. There are three isoforms of deiodinases found in skeletal muscle: Type 1 (D1), Type 2 (D2), and Type 3 (D3).\n2. Type 1 deiodinase (D1) is the most abundant form of deiodinase in skeletal muscle.\n3. Type 2 deiodinase (D2) converts both T4 and T3 to reverse T3 (rT3), which is inactive.\n4. Type 3 deiodinase (D3) is the least abundant form of deiodinase in skeletal muscle.\n5. The expression of deiodinases in skeletal muscle is regulated by thyroid hormone levels, nutrient availability, and exercise.",
    "llama-2-7b-chat-hf_fact": [
      "There are three isoforms of deiodinases found in skeletal muscle: Type 1 (D1), Type 2 (D2), and Type 3 (D3).",
      "Type 1 deiodinase (D1) is the most abundant form of deiodinase in skeletal muscle.",
      "Type 2 deiodinase (D2) converts both T4 and T3 to reverse T3 (rT3), which is inactive.",
      "Type 3 deiodinase (D3) is the least abundant form of deiodinase in skeletal muscle.",
      "The expression of deiodinases in skeletal muscle is regulated by thyroid hormone levels, nutrient availability, and exercise."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Type 2 deiodinase (D2) is the most abundant form of deiodinase in skeletal muscle.\n3. FALSE [correction]: Type 2 deiodinase (D2) primarily converts T4 to T3, but Type 3 deiodinase (D3) is responsible for converting both T4 and T3 to reverse T3 (rT3).\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "llama-2-7b-chat-hf_response": "Certainly! Inflammatory caspase proteins are a subfamily of caspases that play a crucial role in the regulation of inflammation. Here are some of the key inflammatory caspase proteins:\n1. Caspase-1 (also known as interleukin-1 beta converting enzyme, or ICE): Caspase-1 is a cytosolic caspase that is activated in response to inflammatory signals, such as interleukin-1 beta (IL-1) and tumor necrosis factor-alpha (TNF-). Activated caspase-1 cleaves a variety of substrates, including the pro-inflammatory cytokines IL-1 and TNF-, leading to their maturation and secretion.\n2. Caspase-3: Caspase-3 is a cytosolic caspase that is involved in the regulation of apoptosis (programmed cell death) and inflammation. Activated caspase-3 cleaves a variety of substrates, including the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-), leading to its degradation and resolution of inflammation.\n3. Caspase-4 (also known as cytokine-induced ICE-like protein, or CYIL): Caspase-4 is a cytosolic caspase that is activated in response to cytokines, such as interleukin-1 beta (IL-1) and tumor necrosis factor-alpha (TNF-). Activated caspase-4 cleaves a variety of substrates, including the pro-inflammatory cytokines IL-1 and TNF-, leading to their maturation and secretion.\n4. Caspase-5: Caspase-5 is a cytosolic caspase that is involved in the regulation of inflammation and immune response. Activated caspase-5 cleaves a variety of substrates, including the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-), leading to its degradation and resolution of inflammation",
    "llama-2-7b-chat-hf_fact_raw": "1. Caspase-1, also known as interleukin-1 beta converting enzyme or ICE, is activated in response to inflammatory signals like IL-1 and TNF-.\n2. Caspase-3 is involved in the regulation of both apoptosis and inflammation.\n3. Caspase-4, also known as cytokine-induced ICE-like protein or CYIL, is activated in response to cytokines such as IL-1 and TNF-.\n4. Caspase-5 is involved in the regulation of inflammation and immune response.",
    "llama-2-7b-chat-hf_fact": [
      "Caspase-1, also known as interleukin-1 beta converting enzyme or ICE, is activated in response to inflammatory signals like IL-1 and TNF-.",
      "Caspase-3 is involved in the regulation of both apoptosis and inflammation.",
      "Caspase-4, also known as cytokine-induced ICE-like protein or CYIL, is activated in response to cytokines such as IL-1 and TNF-.",
      "Caspase-5 is involved in the regulation of inflammation and immune response."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Caspase-4, also known as cytokine-induced ICE-like protein or CYIL, is primarily involved in the innate immune response, specifically recognizing lipopolysaccharides from Gram-negative bacteria to induce pyroptosis, rather than being activated by cytokines such as IL-1 and TNF-.\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-2-7b-chat-hf_response": "Yes, there is a known link between Aurora B kinase and Polycomb protein Ring1B. Both of these proteins play important roles in the regulation of chromatin dynamics and gene expression, and they have been shown to interact and coordinate their functions in various cellular processes.\nAurora B kinase is a serine/threonine kinase that is involved in the regulation of mitosis and meiosis. It is activated during these processes and phosphorylates various substrates, including histone H3, to facilitate the proper progression of cell division. Aurora B kinase has also been implicated in the regulation of gene expression, particularly during cell differentiation and development.\nPolycomb protein Ring1B, on the other hand, is a component of the Polycomb repressive complex 2 (PRC2), which is responsible for maintaining the repressed state of gene expression during cell differentiation and development. PRC2 is known to be involved in the regulation of both histone modifications and DNA methylation, and it plays a crucial role in the maintenance of cell identity and the prevention of inappropriate gene expression.\nStudies have shown that Aurora B kinase and Ring1B interact and coordinate their functions in various cellular processes. For example, it has been shown that Aurora B kinase phosphorylates Ring1B, which leads to the activation of PRC2 and the repression of target genes. Conversely, Ring1B has been shown to phosphorylate and activate Aurora B kinase, which is involved in the regulation of mitosis and meiosis.\nFurthermore, it has been shown that alterations in the expression or activity of Aurora B kinase and Ring1B are associated with various diseases, including cancer and developmental disorders. For example, overexpression of Aurora B kinase has been linked to the development of cancer, while loss of Ring1B function has been associated with the development of developmental disorders.\nIn summary, there is a clear link between Aurora B kinase and Polycomb protein Ring1B, as they interact and coordinate their functions in various cellular processes, including the regulation of chromatin dynamics and gene expression. Further research into the mechanisms underlying these interactions may provide valuable insights into the development of new therapeut",
    "llama-2-7b-chat-hf_fact_raw": "1. Aurora B kinase and Polycomb protein Ring1B interact and coordinate their functions in various cellular processes.\n2. Aurora B kinase is a serine/threonine kinase involved in the regulation of mitosis and meiosis.\n3. Polycomb protein Ring1B is a component of the Polycomb repressive complex 2 (PRC2).\n4. Aurora B kinase phosphorylates histone H3 during cell division.\n5. Alterations in the expression or activity of Aurora B kinase and Ring1B are associated with various diseases, such as cancer and developmental disorders.",
    "llama-2-7b-chat-hf_fact": [
      "Aurora B kinase and Polycomb protein Ring1B interact and coordinate their functions in various cellular processes.",
      "Aurora B kinase is a serine/threonine kinase involved in the regulation of mitosis and meiosis.",
      "Polycomb protein Ring1B is a component of the Polycomb repressive complex 2 (PRC2).",
      "Aurora B kinase phosphorylates histone H3 during cell division.",
      "Alterations in the expression or activity of Aurora B kinase and Ring1B are associated with various diseases, such as cancer and developmental disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Polycomb protein Ring1B is a component of the Polycomb repressive complex 1 (PRC1), not PRC2.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-2-7b-chat-hf_response": "Non-canonical sequence motifs are alterations in the splice site sequences that can occur in addition to the canonical splice site sequences. These motifs can affect the splicing efficiency, leading to different splice variants or altered protein function. In vertebrates, the most frequent non-canonical sequence motifs at the donor and acceptor splice sites are:\nDonor Splice Site Non-Canonical Motifs:\n1. GU-rich sequences: GU-rich sequences are found in the intron upstream of the donor splice site. These sequences can act as enhancers or silencers of splicing, depending on their context.\n2. AG-rich sequences: AG-rich sequences are found in the intron downstream of the donor splice site. These sequences can also act as enhancers or silencers of splicing.\n3. Intron-acceptor splice site interactions: Intron-acceptor splice site interactions can occur when the intron and acceptor splice site are in close proximity, leading to altered splicing patterns.\n4. 3' splice site slippage: 3' splice site slippage occurs when the spliceosome encounters a barrier at the 3' splice site, leading to the inclusion of downstream sequences in the final mRNA.\n5. Alternative donor splice sites: Alternative donor splice sites are found in the intron upstream of the canonical donor splice site. These sites can be recognized by the spliceosome, leading to the inclusion of different exons or alternative splice variants.\nAcceptor Splice Site Non-Canonical Motifs:\n1. GU-rich sequences: GU-rich sequences are found in the exon downstream of the acceptor splice site. These sequences can act as enhancers or silencers of splicing, depending on their context.\n2. AG-rich sequences: AG-rich sequences are found in the exon upstream of the acceptor splice site. These sequences can also act as enhancers or silencers of splicing.\n3. Intron-donor splice site interactions: Intron-donor splice site interactions can occur when the intron and donor splice",
    "llama-2-7b-chat-hf_fact_raw": "1. Non-canonical sequence motifs at the donor and acceptor splice sites can affect splicing efficiency in vertebrates.\n2. GU-rich sequences are non-canonical motifs found upstream of the donor splice site and downstream of the acceptor splice site in vertebrates.\n3. AG-rich sequences are non-canonical motifs found downstream of the donor splice site and upstream of the acceptor splice site in vertebrates.\n4. 3' splice site slippage is a non-canonical motif that can lead to the inclusion of downstream sequences in the final mRNA in vertebrates.\n5. Alternative donor splice sites are non-canonical motifs that can lead to the inclusion of different exons or alternative splice variants in vertebrates.",
    "llama-2-7b-chat-hf_fact": [
      "Non-canonical sequence motifs at the donor and acceptor splice sites can affect splicing efficiency in vertebrates.",
      "GU-rich sequences are non-canonical motifs found upstream of the donor splice site and downstream of the acceptor splice site in vertebrates.",
      "AG-rich sequences are non-canonical motifs found downstream of the donor splice site and upstream of the acceptor splice site in vertebrates.",
      "3' splice site slippage is a non-canonical motif that can lead to the inclusion of downstream sequences in the final mRNA in vertebrates.",
      "Alternative donor splice sites are non-canonical motifs that can lead to the inclusion of different exons or alternative splice variants in vertebrates."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: AG-rich sequences are non-canonical motifs found upstream of the donor splice site and downstream of the acceptor splice site in vertebrates.\n4. FALSE [correction]: 3' splice site slippage is a splicing error, not a motif, that can lead to the inclusion of intronic downstream sequences in the final mRNA in vertebrates.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "llama-2-7b-chat-hf_response": "S6K1 (S6 kinase 1) is a key regulator of protein synthesis and cellular metabolism, and its acetylation plays a crucial role in various cellular processes. There are several events that can result in the acetylation of S6K1, including:\n1. Insulin signaling: Insulin stimulates the phosphorylation and acetylation of S6K1, leading to its activation and promotion of protein synthesis in muscle and liver cells.\n2. Mechanistic target of rapamycin (mTOR) signaling: mTOR is a key regulator of cellular metabolism and growth, and it can phosphorylate and acetylate S6K1, leading to its activation and promotion of protein synthesis.\n3. Nutrient availability: The availability of nutrients, such as amino acids, can activate S6K1 through phosphorylation and acetylation, leading to increased protein synthesis.\n4. Growth factors: Certain growth factors, such as epidermal growth factor (EGF), can stimulate the phosphorylation and acetylation of S6K1, leading to its activation and promotion of protein synthesis.\n5. Oxidative stress: Oxidative stress, which results from an imbalance between the production of reactive oxygen species (ROS) and the body's antioxidant defenses, can lead to the acetylation of S6K1, leading to its activation and promotion of protein synthesis.\n6. AMP-activated protein kinase (AMPK) activation: AMPK is a metabolic sensor that regulates cellular metabolism and energy homeostasis, and its activation can lead to the phosphorylation and acetylation of S6K1, leading to its activation and promotion of protein synthesis.\n7. Peroxisome proliferator-activated receptor (PPAR) activation: PPAR is a nuclear receptor that regulates glucose and lipid metabolism, and its activation can lead to the phosphorylation and acetylation of S6K1, leading to its activation and promotion of protein synthesis.\n8. DNA damage: DNA damage,",
    "llama-2-7b-chat-hf_fact_raw": "1. Insulin signaling can stimulate the phosphorylation and acetylation of S6K1, activating it and promoting protein synthesis in muscle and liver cells.\n2. mTOR signaling can phosphorylate and acetylate S6K1, leading to its activation and promotion of protein synthesis.\n3. The availability of nutrients such as amino acids can activate S6K1 through phosphorylation and acetylation, increasing protein synthesis.\n4. Growth factors like epidermal growth factor (EGF) can stimulate the phosphorylation and acetylation of S6K1, leading to its activation and promotion of protein synthesis.\n5. Oxidative stress can result in the acetylation of S6K1, leading to its activation and promotion of protein synthesis.",
    "llama-2-7b-chat-hf_fact": [
      "Insulin signaling can stimulate the phosphorylation and acetylation of S6K1, activating it and promoting protein synthesis in muscle and liver cells.",
      "mTOR signaling can phosphorylate and acetylate S6K1, leading to its activation and promotion of protein synthesis.",
      "The availability of nutrients such as amino acids can activate S6K1 through phosphorylation and acetylation, increasing protein synthesis.",
      "Growth factors like epidermal growth factor (EGF) can stimulate the phosphorylation and acetylation of S6K1, leading to its activation and promotion of protein synthesis.",
      "Oxidative stress can result in the acetylation of S6K1, leading to its activation and promotion of protein synthesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Oxidative stress can result in the inactivation of S6K1, not its activation.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "llama-2-7b-chat-hf_response": "Episodic ataxia type 6 (EA6) is a rare genetic disorder that affects the nervous system, particularly the cerebellum and brainstem. The exact cause of EA6 is not fully understood, but research has identified several genetic mutations that are associated with the disorder.\nEA6 is caused by mutations in the PPP1R12A gene, which codes for a protein called PP1-R12A. This protein plays a critical role in the regulation of the cellular process called protein phosphatase 1 (PP1), which is involved in various cellular functions, including the regulation of gene expression, cell signaling, and protein degradation.\nMutations in the PPP1R12A gene lead to a deficiency of PP1-R12A protein, which disrupts the normal functioning of PP1 and leads to a variety of cellular changes that contribute to the symptoms of EA6. These changes include:\n1. Cerebellar atrophy: The cerebellum is the part of the brain that coordinates movement, balance, and coordination. Mutations in PPP1R12A lead to a progressive degeneration of the cerebellum, which can result in problems with coordination, balance, and movement.\n2. Brainstem dysfunction: The brainstem is the part of the brain that controls many of the body's vital functions, including breathing, heart rate, and blood pressure. Mutations in PPP1R16A can lead to dysfunction of the brainstem, which can result in a range of symptoms, including difficulty swallowing, slurred speech, and problems with breathing.\n3. Abnormal protein phosphorylation: PP1 is involved in the regulation of protein phosphorylation, which is a critical cellular process that helps to control various cellular functions. Mutations in PPP1R12A can lead to abnormal protein phosphorylation, which can disrupt the normal functioning of various cellular pathways and contribute to the symptoms of EA6.\n4. Oxidative stress: Oxidative stress is an imbalance between the production of reactive oxygen species (ROS) and the body's",
    "llama-2-7b-chat-hf_fact_raw": "1. Episodic ataxia type 6 (EA6) is a rare genetic disorder that affects the nervous system.\n2. EA6 is caused by mutations in the PPP1R12A gene.\n3. The PPP1R12A gene codes for a protein called PP1-R12A, which is involved in the regulation of the cellular process called protein phosphatase 1 (PP1).\n4. Mutations in the PPP1R12A gene can lead to cerebellar atrophy, which affects movement, balance, and coordination.\n5. Mutations in the PPP1R12A gene can also lead to brainstem dysfunction, affecting vital functions like breathing and heart rate.",
    "llama-2-7b-chat-hf_fact": [
      "Episodic ataxia type 6 (EA6) is a rare genetic disorder that affects the nervous system.",
      "EA6 is caused by mutations in the PPP1R12A gene.",
      "The PPP1R12A gene codes for a protein called PP1-R12A, which is involved in the regulation of the cellular process called protein phosphatase 1 (PP1).",
      "Mutations in the PPP1R12A gene can lead to cerebellar atrophy, which affects movement, balance, and coordination.",
      "Mutations in the PPP1R12A gene can also lead to brainstem dysfunction, affecting vital functions like breathing and heart rate."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: EA6 is caused by mutations in the SLC1A3 gene.\n3. TRUE\n4. FALSE [correction]: Mutations in the SLC1A3 gene can lead to cerebellar atrophy, which affects movement, balance, and coordination.\n5. FALSE [correction]: Mutations in the SLC1A3 gene can also lead to brainstem dysfunction, affecting vital functions like breathing and heart rate.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "llama-2-7b-chat-hf_response": "Yes, chromomethylases are present in animal genomes. Chromomethylases are enzymes that add a methyl group to DNA, and they play a crucial role in various biological processes, including DNA methylation and epigenetic regulation.\nWhile the majority of chromomethylases are found in prokaryotic organisms, there are also several families of chromomethylases present in eukaryotic genomes, including animals. These enzymes are involved in the methylation of various DNA sequences, including CpG islands, which are found in the promoter regions of many genes.\nIn animals, chromomethylases are known to be involved in a variety of processes, including:\n1. Gene silencing: Chromomethylases can methylate CpG islands in the promoter regions of genes, leading to their silencing and preventing their expression. This process is known as epigenetic gene silencing.\n2. Cell differentiation: Chromomethylases can also be involved in the regulation of cell differentiation by methylating specific DNA sequences in the promoter regions of genes involved in cell fate determination.\n3. Cancer: Chromomethylases have been implicated in the development and progression of cancer. Methylation of CpG islands in tumor suppressor genes can lead to their silencing, contributing to the development of cancer.\n4. Aging: Chromomethylases have also been linked to the aging process. Methylation of specific DNA sequences can lead to the silencing of genes involved in the maintenance of cellular homeostasis, contributing to the aging process.\nSome of the chromomethylases found in animal genomes include:\n1. DNMT1 (DNA methyltransferase 1): This enzyme is one of the most well-studied chromomethylases in animals. It is responsible for the maintenance of DNA methylation in various tissues, including the brain, liver, and blood.\n2. DNMT3A (DNA methyltransferase 3A): This enzyme is involved in the de novo methylation of DNA and is expressed in various tissues, including the brain,",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromomethylases are enzymes that add a methyl group to DNA.\n2. Chromomethylases are present in both prokaryotic and eukaryotic genomes, including animals.\n3. Chromomethylases in animals are involved in the methylation of CpG islands found in the promoter regions of many genes.\n4. DNMT1 (DNA methyltransferase 1) is a well-studied chromomethylase present in animal genomes, and it maintains DNA methylation in various tissues.\n5. DNMT3A (DNA methyltransferase 3A) is an enzyme in animals involved in the de novo methylation of DNA.",
    "llama-2-7b-chat-hf_fact": [
      "Chromomethylases are enzymes that add a methyl group to DNA.",
      "Chromomethylases are present in both prokaryotic and eukaryotic genomes, including animals.",
      "Chromomethylases in animals are involved in the methylation of CpG islands found in the promoter regions of many genes.",
      "DNMT1 (DNA methyltransferase 1) is a well-studied chromomethylase present in animal genomes, and it maintains DNA methylation in various tissues.",
      "DNMT3A (DNA methyltransferase 3A) is an enzyme in animals involved in the de novo methylation of DNA."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Chromomethylases are predominantly found in plants, not in animals.\n3. FALSE [correction]: In animals, DNA methyltransferases, not chromomethylases, are involved in the methylation of CpG islands.\n4. FALSE [correction]: DNMT1 is not classified as a chromomethylase; it is a DNA methyltransferase.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-2-7b-chat-hf_response": "Certainly! There are several packages available in R/Bioconductor for transcription factor binding site (TFBS) analysis. Here are some of the most popular ones:\n1. TFBStoolbox: This package provides a collection of tools for the analysis of TFBSs, including the calculation of motif frequencies, the identification of potential TFBSs, and the prediction of TF-DNA interactions. It also includes a number of pre-computed databases of TFBSs for various organisms.\n2. TFTools: This package provides a variety of tools for the analysis of TFBSs, including the calculation of motif frequencies, the identification of potential TFBSs, and the prediction of TF-DNA interactions. It also includes a number of pre-computed databases of TFBSs for various organisms.\n3. TRANSFAC: This package provides a comprehensive collection of TFBSs for various organisms, including humans, mice, and yeast. It also includes tools for the analysis of TFBSs, such as the calculation of motif frequencies and the prediction of TF-DNA interactions.\n4. ChIPseek: This package provides tools for the analysis of ChIP-seq data, including the identification of potential TFBSs and the prediction of TF-DNA interactions. It also includes a number of pre-computed databases of TFBSs for various organisms.\n5. HISAT2: This package provides tools for the analysis of ChIP-seq data, including the identification of potential TFBSs and the prediction of TF-DNA interactions. It also includes a number of pre-computed databases of TFBSs for various organisms.\n6. DeepTools: This package provides a variety of tools for the analysis of ChIP-seq data, including the identification of potential TFBSs and the prediction of TF-DNA interactions. It also includes a number of pre-computed databases of TFBSs for various organisms.\n7. ChIPster: This package provides tools for the analysis of ChIP-seq data, including the identification of potential TFBSs and the prediction of TF-DNA interactions. It also includes a number of pre-computed databases of TFBSs for various organisms.\n8. BEDTools: This",
    "llama-2-7b-chat-hf_fact_raw": "1. TFBStoolbox is a package available in R/Bioconductor for TFBS analysis.\n2. TFTools is another R/Bioconductor package designed for TFBS analysis.\n3. TRANSFAC is an R/Bioconductor package that provides a collection of TFBSs for various organisms.\n4. ChIPseek is an R/Bioconductor package for analyzing ChIP-seq data and identifying potential TFBSs.\n5. HISAT2 is an R/Bioconductor package with tools for analysing ChIP-seq data, including the identification of potential TFBSs.",
    "llama-2-7b-chat-hf_fact": [
      "TFBStoolbox is a package available in R/Bioconductor for TFBS analysis.",
      "TFTools is another R/Bioconductor package designed for TFBS analysis.",
      "TRANSFAC is an R/Bioconductor package that provides a collection of TFBSs for various organisms.",
      "ChIPseek is an R/Bioconductor package for analyzing ChIP-seq data and identifying potential TFBSs.",
      "HISAT2 is an R/Bioconductor package with tools for analysing ChIP-seq data, including the identification of potential TFBSs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. FALSE [correction]: TRANSFAC is a database that provides a collection of TFBSs for various organisms, but it is not an R/Bioconductor package.\n4. TRUE\n5. FALSE [correction]: HISAT2 is not an R/Bioconductor package, it is a fast and sensitive alignment program for mapping next-generation sequencing reads but does not specifically focus on the identification of potential TFBSs.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "llama-2-7b-chat-hf_response": "Certainly! Here are some ongoing and completed clinical trials related to the prevention of sarcopenia:\n1. A Randomized Controlled Trial to Evaluate the Efficacy and Safety of Metformin in Preventing Sarcopenia in Older Adults with Type 2 Diabetes (NCT03174377)\nThis clinical trial, conducted by the University of California, San Francisco, is evaluating the effectiveness and safety of metformin in preventing sarcopenia in older adults with type 2 diabetes. The trial is recruiting 120 participants and is expected to be completed in 2023.\n2. Effects of Resistance Training on Sarcopenia in Older Adults: A Randomized Controlled Trial (NCT03155177)\nThis study, conducted by the University of Texas Health Science Center at San Antonio, is investigating the effects of resistance training on sarcopenia in older adults. The trial is recruiting 120 participants and is expected to be completed in 2023.\n3. Nutritional Interventions to Prevent Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis (NCT03127577)\nThis systematic review and meta-analysis, conducted by the University of California, Los Angeles, is examining the effectiveness of various nutritional interventions in preventing sarcopenia in older adults. The review includes 23 randomized controlled trials and is expected to be completed in 2023.\n4. The Effects of Omega-3 Fatty Acids on Sarcopenia in Older Adults: A Randomized Controlled Trial (NCT03074659)\nThis clinical trial, conducted by the University of Illinois at Chicago, is investigating the effects of omega-3 fatty acids on sarcopenia in older adults. The trial is recruiting 120 participants and is expected to be completed in 2023.\n5. The Effect of Yoga on Sarcopenia in Older Adults: A Randomized Controlled Trial",
    "llama-2-7b-chat-hf_fact_raw": "1. The University of California, San Francisco is conducting a trial evaluating the effectiveness of metformin in preventing sarcopenia in older adults with type 2 diabetes (NCT03174377).\n2. The University of Texas Health Science Center at San Antonio is investigating the effects of resistance training on sarcopenia in older adults (NCT03155177).\n3. The University of California, Los Angeles is conducting a systematic review and meta-analysis on nutritional interventions to prevent sarcopenia in older adults (NCT03127577).\n4. The University of Illinois at Chicago is investigating the effects of omega-3 fatty acids on sarcopenia in older adults (NCT03074659). \n5. All trials mentioned are expected to be completed in 2023.",
    "llama-2-7b-chat-hf_fact": [
      "The University of California, San Francisco is conducting a trial evaluating the effectiveness of metformin in preventing sarcopenia in older adults with type 2 diabetes (NCT03174377).",
      "The University of Texas Health Science Center at San Antonio is investigating the effects of resistance training on sarcopenia in older adults (NCT03155177).",
      "The University of California, Los Angeles is conducting a systematic review and meta-analysis on nutritional interventions to prevent sarcopenia in older adults (NCT03127577).",
      "The University of Illinois at Chicago is investigating the effects of omega-3 fatty acids on sarcopenia in older adults (NCT03074659).",
      "All trials mentioned are expected to be completed in 2023."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The University of California, Los Angeles is conducting a systematic review and meta-analysis on the role of physical activity in preventing sarcopenia in older adults (NCT03127577).\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "llama-2-7b-chat-hf_response": "There are several databases of molecular recognition features in membrane proteins that can be used to aid in the prediction of protein-ligand interactions. Here are some of the most popular and widely used databases:\n1. The Membrane Protein Database (MPD): This database contains a collection of structurally characterized membrane proteins, including their three-dimensional structures, functional information, and binding sites. The database also includes a section on molecular recognition features, which provides information on the types of molecular recognition sites found in membrane proteins, such as binding sites, active sites, and binding pocket residues.\n2. The Protein Data Bank (PDB): The PDB is a comprehensive database of three-dimensional structures of proteins, including membrane proteins. The database contains structures of membrane proteins in various states, including bound and unbound states, which can be used to predict binding sites and molecular recognition features.\n3. The Membrane Protein Interaction Database (MPII): This database contains information on the interactions between membrane proteins and their ligands, including the binding affinity, specificity, and dynamics. The database also includes information on the molecular recognition features of membrane proteins, such as the presence of binding sites, active sites, and binding pocket residues.\n4. The Membrane Protein Structure Prediction (MPSP): This database contains a collection of predicted three-dimensional structures of membrane proteins, including their binding sites and molecular recognition features. The database also includes information on the prediction methods used to generate the structures, which can be useful for evaluating the accuracy of the predictions.\n5. The Membrane Protein-Ligand Interaction Database (MPLID): This database contains information on the interactions between membrane proteins and their ligands, including the binding affinity, specificity, and dynamics. The database also includes information on the molecular recognition features of membrane proteins, such as the presence of binding sites, active sites, and binding pocket residues.\n6. The Membrane Protein-Protein Interaction Database (MPPI): This database contains information on the interactions between membrane proteins and other proteins, including the binding affinity, specificity, and dynamics. The database also includes information on the molecular recognition features of membrane proteins, such as the presence of binding sites, active sites",
    "llama-2-7b-chat-hf_fact_raw": "1. The Membrane Protein Database (MPD) contains structurally characterized membrane proteins and their three-dimensional structures.\n2. The Protein Data Bank (PDB) is a comprehensive database of three-dimensional structures of proteins, including membrane proteins.\n3. The Membrane Protein Interaction Database (MPII) contains information on the interactions between membrane proteins and their ligands.\n4. The Membrane Protein Structure Prediction (MPSP) includes predicted three-dimensional structures of membrane proteins and their molecular recognition features.\n5. The Membrane Protein-Ligand Interaction Database (MPLID) contains information on the interactions between membrane proteins and their ligands, including binding affinity and specificity.",
    "llama-2-7b-chat-hf_fact": [
      "The Membrane Protein Database (MPD) contains structurally characterized membrane proteins and their three-dimensional structures.",
      "The Protein Data Bank (PDB) is a comprehensive database of three-dimensional structures of proteins, including membrane proteins.",
      "The Membrane Protein Interaction Database (MPII) contains information on the interactions between membrane proteins and their ligands.",
      "The Membrane Protein Structure Prediction (MPSP) includes predicted three-dimensional structures of membrane proteins and their molecular recognition features.",
      "The Membrane Protein-Ligand Interaction Database (MPLID) contains information on the interactions between membrane proteins and their ligands, including binding affinity and specificity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "llama-2-7b-chat-hf_response": "Thank you for asking! Rivaroxaban, a direct oral anticoagulant (DOAC), is metabolized in the liver and kidneys to a lesser extent.\nRivaroxaban is primarily metabolized by the liver enzyme CYP2C9, with a minor contribution from CYP3A4. The main circulating metabolite, rivaroxaban sulfoxide, is formed through the oxidation of the parent compound by CYP2C9. This metabolite is inactive and is excreted primarily in the feces.\nHowever, the kidneys play a minor role in the elimination of rivaroxaban. Only a small amount of the drug is excreted unchanged in the urine, primarily as a result of renal clearance. The majority of rivaroxaban is eliminated through the liver, with the liver accounting for approximately 70% of the drug's clearance.\nIt's important to note that renal impairment can affect the elimination of rivaroxaban, leading to increased exposure to the drug and potentially increasing the risk of bleeding. Therefore, patients with renal impairment may require a lower dose of rivaroxaban or closer monitoring to avoid adverse events.\nIn summary, while the kidneys do play a role in the elimination of rivaroxaban, the liver is the primary site of metabolism and elimination of this drug. Renal impairment can impact the elimination of rivaroxaban, and patients with renal impairment may require dosage adjustments or closer monitoring to avoid adverse events.",
    "llama-2-7b-chat-hf_fact_raw": "1. Rivaroxaban is metabolized in the liver and to a lesser extent in the kidneys.\n2. The liver enzyme CYP2C9 is the primary metabolizer of rivaroxaban, with a minor contribution from CYP3A4.\n3. The main circulating metabolite of rivaroxaban, rivaroxaban sulfoxide, is inactive and primarily excreted in the feces.\n4. A small amount of rivaroxaban is excreted unchanged in the urine due to renal clearance.\n5. Approximately 70% of rivaroxaban's clearance is through the liver.",
    "llama-2-7b-chat-hf_fact": [
      "Rivaroxaban is metabolized in the liver and to a lesser extent in the kidneys.",
      "The liver enzyme CYP2C9 is the primary metabolizer of rivaroxaban, with a minor contribution from CYP3A4.",
      "The main circulating metabolite of rivaroxaban, rivaroxaban sulfoxide, is inactive and primarily excreted in the feces.",
      "A small amount of rivaroxaban is excreted unchanged in the urine due to renal clearance.",
      "Approximately 70% of rivaroxaban's clearance is through the liver."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The liver enzyme CYP3A4 and CYP2J2 are the primary metabolizers of rivaroxaban, with a minor contribution from CYP2C9.\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "llama-2-7b-chat-hf_response": "TRalpha2 (also known as retinoic acid receptor alpha 2) is a nuclear receptor that plays a crucial role in regulating various physiological processes, including cardiovascular development and function. In the heart, TRalpha2 regulates the expression of several genes involved in cardiac function, including:\n1. Atrial natriuretic peptide (ANP): TRalpha2 regulates the expression of the ANP gene, which encodes a hormone that helps regulate blood pressure, sodium and water balance, and heart function.\n2. Brain natriuretic peptide (BNP): TRalpha2 also regulates the expression of the BNP gene, which encodes a hormone that helps regulate heart failure and cardiac remodeling.\n3. Cardiac troponin I (TNNI): TRalpha2 regulates the expression of the TNNI gene, which encodes a protein that plays a crucial role in the regulation of muscle contraction and relaxation in the heart.\n4. Connexin 43 (CX43): TRalpha2 regulates the expression of the CX43 gene, which encodes a gap junction protein that plays a crucial role in the coordination of electrical and mechanical activity between cardiac cells.\n5. GATA4: TRalpha2 regulates the expression of the GATA4 gene, which encodes a transcription factor that plays a crucial role in the development and differentiation of the cardiac ventricles.\n6. Myosin heavy chain 7 (MHC7): TRalpha2 regulates the expression of the MHC7 gene, which encodes a protein that plays a crucial role in the regulation of muscle contraction and relaxation in the heart.\n7. Nuclear factor of kappa light chain enhancer in B cells 1 (NF-B1): TRalpha2 regulates the expression of the NF-B1 gene, which encodes a transcription factor that plays a crucial role in the regulation of inflammation and immune response in the heart.\n8. Peroxisome proliferator-activated receptor gamma (PPAR): TRalpha2 regulates the expression of the PPAR gene, which encodes a nuclear receptor that plays",
    "llama-2-7b-chat-hf_fact_raw": "1. TRalpha2 regulates the expression of the Atrial natriuretic peptide (ANP) gene in the heart.\n2. TRalpha2 regulates the expression of the Brain natriuretic peptide (BNP) gene in the heart.\n3. TRalpha2 regulates the expression of the Cardiac troponin I (TNNI) gene in the heart.\n4. TRalpha2 regulates the expression of the Connexin 43 (CX43) gene in the heart.\n5. TRalpha2 regulates the expression of the GATA4 gene in the heart.",
    "llama-2-7b-chat-hf_fact": [
      "TRalpha2 regulates the expression of the Atrial natriuretic peptide (ANP) gene in the heart.",
      "TRalpha2 regulates the expression of the Brain natriuretic peptide (BNP) gene in the heart.",
      "TRalpha2 regulates the expression of the Cardiac troponin I (TNNI) gene in the heart.",
      "TRalpha2 regulates the expression of the Connexin 43 (CX43) gene in the heart.",
      "TRalpha2 regulates the expression of the GATA4 gene in the heart."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific context or reference to scientific literature confirming the regulatory functions of TRalpha2 on the mentioned genes, it is not possible to determine the truthfulness of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "llama-2-7b-chat-hf_response": "Certainly! There are several biomedical question answering systems available, which can be broadly classified into the following categories:\n1. Natural Language Processing (NLP) Based Systems: These systems use NLP techniques to analyze the user's question and generate answers from a knowledge base or database. Some examples of NLP-based biomedical question answering systems include:\n* PubMed Central's PubMed Question Answering Service (PMQAS): This system uses NLP to extract relevant information from the PubMed database and provide answers to user questions.\n* BioMed Central's BioQA: This system uses NLP to analyze user questions and generate answers from a database of biomedical literature.\n* Google's Biomedical Natural Language Processing (BioNLP) Toolkit: This toolkit provides a range of NLP tools and resources for analyzing biomedical text, including question answering.\n2. Machine Learning (ML) Based Systems: These systems use machine learning algorithms to learn from large datasets of biomedical text and generate answers to user questions. Some examples of ML-based biomedical question answering systems include:\n* IBM's Watson for Oncology: This system uses ML to analyze large datasets of cancer-related text and provide personalized treatment recommendations to clinicians.\n* Microsoft's Healthbot: This system uses ML to analyze user questions and provide personalized health recommendations based on user data and medical knowledge.\n* Stanford University's Biomedical Informatics Research Laboratory's (BMIR) Question Answering System (QA-System): This system uses ML to analyze biomedical text and provide answers to user questions.\n3. Hybrid Systems: These systems combine NLP and ML techniques to generate answers to user questions. Some examples of hybrid biomedical question answering systems include:\n* The Biomedical Informatics Research Laboratory's (BMIR) Hybrid Question Answering System (HQAS): This system combines NLP and ML techniques to analyze user questions and generate answers from a database of biomedical text.\n* The University of California, San Diego's (UCSD) BioCreative V: This system uses a combination of NLP and ML techniques to analyze biomedical text and provide answers to user questions.\n4. Rule-Based Systems: These systems use pre-defined rules and knowledge",
    "llama-2-7b-chat-hf_fact_raw": "1. PubMed Central's PubMed Question Answering Service (PMQAS) uses NLP to extract information from the PubMed database for answering questions.\n2. BioMed Central's BioQA utilizes NLP to analyze questions and generate answers from biomedical literature.\n3. IBM's Watson for Oncology uses machine learning to provide personalized cancer treatment recommendations.\n4. Microsoft's Healthbot employs machine learning to provide personalized health recommendations based on user data and medical knowledge.\n5. The University of California, San Diego's BioCreative V combines NLP and ML techniques for biomedical text analysis and question answering.",
    "llama-2-7b-chat-hf_fact": [
      "PubMed Central's PubMed Question Answering Service (PMQAS) uses NLP to extract information from the PubMed database for answering questions.",
      "BioMed Central's BioQA utilizes NLP to analyze questions and generate answers from biomedical literature.",
      "IBM's Watson for Oncology uses machine learning to provide personalized cancer treatment recommendations.",
      "Microsoft's Healthbot employs machine learning to provide personalized health recommendations based on user data and medical knowledge.",
      "The University of California, San Diego's BioCreative V combines NLP and ML techniques for biomedical text analysis and question answering."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "llama-2-7b-chat-hf_response": "The betalain pathway is a complex metabolic pathway involved in the biosynthesis of betalains, a group of natural pigments found in plants. The regulation of this pathway is mediated by various transcription factors, including:\n1. ABF (ABSCISIC ACID INSENSITIVE 3) transcription factor: ABF is a key regulator of the betalain pathway in plants. It is activated by abscisic acid (ABA), a plant hormone that plays a key role in plant stress responses. Once activated, ABF binds to specific DNA sequences in the promoter region of betalain biosynthetic genes, leading to their transcriptional activation.\n2. MYB transcription factor: MYB transcription factors are also involved in the regulation of the betalain pathway. These factors are activated by various signals, including light, temperature, and hormones, and play a crucial role in the expression of betalain biosynthetic genes.\n3. WRKY transcription factor: WRKY transcription factors are another important class of regulators involved in the betalain pathway. These factors are activated by various signals, including salicylic acid (SA), a hormone involved in plant defense responses. Once activated, WRKY factors bind to specific DNA sequences in the promoter region of betalain biosynthetic genes, leading to their transcriptional activation.\n4. bHLH (basic helix-loop-helix) transcription factor: bHLH factors are also involved in the regulation of the betalain pathway. These factors are activated by various signals, including light and hormones, and play a crucial role in the expression of betalain biosynthetic genes.\n5. HY5 (HYPOCOTYL 5) transcription factor: HY5 is a transcription factor that plays a key role in the regulation of the betalain pathway in Arabidopsis thaliana. It is activated by light and other signals, and regulates the expression of betalain biosynthetic genes.\n6. DWF (DWARF WINGED BEAN) transcription factor: DWF is",
    "llama-2-7b-chat-hf_fact_raw": "1. ABF (ABSCISIC ACID INSENSITIVE 3) transcription factor is a key regulator of the betalain pathway in plants.\n2. MYB transcription factors are involved in the regulation of the betalain pathway and are activated by signals such as light, temperature, and hormones.\n3. WRKY transcription factors are regulators involved in the betalain pathway and are activated by signals like salicylic acid.\n4. bHLH (basic helix-loop-helix) transcription factors participate in regulating the betalain pathway and are activated by signals including light and hormones.\n5. HY5 (HYPOCOTYL 5) transcription factor plays a key role in regulating the betalain pathway in Arabidopsis thaliana and is activated by light.",
    "llama-2-7b-chat-hf_fact": [
      "ABF (ABSCISIC ACID INSENSITIVE 3) transcription factor is a key regulator of the betalain pathway in plants.",
      "MYB transcription factors are involved in the regulation of the betalain pathway and are activated by signals such as light, temperature, and hormones.",
      "WRKY transcription factors are regulators involved in the betalain pathway and are activated by signals like salicylic acid.",
      "bHLH (basic helix-loop-helix) transcription factors participate in regulating the betalain pathway and are activated by signals including light and hormones.",
      "HY5 (HYPOCOTYL 5) transcription factor plays a key role in regulating the betalain pathway in Arabidopsis thaliana and is activated by light."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: WRKY transcription factors are not directly involved in the betalain pathway but are known to regulate other plant defense responses.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-2-7b-chat-hf_response": "Global quantitative phosphoproteomic analyses are indeed emerging as a powerful tool for understanding protein phosphorylation dynamics in various biological systems. The enrichment of phosphorylated peptides is a crucial step in these analyses, as it allows for the identification and quantification of phosphorylated proteins in a complex biological sample. Here are some of the preferred technologies for enriching phosphorylated peptides:\n1. TiO2-based enrichment: TiO2 is a popular material for phosphoprotein enrichment due to its high affinity for phosphate groups. TiO2-based enrichment methods typically involve incubating the sample with TiO2 beads, which capture phosphorylated peptides through ion-exchange interactions. The beads are then washed and analyzed using mass spectrometry.\n2. Cation exchange (CX) chromatography: CX chromatography is another commonly used method for phosphoprotein enrichment. This method takes advantage of the ionic interactions between phosphate groups and cation exchange resins, which capture phosphorylated peptides. The CX resin is typically equilibrated with a buffer containing high salt concentration to remove non-phosphorylated peptides.\n3. Hydrophilic interaction liquid chromatography (HILIC): HILIC is a type of liquid chromatography that separates peptides based on their hydrophilicity. Phosphorylated peptides are more hydrophilic than non-phosphorylated peptides, so they can be enriched using HILIC columns. This method is particularly useful for separating phosphorylated peptides from other hydrophobic compounds in the sample.\n4. IMAC (Immobilized Metal Affinity Chromatography): IMAC is a method that utilizes metal ions (e.g., Ni2+ or Co2+) immobilized on a resin to capture phosphorylated peptides. Phosphate groups in the peptides bind to the metal ions, allowing for their separation from non-phosphorylated peptides. IMAC is particularly useful for enriching phosphoryl",
    "llama-2-7b-chat-hf_fact_raw": "1. TiO2-based enrichment uses TiO2 beads to capture phosphorylated peptides through ion-exchange interactions.\n2. Cation exchange (CX) chromatography enriches phosphoproteins using ionic interactions between phosphate groups and cation exchange resins.\n3. Hydrophilic interaction liquid chromatography (HILIC) separates peptides based on their hydrophilicity and is useful for enriching phosphorylated peptides.\n4. IMAC (Immobilized Metal Affinity Chromatography) employs metal ions immobilized on a resin to separate phosphorylated peptides from non-phosphorylated ones.",
    "llama-2-7b-chat-hf_fact": [
      "TiO2-based enrichment uses TiO2 beads to capture phosphorylated peptides through ion-exchange interactions.",
      "Cation exchange (CX) chromatography enriches phosphoproteins using ionic interactions between phosphate groups and cation exchange resins.",
      "Hydrophilic interaction liquid chromatography (HILIC) separates peptides based on their hydrophilicity and is useful for enriching phosphorylated peptides.",
      "IMAC (Immobilized Metal Affinity Chromatography) employs metal ions immobilized on a resin to separate phosphorylated peptides from non-phosphorylated ones."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TiO2-based enrichment uses TiO2 beads to capture phosphorylated peptides through affinity interactions, not ion-exchange interactions.\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "llama-2-7b-chat-hf_response": "The Palmini classification is a system used to classify mental disorders based on their severity and impact on daily functioning. It was developed by Dr. Anthony Palmini and is used to help clinicians and researchers understand the level of impairment and distress associated with different mental health conditions.\nAccording to the Palmini classification, the following disorders are rated:\n1. Anxiety disorders: These disorders are characterized by excessive fear, worry, or anxiety that interferes with daily life. Examples of anxiety disorders include generalized anxiety disorder, panic disorder, and social anxiety disorder.\n2. Mood disorders: These disorders are characterized by persistent changes in mood, such as depression or mania. Examples of mood disorders include major depressive disorder, bipolar disorder, and dysthymia.\n3. Personality disorders: These disorders are characterized by patterns of behavior and thinking that deviate from the norm of the average person. Examples of personality disorders include borderline personality disorder, narcissistic personality disorder, and antisocial personality disorder.\n4. Psychotic disorders: These disorders are characterized by a disconnection from reality, such as hallucinations or delusions. Examples of psychotic disorders include schizophrenia, schizoaffective disorder, and brief psychotic disorder.\n5. Trauma and stressor-related disorders: These disorders are characterized by symptoms that occur after a person experiences a traumatic event, such as post-traumatic stress disorder (PTSD).\n6. Dissociative disorders: These disorders are characterized by a disconnection from one's thoughts, feelings, or surroundings. Examples of dissociative disorders include dissociative identity disorder (DID), dissociative amnesia, and depersonalization disorder.\n7. Somatic symptom and related disorders: These disorders are characterized by symptoms that are not caused by a medical condition, but are severe enough to interfere with daily life. Examples of somatic symptom disorders include somatic symptom disorder, illness anxiety disorder, and conversion disorder.\n8.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Palmini classification is used to classify mental disorders.\n2. Dr. Anthony Palmini developed the Palmini classification.\n3. Anxiety disorders, mood disorders, personality disorders, psychotic disorders, trauma and stressor-related disorders, dissociative disorders, and somatic symptom and related disorders are rated by the Palmini classification.\n4. Anxiety disorders include generalized anxiety disorder, panic disorder, and social anxiety disorder.\n5. Mood disorders include major depressive disorder, bipolar disorder, and dysthymia.",
    "llama-2-7b-chat-hf_fact": [
      "The Palmini classification is used to classify mental disorders.",
      "Dr. Anthony Palmini developed the Palmini classification.",
      "Anxiety disorders, mood disorders, personality disorders, psychotic disorders, trauma and stressor-related disorders, dissociative disorders, and somatic symptom and related disorders are rated by the Palmini classification.",
      "Anxiety disorders include generalized anxiety disorder, panic disorder, and social anxiety disorder.",
      "Mood disorders include major depressive disorder, bipolar disorder, and dysthymia."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Palmini classification is not used to classify mental disorders; it is used to classify lesions in epilepsy.\n2. TRUE\n3. FALSE [correction]: The Palmini classification does not rate mental disorders; it is related to epilepsy lesion classification.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-2-7b-chat-hf_response": "Yes, viruses have been implicated in the etiology of human subacute thyroiditis. Subacute thyroiditis is a relatively rare inflammatory disorder of the thyroid gland that typically presents with symptoms of thyroid dysfunction, such as fatigue, weight loss, and pain in the neck and throat, along with laboratory abnormalities consistent with thyroid inflammation. While the exact cause of subacute thyroiditis is not fully understood, there is evidence to suggest that viral infections may play a role in its pathogenesis.\nSeveral studies have reported the presence of viral antigens and/or genetic material in the thyroid glands of patients with subacute thyroiditis. For example, one study found that 75% of patients with subacute thyroiditis had evidence of viral infection in their thyroid glands, with the most common viruses identified being influenza A and B, as well as adenovirus. Another study found that the presence of viral antigens in the thyroid gland was associated with more severe thyroid inflammation and longer duration of illness.\nThe exact mechanisms by which viruses may contribute to the development of subacute thyroiditis are not well understood, but several possibilities have been proposed. One possibility is that viral infection may trigger an immune response in the thyroid gland, leading to inflammation and damage to thyroid tissue. Another possibility is that viruses may directly infect thyroid cells, leading to cell death and disruption of thyroid function.\nIt is worth noting that the role of viruses in the etiology of subacute thyroiditis is still a subject of debate, and other factors, such as autoimmune disorders and iodine deficiency, may also play a role in the development of the disease. However, the evidence suggesting a link between viruses and subacute thyroiditis is growing, and further research is needed to fully understand the relationship between these two entities.\nIn summary, while the exact cause of subacute thyroiditis is not fully understood, there is evidence to suggest that viruses may play a role in its pathogenesis. Further research is needed to determine the specific mechanisms by which viruses contribute to the development of this disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. Subacute thyroiditis is an inflammatory disorder of the thyroid gland.\n2. Symptoms of subacute thyroiditis include fatigue, weight loss, and pain in the neck and throat.\n3. Studies have reported the presence of viral antigens and/or genetic material in the thyroid glands of patients with subacute thyroiditis.\n4. In one study, 75% of patients with subacute thyroiditis had evidence of viral infection in their thyroid glands.\n5. The most common viruses identified in subacute thyroiditis patients were influenza A and B, and adenovirus.",
    "llama-2-7b-chat-hf_fact": [
      "Subacute thyroiditis is an inflammatory disorder of the thyroid gland.",
      "Symptoms of subacute thyroiditis include fatigue, weight loss, and pain in the neck and throat.",
      "Studies have reported the presence of viral antigens and/or genetic material in the thyroid glands of patients with subacute thyroiditis.",
      "In one study, 75% of patients with subacute thyroiditis had evidence of viral infection in their thyroid glands.",
      "The most common viruses identified in subacute thyroiditis patients were influenza A and B, and adenovirus."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-2-7b-chat-hf_response": "Yes, STAT3 (Signal Transducer and Activator of Transcription 3) is involved in the regulation of EIF2AK2-dependent suppression of autophagy.\nEIF2AK2 (Eukaryotic Translation Initiation Factor 2-Associated Kinase 2) is a kinase that phosphorylates and inhibits the translation initiation factor eIF2, leading to the suppression of global protein synthesis and the induction of autophagy. STAT3 is a transcription factor that plays a key role in the regulation of inflammation and immune responses.\nRecent studies have shown that STAT3 is involved in the regulation of EIF2AK2-dependent suppression of autophagy. When EIF2AK2 is activated, it phosphorylates and inhibits STAT3, leading to the suppression of STAT3-dependent gene expression. This inhibition of STAT3 activity is thought to be an important mechanism by which EIF2AK2 regulates autophagy.\nIn addition, STAT3 has been shown to play a role in the regulation of the expression of genes involved in autophagy, such as ATG5 and ATG12. When STAT3 is activated, it can bind to the promoter regions of these genes and induce their expression, leading to the enhancement of autophagy.\nFurthermore, STAT3 has been shown to interact with the mTOR complex, which is a key regulator of autophagy, and this interaction can also contribute to the regulation of autophagy by STAT3.\nIn summary, STAT3 is involved in the regulation of EIF2AK2-dependent suppression of autophagy by inhibiting the activity of STAT3 and enhancing the expression of genes involved in autophagy.\nReferences:\n1. Kim J, et al. (2010). Stat3 is a negative regulator of autophagy in macrophages. J Biol Chem. 285(41):32413-2420.\n2. Zhang H, et al. (2013). Stat3 regulates autophagy in adipocytes through the mTOR signaling pathway.",
    "llama-2-7b-chat-hf_fact_raw": "1. STAT3 is involved in the regulation of EIF2AK2-dependent suppression of autophagy.\n2. EIF2AK2 phosphorylates and inhibits the translation initiation factor eIF2, leading to the suppression of global protein synthesis and induction of autophagy.\n3. STAT3 is a transcription factor that regulates inflammation and immune responses.\n4. When EIF2AK2 is activated, it phosphorylates and inhibits STAT3, leading to a suppression of STAT3-dependent gene expression.\n5. STAT3 can enhance autophagy by inducing the expression of genes such as ATG5 and ATG12.",
    "llama-2-7b-chat-hf_fact": [
      "STAT3 is involved in the regulation of EIF2AK2-dependent suppression of autophagy.",
      "EIF2AK2 phosphorylates and inhibits the translation initiation factor eIF2, leading to the suppression of global protein synthesis and induction of autophagy.",
      "STAT3 is a transcription factor that regulates inflammation and immune responses.",
      "When EIF2AK2 is activated, it phosphorylates and inhibits STAT3, leading to a suppression of STAT3-dependent gene expression.",
      "STAT3 can enhance autophagy by inducing the expression of genes such as ATG5 and ATG12."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: EIF2AK2 phosphorylates and inhibits the translation initiation factor eIF2, leading to the suppression of global protein synthesis and induction of stress responses, including autophagy.\n3. TRUE\n4. FALSE [correction]: When EIF2AK2 is activated, it does not directly phosphorylate and inhibit STAT3. The relationship between EIF2AK2 activation and STAT3 activity is more complex and involves multiple signaling pathways.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-2-7b-chat-hf_response": "Theatre is a software tool designed for genomic analysis, specifically for the analysis of next-generation sequencing (NGS) data. It is a widely used tool in the bioinformatics field, and it offers a range of features and functionalities that make it a powerful tool for genomic analysis. Here are some of the key uses of Theatre software:\n1. Read alignment: Theatre can align sequencing reads to a reference genome, allowing researchers to identify variations between the sequenced DNA and the reference genome. This is a crucial step in many genomic analyses, including variant calling, gene expression analysis, and epigenetic analysis.\n2. Variant calling: Theatre can identify genetic variants between the sequenced DNA and the reference genome, including single nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations. These variants can be used to identify genetic mutations associated with diseases, develop personalized medicine approaches, and study genetic variation in different populations.\n3. Gene expression analysis: Theatre can be used to analyze the expression levels of genes across different samples, including RNA-seq data. It can identify differentially expressed genes, which are genes that have different expression levels between different samples, and it can also be used to study the regulation of gene expression.\n4. Epigenetic analysis: Theatre can be used to analyze epigenetic marks, such as DNA methylation and histone modifications, which play a crucial role in gene regulation. It can identify differentially methylated regions (DMRs) and differentially modified histones (DMHs) between different samples, which can be used to study the epigenetic regulation of gene expression.\n5. Transcriptome analysis: Theatre can be used to analyze the transcriptome, which is the set of all RNA molecules present in a cell or organism. It can identify differentially expressed genes, alternative splicing events, and novel transcripts.\n6. Genome assembly: Theatre can be used to assemble genomes from NGS data, which is a crucial step in many genomic analyses. It can produce high-quality assemblies that can be used for downstream analyses, such as variant calling, gene expression analysis, and epigenetic analysis.\n7. Genome annotation: Theatre can be used to annotate",
    "llama-2-7b-chat-hf_fact_raw": "1. Theatre is a software tool designed for genomic analysis, particularly for next-generation sequencing (NGS) data.\n2. Theatre can align sequencing reads to a reference genome, allowing for the identification of variations.\n3. The software can identify different types of genetic variants, including single nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations.\n4. Theatre can be used to analyze gene expression levels across different samples.\n5. The tool can assist in genome assembly from NGS data, a crucial step in many genomic analyses.",
    "llama-2-7b-chat-hf_fact": [
      "Theatre is a software tool designed for genomic analysis, particularly for next-generation sequencing (NGS) data.",
      "Theatre can align sequencing reads to a reference genome, allowing for the identification of variations.",
      "The software can identify different types of genetic variants, including single nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations.",
      "Theatre can be used to analyze gene expression levels across different samples.",
      "The tool can assist in genome assembly from NGS data, a crucial step in many genomic analyses."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Theatre is not a known software tool for genomic analysis. This may be a mistake and might refer to a different software tool.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-2-7b-chat-hf_response": "The execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences depends on the specific implementation and the size of the sequences. However, here are some general guidelines on the complexity of the Smith-Waterman algorithm:\n1. Time complexity: The time complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence. This is because the algorithm needs to compare each element in the shorter sequence with every element in the longer sequence, which leads to a total of n^2 comparisons.\n2. Space complexity: The space complexity of the Smith-Waterman algorithm is O(n), where n is the length of the shorter sequence. This is because the algorithm only needs to store the similarity matrix, which has a size of n x n.\n3. Worst-case time complexity: The worst-case time complexity of the Smith-Waterman algorithm is O(n^3), which occurs when the two sequences are perfectly complementary, meaning that they have the same elements in the opposite order. In this case, the algorithm needs to compare each element in the shorter sequence with every element in the longer sequence, leading to a total of n^3 comparisons.\n4. Average-case time complexity: The average-case time complexity of the Smith-Waterman algorithm is typically much faster than the worst-case time complexity, with a time complexity of O(n^2) or O(n^2 log n) in the worst case.\n5. Optimal implementation: The time complexity of the Smith-Waterman algorithm can be improved through various optimizations, such as using a sparse matrix representation, using a sliding window approach, or using a divide-and-conquer approach. These optimizations can reduce the time complexity to O(n log n) or even O(n log log n) in the worst case.\nIn summary, the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences depends on the specific implementation and the size of the sequences. However, the general time complexity of the algorithm is O(n^2), with the worst-case time complexity being O(n^3) and the average-case time complexity being much faster.",
    "llama-2-7b-chat-hf_fact_raw": "1. The time complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence.\n2. The space complexity of the Smith-Waterman algorithm is O(n), where n is the length of the shorter sequence.\n3. The worst-case time complexity of the Smith-Waterman algorithm is O(n^3), which occurs when the two sequences are perfectly complementary.\n4. The average-case time complexity of the Smith-Waterman algorithm is typically faster than O(n^3), generally being O(n^2) or O(n^2 log n).\n5. Optimizations can reduce the time complexity of the Smith-Waterman algorithm to O(n log n) or O(n log log n) in the worst case.",
    "llama-2-7b-chat-hf_fact": [
      "The time complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence.",
      "The space complexity of the Smith-Waterman algorithm is O(n), where n is the length of the shorter sequence.",
      "The worst-case time complexity of the Smith-Waterman algorithm is O(n^3), which occurs when the two sequences are perfectly complementary.",
      "The average-case time complexity of the Smith-Waterman algorithm is typically faster than O(n^3), generally being O(n^2) or O(n^2 log n).",
      "Optimizations can reduce the time complexity of the Smith-Waterman algorithm to O(n log n) or O(n log log n) in the worst case."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The space complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence.\n3. FALSE [correction]: The worst-case time complexity of the Smith-Waterman algorithm is O(n^2), not O(n^3).\n4. UNKNOWN\n5. FALSE [correction]: There are no known optimizations that can reduce the time complexity of the Smith-Waterman algorithm to O(n log n) or O(n log log n) in the worst case.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "llama-2-7b-chat-hf_response": "FLVCR1 (Fluid Vesicle-Associated Cellular Recognition 1) is a protein that is involved in various cellular processes, including cell adhesion, migration, and signaling. It is a member of the SLC (Solute Carrier) family of proteins, which are a group of membrane transport proteins that facilitate the movement of solutes across cellular membranes.\nSpecifically, FLVCR1 is a member of the SLC12 (Sodium-dependent Vitamin C Transporter) subfamily of the SLC family. This subfamily is responsible for the transport of vitamin C (ascorbate) across cellular membranes, and FLVCR1 is one of the key proteins involved in this process.\nIn addition to its role in vitamin C transport, FLVCR1 has also been implicated in the regulation of other solutes, including glucose and amino acids, and it may play a role in the development and progression of certain diseases, including cancer and neurodegenerative disorders.\nI hope this information helps! Let me know if you have any further questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. FLVCR1 stands for Fluid Vesicle-Associated Cellular Recognition 1.\n2. FLVCR1 is a member of the Solute Carrier (SLC) family of proteins.\n3. FLVCR1 belongs to the SLC12 subfamily, which is involved in vitamin C transport across cellular membranes.\n4. FLVCR1 plays a role in cell adhesion, migration, and signaling. \n5. FLVCR1 has been implicated in the regulation of glucose and amino acids and may be associated with cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact": [
      "FLVCR1 stands for Fluid Vesicle-Associated Cellular Recognition 1.",
      "FLVCR1 is a member of the Solute Carrier (SLC) family of proteins.",
      "FLVCR1 belongs to the SLC12 subfamily, which is involved in vitamin C transport across cellular membranes.",
      "FLVCR1 plays a role in cell adhesion, migration, and signaling.",
      "FLVCR1 has been implicated in the regulation of glucose and amino acids and may be associated with cancer and neurodegenerative disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: FLVCR1 stands for Feline Leukemia Virus, Subgroup C, Receptor 1.\n2. TRUE\n3. FALSE [correction]: FLVCR1 belongs to the Slc7 subfamily, which is involved in the transport of small solute molecules, not specifically vitamin C.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-2-7b-chat-hf_response": "Certainly! GATA-1 is a transcription factor that plays a crucial role in regulating gene expression during erythropoiesis, the process of red blood cell production. The biotinylation tagging approach has been used to identify and study GATA-1 interacting partners. Here are some of the key interacting partners of GATA-1 that have been identified through this approach:\n1. Runx1 (also known as Runt-related gene 1): Runx1 is a transcription factor that functions as a corepressor of GATA-1 and regulates the expression of genes involved in erythropoiesis. The biotinylation tagging approach has shown that Runx1 interacts with GATA-1 in a ligand-dependent manner, suggesting that Runx1 may play a role in regulating GATA-1 activity.\n2. EpoR (also known as erythropoietin receptor): EpoR is a transmembrane receptor that responds to erythropoietin (Epo), a hormone that stimulates red blood cell production. The biotinylation tagging approach has shown that GATA-1 interacts with EpoR in a ligand-dependent manner, suggesting that GATA-1 may play a role in regulating EpoR signaling.\n3. Bcl-xL (also known as Bcl-2-like protein 1): Bcl-xL is a pro-apoptotic protein that regulates programmed cell death (apoptosis) in erythroid cells. The biotinylation tagging approach has shown that GATA-1 interacts with Bcl-xL in a ligand-dependent manner, suggesting that GATA-1 may play a role in regulating Bcl-xL activity.\n4. Fli-1 (also known as VAV-1): Fli-1 is a guanine nucleotide exchange factor that regulates the activity of the small GTPase RhoA. The biotinylation tagging approach has shown that GATA-1 interacts with Fli-1 in a ligand-dependent manner, suggesting that GATA-1 may play a role in regulating RhoA activity in erythroid cells.\n5. Tal1 (also known as transcription factor A",
    "llama-2-7b-chat-hf_fact_raw": "1. Runx1 is a transcription factor that interacts with GATA-1, as identified using the biotinylation tagging approach.\n2. EpoR, a transmembrane receptor, interacts with GATA-1 in a ligand-dependent manner as discovered through the biotinylation tagging approach.\n3. Bcl-xL, a pro-apoptotic protein, has been identified as an interacting partner of GATA-1 using the biotinylation tagging approach.\n4. Fli-1, a guanine nucleotide exchange factor, interacts with GATA-1, as shown by the biotinylation tagging approach.\n5. The biotinylation tagging approach has been utilized to study and identify interacting partners of GATA-1 during erythropoiesis.",
    "llama-2-7b-chat-hf_fact": [
      "Runx1 is a transcription factor that interacts with GATA-1, as identified using the biotinylation tagging approach.",
      "EpoR, a transmembrane receptor, interacts with GATA-1 in a ligand-dependent manner as discovered through the biotinylation tagging approach.",
      "Bcl-xL, a pro-apoptotic protein, has been identified as an interacting partner of GATA-1 using the biotinylation tagging approach.",
      "Fli-1, a guanine nucleotide exchange factor, interacts with GATA-1, as shown by the biotinylation tagging approach.",
      "The biotinylation tagging approach has been utilized to study and identify interacting partners of GATA-1 during erythropoiesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Bcl-xL, an anti-apoptotic protein, has been identified as an interacting partner of GATA-1 using the biotinylation tagging approach.\n4. FALSE [correction]: Fli-1 is not a guanine nucleotide exchange factor, but a transcription factor that interacts with GATA-1, as shown by the biotinylation tagging approach.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-2-7b-chat-hf_response": "TAF10 (TATA-box protein 10) and GATA1 are both transcription factors that play critical roles in regulating gene expression in various cell types, including hematopoietic cells. When these two proteins interact, they can modulate the expression of specific genes involved in hematopoiesis, immune response, and cell fate determination. Here's a detailed answer to your question:\nInteraction between TAF10 and GATA1:\nTAF10 and GATA1 are both transcription factors that recognize specific DNA sequences and recruit other proteins to modulate gene expression. While TAF10 is primarily involved in the regulation of gene expression during the G1 phase of the cell cycle, GATA1 is primarily involved in the regulation of gene expression during the G0/G1 phase. When TAF10 and GATA1 interact, they can modulate the expression of genes involved in hematopoiesis, immune response, and cell fate determination.\nStudies have shown that TAF10 and GATA1 interact in several ways:\n1. Co-localization: TAF10 and GATA1 have been shown to co-localize at specific genomic loci, such as the promoter regions of hematopoietic genes. This co-localization is important for the regulation of gene expression, as it allows TAF10 and GATA1 to interact with other transcription factors and coregulators.\n2. Protein-protein interaction: TAF10 and GATA1 have been shown to interact directly through their DNA-binding domains. This interaction is important for the recruitment of other transcription factors and coregulators to the promoter regions of hematopoietic genes.\n3. Modulation of gene expression: TAF10 and GATA1 have been shown to modulate the expression of specific genes involved in hematopoiesis, immune response, and cell fate determination. For example, TAF10 has been shown to activate the expression of the gene encoding the hematopoietic transcription factor GATA2, while GATA1 has been shown to activate the expression of the gene encoding the hematopoietic transcription factor GATA1.\n4. Regulation of cell fate determination: TAF10",
    "llama-2-7b-chat-hf_fact_raw": "1. TAF10 (TATA-box protein 10) and GATA1 are transcription factors that regulate gene expression in various cell types.\n2. TAF10 is primarily involved in the regulation of gene expression during the G1 phase of the cell cycle.\n3. GATA1 is primarily involved in the regulation of gene expression during the G0/G1 phase.\n4. TAF10 and GATA1 co-localize at specific genomic loci, such as promoter regions of hematopoietic genes.\n5. TAF10 and GATA1 interact directly through their DNA-binding domains.",
    "llama-2-7b-chat-hf_fact": [
      "TAF10 (TATA-box protein 10) and GATA1 are transcription factors that regulate gene expression in various cell types.",
      "TAF10 is primarily involved in the regulation of gene expression during the G1 phase of the cell cycle.",
      "GATA1 is primarily involved in the regulation of gene expression during the G0/G1 phase.",
      "TAF10 and GATA1 co-localize at specific genomic loci, such as promoter regions of hematopoietic genes.",
      "TAF10 and GATA1 interact directly through their DNA-binding domains."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: TAF10 is not primarily involved in a specific phase of the cell cycle; it functions generally in forming transcription initiation complexes at promoters. \n3. FALSE [correction]: GATA1 regulates gene expression primarily in erythroid cells and during erythroid differentiation, not specifically during the G0/G1 phase.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "llama-2-7b-chat-hf_response": "Yes, there are several decision support systems (DSS) available for chronic pain management. These systems are designed to help healthcare providers and patients make informed decisions about the management of chronic pain, taking into account the individual's specific needs and circumstances.\nHere are some examples of DSS for chronic pain management:\n1. Chronic Pain Management Decision Support System (CPM-DSS): This system is a web-based tool that provides healthcare providers with evidence-based recommendations for managing chronic pain. It takes into account the patient's medical history, current symptoms, and lifestyle factors to provide personalized treatment recommendations.\n2. Pain Navigator: This is a mobile app that provides patients with a personalized pain management plan based on their individual needs and preferences. It includes a symptom tracker, pain scale, and medication management features, as well as educational resources and support.\n3. Pain Management Decision Support (PMDSS): This system is designed for primary care providers and provides recommendations for managing chronic pain based on the latest research and clinical guidelines. It includes a decision tree algorithm that takes into account the patient's symptoms, medical history, and other factors to provide a treatment plan.\n4. Chronic Pain Management System (CPMS): This system is a comprehensive platform that provides healthcare providers with a range of tools and resources for managing chronic pain. It includes a patient registry, pain assessment tools, and a decision support system that provides personalized treatment recommendations based on the patient's individual needs.\n5. Pain-QoL: This is a web-based platform that provides patients with a personalized assessment of their chronic pain and quality of life. It includes a range of questionnaires and assessment tools that help patients track their symptoms and monitor their progress over time.\n6. Chronic Pain Self-Management Program (CPSMP): This is a comprehensive program that provides patients with the skills and knowledge they need to manage their chronic pain. It includes a range of educational resources, including workbooks, videos, and online courses, as well as support groups and coaching.\n7. Pain-Care: This is a mobile app that provides patients with a personalized pain management plan based on their individual needs and preferences. It includes a sympt",
    "llama-2-7b-chat-hf_fact_raw": "1. Chronic Pain Management Decision Support System (CPM-DSS) is a web-based tool that provides personalized treatment recommendations for managing chronic pain.\n2. Pain Navigator is a mobile app that offers a personalized pain management plan, including a symptom tracker and medication management features.\n3. Pain Management Decision Support (PMDSS) is designed for primary care providers to offer chronic pain management recommendations based on research and clinical guidelines.\n4. Chronic Pain Management System (CPMS) is a platform with a patient registry, pain assessment tools, and a decision support system for chronic pain management.\n5. Pain-QoL is a web-based platform that provides personalized assessments of chronic pain and quality of life for patients.",
    "llama-2-7b-chat-hf_fact": [
      "Chronic Pain Management Decision Support System (CPM-DSS) is a web-based tool that provides personalized treatment recommendations for managing chronic pain.",
      "Pain Navigator is a mobile app that offers a personalized pain management plan, including a symptom tracker and medication management features.",
      "Pain Management Decision Support (PMDSS) is designed for primary care providers to offer chronic pain management recommendations based on research and clinical guidelines.",
      "Chronic Pain Management System (CPMS) is a platform with a patient registry, pain assessment tools, and a decision support system for chronic pain management.",
      "Pain-QoL is a web-based platform that provides personalized assessments of chronic pain and quality of life for patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "llama-2-7b-chat-hf_response": "Angiogenin is a protein that plays a crucial role in angiogenesis, the process of blood vessel formation. It is a secreted protein that is involved in the regulation of endothelial cell behavior, and it has been implicated in various physiological and pathological processes, including embryonic development, wound healing, and cancer.\nThe subcellular localization of angiogenin is primarily cytoplasmic, but it can also be found in the nucleus of endothelial cells.\nIn endothelial cells, angiogenin is primarily localized to the cytoplasm, where it can interact with various signaling molecules and regulatory proteins. For example, angiogenin can bind to the endothelial cell adhesion molecule VE-cadherin, which is involved in cell adhesion and signaling. Angiogenin can also interact with the protein tyrosine kinase Src, which is involved in cell signaling and the regulation of endothelial cell behavior.\nIn addition to its cytoplasmic localization, angiogenin has been shown to be nuclear localized in some contexts. For example, in response to hypoxia, angiogenin can translocate to the nucleus, where it can regulate the expression of genes involved in angiogenesis.\nOverall, the subcellular localization of angiogenin is complex and context-dependent, and it plays a critical role in the regulation of endothelial cell behavior and angiogenesis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Angiogenin is involved in angiogenesis, the process of blood vessel formation.\n2. It is a secreted protein that regulates endothelial cell behavior.\n3. Angiogenin's primary subcellular localization is cytoplasmic in endothelial cells.\n4. Angiogenin can bind to the endothelial cell adhesion molecule VE-cadherin.\n5. Angiogenin has been shown to translocate to the nucleus in response to hypoxia.",
    "llama-2-7b-chat-hf_fact": [
      "Angiogenin is involved in angiogenesis, the process of blood vessel formation.",
      "It is a secreted protein that regulates endothelial cell behavior.",
      "Angiogenin's primary subcellular localization is cytoplasmic in endothelial cells.",
      "Angiogenin can bind to the endothelial cell adhesion molecule VE-cadherin.",
      "Angiogenin has been shown to translocate to the nucleus in response to hypoxia."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "llama-2-7b-chat-hf_response": "Ranolazine is a medication that is primarily used to treat angina, a condition characterized by chest pain due to reduced blood flow to the heart muscle. While its primary mechanism of action is to improve blood flow to the heart muscle, ranolazine has been shown to have additional effects on kinase signaling activation in the heart.\nKinases are enzymes that play a crucial role in various cellular signaling pathways, including those involved in cardiac function. In the heart, kinases regulate a variety of processes, including contraction, relaxation, and electrophysiology. Activation of kinase signaling pathways is essential for maintaining proper cardiac function, and dysregulation of these pathways can contribute to the development of cardiovascular disease.\nRanolazine has been shown to affect several kinase signaling pathways in the heart, including the following:\n1. Protein kinase C (PKC): Ranolazine has been shown to inhibit PKC activity in the heart, which can help to reduce the development of cardiac hypertrophy and fibrosis. PKC is a key regulator of cardiac contractility and excitability, and its dysregulation can contribute to the development of heart failure.\n2. Mitogen-activated protein kinase (MAPK): Ranolazine has been shown to activate the MAPK pathway in the heart, which can help to promote cardiac differentiation and maturation. MAPK is a key regulator of cellular proliferation and differentiation, and its dysregulation can contribute to the development of cardiovascular disease.\n3. Extracellular signal-regulated kinase (ERK): Ranolazine has been shown to activate the ERK pathway in the heart, which can help to promote cardiac hypertrophy and fibrosis. ERK is a key regulator of cellular proliferation and differentiation, and its dysregulation can contribute to the development of cardiovascular disease.\n4. Akt/protein kinase B (PKB): Ranolazine has been shown to activate the Akt/PKB pathway in the heart, which can help to promote cardiac survival and protection. Akt/PKB is a key regulator of cellular survival and met",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-2-7b-chat-hf_response": "Vsr endonuclease is an enzyme that plays a crucial role in the SOS response of bacteria, which is a mechanism that bacteria use to repair DNA damage caused by environmental stressors or mutations. The regulation of Vsr endonuclease is complex and involves multiple factors, including transcriptional regulation, post-transcriptional modification, and protein-protein interactions.\nThe growth phase of bacteria can have an impact on the regulation of Vsr endonuclease, but it is not the only factor that determines its activity. Here are some key points to consider:\n1. Transcriptional regulation: The expression of vsr is tightly regulated at the transcriptional level by a variety of transcription factors, including the E. coli DNA damage response regulator, DdrA. The expression of vsr is induced in response to DNA damage, and the level of vsr mRNA is tightly regulated to ensure that the enzyme is only active when needed.\n2. Post-transcriptional modification: Vsr endonuclease is modified post-transcriptionally by the addition of a methyl group to its active site residue, which is mediated by the enzyme, Methyltransferase. This modification is important for the enzyme's activity and stability.\n3. Protein-protein interactions: Vsr endonuclease interacts with a variety of other proteins, including the DNA damage response protein, RecA, and the transcriptional regulator, DdrA. These interactions are important for the proper regulation of vsr expression and activity.\n4. Growth phase: The growth phase of bacteria can also impact the regulation of Vsr endonuclease. For example, during the stationary phase of growth, the level of vsr expression is reduced, which can limit the enzyme's activity and prevent the SOS response from becoming overactive.\n5. DNA damage: The level of DNA damage can also impact the regulation of Vsr endonuclease. When DNA damage is high, the level of vsr expression is induced to repair the damage.\nIn summary, the regulation of Vsr endonuclease is complex and involves multiple factors, including transcriptional regulation, post-transcriptional modification, protein-protein interactions,",
    "llama-2-7b-chat-hf_fact_raw": "1. Vsr endonuclease plays a role in the SOS response of bacteria to repair DNA damage.\n2. The regulation of Vsr endonuclease involves transcriptional regulation by transcription factors such as DdrA.\n3. Vsr endonuclease is modified post-transcriptionally by the addition of a methyl group.\n4. The growth phase of bacteria can impact the level of Vsr endonuclease expression.\n5. High levels of DNA damage induce the expression of Vsr endonuclease to repair the damage.",
    "llama-2-7b-chat-hf_fact": [
      "Vsr endonuclease plays a role in the SOS response of bacteria to repair DNA damage.",
      "The regulation of Vsr endonuclease involves transcriptional regulation by transcription factors such as DdrA.",
      "Vsr endonuclease is modified post-transcriptionally by the addition of a methyl group.",
      "The growth phase of bacteria can impact the level of Vsr endonuclease expression.",
      "High levels of DNA damage induce the expression of Vsr endonuclease to repair the damage."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The regulation of Vsr endonuclease involves transcriptional regulation by the SOS response regulator, LexA.\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-2-7b-chat-hf_response": "Computational tools for the prediction of beta-barrel transmembrane proteins are software programs that use algorithms and machine learning techniques to predict the structure and function of these proteins. Here are some of the commonly used computational tools for predicting beta-barrel transmembrane proteins:\n1. BARLIP: BARLIP is a widely used tool for predicting beta-barrel transmembrane proteins. It uses a combination of sequence analysis and structural bioinformatics techniques to predict the transmembrane helices and the location of the beta-barrel structure. BARLIP can also predict the membrane spanning segments and the hydrophobic core of the protein.\n2. TMHMM: TMHMM is another popular tool for predicting beta-barrel transmembrane proteins. It uses a combination of sequence analysis and structural bioinformatics techniques to predict the transmembrane helices and the location of the beta-barrel structure. TMHMM can also predict the membrane spanning segments and the hydrophobic core of the protein.\n3. PredictProtein: PredictProtein is a web server that can predict the structure and function of beta-barrel transmembrane proteins. It uses a combination of sequence analysis and structural bioinformatics techniques to predict the transmembrane helices and the location of the beta-barrel structure. PredictProtein can also predict the membrane spanning segments and the hydrophobic core of the protein.\n4. PredictTMB: PredictTMB is a tool that can predict the transmembrane helices and the location of the beta-barrel structure in beta-barrel transmembrane proteins. It uses a combination of sequence analysis and structural bioinformatics techniques to predict the transmembrane helices and the hydrophobic core of the protein.\n5. TMBpred: TMBpred is a tool that can predict the transmembrane helices and the location of the beta-barrel structure in beta-barrel transmembrane proteins. It uses a combination of sequence analysis and structural bioinformatics techniques to predict the transmembrane helices and the hydrophobic core of the protein.\n6. Membrane Protein Prediction Server (MPPS): MPPS is a web server that can predict",
    "llama-2-7b-chat-hf_fact_raw": "1. BARLIP is a computational tool used for predicting beta-barrel transmembrane proteins.\n2. TMHMM is a computational tool that predicts the transmembrane helices and beta-barrel structure of beta-barrel transmembrane proteins.\n3. PredictProtein is a web server for predicting the structure and function of beta-barrel transmembrane proteins.\n4. PredictTMB is a tool used to predict the transmembrane helices and beta-barrel structure of beta-barrel transmembrane proteins.\n5. TMBpred is a computational tool that predicts the transmembrane helices and beta-barrel structure of beta-barrel transmembrane proteins.",
    "llama-2-7b-chat-hf_fact": [
      "BARLIP is a computational tool used for predicting beta-barrel transmembrane proteins.",
      "TMHMM is a computational tool that predicts the transmembrane helices and beta-barrel structure of beta-barrel transmembrane proteins.",
      "PredictProtein is a web server for predicting the structure and function of beta-barrel transmembrane proteins.",
      "PredictTMB is a tool used to predict the transmembrane helices and beta-barrel structure of beta-barrel transmembrane proteins.",
      "TMBpred is a computational tool that predicts the transmembrane helices and beta-barrel structure of beta-barrel transmembrane proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: TMHMM is a computational tool that predicts only the transmembrane helices of proteins, not the beta-barrel structure.\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "llama-2-7b-chat-hf_response": "Galassi classification is a system used to classify and diagnose mental disorders, particularly those related to mood and personality. It was developed by psychiatrist Giovanni Galassi and is based on the idea that different mental disorders have distinct patterns of symptoms and behaviors.\nAccording to the Galassi classification, there are six main categories of mental disorders:\n1. Affective disorders: These are disorders related to mood and emotions, such as depression, bipolar disorder, and anxiety disorders.\n2. Personality disorders: These are disorders related to an individual's personality and behavior, such as borderline personality disorder, narcissistic personality disorder, and antisocial personality disorder.\n3. Psychotic disorders: These are disorders in which an individual experiences a disconnection from reality, such as schizophrenia and schizoaffective disorder.\n4. Neurotic disorders: These are disorders related to stress and anxiety, such as generalized anxiety disorder and panic disorder.\n5. Obsessive-compulsive and related disorders: These are disorders characterized by obsessive thoughts and compulsive behaviors, such as obsessive-compulsive disorder and hoarding disorder.\n6. Dissociative disorders: These are disorders in which an individual experiences a disconnection or separation from their thoughts, feelings, or experiences, such as dissociative identity disorder (formerly known as multiple personality disorder) and depersonalization disorder.\nEach of these categories is further subdivided into more specific disorders, and the Galassi classification system provides a framework for diagnosing and treating these disorders.\nIt is important to note that the Galassi classification system is one of many systems used to classify and diagnose mental disorders, and it is not universally accepted or used by all mental health professionals. Other systems, such as the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and the International Classification of Diseases (ICD-10), also exist and have their own classification systems.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Galassi classification is used to classify and diagnose mental disorders.\n2. It was developed by psychiatrist Giovanni Galassi.\n3. The Galassi classification includes six main categories of mental disorders: Affective, Personality, Psychotic, Neurotic, Obsessive-compulsive and related, and Dissociative disorders.\n4. The Galassi classification system provides a framework for diagnosing and treating mental disorders.\n5. The Galassi classification system is not universally accepted by all mental health professionals and is one of many systems used for classifying mental disorders.",
    "llama-2-7b-chat-hf_fact": [
      "The Galassi classification is used to classify and diagnose mental disorders.",
      "It was developed by psychiatrist Giovanni Galassi.",
      "The Galassi classification includes six main categories of mental disorders: Affective, Personality, Psychotic, Neurotic, Obsessive-compulsive and related, and Dissociative disorders.",
      "The Galassi classification system provides a framework for diagnosing and treating mental disorders.",
      "The Galassi classification system is not universally accepted by all mental health professionals and is one of many systems used for classifying mental disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Galassi classification is not used to classify and diagnose mental disorders, it is a staging system for mucoceles of the paranasal sinuses.\n2. UNKNOWN\n3. FALSE [correction]: The Galassi classification does not include categories of mental disorders, it stages mucoceles based on their involvement with the paranasal sinuses.\n4. FALSE [correction]: The Galassi classification system provides a framework for staging mucoceles of the paranasal sinuses, not for diagnosing and treating mental disorders.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "llama-2-7b-chat-hf_response": "Shapiro syndrome, also known as Shapiro-Thompson syndrome or oculocerebrorenal syndrome (OCRS), is a rare genetic disorder that affects multiple systems in the body. Here are some common features of Shapiro syndrome:\n1. Ocular abnormalities: Shapiro syndrome is characterized by distinctive eye abnormalities, including microphthalmia (small eyes), anophthalmia (absence of one or both eyes), coloboma (a defect in the structure of the eye), and cataracts.\n2. Cerebral abnormalities: People with Shapiro syndrome may experience cerebral abnormalities, such as hydrocephalus (fluid accumulation in the brain), cerebral atrophy (wasting of brain tissue), and cognitive impairment.\n3. Renal abnormalities: Shapiro syndrome can cause renal abnormalities, including nephrocalcinosis (deposits of calcium in the kidneys), nephrolithiasis (kidney stones), and chronic kidney disease.\n4. Endocrine abnormalities: People with Shapiro syndrome may experience endocrine abnormalities, such as growth hormone deficiency, hypothyroidism (underactive thyroid), and adrenal insufficiency (inadequate production of cortisol).\n5. Skeletal abnormalities: Shapiro syndrome can cause skeletal abnormalities, including short stature, scoliosis (curvature of the spine), and other bone deformities.\n6. Cardiovascular abnormalities: People with Shapiro syndrome may experience cardiovascular abnormalities, such as patent ductus arteriosus (a congenital heart defect), atrial septal defect (a hole in the wall between the two upper chambers of the heart), and ventricular septal defect (a hole in the wall between the two lower chambers of the heart).\n7. Gastrointestinal abnormalities: Shapiro syndrome can cause gastrointestinal abnormalities, including gastroesophageal reflux disease (GERD), const",
    "llama-2-7b-chat-hf_fact_raw": "1. Shapiro syndrome is characterized by distinctive eye abnormalities, such as microphthalmia, anophthalmia, coloboma, and cataracts.\n2. People with Shapiro syndrome may experience cerebral abnormalities, including hydrocephalus, cerebral atrophy, and cognitive impairment.\n3. Shapiro syndrome can cause renal abnormalities like nephrocalcinosis, nephrolithiasis, and chronic kidney disease.\n4. Individuals with Shapiro syndrome may have endocrine abnormalities, such as growth hormone deficiency, hypothyroidism, and adrenal insufficiency.\n5. Shapiro syndrome can lead to skeletal abnormalities, including short stature, scoliosis, and bone deformities.",
    "llama-2-7b-chat-hf_fact": [
      "Shapiro syndrome is characterized by distinctive eye abnormalities, such as microphthalmia, anophthalmia, coloboma, and cataracts.",
      "People with Shapiro syndrome may experience cerebral abnormalities, including hydrocephalus, cerebral atrophy, and cognitive impairment.",
      "Shapiro syndrome can cause renal abnormalities like nephrocalcinosis, nephrolithiasis, and chronic kidney disease.",
      "Individuals with Shapiro syndrome may have endocrine abnormalities, such as growth hormone deficiency, hypothyroidism, and adrenal insufficiency.",
      "Shapiro syndrome can lead to skeletal abnormalities, including short stature, scoliosis, and bone deformities."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Shapiro syndrome is characterized by the clinical triad of recurrent episodes of spontaneous hypothermia, hyperhidrosis, and agenesis of the corpus callosum. The eye abnormalities mentioned are not typically associated with Shapiro syndrome.\n2. TRUE\n3. FALSE [correction]: Renal abnormalities are not typically associated with Shapiro syndrome.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "llama-2-7b-chat-hf_response": "BRAG1 (Brentuximab RAR alpha-glucosyltransferase 1) is a protein that plays a crucial role in the development and progression of certain types of cancer, including Hodgkin lymphoma and T-cell lymphoma. Mutations within the BRAG1 gene have been found to be associated with the development of these cancers.\nHodgkin lymphoma is a type of cancer that affects the immune system, specifically the lymphatic system. It is characterized by the presence of Reed-Sternberg cells, which are abnormal cells that can be identified under a microscope. BRAG1 mutations have been found to be present in a significant proportion of Hodgkin lymphoma cases, particularly those that are aggressive or recurrent.\nT-cell lymphoma, on the other hand, is a type of cancer that affects the T-lymphocytes (T-cells), which are a type of immune cell. There are several subtypes of T-cell lymphoma, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and adult T-cell lymphoma. BRAG1 mutations have been found to be associated with some subtypes of T-cell lymphoma, particularly those that are cutaneous or peripheral in nature.\nThe exact mechanism by which BRAG1 mutations contribute to the development and progression of these cancers is not fully understood, but it is thought to involve disruptions to normal cellular processes, such as cell growth and division, and the ability of cancer cells to evade the immune system.\nIn summary, BRAG1 mutations have been linked to the development and progression of Hodgkin lymphoma and certain subtypes of T-cell lymphoma. Further research is needed to fully understand the role of BRAG1 mutations in these cancers and to identify potential therapeutic targets for treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. BRAG1 is associated with the development and progression of certain types of cancer, including Hodgkin lymphoma and T-cell lymphoma.\n2. Mutations within the BRAG1 gene have been found in a significant proportion of Hodgkin lymphoma cases.\n3. Reed-Sternberg cells, which are indicative of Hodgkin lymphoma, can be identified under a microscope.\n4. BRAG1 mutations are associated with some subtypes of T-cell lymphoma, particularly cutaneous and peripheral types.\n5. The exact mechanism of how BRAG1 mutations contribute to cancer progression involves disruptions to normal cellular processes.",
    "llama-2-7b-chat-hf_fact": [
      "BRAG1 is associated with the development and progression of certain types of cancer, including Hodgkin lymphoma and T-cell lymphoma.",
      "Mutations within the BRAG1 gene have been found in a significant proportion of Hodgkin lymphoma cases.",
      "Reed-Sternberg cells, which are indicative of Hodgkin lymphoma, can be identified under a microscope.",
      "BRAG1 mutations are associated with some subtypes of T-cell lymphoma, particularly cutaneous and peripheral types.",
      "The exact mechanism of how BRAG1 mutations contribute to cancer progression involves disruptions to normal cellular processes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-2-7b-chat-hf_response": "Protein phosphatase 1 (PP1) is an enzyme that dephosphorylates various protein substrates, playing a crucial role in various cellular processes, including signal transduction, cell cycle regulation, and protein synthesis. PP1 is inhibited by several proteins, but the main inhibitor of PP1 is the protein called \"PP1-specific inhibitor\" or \"I-1.\"\nPP1-specific inhibitor (I-1) is a regulatory protein that specifically binds to and inhibits the activity of PP1. I-1 was first identified in the early 1990s, and since then, numerous studies have shown that it is a crucial regulator of PP1 activity in various cellular processes. I-1 is a 16-kDa protein that contains a characteristic amino acid sequence motif, called the \"I-1 motif,\" which is responsible for its specific binding to PP1.\nThe inhibition of PP1 by I-1 is a reversible process, and the dissociation constant (Kd) of I-1 for PP1 has been reported to be around 1-2 M. This means that I-1 can bind to PP1 with high affinity and specifically inhibit its activity. The inhibition of PP1 by I-1 is thought to be mediated by a mechanism that involves the formation of a stable complex between I-1 and PP1, which prevents PP1 from interacting with its substrate proteins.\nIn addition to I-1, there are other proteins that have been identified as inhibitors of PP1, including protein phosphatase 2A (PP2A), protein phosphatase 2B (PP2B), and the tumor suppressor protein, p53. However, I-1 is the most well-studied and characterized inhibitor of PP1, and it has been shown to play a crucial role in regulating PP1 activity in various cellular processes, including cell cycle progression, apoptosis, and signal transduction.\nIn summary, the main inhibitor of protein phosphatase 1 (PP1) is the protein called PP1-specific inhibitor (I-1",
    "llama-2-7b-chat-hf_fact_raw": "1. The main inhibitor of protein phosphatase 1 (PP1) is the protein called PP1-specific inhibitor or I-1.\n2. I-1 was first identified in the early 1990s.\n3. I-1 is a 16-kDa protein that contains a characteristic amino acid sequence motif known as the \"I-1 motif.\"\n4. The dissociation constant (Kd) of I-1 for PP1 has been reported to be around 1-2 M.\n5. Other proteins identified as inhibitors of PP1 include protein phosphatase 2A (PP2A), protein phosphatase 2B (PP2B), and the tumor suppressor protein, p53.",
    "llama-2-7b-chat-hf_fact": [
      "The main inhibitor of protein phosphatase 1 (PP1) is the protein called PP1-specific inhibitor or I-1.",
      "I-1 was first identified in the early 1990s.",
      "I-1 is a 16-kDa protein that contains a characteristic amino acid sequence motif known as the \"I-1 motif.\"",
      "The dissociation constant (Kd) of I-1 for PP1 has been reported to be around 1-2 M.",
      "Other proteins identified as inhibitors of PP1 include protein phosphatase 2A (PP2A), protein phosphatase 2B (PP2B), and the tumor suppressor protein, p53."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. FALSE [correction]: Protein phosphatase 2A (PP2A) and protein phosphatase 2B (PP2B) are different types of phosphatases and not inhibitors of PP1. The tumor suppressor protein, p53, has also not been identified as an inhibitor of PP1. Other known inhibitors of PP1 include DARPP-32 and Inhibitor-2 (I-2).",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-2-7b-chat-hf_response": "Adaptive mutagenesis, also known as stationary-phase mutagenesis, is a process by which bacteria generate genetic diversity during the stationary phase of growth. In Bacillus subtilis, several mechanisms underlie adaptive mutagenesis, including:\n1. DNA damage and repair: During the stationary phase, bacteria experience increased DNA damage due to the accumulation of reactive oxygen species (ROS) and the degradation of DNA repair pathways. To cope with this stress, B. subtilis has evolved multiple DNA repair pathways, including base excision repair, nucleotide excision repair, and double-strand break repair. These pathways can introduce mutations into the genome, providing a source of genetic variation.\n2. MutY and MutL: The MutY and MutL genes are involved in the repair of DNA mutations caused by oxidative stress. MutY is a DNA glycosylase that removes damaged bases from the DNA strand, while MutL is a DNA ligase that seals the resulting DNA breaks. During the stationary phase, the activity of these enzymes can lead to the formation of mutations.\n3. RecA-mediated recombination: RecA is a DNA recombinase that plays a key role in homologous recombination, a process that involves the exchange of genetic information between two identical or similar DNA molecules. During the stationary phase, RecA can catalyze the exchange of genetic information between different parts of the genome, leading to the formation of new genetic combinations and mutations.\n4. Polymerase errors: During the stationary phase, the activity of DNA polymerases can lead to errors in DNA synthesis, resulting in the formation of mutations. This can occur due to the accumulation of errors during DNA replication or the incorporation of incorrect nucleotides into the growing DNA strand.\n5. Transposable elements: Transposable elements are mobile genetic elements that can insert themselves into different parts of the genome. During the stationary phase, the activity of transposable elements can lead to the introduction of new genetic combinations and mutations.\n6. RNA-mediated mutagenesis: RNA molecules, such as small RNAs and siRNAs, can base-pair with",
    "llama-2-7b-chat-hf_fact_raw": "1. Bacillus subtilis experiences increased DNA damage due to reactive oxygen species (ROS) during the stationary phase of growth.\n2. Bacillus subtilis has evolved multiple DNA repair pathways including base excision repair, nucleotide excision repair, and double-strand break repair.\n3. The MutY and MutL genes in Bacillus subtilis are involved in the repair of DNA mutations caused by oxidative stress.\n4. RecA is a DNA recombinase in Bacillus subtilis that plays a key role in homologous recombination during the stationary phase.\n5. Transposable elements in Bacillus subtilis can insert themselves into different parts of the genome, leading to new genetic combinations and mutations during the stationary phase.",
    "llama-2-7b-chat-hf_fact": [
      "Bacillus subtilis experiences increased DNA damage due to reactive oxygen species (ROS) during the stationary phase of growth.",
      "Bacillus subtilis has evolved multiple DNA repair pathways including base excision repair, nucleotide excision repair, and double-strand break repair.",
      "The MutY and MutL genes in Bacillus subtilis are involved in the repair of DNA mutations caused by oxidative stress.",
      "RecA is a DNA recombinase in Bacillus subtilis that plays a key role in homologous recombination during the stationary phase.",
      "Transposable elements in Bacillus subtilis can insert themselves into different parts of the genome, leading to new genetic combinations and mutations during the stationary phase."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "llama-2-7b-chat-hf_response": "Erucism, also known as erythromelalgia, is a rare and complex disorder characterized by episodes of intense burning pain, redness, and warmth in the hands and feet. The exact cause of erucism is not fully understood, but research suggests that it may be related to abnormalities in the nerves that control blood flow and temperature regulation in the affected areas.\nHere are some possible causes of erucism:\n1. Genetic mutations: Erucism may be inherited in some cases, with mutations in genes involved in the regulation of nerve function and blood flow.\n2. Nerve damage: Trauma or compression of the nerves that control blood flow and temperature regulation in the hands and feet can lead to erucism.\n3. Autoimmune disorders: In some cases, erucism may be associated with autoimmune disorders such as rheumatoid arthritis or lupus, in which the immune system mistakenly attacks the body's own tissues.\n4. Infections: Certain infections, such as Lyme disease or shingles, can cause nerve damage that leads to erucism.\n5. Vasculitis: This is a condition in which the blood vessels become inflamed, which can lead to nerve damage and erucism.\n6. Other medical conditions: Certain medical conditions, such as diabetes, thyroid disorders, or multiple sclerosis, can also cause erucism.\n7. Medications: Certain medications, such as chemotherapy drugs or narcotics, can cause erucism as a side effect.\n8. Nutritional deficiencies: Deficiencies in certain nutrients, such as vitamin B12 or iron, can contribute to the development of erucism.\n9. Hormonal changes: Hormonal changes during pregnancy or menopause can also cause erucism in some cases.\nIt's important to note that erucism is a rare disorder, and the underlying cause may not be identified in some cases. A thorough medical evaluation and diagnostic testing are necessary to determine the underlying cause of erucism in an individual.",
    "llama-2-7b-chat-hf_fact_raw": "1. Erucism, also known as erythromelalgia, is characterized by episodes of intense burning pain, redness, and warmth in the hands and feet.\n2. Genetic mutations, specifically in genes involved in the regulation of nerve function and blood flow, may cause erucism.\n3. Trauma or compression of the nerves controlling blood flow and temperature regulation can lead to erucism.\n4. Erucism may be associated with autoimmune disorders like rheumatoid arthritis or lupus.\n5. Vasculitis, where the blood vessels become inflamed, can lead to erucism.",
    "llama-2-7b-chat-hf_fact": [
      "Erucism, also known as erythromelalgia, is characterized by episodes of intense burning pain, redness, and warmth in the hands and feet.",
      "Genetic mutations, specifically in genes involved in the regulation of nerve function and blood flow, may cause erucism.",
      "Trauma or compression of the nerves controlling blood flow and temperature regulation can lead to erucism.",
      "Erucism may be associated with autoimmune disorders like rheumatoid arthritis or lupus.",
      "Vasculitis, where the blood vessels become inflamed, can lead to erucism."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Erucism is a term related to caterpillar envenomation, not erythromelalgia, which is characterized by episodes of intense burning pain, redness, and warmth in the hands and feet.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "llama-2-7b-chat-hf_response": "Hydrochlorothiazide is a diuretic medication that is commonly used to treat a variety of medical conditions. Here are some of the most common indications for hydrochlorothiazide:\n1. Hypertension (high blood pressure): Hydrochlorothiazide is often used to treat mild to moderate hypertension, as it can help to reduce blood pressure by increasing urine production and removing excess fluid from the body.\n2. Heart failure: Hydrochlorothiazide can help to reduce fluid buildup in the body, which can occur in people with heart failure. This can help to improve breathing and reduce fatigue.\n3. Edema (swelling): Hydrochlorothiazide can help to reduce swelling in the feet, ankles, and hands, which can occur due to various medical conditions such as liver disease, kidney disease, or cancer.\n4. Nephrotic syndrome: Hydrochlorothiazide can help to reduce proteinuria (excess protein in the urine) in people with nephrotic syndrome, a condition that can cause excess protein loss in the urine.\n5. Kidney disease: Hydrochlorothiazide can help to reduce the risk of kidney damage in people with kidney disease by reducing fluid buildup in the body and improving blood flow to the kidneys.\n6. Cerebral edema: Hydrochlorothiazide can help to reduce swelling in the brain, which can occur due to various medical conditions such as stroke, brain tumors, or head injury.\n7. Angiogenic edema: Hydrochlorothiazide can help to reduce swelling in the skin and underlying tissues, which can occur due to various medical conditions such as cancer or inflammatory diseases.\n8. Pulmonary edema: Hydrochlorothiazide can help to reduce swelling in the lungs, which can occur due to various medical conditions such as pneumonia, pulmonary embolism, or asthma.\n9. Renal impairment: Hydrochlorothiazide can help to reduce the risk of kidney damage in people with renal impairment by reducing fluid buildup in the body and improving blood flow",
    "llama-2-7b-chat-hf_fact_raw": "1. Hydrochlorothiazide is used to treat mild to moderate hypertension by increasing urine production and removing excess fluid from the body.\n2. Hydrochlorothiazide is used to reduce fluid buildup in people with heart failure, which can improve breathing and reduce fatigue.\n3. Hydrochlorothiazide can reduce swelling in the feet, ankles, and hands due to various medical conditions such as liver disease, kidney disease, or cancer.\n4. Hydrochlorothiazide can help reduce proteinuria in people with nephrotic syndrome.\n5. Hydrochlorothiazide can reduce the risk of kidney damage in people with kidney disease by improving blood flow to the kidneys.",
    "llama-2-7b-chat-hf_fact": [
      "Hydrochlorothiazide is used to treat mild to moderate hypertension by increasing urine production and removing excess fluid from the body.",
      "Hydrochlorothiazide is used to reduce fluid buildup in people with heart failure, which can improve breathing and reduce fatigue.",
      "Hydrochlorothiazide can reduce swelling in the feet, ankles, and hands due to various medical conditions such as liver disease, kidney disease, or cancer.",
      "Hydrochlorothiazide can help reduce proteinuria in people with nephrotic syndrome.",
      "Hydrochlorothiazide can reduce the risk of kidney damage in people with kidney disease by improving blood flow to the kidneys."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Hydrochlorothiazide is not typically used to reduce proteinuria in people with nephrotic syndrome. Other medications such as ACE inhibitors or angiotensin receptor blockers are used for this purpose.\n5. FALSE [correction]: Hydrochlorothiazide does not directly improve blood flow to the kidneys or reduce the risk of kidney damage in people with kidney disease. It is used to manage fluid retention and hypertension, which can indirectly benefit kidney function.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "llama-2-7b-chat-hf_response": "Yes, silicon has been used in the treatment of incontinence. Silicon-based materials have been developed and used in various medical applications, including the treatment of urinary incontinence.\nUrinary incontinence is a common condition characterized by the loss of bladder control, resulting in involuntary leakage of urine. It can be caused by a variety of factors, including neurological disorders, muscle weakness, and anatomical abnormalities.\nSilicon-based materials have been used in the development of medical devices designed to treat urinary incontinence. These materials have several advantages, including:\n1. Biocompatibility: Silicon is a biocompatible material that is well-tolerated by the body. It is non-toxic and does not cause any adverse reactions.\n2. Durability: Silicon-based materials are known for their durability and long lifespan. They can withstand repeated use and cleaning without degrading or losing their effectiveness.\n3. Flexibility: Silicon-based materials can be molded into various shapes and sizes to fit different anatomical structures. They can also be designed to conform to the body's contours, providing a more comfortable and secure fit.\n4. Implantability: Silicon-based materials can be used to create implantable devices, such as pelvic floor stimulators, that can be used to treat urinary incontinence. These devices can be implanted in the body and can provide long-term treatment.\n5. Electrical conductivity: Silicon-based materials can conduct electrical signals, making them useful in the development of electrical stimulation devices for treating urinary incontinence.\nExamples of silicon-based materials used in the treatment of urinary incontinence include:\n1. Silicone gel: Silicone gel is a soft, flexible material that can be used to create implantable devices, such as pelvic floor stimulators. It is biocompatible and can be used to treat a variety of conditions, including urinary incontinence.\n2. Silicon elastomers: Silicon elastomers are a type of silicon-based material that can be used to create devices with elastic properties. They can be used to treat urinary incontinence by",
    "llama-2-7b-chat-hf_fact_raw": "1. Silicon has been used in the treatment of urinary incontinence.\n2. Silicon-based materials are biocompatible, non-toxic, and do not cause adverse reactions.\n3. Silicon-based materials are known for their durability and can withstand repeated use and cleaning.\n4. Silicon-based materials can be molded into various shapes and sizes for different anatomical structures.\n5. Silicon-based materials can conduct electrical signals and are used in the development of electrical stimulation devices for treating urinary incontinence.",
    "llama-2-7b-chat-hf_fact": [
      "Silicon has been used in the treatment of urinary incontinence.",
      "Silicon-based materials are biocompatible, non-toxic, and do not cause adverse reactions.",
      "Silicon-based materials are known for their durability and can withstand repeated use and cleaning.",
      "Silicon-based materials can be molded into various shapes and sizes for different anatomical structures.",
      "Silicon-based materials can conduct electrical signals and are used in the development of electrical stimulation devices for treating urinary incontinence."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Silicone, not silicon, has been used in the treatment of urinary incontinence.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Silicone-based materials do not conduct electrical signals; it is the use of other conductive materials in combination with silicone that is used in the development of electrical stimulation devices for treating urinary incontinence.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-2-7b-chat-hf_response": "The association between the moon cycle and the rupture risk of intracranial aneurysms is a topic of ongoing research and debate in the medical community. While there is limited scientific evidence to support a direct correlation between the moon cycle and aneurysm rupture risk, some studies have suggested that certain lunar cycles may be associated with an increased risk of aneurysm rupture.\nOne of the earliest studies on this topic was conducted in the 1970s by Dr. J. H. Kim and colleagues. The study analyzed the lunar cycles of 100 patients with ruptured aneurysms and found that the risk of aneurysm rupture was higher during the full moon phase compared to other lunar phases. The study also found that the risk of rupture was higher in the days immediately following the full moon.\nSince then, several other studies have investigated the association between the moon cycle and aneurysm rupture risk, with mixed results. Some studies have found no significant association between the moon cycle and aneurysm rupture risk, while others have suggested that the risk may be higher during certain lunar phases.\nOne possible explanation for the observed association is the effects of the lunar cycle on blood pressure. Some studies have suggested that blood pressure is higher during the full moon phase compared to other lunar phases, and this increase in blood pressure may put additional pressure on the blood vessels in the brain, increasing the risk of aneurysm rupture.\nAnother possible explanation is the effects of the lunar cycle on the immune system. Some studies have suggested that the immune system may be affected by the lunar cycle, with changes in the immune system potentially affecting the risk of aneurysm rupture.\nIt is important to note that the evidence for an association between the moon cycle and aneurysm rupture risk is still limited and inconclusive. More research is needed to fully understand the relationship between the two.\nIn conclusion, while there is some evidence to suggest that the moon cycle may be associated with an increased risk of aneurysm rupture, the evidence is still limited and inconclusive. Further research is needed to fully understand the relationship between the two. In the meantime, patients with known aneurysms should continue to follow their regular treatment and monitoring regimens, regardless of the",
    "llama-2-7b-chat-hf_fact_raw": "1. Some studies suggest that certain lunar cycles may be associated with an increased risk of aneurysm rupture.\n2. Dr. J. H. Kim's study in the 1970s found that the risk of aneurysm rupture was higher during the full moon phase.\n3. The study by Dr. J. H. Kim indicated the risk of rupture was higher in the days following the full moon.\n4. Some studies propose that blood pressure is higher during the full moon, potentially increasing the risk of aneurysm rupture.\n5. Research has suggested that changes in the immune system during the lunar cycle may affect the risk of aneurysm rupture.",
    "llama-2-7b-chat-hf_fact": [
      "Some studies suggest that certain lunar cycles may be associated with an increased risk of aneurysm rupture.",
      "Dr. J. H. Kim's study in the 1970s found that the risk of aneurysm rupture was higher during the full moon phase.",
      "The study by Dr. J. H. Kim indicated the risk of rupture was higher in the days following the full moon.",
      "Some studies propose that blood pressure is higher during the full moon, potentially increasing the risk of aneurysm rupture.",
      "Research has suggested that changes in the immune system during the lunar cycle may affect the risk of aneurysm rupture."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "llama-2-7b-chat-hf_response": "Yes, HuR protein is known to regulate the splicing process in various cell types. HuR (Human RNA-binding protein 1) is a protein that plays a crucial role in the regulation of mRNA splicing, which is the process by which the precursor messenger RNA (pre-mRNA) is converted into the mature mRNA molecule that can be translated into protein.\nHuR is a member of the RNA-binding protein (RBP) family and is highly conserved across species. It was first identified as a protein that binds to the 3' untranslated region (UTR) of the human epidermal growth factor receptor 2 (HER2) mRNA and regulates its splicing. Since then, numerous studies have shown that HuR regulates the splicing of a wide range of mRNAs, including those involved in cell proliferation, differentiation, and survival.\nHuR regulates splicing by binding to specific sequences in the pre-mRNA and recruiting the splicing machinery to the site of splicing. It can also act as a repressor of splicing by blocking the access of the splicing factors to the pre-mRNA. HuR has been shown to regulate the splicing of mRNAs involved in various cellular processes, including cell cycle progression, apoptosis, and stress response.\nIn cancer cells, HuR has been shown to play a tumor-promoting role by regulating the splicing of oncogenic mRNAs, such as c-Myc and HIF1. HuR also regulates the splicing of mRNAs involved in the PI3K/Akt signaling pathway, which is commonly activated in cancer.\nIn summary, HuR protein regulates the splicing process by binding to specific sequences in the pre-mRNA and recruiting the splicing machinery to the site of splicing. It plays a crucial role in regulating the expression of a wide range of mRNAs involved in various cellular processes, including cell proliferation, differentiation, and survival. In cancer cells, HuR has been shown to play a tumor-prom",
    "llama-2-7b-chat-hf_fact_raw": "1. HuR protein is known to regulate the splicing process in various cell types.\n2. HuR protein plays a crucial role in the regulation of mRNA splicing, allowing pre-mRNA to be converted into mature mRNA.\n3. HuR is a member of the RNA-binding protein (RBP) family.\n4. HuR was first identified as a regulator of splicing for the HER2 mRNA.\n5. HuR can regulate splicing by binding to pre-mRNA and recruiting or repressing splicing machinery.",
    "llama-2-7b-chat-hf_fact": [
      "HuR protein is known to regulate the splicing process in various cell types.",
      "HuR protein plays a crucial role in the regulation of mRNA splicing, allowing pre-mRNA to be converted into mature mRNA.",
      "HuR is a member of the RNA-binding protein (RBP) family.",
      "HuR was first identified as a regulator of splicing for the HER2 mRNA.",
      "HuR can regulate splicing by binding to pre-mRNA and recruiting or repressing splicing machinery."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: HuR was first identified as a regulator of stability for the MYC mRNA.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-2-7b-chat-hf_response": "Prothymosin alpha (PA) is a small peptide hormone that plays a crucial role in the regulation of various physiological processes, including immune response, cell proliferation, and differentiation. The c-terminal peptide of PA, also known as prothymosin alpha c-terminal peptide (PCT), is a 13-amino acid peptide that is derived from the C-terminal region of the full-length PA protein.\nHere are some of the known functions of PCT:\n1. Immune response: PCT has been shown to stimulate the production of cytokines, such as interleukin-2 (IL-2) and interferon-gamma (IFN-), which are important in the immune response.\n2. Cell proliferation: PCT has been shown to stimulate the proliferation of various cell types, including T cells, B cells, and fibroblasts.\n3. Differentiation: PCT has been shown to promote the differentiation of immature cells, such as T cells and B cells, into mature functional cells.\n4. Anti-inflammatory effects: PCT has been shown to have anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-) and interleukin-1 beta (IL-1).\n5. Neuroprotection: PCT has been shown to have neuroprotective effects by reducing oxidative stress and inflammation in the brain, which may contribute to its potential therapeutic applications in neurodegenerative diseases.\n6. Anti-cancer effects: PCT has been shown to have anti-cancer effects by inhibiting the growth and proliferation of cancer cells, and inducing apoptosis (programmed cell death) in cancer cells.\n7. Cardiovascular health: PCT has been shown to have potential cardiovascular health benefits, including reducing inflammation and improving endothelial function.\n8. Anti-aging effects: PCT has been shown to have anti-aging effects by reducing oxidative stress and inflammation, which may contribute",
    "llama-2-7b-chat-hf_fact_raw": "1. Prothymosin alpha c-terminal peptide (PCT) is a 13-amino acid peptide derived from the C-terminal region of the full-length prothymosin alpha protein.\n2. PCT stimulates the production of cytokines such as interleukin-2 (IL-2) and interferon-gamma (IFN-), which are important in the immune response.\n3. PCT stimulates the proliferation of various cell types, including T cells, B cells, and fibroblasts.\n4. PCT promotes the differentiation of immature cells, such as T cells and B cells, into mature functional cells.\n5. PCT has been shown to have neuroprotective effects by reducing oxidative stress and inflammation in the brain.",
    "llama-2-7b-chat-hf_fact": [
      "Prothymosin alpha c-terminal peptide (PCT) is a 13-amino acid peptide derived from the C-terminal region of the full-length prothymosin alpha protein.",
      "PCT stimulates the production of cytokines such as interleukin-2 (IL-2) and interferon-gamma (IFN-), which are important in the immune response.",
      "PCT stimulates the proliferation of various cell types, including T cells, B cells, and fibroblasts.",
      "PCT promotes the differentiation of immature cells, such as T cells and B cells, into mature functional cells.",
      "PCT has been shown to have neuroprotective effects by reducing oxidative stress and inflammation in the brain."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-2-7b-chat-hf_response": "Cystatin C is a protein that is primarily involved in the regulation of intracellular levels of zinc ions. It is a member of the cystatin family of proteins, which are known to form fibrils under certain conditions. The fibrillization of cystatin C is a complex process that involves the aggregation of the protein into amyloid fibrils, which are characterized by a beta-sheet structure.\nSeveral peptides within the cystatin C protein have been identified as playing a pivotal role in its fibrillization. These peptides are typically located in the N-terminal region of the protein and are characterized by a conserved sequence of amino acids.\nOne of the most well-studied peptides involved in cystatin C fibrillization is the 24-amino acid peptide residues 1-24 (RQRPGYGDVVVKDVGKGDV). This peptide has been shown to be the primary component of cystatin C fibrils and is responsible for their formation. The peptide is highly hydrophobic and contains a number of conserved aromatic and hydrophobic residues, which are thought to be important for its ability to form fibrils.\nOther peptides that have been implicated in cystatin C fibrillization include the 16-amino acid peptide residues 25-40 (KDVGKGDVVVKDVGK) and the 12-amino acid peptide residues 41-53 (KDVGKGDVVV). These peptides are also located in the N-terminal region of the protein and have been shown to play a role in the formation of cystatin C fibrils.\nIt is worth noting that the exact mechanism by which these peptides contribute to cystatin C fibrillization is still not fully understood and is the subject of ongoing research. However, it is clear that they play a pivotal role in the process and are key targets for the development of therapeutic strategies aimed at preventing or treating cystatin C-related diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cystatin C is a protein involved in the regulation of intracellular levels of zinc ions.\n2. The fibrillization of cystatin C involves the aggregation of the protein into amyloid fibrils with a beta-sheet structure.\n3. Peptides located in the N-terminal region of cystatin C play a pivotal role in its fibrillization.\n4. The 24-amino acid peptide residues 1-24 (RQRPGYGDVVVKDVGKGDV) are the primary component of cystatin C fibrils and responsible for their formation.\n5. Other peptides implicated in cystatin C fibrillization include the 16-amino acid peptide residues 25-40 (KDVGKGDVVVKDVGK) and the 12-amino acid peptide residues 41-53 (KDVGKGDVVV).",
    "llama-2-7b-chat-hf_fact": [
      "Cystatin C is a protein involved in the regulation of intracellular levels of zinc ions.",
      "The fibrillization of cystatin C involves the aggregation of the protein into amyloid fibrils with a beta-sheet structure.",
      "Peptides located in the N-terminal region of cystatin C play a pivotal role in its fibrillization.",
      "The 24-amino acid peptide residues 1-24 (RQRPGYGDVVVKDVGKGDV) are the primary component of cystatin C fibrils and responsible for their formation.",
      "Other peptides implicated in cystatin C fibrillization include the 16-amino acid peptide residues 25-40 (KDVGKGDVVVKDVGK) and the 12-amino acid peptide residues 41-53 (KDVGKGDVVV)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cystatin C is a protein involved in the regulation of intracellular levels of protease activity, not zinc ions.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The 24-amino acid peptide residues 1-24 (RQRPGYGDVVVKDVGKGDV) are not the primary component of cystatin C fibrils; the correct sequence is lacking several amino acids and is not solely responsible for their formation.\n5. FALSE [correction]: Other peptides implicated in cystatin C fibrillization do not include the 16-amino acid peptide residues 25-40 (KDVGKGDVVVKDVGK) and the 12-amino acid peptide residues 41-53 (KDVGKGDVVV), as these sequences are incorrect and do not match the cystatin C sequence.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1 increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-2-7b-chat-hf_response": "Thank you for reaching out with your question! I'm here to help you understand the relationship between the cytoprotective prodrug \"amifostine\" (ethyol) and the concentration of protein HIF-1.\nHIF-1 (Hypoxia-Inducible Factor-1 alpha) is a transcription factor that plays a crucial role in response to hypoxia, a condition of low oxygen availability in the body. HIF-1 is a key regulator of adaptive responses to hypoxia, including the activation of angiogenesis, glucose metabolism, and cell survival pathways.\nNow, to answer your question, there is evidence to suggest that the administration of amifostine (ethyol) can affect the concentration of protein HIF-1 in certain contexts.\nStudies have shown that amifostine can increase the expression of HIF-1 in various cell types, including cancer cells, under normoxic conditions. For example, a study published in the journal Cancer Research found that amifostine treatment increased HIF-1 protein levels in human breast cancer cells. Another study published in the journal Oncogene found that amifostine increased HIF-1 expression in human lung cancer cells.\nHowever, it's important to note that the effects of amifostine on HIF-1 concentration may vary depending on the specific context and cell type. For example, some studies have shown that amifostine can inhibit HIF-1 activity in certain cell types, such as endothelial cells, under hypoxic conditions.\nIn summary, the concentration of protein HIF-1 may increase after the administration of amifostine (ethyol) in certain contexts, such as under normoxic conditions in cancer cells. However, the effects of amifostine on HIF-1 concentration can vary depending on the specific context and cell type, and may also be influenced by other factors such as the dose and duration of amifostine treatment.\nI hope this helps clarify things for you! If you have any further questions or would like more information, please don't hesitate to ask.",
    "llama-2-7b-chat-hf_fact_raw": "1. HIF-1 (Hypoxia-Inducible Factor-1 alpha) is a transcription factor that responds to hypoxia.\n2. Administration of amifostine (ethyol) can increase the expression of HIF-1 in various cell types under normoxic conditions.\n3. A study in the journal Cancer Research found that amifostine treatment increased HIF-1 protein levels in human breast cancer cells.\n4. A study in the journal Oncogene found that amifostine increased HIF-1 expression in human lung cancer cells.\n5. Effects of amifostine on HIF-1 concentration may vary depending on the specific context and cell type.",
    "llama-2-7b-chat-hf_fact": [
      "HIF-1 (Hypoxia-Inducible Factor-1 alpha) is a transcription factor that responds to hypoxia.",
      "Administration of amifostine (ethyol) can increase the expression of HIF-1 in various cell types under normoxic conditions.",
      "A study in the journal Cancer Research found that amifostine treatment increased HIF-1 protein levels in human breast cancer cells.",
      "A study in the journal Oncogene found that amifostine increased HIF-1 expression in human lung cancer cells.",
      "Effects of amifostine on HIF-1 concentration may vary depending on the specific context and cell type."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "llama-2-7b-chat-hf_response": "Set7 is a histone methyltransferase enzyme that deposits several different histone marks, including:\n1. Histone H3 lysine 4 trimethylation (H3K4me3): Set7 is known to be a major enzyme responsible for the deposition of H3K4me3, which is a mark associated with active gene expression, particularly for genes involved in cell growth and proliferation.\n2. Histone H3 lysine 27 trimethylation (H3K27me3): Set7 has also been shown to deposit H3K27me3, which is a mark associated with gene silencing and chromatin repression.\n3. Histone H4 lysine 5 trimethylation (H4K5me3): Set7 has been reported to deposit H4K5me3, which is a mark associated with chromatin remodeling and transcriptional elongation.\n4. Histone H3 lysine 9 trimethylation (H3K9me3): Set7 has been shown to deposit H3K9me3, which is a mark associated with gene silencing and chromatin repression, particularly for genes involved in developmental processes.\n5. Histone H2A lysine 5 trimethylation (H2AK5me3): Set7 has been reported to deposit H2AK5me3, which is a mark associated with chromatin remodeling and transcriptional elongation.\nIt's worth noting that the specific histone marks deposited by Set7 can vary depending on the cellular context and the specific substrate proteins being modified. Additionally, Set7 can interact with other chromatin-modifying enzymes to coordinate its activities and regulate chromatin structure and gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. Set7 is a histone methyltransferase enzyme.\n2. Set7 deposits histone H3 lysine 4 trimethylation (H3K4me3) associated with active gene expression.\n3. Set7 deposits histone H3 lysine 27 trimethylation (H3K27me3) associated with gene silencing and chromatin repression.\n4. Set7 deposits histone H4 lysine 5 trimethylation (H4K5me3) associated with chromatin remodeling and transcriptional elongation.\n5. Set7 deposits histone H3 lysine 9 trimethylation (H3K9me3) associated with gene silencing and chromatin repression.",
    "llama-2-7b-chat-hf_fact": [
      "Set7 is a histone methyltransferase enzyme.",
      "Set7 deposits histone H3 lysine 4 trimethylation (H3K4me3) associated with active gene expression.",
      "Set7 deposits histone H3 lysine 27 trimethylation (H3K27me3) associated with gene silencing and chromatin repression.",
      "Set7 deposits histone H4 lysine 5 trimethylation (H4K5me3) associated with chromatin remodeling and transcriptional elongation.",
      "Set7 deposits histone H3 lysine 9 trimethylation (H3K9me3) associated with gene silencing and chromatin repression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Set7 does not deposit H3K27me3, which is associated with gene silencing and chromatin repression. This is typically deposited by other methyltransferases like EZH2.\n4. FALSE [correction]: Set7 does not deposit H4K5me3. It is specific to H3K4 methylation.\n5. FALSE [correction]: Set7 does not deposit H3K9me3, which is associated with gene silencing and chromatin repression. This modification is typically carried out by enzymes like SUV39H1.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "llama-2-7b-chat-hf_response": "Hepcidin is a protein that plays a crucial role in regulating iron metabolism in the body. It is a small (~12 kDa) cysteine-rich protein that is synthesized in the liver and secreted into the bloodstream, where it binds to iron-regulatory proteins (IRPs) and ferroportin, leading to the repression of iron efflux from cells.\nHepcidin has two disulfide bridges, which are important for its proper folding and function. These disulfide bridges are formed between the two cysteine residues (Cys13 and Cys105) in the protein. The presence of these disulfide bridges helps to stabilize the protein structure and facilitates its interaction with iron-regulatory proteins and ferroportin.\nIt is worth noting that the number of disulfide bridges in a protein can vary depending on the species and the specific protein structure. However, in the case of hepcidin, the presence of two disulfide bridges is a conserved feature across different species, including humans, mice, and other animals.\nIn summary, hepcidin has two disulfide bridges, which are important for its proper folding and function in regulating iron metabolism in the body.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hepcidin is a small cysteine-rich protein synthesized in the liver.\n2. Hepcidin plays a role in regulating iron metabolism in the body.\n3. Hepcidin has two disulfide bridges formed between the cysteine residues Cys13 and Cys105.\n4. The disulfide bridges in hepcidin are important for its proper folding and function.\n5. The presence of two disulfide bridges in hepcidin is a conserved feature across different species.",
    "llama-2-7b-chat-hf_fact": [
      "Hepcidin is a small cysteine-rich protein synthesized in the liver.",
      "Hepcidin plays a role in regulating iron metabolism in the body.",
      "Hepcidin has two disulfide bridges formed between the cysteine residues Cys13 and Cys105.",
      "The disulfide bridges in hepcidin are important for its proper folding and function.",
      "The presence of two disulfide bridges in hepcidin is a conserved feature across different species."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Hepcidin has four disulfide bridges formed between its cysteine residues.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-2-7b-chat-hf_response": "The protein encoded by the gene DNAJC11 is a member of the DJ-1 protein family, which are involved in various cellular processes, including protein degradation, protein folding, and redox signaling. The localization of the DNAJC11 protein is primarily cytoplasmic, but it can also be found in the nucleus in some cell types.\nDNAJC11 is a gene that codes for a protein of approximately 24 kDa in size. The protein is synthesized in the cytoplasm and then transported to the nucleus, where it plays a role in regulating the expression of certain genes. The protein is also localized to the endoplasmic reticulum (ER) and the mitochondria, where it interacts with various proteins involved in protein folding and degradation.\nStudies have shown that the localization of DNAJC11 is dynamic and can be regulated by various cellular signals, including changes in redox state, calcium levels, and nutrient availability. For example, in response to oxidative stress, DNAJC11 can be translocated from the cytoplasm to the nucleus, where it can help to protect against DNA damage and promote the expression of genes involved in antioxidant defense.\nIn addition to its cytoplasmic and nuclear localization, DNAJC11 has also been shown to be secreted from cells and to play a role in intercellular signaling. For example, DNAJC11 has been shown to be secreted from neurons and to play a role in the regulation of synaptic plasticity and learning and memory.\nOverall, the localization of the DNAJC11 protein is complex and dynamic, and it plays a multifaceted role in various cellular processes. Understanding the localization and function of DNAJC11 can provide insights into the mechanisms underlying various diseases, including neurodegenerative disorders and cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein encoded by the gene DNAJC11 is primarily cytoplasmic.\n2. DNAJC11 protein can also be found in the nucleus in some cell types.\n3. The protein is localized to the endoplasmic reticulum (ER) and the mitochondria.\n4. The localization of DNAJC11 is dynamic and can be regulated by cellular signals such as redox state, calcium levels, and nutrient availability.\n5. DNAJC11 can be secreted from cells and plays a role in intercellular signaling.",
    "llama-2-7b-chat-hf_fact": [
      "The protein encoded by the gene DNAJC11 is primarily cytoplasmic.",
      "DNAJC11 protein can also be found in the nucleus in some cell types.",
      "The protein is localized to the endoplasmic reticulum (ER) and the mitochondria.",
      "The localization of DNAJC11 is dynamic and can be regulated by cellular signals such as redox state, calcium levels, and nutrient availability.",
      "DNAJC11 can be secreted from cells and plays a role in intercellular signaling."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: There is no evidence to suggest that DNAJC11 is secreted from cells or plays a role in intercellular signaling. DNAJC11 is primarily localized to the endoplasmic reticulum and mitochondria within the cell.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-2-7b-chat-hf_response": "Thank you for your question! Ultraconserved elements are regions of the genome that are highly conserved across different species, often showing a high degree of sequence similarity. Copy number variants (CNVs), on the other hand, refer to genomic regions that have a different number of copies than the typical number found in a reference genome.\nTo answer your question, there is evidence to suggest that ultraconserved elements are not necessarily depleted among CNVs. While it is true that CNVs can disrupt the normal functioning of genes and genomic regions, including ultraconserved elements, some studies have found that CNVs can also influence the expression of ultraconserved elements.\nFor example, a study published in the journal Nature Communications in 2017 found that CNVs can affect the expression of ultraconserved elements in the human genome. The study analyzed the genomes of over 10,000 individuals and found that CNVs were associated with changes in the expression of ultraconserved elements, particularly in regions that are known to be important for gene regulation.\nAnother study published in the journal American Journal of Human Genetics in 2019 found that CNVs can also affect the expression of ultraconserved elements in the brain. The study analyzed the genomes of over 3,000 individuals and found that CNVs were associated with changes in the expression of ultraconserved elements in brain-specific genes.\nHowever, it is worth noting that not all CNVs are associated with changes in the expression of ultraconserved elements. The effects of CNVs on ultraconserved elements can vary depending on the location and context of the CNV, as well as the specific ultraconserved element being analyzed.\nIn summary, while there is evidence to suggest that CNVs can influence the expression of ultraconserved elements, it is not necessarily the case that ultraconserved elements are depleted among CNVs. Further research is needed to fully understand the relationship between CNVs and ultraconserved elements in the human genome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ultraconserved elements are regions of the genome highly conserved across different species.\n2. Copy number variants (CNVs) refer to genomic regions with a different number of copies than found in a reference genome.\n3. A study published in Nature Communications in 2017 found that CNVs are associated with changes in the expression of ultraconserved elements in the human genome.\n4. A study published in the American Journal of Human Genetics in 2019 found that CNVs are associated with changes in the expression of ultraconserved elements in brain-specific genes.\n5. The effects of CNVs on ultraconserved elements can vary depending on the location and context of the CNV and the specific ultraconserved element being analyzed.",
    "llama-2-7b-chat-hf_fact": [
      "Ultraconserved elements are regions of the genome highly conserved across different species.",
      "Copy number variants (CNVs) refer to genomic regions with a different number of copies than found in a reference genome.",
      "A study published in Nature Communications in 2017 found that CNVs are associated with changes in the expression of ultraconserved elements in the human genome.",
      "A study published in the American Journal of Human Genetics in 2019 found that CNVs are associated with changes in the expression of ultraconserved elements in brain-specific genes.",
      "The effects of CNVs on ultraconserved elements can vary depending on the location and context of the CNV and the specific ultraconserved element being analyzed."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "llama-2-7b-chat-hf_response": "The substrate of the Haspin kinase during mitosis is the microtubule-associated protein (MAP) protein, MAP4. Haspin is a serine/threonine kinase that plays a crucial role in the regulation of mitosis, particularly in the proper separation of chromosomes during cell division.\nDuring mitosis, Haspin is phosphorylated and activated, leading to its association with the microtubule network. Specifically, Haspin binds to the MAP4 protein, which is a key regulator of microtubule dynamics during mitosis. The Haspin-MAP4 complex plays a crucial role in the formation of the spindle fibers that separate the chromosomes during cell division.\nThe Haspin-MAP4 interaction is mediated by a specific binding site on the MAP4 protein, which is located in the N-terminal region of the protein. This binding site is conserved across different species, including humans, and is essential for the proper function of the Haspin kinase during mitosis.\nIn addition to its role in microtubule dynamics, Haspin has been shown to interact with other proteins involved in mitosis, including the aurora kinases and the cohesin complex. These interactions suggest that Haspin may play a broader role in the regulation of mitosis, beyond its direct involvement in microtubule dynamics.\nOverall, the substrate of the Haspin kinase during mitosis is the MAP4 protein, which plays a critical role in the proper separation of chromosomes during cell division. The Haspin-MAP4 interaction is a key component of the mitotic spindle apparatus and is essential for the proper progression of mitosis.",
    "llama-2-7b-chat-hf_fact_raw": "1. The substrate of the Haspin kinase during mitosis is the microtubule-associated protein (MAP) protein, MAP4.\n2. Haspin is a serine/threonine kinase important for regulating mitosis and proper chromosome separation during cell division.\n3. During mitosis, Haspin binds to the MAP4 protein, a key regulator of microtubule dynamics.\n4. The binding site for Haspin on the MAP4 protein is located in the N-terminal region and is conserved across different species.\n5. Haspin interacts with other proteins involved in mitosis, such as the aurora kinases and the cohesin complex.",
    "llama-2-7b-chat-hf_fact": [
      "The substrate of the Haspin kinase during mitosis is the microtubule-associated protein (MAP) protein, MAP4.",
      "Haspin is a serine/threonine kinase important for regulating mitosis and proper chromosome separation during cell division.",
      "During mitosis, Haspin binds to the MAP4 protein, a key regulator of microtubule dynamics.",
      "The binding site for Haspin on the MAP4 protein is located in the N-terminal region and is conserved across different species.",
      "Haspin interacts with other proteins involved in mitosis, such as the aurora kinases and the cohesin complex."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The substrate of the Haspin kinase during mitosis is histone H3, not MAP4.\n2. TRUE\n3. FALSE [correction]: Haspin does not bind to MAP4 protein during mitosis; it phosphorylates histone H3.\n4. FALSE [correction]: The statement is based on the incorrect premise that MAP4 is the substrate of Haspin.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "llama-2-7b-chat-hf_response": "Viroids are small, single-stranded RNA molecules that replicate through a unique mechanism that does not involve the traditional cellular machinery of protein synthesis and DNA replication. Here is a detailed explanation of the mechanism of viroid replication:\n1. Infection: Viroids are transmitted to host plants through various means, such as grafting, insect vectors, or contaminated soil. Once inside the plant, the viroids enter the host cell through a process called endocytosis, where the cell engulfs the viroid particle.\n2. Uncoating: Once inside the host cell, the viroid particle is released from its protective coating, which is composed of lipopolysaccharides and other molecules. This process is mediated by enzymes called endosomal proteases, which break down the coating and expose the viroid to the cytoplasm.\n3. RNA-dependent RNA polymerase: The exposed viroid molecule then binds to a host RNA-dependent RNA polymerase, which is an enzyme that synthesizes RNA molecules from other RNA templates. This binding triggers the polymerase to initiate transcription of the viroid RNA, resulting in the synthesis of new viroid molecules.\n4. Transcription: The viroid RNA is transcribed in the cytoplasm of the host cell, producing a complementary RNA molecule. This complementary RNA molecule is then used as a template for the synthesis of new viroid molecules through a process called RNA-dependent RNA polymerase II (RdRp II) transcription.\n5. Translation: The newly synthesized viroid molecules are then translated into proteins in the cytoplasm of the host cell. This translation process is mediated by ribosomes, which read the sequence of nucleotides in the viroid RNA and synthesize the corresponding proteins.\n6. Assembly: The translated proteins then assemble into mature viroid particles, which are composed of multiple copies of the viroid RNA molecule, surrounded by a protein shell. This protein shell provides structural support and protects the viroid RNA from degradation.\n7. Release: The mature viroid particles are then released",
    "llama-2-7b-chat-hf_fact_raw": "1. Viroids are transmitted to host plants through means such as grafting, insect vectors, or contaminated soil.\n2. Viroids enter host cells through a process called endocytosis.\n3. Viroid particles are released from their protective coating by enzymes called endosomal proteases.\n4. Viroid RNA binds to a host RNA-dependent RNA polymerase, which initiates transcription of the viroid RNA.\n5. The newly synthesized viroid molecules are translated into proteins by ribosomes in the host cell's cytoplasm.",
    "llama-2-7b-chat-hf_fact": [
      "Viroids are transmitted to host plants through means such as grafting, insect vectors, or contaminated soil.",
      "Viroids enter host cells through a process called endocytosis.",
      "Viroid particles are released from their protective coating by enzymes called endosomal proteases.",
      "Viroid RNA binds to a host RNA-dependent RNA polymerase, which initiates transcription of the viroid RNA.",
      "The newly synthesized viroid molecules are translated into proteins by ribosomes in the host cell's cytoplasm."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Viroids do not enter host cells through endocytosis; they typically enter through wounds or natural openings in the plant.\n3. FALSE [correction]: Viroid particles are not coated, so they do not require endosomal proteases for release. Viroids are naked RNA molecules.\n4. TRUE\n5. FALSE [correction]: Viroids do not encode proteins and thus are not translated by ribosomes. They replicate through an RNA-based mechanism.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-2-7b-chat-hf_response": "Fibronectin is a protein that plays a crucial role in the development and maintenance of muscle tissue, and it has been suggested as a potential biomarker for Duchenne muscular dystrophy (DMD), a severe and progressive genetic disorder that affects muscle strength and function.\nStudies have shown that levels of fibronectin are significantly reduced in the blood and muscle tissue of individuals with DMD, particularly in the early stages of the disease. This reduction in fibronectin levels can be used as a biomarker to diagnose DMD and monitor disease progression.\nOne study published in the journal Neuromuscular Disorders found that levels of fibronectin in the blood were significantly lower in individuals with DMD than in healthy controls, and that these levels continued to decrease over time. Another study published in the journal Muscle & Nerve found that levels of fibronectin in the muscle tissue of individuals with DMD were significantly lower than in healthy controls, and that this reduction was associated with muscle weakness and wasting.\nThe reduction in fibronectin levels in DMD is thought to be due to the mutations in the dystrophin gene, which codes for the protein dystrophin. Dystrophin is a critical component of the dystrophin-glycoprotein complex, which plays a key role in maintaining the structure and function of muscle tissue. Without dystrophin, the muscle tissue is weakened and degenerated, leading to the muscle wasting and muscle loss characteristic of DMD.\nWhile fibronectin levels can be used as a biomarker for DMD, it is important to note that it is not a perfect test and may not be able to detect the disease in its early stages. Other biomarkers, such as creatine kinase (CK) and lactate dehydrogenase (LDH), may also be elevated in DMD, and a combination of these tests may be needed to diagnose the disease.\nIn summary, fibronectin constitutes a potential serum biomarker for Duchenne muscular dystrophy, and its levels can be used to diagnose and monitor the disease. However, it is important to use a combination of biomarkers and clinical evaluation",
    "llama-2-7b-chat-hf_fact_raw": "1. Fibronectin is a protein that plays a role in the development and maintenance of muscle tissue.\n2. Levels of fibronectin are significantly reduced in the blood and muscle tissue of individuals with Duchenne muscular dystrophy.\n3. A study published in the journal Neuromuscular Disorders found lower levels of fibronectin in the blood of individuals with DMD compared to healthy controls.\n4. A study published in the journal Muscle & Nerve found that reduced levels of fibronectin in muscle tissue of individuals with DMD were associated with muscle weakness and wasting.\n5. Mutations in the dystrophin gene, which codes for dystrophin, a critical component of the dystrophin-glycoprotein complex, lead to reduced fibronectin levels in DMD.",
    "llama-2-7b-chat-hf_fact": [
      "Fibronectin is a protein that plays a role in the development and maintenance of muscle tissue.",
      "Levels of fibronectin are significantly reduced in the blood and muscle tissue of individuals with Duchenne muscular dystrophy.",
      "A study published in the journal Neuromuscular Disorders found lower levels of fibronectin in the blood of individuals with DMD compared to healthy controls.",
      "A study published in the journal Muscle & Nerve found that reduced levels of fibronectin in muscle tissue of individuals with DMD were associated with muscle weakness and wasting.",
      "Mutations in the dystrophin gene, which codes for dystrophin, a critical component of the dystrophin-glycoprotein complex, lead to reduced fibronectin levels in DMD."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Mutations in the dystrophin gene lead to the absence or dysfunction of dystrophin protein, which in turn affects the dystrophin-glycoprotein complex and may impact fibronectin levels, but fibronectin levels are not directly regulated by the dystrophin gene.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-2-7b-chat-hf_response": "DeepBlue is a comprehensive epigenomic data server that contains data from various major epigenome projects. Here are some of the major epigenome projects whose data are contained in the DeepBlue data server:\n1. The Human Epigenome Project (HEP): The HEP is a large-scale effort to map the epigenetic marks on human cells, including DNA methylation, histone modifications, and chromatin structure. The HEP has generated a wealth of data on human cells, including DNA methylation profiles, histone modification profiles, and chromatin structure data.\n2. The ENCODE (ENCyclopedia Of DNA Elements) Project: The ENCODE project is a large-scale effort to identify all of the functional elements in the human genome, including promoters, enhancers, and other regulatory elements. The ENCODE project has generated a large amount of data on the epigenetic marks associated with these elements, including DNA methylation, histone modifications, and chromatin structure.\n3. The Roadmap Epigenomics Project: The Roadmap Epigenomics Project is a collaborative effort to map the epigenetic landscape of various organisms, including humans, mice, and worms. The project has generated a large amount of data on the epigenetic marks associated with different genomic regions, including DNA methylation, histone modifications, and chromatin structure.\n4. The Mouse Epigenome Project: The Mouse Epigenome Project is a large-scale effort to map the epigenetic marks on the mouse genome. The project has generated a wealth of data on the epigenetic marks associated with different genomic regions, including DNA methylation, histone modifications, and chromatin structure.\n5. The Arabidopsis Epigenomics Project: The Arabidopsis Epigenomics Project is a large-scale effort to map the epigenetic marks on the Arabidopsis thaliana genome. The project has generated a wealth of data on the epigenetic marks associated with different genomic regions, including DNA methylation, histone modifications, and chromatin structure.\n6. The Yeast Epigenomics Project: The Yeast Epigenomics Project is a large-scale effort to map the epigenetic marks on the Saccharomyces cerevisiae genome. The project has generated a wealth",
    "llama-2-7b-chat-hf_fact_raw": "1. DeepBlue is a comprehensive epigenomic data server that contains data from the Human Epigenome Project (HEP).\n2. The ENCODE Project's data are contained in the DeepBlue data server.\n3. The Roadmap Epigenomics Project's data are contained in the DeepBlue data server.\n4. Data from the Mouse Epigenome Project are included in the DeepBlue data server.\n5. The Arabidopsis Epigenomics Project's data are contained in the DeepBlue data server.",
    "llama-2-7b-chat-hf_fact": [
      "DeepBlue is a comprehensive epigenomic data server that contains data from the Human Epigenome Project (HEP).",
      "The ENCODE Project's data are contained in the DeepBlue data server.",
      "The Roadmap Epigenomics Project's data are contained in the DeepBlue data server.",
      "Data from the Mouse Epigenome Project are included in the DeepBlue data server.",
      "The Arabidopsis Epigenomics Project's data are contained in the DeepBlue data server."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: DeepBlue is a comprehensive epigenomic data server but does not contain data from the Human Epigenome Project (HEP).\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The Arabidopsis Epigenomics Project's data are not contained in the DeepBlue data server.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-2-7b-chat-hf_response": "Thank you for your question! Self-organizing maps (SOMs) are a type of neural network that can be used for data visualization and clustering. In the context of bioinformatics, SOMs have been used to analyze synonymous codon usage in proteins.\nOne tool that employs SOMs for this purpose is \"CodonUsage\". This tool uses a SOM to visualize and analyze the codon usage patterns in a protein sequence. It can identify areas of high codon usage and low codon usage, which can be indicative of selective pressure or other evolutionary forces.\nCodonUsage works by first aligning the protein sequence with a reference database of codon usage frequencies. It then uses a SOM to map the protein sequence to a lower-dimensional representation, where each dimension represents a different codon. This allows for the visualization of the codon usage patterns in the protein sequence.\nSome of the key features of \"CodonUsage\" include:\n* Codon usage analysis: The tool can identify areas of high codon usage and low codon usage in the protein sequence, which can be indicative of selective pressure or other evolutionary forces.\n* Codon frequency analysis: The tool can provide a detailed analysis of the codon frequencies in the protein sequence, including the frequency of each codon and the frequency of each codon in each region of the sequence.\n* Codon context analysis: The tool can provide an analysis of the codon context in the protein sequence, including the frequency of each codon in each context (e.g. the frequency of each codon in the N-terminal region of the sequence).\n* Visualization: The tool can visualize the codon usage patterns in the protein sequence using a SOM, which can help identify patterns and trends in the data.\n* Interactive analysis: The tool allows for interactive analysis of the codon usage data, including the ability to zoom in and out of the SOM, and to view the data in different ways (e.g. by codon or by region).\nOverall, \"CodonUsage\" is a powerful tool for analyzing synonymous codon usage in proteins, and can be useful for a wide range of applications, including evolutionary studies, protein engineering, and drug discovery.",
    "llama-2-7b-chat-hf_fact_raw": "1. Self-organizing maps (SOMs) are a type of neural network used for data visualization and clustering.\n2. \"CodonUsage\" is a tool that employs SOMs to analyze synonymous codon usage in proteins.\n3. \"CodonUsage\" aligns the protein sequence with a reference database to analyze codon usage frequencies.\n4. The tool can identify high and low codon usage areas in a protein sequence, indicating selective pressure or evolutionary forces.\n5. \"CodonUsage\" provides a detailed analysis of codon frequencies and context in the protein sequence.",
    "llama-2-7b-chat-hf_fact": [
      "Self-organizing maps (SOMs) are a type of neural network used for data visualization and clustering.",
      "\"CodonUsage\" is a tool that employs SOMs to analyze synonymous codon usage in proteins.",
      "\"CodonUsage\" aligns the protein sequence with a reference database to analyze codon usage frequencies.",
      "The tool can identify high and low codon usage areas in a protein sequence, indicating selective pressure or evolutionary forces.",
      "\"CodonUsage\" provides a detailed analysis of codon frequencies and context in the protein sequence."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "llama-2-7b-chat-hf_response": "MINDY-1 is a cutting-edge AI language model developed by Meta AI that is specifically designed to understand and respond to natural language inputs in a helpful and informative manner. MINDY-1 is the first model in a new generation of language models that are capable of understanding and responding to complex and open-ended questions in a way that is both accurate and empathetic.\nMINDY-1 is trained on a massive dataset of text from the internet, and uses a combination of natural language processing (NLP) and deep learning techniques to understand the context and intent behind a user's question. This allows MINDY-1 to provide detailed and relevant responses that are tailored to the user's specific needs and preferences.\nSome of the key features of MINDY-1 include:\n1. Contextual understanding: MINDY-1 is able to understand the context of a question, including the user's intent and the topic being discussed.\n2. Emotional intelligence: MINDY-1 is able to recognize and respond to emotions expressed in a question, and can provide empathetic and supportive responses when appropriate.\n3. Knowledge base: MINDY-1 has access to a vast knowledge base that it can draw upon to provide accurate and informative responses to a wide range of questions.\n4. Personalization: MINDY-1 can be trained to respond in a personalized manner, taking into account the user's preferences and past interactions.\n5. Conversational capabilities: MINDY-1 is able to engage in natural-sounding conversations, using context and intent to guide its responses.\n6. Multi-modal understanding: MINDY-1 can understand and respond to questions in a variety of formats, including text, voice, and image-based inputs.\n7. Real-time response: MINDY-1 can provide real-time responses to questions, allowing users to get the information they need quickly and efficiently.\nOverall, MINDY-1 is a powerful and versatile language model that has the potential to revolutionize the way we interact with technology. With its advanced capabilities and personalized approach, MINDY-1 is poised to become an indispensable tool for users around the world.",
    "llama-2-7b-chat-hf_fact_raw": "1. MINDY-1 is an AI language model developed by Meta AI.\n2. MINDY-1 is trained on a massive dataset of text from the internet.\n3. The model uses natural language processing and deep learning techniques.\n4. MINDY-1 has features such as contextual understanding and emotional intelligence.\n5. MINDY-1 has real-time response capabilities.",
    "llama-2-7b-chat-hf_fact": [
      "MINDY-1 is an AI language model developed by Meta AI.",
      "MINDY-1 is trained on a massive dataset of text from the internet.",
      "The model uses natural language processing and deep learning techniques.",
      "MINDY-1 has features such as contextual understanding and emotional intelligence.",
      "MINDY-1 has real-time response capabilities."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MINDY-1 is not AI language model developed by Meta AI. It might be referring to GPT-3 which is developed by OpenAI.\n2. UNKNOWN (The statement could refer to AI models in general, which are often trained on large datasets from the internet, but it's not clear if it specifically refers to MINDY-1 as it's not a known model.)\n3. UNKNOWN (Without specific information about MINDY-1, which doesn't seem to exist, we cannot confirm the techniques it uses.)\n4. UNKNOWN (There is no information about MINDY-1 having such features as it doesn't appear to be a real AI model.)\n5. UNKNOWN (Without valid information about the existence of MINDY-1, we cannot confirm its capabilities.)",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "llama-2-7b-chat-hf_response": "There are several software packages available for the analysis of conserved genomic loci, each with their own strengths and limitations. Here are some of the most popular ones:\n1. PhyloBayes: PhyloBayes is a widely used software package for inferring phylogenetic trees from large-scale DNA sequence data. It can also be used for the analysis of conserved genomic loci, particularly those that are associated with evolutionary important genes or regulatory elements. PhyloBayes uses a Bayesian approach to estimate the phylogenetic relationships among multiple sequences, and can incorporate information about conserved genomic regions to improve the accuracy of the tree reconstruction.\n2. MAFFT: MAFFT (Multiple Alignment using Fast Fourier Transform) is a widely used software package for multiple sequence alignment. It can be used to align multiple sequences, including those from different species, and identify conserved regions. MAFFT uses a combination of progressive and iterative methods to align sequences quickly and accurately, and can also be used for phylogenetic analysis.\n3. MUSCLE: MUSCLE (Multiple Sequence Comparison by Log-Expectation) is another popular software package for multiple sequence alignment. It is particularly useful for aligning sequences with high levels of variability, and can be used to identify conserved regions. MUSCLE uses a fast and accurate method for aligning sequences, and can also be used for phylogenetic analysis.\n4. HMMER: HMMER is a software package for protein sequence analysis that can be used to identify conserved regions. It uses hidden Markov models (HMMs) to model the evolution of protein sequences, and can be used to identify sequences that are highly conserved across different species. HMMER can also be used for phylogenetic analysis, and can be combined with other software packages for more detailed analysis of conserved genomic loci.\n5. PILER: PILER (Protein Infernal Locations and Evolutionary Rates) is a software package for the analysis of conserved genomic loci. It can be used to identify conserved regions in protein sequences, and can also be used for phylogenetic analysis. PILER uses a combination of HMMs and progressive methods to align sequences and identify",
    "llama-2-7b-chat-hf_fact_raw": "1. PhyloBayes is a software package used for inferring phylogenetic trees from DNA sequence data and analyzing conserved genomic loci.\n2. MAFFT is a software package for multiple sequence alignment that identifies conserved regions across different species.\n3. MUSCLE is a software package for multiple sequence alignment, particularly useful for sequences with high variability.\n4. HMMER is a software package for protein sequence analysis that uses hidden Markov models to identify conserved regions.\n5. PILER is a software package used for analyzing conserved genomic loci in protein sequences.",
    "llama-2-7b-chat-hf_fact": [
      "PhyloBayes is a software package used for inferring phylogenetic trees from DNA sequence data and analyzing conserved genomic loci.",
      "MAFFT is a software package for multiple sequence alignment that identifies conserved regions across different species.",
      "MUSCLE is a software package for multiple sequence alignment, particularly useful for sequences with high variability.",
      "HMMER is a software package for protein sequence analysis that uses hidden Markov models to identify conserved regions.",
      "PILER is a software package used for analyzing conserved genomic loci in protein sequences."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: PILER is a software package used for identifying and analyzing repetitive elements in genomic DNA, not just protein sequences.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-2-7b-chat-hf_response": "Certainly! The PIEZO2 gene is a gene that plays a crucial role in the development and maintenance of sensory neurons, particularly those involved in the sensation of touch and pain. Mutations in the PIEZO2 gene have been associated with several rare genetic disorders that affect the nervous system and cause a range of symptoms, including sensory impairments, pain, and developmental delays. Here are three diseases associated with the PIEZO2 gene:\n1. PIEZO2-related cutaneous sensory neuropathy: This is a rare genetic disorder that affects the nerves responsible for transmitting touch and pain sensations from the skin to the brain. People with this condition typically experience numbness, tingling, and pain in their skin, particularly in the hands and feet. They may also have difficulty feeling temperature changes or vibrations in their skin.\n2. PIEZO2-related hearing loss: This is a rare genetic disorder that affects the nerves responsible for hearing. People with this condition typically experience progressive hearing loss, starting in childhood or adolescence. They may also have difficulty with balance and coordination, and may experience tinnitus (ringing in the ears).\n3. PIEZO2-related cerebellar ataxia: This is a rare genetic disorder that affects the cerebellum, a part of the brain that plays a crucial role in coordination, balance, and movement. People with this condition typically experience difficulty with coordination, balance, and movement, including walking, speaking, and writing. They may also experience tremors, rigidity, and other movement problems.\nIt's important to note that these are rare genetic disorders, and the vast majority of people with a mutation in the PIEZO2 gene will not develop these conditions. However, if you have a family history of these disorders or are concerned about your risk, it's important to speak with a healthcare provider or genetic counselor for further evaluation and testing.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the PIEZO2 gene have been associated with PIEZO2-related cutaneous sensory neuropathy, which affects the nerves responsible for transmitting touch and pain sensations.\n2. PIEZO2-related hearing loss is a condition that starts with progressive hearing loss in childhood or adolescence due to mutations in the PIEZO2 gene.\n3. PIEZO2-related cerebellar ataxia is a genetic disorder affecting the cerebellum and is associated with mutations in the PIEZO2 gene.\n4. People with PIEZO2-related cutaneous sensory neuropathy typically experience numbness, tingling, and pain in their skin.\n5. Individuals with PIEZO2-related cerebellar ataxia typically have difficulty with coordination, balance, and movement.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the PIEZO2 gene have been associated with PIEZO2-related cutaneous sensory neuropathy, which affects the nerves responsible for transmitting touch and pain sensations.",
      "PIEZO2-related hearing loss is a condition that starts with progressive hearing loss in childhood or adolescence due to mutations in the PIEZO2 gene.",
      "PIEZO2-related cerebellar ataxia is a genetic disorder affecting the cerebellum and is associated with mutations in the PIEZO2 gene.",
      "People with PIEZO2-related cutaneous sensory neuropathy typically experience numbness, tingling, and pain in their skin.",
      "Individuals with PIEZO2-related cerebellar ataxia typically have difficulty with coordination, balance, and movement."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: PIEZO2-related hearing loss is not a recognized condition; the PIEZO2 gene is primarily associated with mechanosensation and proprioception, not hearing.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-2-7b-chat-hf_response": "ERAP1-ERAP2 dimerization is the process by which two proteins, ERAP1 and ERAP2, come together to form a dimer. This dimerization is important for the proper functioning of the endoplasmic reticulum (ER) and is involved in various cellular processes, including:\n1. Endoplasmic reticulum-associated degradation (ERAD): ERAP1 and ERAP2 are components of the ERAD pathway, which is responsible for the degradation of misfolded or damaged proteins in the ER. The dimerization of ERAP1 and ERAP2 facilitates the recognition and degradation of these proteins.\n2. Protein folding and maturation: ERAP1 and ERAP2 play a role in the folding and maturation of secretory and membrane proteins in the ER. The dimerization of these proteins helps to facilitate their proper folding and maturation.\n3. Autophagy: ERAP1 and ERAP2 are also involved in the process of autophagy, which is the degradation of cellular components, including proteins, in response to stress or starvation. The dimerization of these proteins helps to facilitate the degradation of these components.\n4. Cellular stress response: ERAP1 and ERAP2 are involved in the cellular stress response, which is the body's response to stress or damage. The dimerization of these proteins helps to facilitate the response to stress and the proper folding and degradation of proteins.\n5. Cancer: ERAP1 and ERAP2 have been implicated in cancer, with altered expression and function in various types of cancer. The dimerization of these proteins may play a role in the development and progression of cancer.\n6. Neurodegeneration: ERAP1 and ERAP2 have been implicated in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The dimerization of these proteins may play a role in the development and progression of these diseases.\n7. Immune response: ERAP1 and ERAP2 are involved in the immune response, with ERAP1 playing a role in the recognition and degradation of pathogenic prote",
    "llama-2-7b-chat-hf_fact_raw": "1. ERAP1-ERAP2 dimerization is involved in endoplasmic reticulum-associated degradation (ERAD) pathway.\n2. ERAP1 and ERAP2 facilitate the folding and maturation of secretory and membrane proteins in the endoplasmic reticulum.\n3. ERAP1 and ERAP2 play a role in autophagy, the degradation of cellular components.\n4. ERAP1 and ERAP2 are involved in the cellular stress response.\n5. Altered expression and function of ERAP1 and ERAP2 have been implicated in various types of cancer.",
    "llama-2-7b-chat-hf_fact": [
      "ERAP1-ERAP2 dimerization is involved in endoplasmic reticulum-associated degradation (ERAD) pathway.",
      "ERAP1 and ERAP2 facilitate the folding and maturation of secretory and membrane proteins in the endoplasmic reticulum.",
      "ERAP1 and ERAP2 play a role in autophagy, the degradation of cellular components.",
      "ERAP1 and ERAP2 are involved in the cellular stress response.",
      "Altered expression and function of ERAP1 and ERAP2 have been implicated in various types of cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ERAP1-ERAP2 dimerization is not specifically involved in the endoplasmic reticulum-associated degradation (ERAD) pathway, but rather in the generation of peptide ligands for the major histocompatibility complex (MHC) class I molecules.\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-2-7b-chat-hf_response": "R-spondin 1 and Noggin are two proteins that play important roles in the regulation of gallbladder function, particularly in non-damaged gallbladders. Here is a detailed answer to your question:\nR-spondin 1 (Rspo1) is a secreted protein that is primarily expressed in the gallbladder. It is a member of the R-spondin family of proteins, which are characterized by their ability to bind to and inhibit the activity of the bone morphogenetic protein (BMP) receptor complex. In the gallbladder, Rspo1 plays a crucial role in regulating the contractility of the gallbladder muscle and the secretion of bile.\nStudies have shown that Rspo1 is upregulated in response to feeding and hormonal stimulation, and it is required for the normal secretion of bile from the gallbladder. Rspo1 regulates the expression of genes involved in bile secretion, such as the canalicular bile acid transporter (ABCB11) and the bile salt export pump (BSEP), and it also inhibits the expression of genes involved in the contraction of the gallbladder muscle.\nNoggin (Ngn) is a secreted protein that is also expressed in the gallbladder. It is a member of the BMP antagonist family, which includes other proteins such as Rspo1 and chordin. Noggin functions as a negative regulator of BMP signaling, and it is required for the proper formation and maintenance of the gallbladder.\nStudies have shown that Noggin is upregulated in response to feeding and hormonal stimulation, and it is required for the normal secretion of bile from the gallbladder. Noggin regulates the expression of genes involved in bile secretion, such as ABCB11 and BSEP, and it also inhibits the expression of genes involved in the contraction of the gallbladder muscle.\nIn non-damaged gallbladders, Rspo1 and Noggin work together to regulate the balance between bile secretion and gallbladder contractility. Rspo1 promotes",
    "llama-2-7b-chat-hf_fact_raw": "1. R-spondin 1 (Rspo1) is a secreted protein primarily expressed in the gallbladder.\n2. Rspo1 is a member of the R-spondin family of proteins which inhibit the activity of the BMP receptor complex.\n3. Rspo1 regulates the contraction of the gallbladder muscle and the secretion of bile.\n4. Noggin (Ngn) is a secreted protein belonging to the BMP antagonist family and is expressed in the gallbladder.\n5. Rspo1 and Noggin regulate genes involved in bile secretion, such as ABCB11 and BSEP, and inhibit genes involved in gallbladder muscle contraction.",
    "llama-2-7b-chat-hf_fact": [
      "R-spondin 1 (Rspo1) is a secreted protein primarily expressed in the gallbladder.",
      "Rspo1 is a member of the R-spondin family of proteins which inhibit the activity of the BMP receptor complex.",
      "Rspo1 regulates the contraction of the gallbladder muscle and the secretion of bile.",
      "Noggin (Ngn) is a secreted protein belonging to the BMP antagonist family and is expressed in the gallbladder.",
      "Rspo1 and Noggin regulate genes involved in bile secretion, such as ABCB11 and BSEP, and inhibit genes involved in gallbladder muscle contraction."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: R-spondin family proteins actually activate the Wnt signaling pathway, not inhibit the BMP receptor complex.\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "llama-2-7b-chat-hf_response": "Yes, NADPH oxidase 5 (NOX5) is a heterotetrameric enzyme, meaning it is composed of four subunits: two catalytic subunits (Nox5A and Nox5B) and two regulatory subunits (Nox5R1 and Nox5R2). These subunits work together to form a functional enzyme complex.\nThe catalytic subunits (Nox5A and Nox5B) are responsible for the transfer of electrons from NADPH to oxygen, resulting in the production of superoxide anions (O2-). The regulatory subunits (Nox5R1 and Nox5R2) play a crucial role in regulating the activity of the enzyme, including substrate binding, enzyme-enzyme interactions, and the response to oxidative stress.\nStudies have shown that the activity of NOX5 is modulated by the interaction of its regulatory subunits with other proteins, such as the small GTPase Rac1 and the protein kinase C (PKC). These interactions can affect the localization and activity of the enzyme, and are important for regulating the production of reactive oxygen species (ROS) in response to various signals.\nIn addition, recent studies have identified multiple phosphorylation sites on the Nox5 subunits, which can also regulate its activity. For example, phosphorylation of Nox5A on serine 142 has been shown to enhance its activity, while phosphorylation of Nox5B on threonine 174 can inhibit its activity.\nOverall, the function of NOX5 requires the coordinated action of its four subunits, and the regulation of its activity by multiple mechanisms, including subunit interactions, phosphorylation, and binding to other proteins.",
    "llama-2-7b-chat-hf_fact_raw": "1. NADPH oxidase 5 (NOX5) is a heterotetrameric enzyme composed of four subunits.\n2. The catalytic subunits of NOX5 include Nox5A and Nox5B.\n3. The regulatory subunits of NOX5 include Nox5R1 and Nox5R2.\n4. The activity of NOX5 can be modulated by interactions with proteins such as Rac1 and PKC.\n5. Phosphorylation can regulate the activity of NOX5 subunits, such as Nox5A on serine 142 and Nox5B on threonine 174.",
    "llama-2-7b-chat-hf_fact": [
      "NADPH oxidase 5 (NOX5) is a heterotetrameric enzyme composed of four subunits.",
      "The catalytic subunits of NOX5 include Nox5A and Nox5B.",
      "The regulatory subunits of NOX5 include Nox5R1 and Nox5R2.",
      "The activity of NOX5 can be modulated by interactions with proteins such as Rac1 and PKC.",
      "Phosphorylation can regulate the activity of NOX5 subunits, such as Nox5A on serine 142 and Nox5B on threonine 174."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: NADPH oxidase 5 (NOX5) is not a heterotetrameric enzyme; it is a homologous enzyme that does not require cytosolic subunits for its activity.\n2. FALSE [correction]: The catalytic subunit of NOX5 is simply referred to as NOX5 or Nox5; there are no distinct subunits called Nox5A and Nox5B.\n3. FALSE [correction]: NOX5 does not have regulatory subunits named Nox5R1 and Nox5R2.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "llama-2-7b-chat-hf_response": "Furin and hepcidin are two proteins that are closely related in their functions, particularly in the regulation of iron metabolism. Here's a detailed explanation of their connection:\nFurin is a protease enzyme that is primarily involved in the processing and activation of other proteins. It is synthesized in the liver and secreted into the bloodstream, where it can cleave a variety of target proteins, including other proteases, growth factors, and hormones. One of the key targets of furin is the iron-regulatory hormone hepcidin.\nHepcidin is a small peptide hormone that is produced in the liver and plays a central role in regulating iron metabolism. It does this by binding to iron-regulatory proteins (IRPs) in the cytoplasm of cells, where it inhibits the activity of iron-responsive elements (IREs) in the messenger RNA (mRNA) of iron-uptake genes. This results in a decrease in the expression of genes involved in iron uptake and storage, leading to reduced iron availability in the body.\nThe connection between furin and hepcidin lies in the fact that furin is involved in the processing and activation of hepcidin. Specifically, furin cleaves hepcidin into two main fragments: the N-terminal fragment (NT-hepcidin) and the C-terminal fragment (CT-hepcidin). These fragments have different functions in regulating iron metabolism.\nNT-hepcidin is the major form of hepcidin that is produced in the liver and is secreted into the bloodstream. It is primarily involved in the regulation of iron uptake and storage in the liver and other organs. NT-hepcidin binds to IRPs in the cytoplasm of cells, where it inhibits the activity of IREs in the mRNA of iron-uptake genes.\nCT-hepcidin, on the other hand, is produced in the liver and is secreted into the bloodstream in a proteolytically processed form. It is primarily involved in the regulation of iron metabolism in the bone marrow, where it inhibits the expression",
    "llama-2-7b-chat-hf_fact_raw": "1. Furin is a protease enzyme involved in the processing and activation of other proteins.\n2. Furin is synthesized in the liver and secreted into the bloodstream.\n3. Hepcidin is a small peptide hormone produced in the liver that plays a central role in regulating iron metabolism.\n4. Furin cleaves hepcidin into two main fragments: the N-terminal fragment (NT-hepcidin) and the C-terminal fragment (CT-hepcidin).\n5. NT-hepcidin is the major form of hepcidin that regulates iron uptake and storage in the liver and other organs.",
    "llama-2-7b-chat-hf_fact": [
      "Furin is a protease enzyme involved in the processing and activation of other proteins.",
      "Furin is synthesized in the liver and secreted into the bloodstream.",
      "Hepcidin is a small peptide hormone produced in the liver that plays a central role in regulating iron metabolism.",
      "Furin cleaves hepcidin into two main fragments: the N-terminal fragment (NT-hepcidin) and the C-terminal fragment (CT-hepcidin).",
      "NT-hepcidin is the major form of hepcidin that regulates iron uptake and storage in the liver and other organs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Furin is synthesized in various tissues and cells, not specifically in the liver.\n3. TRUE\n4. FALSE [correction]: Furin does not cleave hepcidin; hepcidin is synthesized as a precursor that is cleaved by other proteases.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "llama-2-7b-chat-hf_response": "The largest metabolic gene cluster in yeast is the glycolysis/gluconeogenesis gene cluster, also known as the \"Triosephosphate Pathway\" or \"Glycolytic Pathway\". This gene cluster is responsible for the breakdown of glucose and other sugars to produce energy and building blocks for the cell.\nThe glycolysis/gluconeogenesis gene cluster in yeast consists of 14 genes that are organized into three operons:\n1. HXK1-HXK2-PFK1: These genes encode for the enzymes involved in the first step of glycolysis, the conversion of glucose-6-phosphate to fructose-6-phosphate.\n2. PFK2-ENO1-PK: These genes encode for the enzymes involved in the second step of glycolysis, the conversion of fructose-6-phosphate to glyceraldehyde-3-phosphate.\n3. Gluconeogenesis: These genes encode for the enzymes involved in the synthesis of glucose from non-carbohydrate precursors, such as pyruvate, in the absence of glucose.\nThe genes in this gene cluster are highly expressed in yeast, and their products play critical roles in maintaining cellular energy homeostasis and supporting cell growth.\nIt's worth noting that the glycolysis/gluconeogenesis gene cluster in yeast is not the only metabolic gene cluster in the organism, other gene clusters such as the pentose phosphate pathway, the citric acid cycle, and the electron transport chain are also important for yeast metabolism.",
    "llama-2-7b-chat-hf_fact_raw": "1. The largest metabolic gene cluster in yeast is the glycolysis/gluconeogenesis gene cluster.\n2. The glycolysis/gluconeogenesis gene cluster is also known as the \"Triosephosphate Pathway\" or \"Glycolytic Pathway\".\n3. This gene cluster consists of 14 genes organized into three operons.\n4. The glycolysis/gluconeogenesis gene cluster is responsible for the breakdown of glucose and other sugars to produce energy and building blocks for the cell.\n5. The genes in this gene cluster are highly expressed in yeast and are critical for maintaining cellular energy homeostasis and supporting cell growth.",
    "llama-2-7b-chat-hf_fact": [
      "The largest metabolic gene cluster in yeast is the glycolysis/gluconeogenesis gene cluster.",
      "The glycolysis/gluconeogenesis gene cluster is also known as the \"Triosephosphate Pathway\" or \"Glycolytic Pathway\".",
      "This gene cluster consists of 14 genes organized into three operons.",
      "The glycolysis/gluconeogenesis gene cluster is responsible for the breakdown of glucose and other sugars to produce energy and building blocks for the cell.",
      "The genes in this gene cluster are highly expressed in yeast and are critical for maintaining cellular energy homeostasis and supporting cell growth."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "llama-2-7b-chat-hf_response": "LIMT (Long Non-Coding RNA in Testis) is a long non-coding RNA (lncRNA) that plays a crucial role in the regulation of male germ cell development and spermatogenesis. Here are some of the key functions of LIMT lncRNA:\n1. Transcriptional regulation: LIMT lncRNA acts as a transcriptional repressor by binding to the DNA of target genes and preventing their transcription. It has been shown to regulate the expression of genes involved in meiosis, spermatogenesis, and cell cycle progression in the testis.\n2. Epigenetic modification: LIMT lncRNA has been shown to regulate the epigenetic landscape of the genome by controlling the distribution of histone modifications and DNA methylation. This is important for the proper organization of chromatin and the activation of gene expression during spermatogenesis.\n3. Maintenance of genomic stability: LIMT lncRNA has been shown to be involved in the maintenance of genomic stability by regulating the expression of genes involved in DNA repair and by preventing the accumulation of DNA damage.\n4. Regulation of stem cell self-renewal: LIMT lncRNA has been shown to regulate the self-renewal of stem cells in the testis by controlling the expression of genes involved in stem cell maintenance and proliferation.\n5. Regulation of spermatid differentiation: LIMT lncRNA has been shown to regulate the differentiation of spermatids during spermatogenesis by controlling the expression of genes involved in this process.\n6. Regulation of meiosis: LIMT lncRNA has been shown to regulate meiosis by controlling the expression of genes involved in this process, including the meiosis-specific genes DMC1 and SYCP3.\n7. Regulation of the PI3K/Akt signaling pathway: LIMT lncRNA has been shown to regulate the PI3K/Akt signaling pathway, which is important for the regulation of cell survival and proliferation in the testis.\n8. Regulation of the Notch signaling pathway: LIMT lncRNA has",
    "llama-2-7b-chat-hf_fact_raw": "1. LIMT lncRNA plays a crucial role in the regulation of male germ cell development and spermatogenesis.\n2. LIMT lncRNA acts as a transcriptional repressor by binding to the DNA of target genes.\n3. LIMT lncRNA regulates the epigenetic landscape of the genome by controlling histone modifications and DNA methylation.\n4. LIMT lncRNA is involved in the maintenance of genomic stability by regulating genes involved in DNA repair.\n5. LIMT lncRNA regulates the self-renewal of stem cells in the testis.",
    "llama-2-7b-chat-hf_fact": [
      "LIMT lncRNA plays a crucial role in the regulation of male germ cell development and spermatogenesis.",
      "LIMT lncRNA acts as a transcriptional repressor by binding to the DNA of target genes.",
      "LIMT lncRNA regulates the epigenetic landscape of the genome by controlling histone modifications and DNA methylation.",
      "LIMT lncRNA is involved in the maintenance of genomic stability by regulating genes involved in DNA repair.",
      "LIMT lncRNA regulates the self-renewal of stem cells in the testis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Without additional context or specific scientific references provided, it cannot be determined whether these statements regarding the functions of LIMT lncRNA are true or false.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-2-7b-chat-hf_response": "Great question! There are several R packages available for performing SNP (Single Nucleotide Polymorphism) enrichment analysis, but some of the most popular and widely used packages are:\n1. \"SNPave\" package: This package provides a comprehensive set of tools for performing SNP enrichment analysis, including Fisher's exact test, chi-square test, and others. It also allows for the calculation of expected values for the observed test statistics, which can be useful for comparing the results to a null hypothesis.\n2. \"GSEA\" package: This package (Broad Institute) is a popular tool for identifying gene sets that are enriched among a set of genes that are associated with a particular disease or trait. It uses a ranking-based approach to identify the most important gene sets, and can be used for both fixed and random effect models.\n3. \"Enrichr\" package: This package (University of California, San Diego) provides a comprehensive set of tools for performing gene set enrichment analysis, including Fisher's exact test, chi-square test, and others. It also allows for the calculation of expected values for the observed test statistics, which can be useful for comparing the results to a null hypothesis.\n4. \"Plink\" package: This package (University of California, San Diego) is a popular tool for performing association studies, including SNP enrichment analysis. It provides a simple and efficient way to perform association tests, and can be used for both fixed and random effect models.\n5. \"MuMIn\" package: This package (University of California, San Diego) is a popular tool for performing gene set enrichment analysis, including Fisher's exact test, chi-square test, and others. It also allows for the calculation of expected values for the observed test statistics, which can be useful for comparing the results to a null hypothesis.\n6. \"limma\" package: This package (University of California, San Diego) is a popular tool for performing gene expression analysis, including SNP enrichment analysis. It provides a comprehensive set of tools for analyzing gene expression data, including limma, which is a linear model for microarray analysis.\n7. \"ggsnpex\" package: This package (University of California, San Diego) is a popular tool for performing SNP enrichment analysis, including",
    "llama-2-7b-chat-hf_fact_raw": "1. \"SNPave\" package provides tools for SNP enrichment analysis including Fisher's exact test and chi-square test.\n2. \"GSEA\" package is used for identifying gene sets enriched among genes associated with a disease or trait using a ranking-based approach.\n3. \"Enrichr\" package offers tools for gene set enrichment analysis including Fisher's exact test and chi-square test.\n4. \"Plink\" package is used for performing association studies, including SNP enrichment analysis.\n5. \"limma\" package is used for gene expression analysis, including SNP enrichment analysis.",
    "llama-2-7b-chat-hf_fact": [
      "\"SNPave\" package provides tools for SNP enrichment analysis including Fisher's exact test and chi-square test.",
      "\"GSEA\" package is used for identifying gene sets enriched among genes associated with a disease or trait using a ranking-based approach.",
      "\"Enrichr\" package offers tools for gene set enrichment analysis including Fisher's exact test and chi-square test.",
      "\"Plink\" package is used for performing association studies, including SNP enrichment analysis.",
      "\"limma\" package is used for gene expression analysis, including SNP enrichment analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. FALSE [correction]: \"Plink\" package is used for whole genome association analysis and not specifically for SNP enrichment analysis.\n5. FALSE [correction]: \"limma\" package is used for analyzing gene expression data but does not include SNP enrichment analysis.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "llama-2-7b-chat-hf_response": "Radial glial cells are a type of glial cell that are found in the developing brain and play a crucial role in the specification and differentiation of ependymal cells. Ependymal cells are a type of glial cell that line the ventricles of the brain and play a critical role in the production and circulation of cerebrospinal fluid (CSF). Here are some of the key players involved in radial glial specification to ependymal cells:\n1. Notch signaling pathway: The Notch signaling pathway is a critical regulator of radial glial specification and differentiation to ependymal cells. Notch is a transmembrane receptor that is activated by the binding of its ligands, Jagged1 and Delta-like 1, on the surface of radial glia. Activation of Notch signaling leads to the expression of genes involved in ependymal cell differentiation and the maintenance of radial glial identity.\n2. Sox2: Sox2 is a transcription factor that is essential for the maintenance of radial glial identity and the specification of ependymal cells. Sox2 is expressed in radial glia and is required for the proper differentiation of ependymal cells.\n3. Pax7: Pax7 is a transcription factor that is expressed in radial glia and is required for the proper differentiation of ependymal cells. Pax7 regulates the expression of genes involved in ependymal cell differentiation and is necessary for the maintenance of ependymal cell identity.\n4. NeuroD: NeuroD is a transcription factor that is expressed in radial glia and is required for the proper differentiation of ependymal cells. NeuroD regulates the expression of genes involved in ependymal cell differentiation and is necessary for the maintenance of ependymal cell identity.\n5. Shh: Shh is a secreted signaling molecule that is involved in the regulation of radial glial specification and differentiation to ependymal cells. Shh signaling is important for the proper differentiation of ependymal cells and is necessary for the maintenance of ependymal cell identity.\n6. Wnt/-catenin signaling pathway: The Wnt/-catenin signaling pathway is also",
    "llama-2-7b-chat-hf_fact_raw": "1. Radial glial cells play a crucial role in the specification and differentiation of ependymal cells.\n2. Notch signaling pathway is a critical regulator of radial glial specification to ependymal cells.\n3. Sox2 is essential for the maintenance of radial glial identity and the specification of ependymal cells.\n4. Pax7 is required for the proper differentiation of ependymal cells and the maintenance of ependymal cell identity.\n5. Shh signaling is important for the proper differentiation of ependymal cells and the maintenance of ependymal cell identity.",
    "llama-2-7b-chat-hf_fact": [
      "Radial glial cells play a crucial role in the specification and differentiation of ependymal cells.",
      "Notch signaling pathway is a critical regulator of radial glial specification to ependymal cells.",
      "Sox2 is essential for the maintenance of radial glial identity and the specification of ependymal cells.",
      "Pax7 is required for the proper differentiation of ependymal cells and the maintenance of ependymal cell identity.",
      "Shh signaling is important for the proper differentiation of ependymal cells and the maintenance of ependymal cell identity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "llama-2-7b-chat-hf_response": "Triple negative gliomas are a type of brain tumor that is characterized by the lack of expression of certain proteins that are typically used to diagnose and classify gliomas. These proteins include:\n1. Tumor Suppressor Proteins: Triple negative gliomas typically lack the expression of tumor suppressor proteins such as TP53, PTEN, and BRCA1. These proteins play a crucial role in regulating cell growth and preventing the formation of tumors.\n2. Markers of Malignancy: Triple negative gliomas often lack the expression of markers of malignancy such as EGFR, HER2, and MIB1. These markers are used to diagnose and classify gliomas based on their degree of malignancy.\n3. GLI1 and GLI2: Triple negative gliomas typically express low levels of GLI1 and GLI2, which are transcription factors that play a role in regulating the expression of genes involved in cell growth and differentiation.\n4. IDH1 and IDH2: Triple negative gliomas often have mutations in the IDH1 and IDH2 genes, which are involved in the production of energy in cells. These mutations are found in a subset of gliomas and are associated with a more aggressive tumor phenotype.\n5. P53 Mutations: Triple negative gliomas often have mutations in the TP53 gene, which is a tumor suppressor gene that plays a crucial role in regulating cell growth and preventing the formation of tumors.\n6. Cytogenetic Abnormalities: Triple negative gliomas may have cytogenetic abnormalities such as aneuploidy, polyploidy, and structural abnormalities.\n7. Immunophenotype: Triple negative gliomas often have a distinct immunophenotype, which can be used to differentiate them from other types of gliomas. This includes the absence of expression of certain markers such as MART1 and CD133.\n8. Genetic Alterations: Triple negative gliomas often have genetic alterations such as mutations in the TP53, PTEN, and BRCA1 genes, as well as amplification of the",
    "llama-2-7b-chat-hf_fact_raw": "1. Triple negative gliomas lack the expression of tumor suppressor proteins such as TP53, PTEN, and BRCA1.\n2. Triple negative gliomas often lack the expression of markers of malignancy such as EGFR, HER2, and MIB1.\n3. Triple negative gliomas typically express low levels of transcription factors GLI1 and GLI2.\n4. Triple negative gliomas often have mutations in the IDH1 and IDH2 genes.\n5. Triple negative gliomas often have a distinct immunophenotype, including the absence of expression of certain markers such as MART1 and CD133.",
    "llama-2-7b-chat-hf_fact": [
      "Triple negative gliomas lack the expression of tumor suppressor proteins such as TP53, PTEN, and BRCA1.",
      "Triple negative gliomas often lack the expression of markers of malignancy such as EGFR, HER2, and MIB1.",
      "Triple negative gliomas typically express low levels of transcription factors GLI1 and GLI2.",
      "Triple negative gliomas often have mutations in the IDH1 and IDH2 genes.",
      "Triple negative gliomas often have a distinct immunophenotype, including the absence of expression of certain markers such as MART1 and CD133."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Triple negative gliomas often lack the expression of hormone receptors such as estrogen receptor (ER), progesterone receptor (PR), and HER2 (also known as ERBB2), not markers of malignancy like EGFR, HER2, and MIB1.\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "llama-2-7b-chat-hf_response": "TOPAZ1 is a software framework designed for modeling and simulation of various types of physical systems, including quantum systems, condensed matter systems, and optical systems. It is an open-source software package developed by the Topaz Project, a collaboration between researchers at the University of California, Berkeley and the University of Michigan.\nTOPAZ1 is built on top of the Python programming language and uses a modular architecture to provide a flexible and extensible platform for a wide range of simulations. It is designed to be user-friendly and accessible to researchers with varying levels of expertise, from beginners to experienced simulators.\nSome of the key features of TOPAZ1 include:\n1. Quantum Simulation: TOPAZ1 provides a range of tools for simulating quantum systems, including quantum circuits, quantum field theories, and many-body localization. It also includes a number of pre-built simulations for quantum devices such as superconducting qubits and ion traps.\n2. Condensed Matter Simulation: TOPAZ1 can be used to simulate a wide range of condensed matter systems, including metals, semiconductors, and insulators. It includes tools for modeling electronic structures, phonons, and other relevant excitations.\n3. Optical Simulation: TOPAZ1 provides a number of tools for simulating optical systems, including waveguides, optical fibers, and optical resonators. It also includes a number of pre-built simulations for optical devices such as lasers and optical filters.\n4. Plugins and Extensions: TOPAZ1 has a number of plugins and extensions available, including tools for simulating quantum field theories, condensed matter systems, and optical systems. It also includes a number of pre-built simulations for a wide range of physical systems.\n5. User-Friendly Interface: TOPAZ1 has a user-friendly interface that allows users to easily define and simulate physical systems. It includes a number of pre-built examples and tutorials to help users get started with the software.\n6. Scalability: TOPAZ1 is designed to be highly scalable, allowing users to simulate large and complex systems on high-performance computing platforms.\n7. Flexibility: TOPAZ1 is highly flexible and can be used to simulate a wide range of physical systems",
    "llama-2-7b-chat-hf_fact_raw": "1. TOPAZ1 is a software framework designed for modeling and simulation of various types of physical systems.\n2. The Topaz Project, a collaboration between researchers at the University of California, Berkeley and the University of Michigan, developed TOPAZ1.\n3. TOPAZ1 is built on top of the Python programming language.\n4. TOPAZ1 includes tools for simulating quantum systems, condensed matter systems, and optical systems.\n5. TOPAZ1 is designed to be user-friendly and accessible to researchers with varying levels of expertise.",
    "llama-2-7b-chat-hf_fact": [
      "TOPAZ1 is a software framework designed for modeling and simulation of various types of physical systems.",
      "The Topaz Project, a collaboration between researchers at the University of California, Berkeley and the University of Michigan, developed TOPAZ1.",
      "TOPAZ1 is built on top of the Python programming language.",
      "TOPAZ1 includes tools for simulating quantum systems, condensed matter systems, and optical systems.",
      "TOPAZ1 is designed to be user-friendly and accessible to researchers with varying levels of expertise."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "llama-2-7b-chat-hf_response": "GATA-1 is a transcription factor that plays a crucial role in the development and function of hematopoietic cells, including red blood cells, white blood cells, and platelets. There are several isoforms of the GATA-1 protein, each with distinct functions and expression patterns. The expression of these isoforms is controlled by multiple genetic and epigenetic factors, including transcriptional regulators, post-transcriptional modifications, and chromatin structure.\nThe gene that controls the expression of GATA-1 isoforms is a complex and multi-step process, involving several genetic and epigenetic factors. Here are some of the key factors that influence the expression of GATA-1 isoforms:\n1. Transcriptional regulators: GATA-1 is a transcriptional target of several transcription factors, including GATA-2, GATA-3, and NF-E2. These transcription factors bind to specific DNA sequences in the GATA-1 promoter region and enhance its transcription.\n2. Post-transcriptional modifications: GATA-1 is subject to several post-transcriptional modifications, including phosphorylation, acetylation, and ubiquitination. These modifications can affect the stability, localization, and activity of GATA-1, and thereby influence its isoform expression.\n3. Chromatin structure: The chromatin structure of the GATA-1 locus can also influence its expression. The locus is located on chromosome 2q37, and its expression is influenced by the presence of specific chromatin modifications, such as histone acetylation and histone methylation.\n4. Non-coding RNAs: Non-coding RNAs, such as microRNAs and long non-coding RNAs, can also regulate the expression of GATA-1 isoforms. These RNAs can bind to specific sequences in the GATA-1 mRNA and prevent its translation or induce its degradation.\n5. Epigenetic modifications: Epigenetic modifications, such as DNA methylation and histone modifications, can also influence the expression of GATA-1 isoforms. These modifications can affect the accessibility of the GATA-1 locus to transcription factors and other regulatory proteins, thereby controlling",
    "llama-2-7b-chat-hf_fact_raw": "1. GATA-1 is a transcription factor that plays a role in the development and function of hematopoietic cells.\n2. There are several isoforms of the GATA-1 protein.\n3. The expression of GATA-1 isoforms is a complex process involving multiple genetic and epigenetic factors.\n4. The gene for GATA-1 is located on chromosome 2q37.\n5. Non-coding RNAs, such as microRNAs and long non-coding RNAs, can regulate the expression of GATA-1 isoforms.",
    "llama-2-7b-chat-hf_fact": [
      "GATA-1 is a transcription factor that plays a role in the development and function of hematopoietic cells.",
      "There are several isoforms of the GATA-1 protein.",
      "The expression of GATA-1 isoforms is a complex process involving multiple genetic and epigenetic factors.",
      "The gene for GATA-1 is located on chromosome 2q37.",
      "Non-coding RNAs, such as microRNAs and long non-coding RNAs, can regulate the expression of GATA-1 isoforms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The gene for GATA-1 is located on the X chromosome, specifically Xp11.23.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "llama-2-7b-chat-hf_response": "MIRA-seq is a powerful tool in the field of RNA sequencing (RNA-seq) that enables the analysis of large-scale RNA sequencing data. It was developed by the computational biology group at the University of California, San Diego, and is widely used in research institutions and biotech companies around the world.\nMIRA-seq stands for \"Motif-based Inference of RNA sequence\" and it is designed to identify and characterize the functional elements in RNA transcripts, such as gene expression, splicing, and alternative splicing events. The tool uses a novel computational approach that combines motif discovery, de novo motif finding, and sequence conservation analysis to identify functional elements in RNA transcripts.\nHere are some key features and applications of MIRA-seq:\n1. Motif discovery: MIRA-seq uses a probabilistic model to identify short, conserved sequence motifs in RNA transcripts. These motifs can be functional elements such as splice sites, start and stop codons, or other regulatory elements.\n2. De novo motif finding: In addition to identifying known motifs, MIRA-seq can also discover new motifs that are not present in the training data. This makes it possible to identify novel functional elements in RNA transcripts.\n3. Sequence conservation analysis: MIRA-seq uses a phylogenetic footprinting approach to identify highly conserved regions in RNA transcripts. These regions are likely to be functional elements that are important for the proper expression and regulation of genes.\n4. Gene ontology enrichment analysis: MIRA-seq can be used to identify overrepresented gene ontology (GO) terms in the functional elements identified by the tool. This can help researchers understand the biological processes and pathways that are affected by the identified functional elements.\n5. Visualization and interpretation: MIRA-seq provides a range of visualization tools to help researchers interpret the results of their analysis. These tools include heat maps, conservation plots, and motif visualization.\nSome of the applications of MIRA-seq include:\n1. Identifying novel regulatory elements: MIRA-seq can be used to identify new regulatory elements that are not present in the reference genome. These elements can be important for",
    "llama-2-7b-chat-hf_fact_raw": "1. MIRA-seq is a tool used for the analysis of large-scale RNA sequencing data.\n2. MIRA-seq was developed by the computational biology group at the University of California, San Diego.\n3. MIRA-seq stands for \"Motif-based Inference of RNA sequence.\"\n4. MIRA-seq uses a probabilistic model to identify short, conserved sequence motifs in RNA transcripts.\n5. MIRA-seq can perform gene ontology enrichment analysis to identify overrepresented gene ontology terms.",
    "llama-2-7b-chat-hf_fact": [
      "MIRA-seq is a tool used for the analysis of large-scale RNA sequencing data.",
      "MIRA-seq was developed by the computational biology group at the University of California, San Diego.",
      "MIRA-seq stands for \"Motif-based Inference of RNA sequence.\"",
      "MIRA-seq uses a probabilistic model to identify short, conserved sequence motifs in RNA transcripts.",
      "MIRA-seq can perform gene ontology enrichment analysis to identify overrepresented gene ontology terms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: MIRA-seq stands for \"Massively Integrated RNA-seq.\"\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "llama-2-7b-chat-hf_response": "ARCALYST is a medication used to treat inflammatory conditions, specifically for the treatment of acute and chronic pain, and for the management of osteoarthritis. The active ingredient in ARCALYST is rilonacept, which is a recombinant drug that works by blocking the activity of a protein called interleukin-1 (IL-1).\nIL-1 is a pro-inflammatory cytokine that plays a key role in the inflammatory response. When IL-1 is present in the body, it can cause inflammation and pain, which can lead to a range of conditions, including osteoarthritis, acute and chronic pain, and other inflammatory conditions. By blocking the activity of IL-1, rilonacept can help to reduce inflammation and pain, and improve the overall condition of the patient.\nARCALYST is administered via injection, usually given every two weeks. The dosage and frequency of administration may vary depending on the specific condition being treated and the patient's response to the medication.\nSome of the potential side effects of ARCALYST include:\n* Injection site reactions (such as redness, swelling, or itching)\n* Headache\n* Fatigue\n* Nausea\n* Abdominal pain\n* Muscle or joint pain\n* Chest tightness\n* Dizziness\n* Rash\nIt is important to note that ARCALYST can lower the body's ability to fight infections, so patients should avoid contact with people who have infections and avoid taking live vaccines while taking this medication.\nIt is also important to inform your doctor of any other medications you are taking, including over-the-counter medications and supplements, as these can interact with ARCALYST and increase the risk of side effects.\nIn summary, ARCALYST is a medication used to treat inflammatory conditions, specifically for the treatment of acute and chronic pain, and for the management of osteoarthritis. It works by blocking the activity of the protein IL-1, which is a key player in the inflammatory response. While it can be effective in reducing inflammation and pain, it is important to",
    "llama-2-7b-chat-hf_fact_raw": "1. ARCALYST is used to treat inflammatory conditions including acute and chronic pain, and osteoarthritis.\n2. The active ingredient in ARCALYST is rilonacept.\n3. Rilonacept works by blocking the activity of the protein interleukin-1 (IL-1).\n4. ARCALYST is administered via injection every two weeks.\n5. Potential side effects of ARCALYST include injection site reactions, headache, fatigue, nausea, abdominal pain, muscle or joint pain, chest tightness, dizziness, and rash.",
    "llama-2-7b-chat-hf_fact": [
      "ARCALYST is used to treat inflammatory conditions including acute and chronic pain, and osteoarthritis.",
      "The active ingredient in ARCALYST is rilonacept.",
      "Rilonacept works by blocking the activity of the protein interleukin-1 (IL-1).",
      "ARCALYST is administered via injection every two weeks.",
      "Potential side effects of ARCALYST include injection site reactions, headache, fatigue, nausea, abdominal pain, muscle or joint pain, chest tightness, dizziness, and rash."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ARCALYST is used to treat cryopyrin-associated periodic syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome. It is not indicated for acute or chronic pain or osteoarthritis.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-2-7b-chat-hf_response": "Certainly! Robertsonian translocation is a type of chromosomal abnormality that involves the exchange of genetic material between two acrocentric chromosomes (chromosomes 1, 9, 10, or 11). Acrocentric chromosomes are characterized by their short arms and long arms, and they typically contain most of the genetic material that is important for the development and function of the body.\nIn a Robertsonian translocation, a portion of one acrocentric chromosome breaks off and attaches to another acrocentric chromosome, resulting in a change in the number or structure of the chromosomes. The human acrocentric chromosomes that are involved in Robertsonian translocation are:\n1. Chromosome 14: This chromosome is involved in approximately 75% of all Robertsonian translocations. The translocation typically involves the short arm of chromosome 14 (14q) and can result in a variety of clinical features, including growth retardation, intellectual disability, and congenital anomalies.\n2. Chromosome 17: This chromosome is involved in approximately 10% of all Robertsonian translocations. The translocation typically involves the long arm of chromosome 17 (17q) and can result in a variety of clinical features, including growth retardation, intellectual disability, and congenital anomalies.\n3. Chromosome 15: This chromosome is involved in approximately 5% of all Robertsonian translocations. The translocation typically involves the short arm of chromosome 15 (15q) and can result in a variety of clinical features, including growth retardation, intellectual disability, and congenital anomalies.\n4. Chromosome 9: This chromosome is involved in approximately 5% of all Robertsonian translocations. The translocation typically involves the long arm of chromosome 9 (9q) and can result in a variety of clinical features, including growth retardation, intellectual disability, and congenital anomalies.\n5. Chromosome 10: This chromosome is involved in approximately 5",
    "llama-2-7b-chat-hf_fact_raw": "1. Robertsonian translocation involves the exchange of genetic material between acrocentric chromosomes.\n2. The acrocentric chromosomes that can be involved in Robertsonian translocation are 14, 17, 15, 9, and sometimes 10.\n3. Chromosome 14 is involved in approximately 75% of all Robertsonian translocations.\n4. Chromosome 17 is involved in approximately 10% of all Robertsonian translocations.\n5. Chromosomes 15 and 9 each are involved in approximately 5% of all Robertsonian translocations.",
    "llama-2-7b-chat-hf_fact": [
      "Robertsonian translocation involves the exchange of genetic material between acrocentric chromosomes.",
      "The acrocentric chromosomes that can be involved in Robertsonian translocation are 14, 17, 15, 9, and sometimes 10.",
      "Chromosome 14 is involved in approximately 75% of all Robertsonian translocations.",
      "Chromosome 17 is involved in approximately 10% of all Robertsonian translocations.",
      "Chromosomes 15 and 9 each are involved in approximately 5% of all Robertsonian translocations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The acrocentric chromosomes that can be involved in Robertsonian translocation are 13, 14, 15, 21, and 22.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "llama-2-7b-chat-hf_response": "There are several R packages that can be used for the identification of pediatric brain tumors, depending on the specific type of analysis and the data available. Here are a few options:\n1. `brainTumor`: This package is specifically designed for the analysis of brain tumor data. It provides functions for segmenting brain structures, identifying tumor regions, and calculating tumor volumes. It also includes tools for visualizing brain tumor data and performing statistical analysis.\n2. `pediatricTumor`: This package is a collection of R functions for the analysis of pediatric tumor data. It includes functions for analyzing brain tumor data, as well as data from other pediatric tumor types, such as leukemia and neuroblastoma. It also provides tools for visualizing tumor data and performing statistical analysis.\n3. `survival`: This package is used for analyzing survival data, which can be useful for analyzing the progression of pediatric brain tumors. It provides functions for estimating survival curves, calculating survival rates, and performing statistical analysis of survival data.\n4. `rstan`: This package is a Bayesian statistical software package that can be used for analyzing pediatric brain tumor data. It provides functions for fitting Bayesian models to tumor data, as well as functions for visualizing and interpreting the results of these models.\n5. ` packages`: This package provides a collection of R functions for analyzing pediatric tumor data. It includes functions for analyzing brain tumor data, as well as data from other pediatric tumor types, such as leukemia and neuroblastoma. It also provides tools for visualizing tumor data and performing statistical analysis.\n6. `brainMRI`: This package is specifically designed for analyzing brain MRI data. It provides functions for segmenting brain structures, identifying tumor regions, and calculating tumor volumes. It also includes tools for visualizing brain MRI data and performing statistical analysis.\n7. `pediatricOncology`: This package is a collection of R functions for analyzing pediatric oncology data. It includes functions for analyzing brain tumor data, as well as data from other pediatric tumor types, such as leukemia and neuroblastoma. It also provides tools for visualizing tumor data and performing statistical",
    "llama-2-7b-chat-hf_fact_raw": "1. The `brainTumor` R package is designed for the analysis of brain tumor data and provides functions for segmenting brain structures and identifying tumor regions.\n2. The `pediatricTumor` R package includes functions for analyzing pediatric brain tumor data as well as other tumor types like leukemia and neuroblastoma.\n3. The `survival` R package is used for analyzing survival data, which can be relevant to the study of pediatric brain tumor progression.\n4. The `rstan` R package is a Bayesian statistical software package that can be utilized for analyzing pediatric brain tumor data.\n5. The `brainMRI` R package is specifically designed for analyzing brain MRI data, including functions for segmenting brain structures and identifying tumor regions.",
    "llama-2-7b-chat-hf_fact": [
      "The `brainTumor` R package is designed for the analysis of brain tumor data and provides functions for segmenting brain structures and identifying tumor regions.",
      "The `pediatricTumor` R package includes functions for analyzing pediatric brain tumor data as well as other tumor types like leukemia and neuroblastoma.",
      "The `survival` R package is used for analyzing survival data, which can be relevant to the study of pediatric brain tumor progression.",
      "The `rstan` R package is a Bayesian statistical software package that can be utilized for analyzing pediatric brain tumor data.",
      "The `brainMRI` R package is specifically designed for analyzing brain MRI data, including functions for segmenting brain structures and identifying tumor regions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "llama-2-7b-chat-hf_response": "NEMO (Nuclear Envelope-Associated Matrix-Organizing) is a protein that plays a crucial role in the regulation of nuclear transport and the maintenance of nuclear shape. While NEMO does contain zinc finger motifs, it is not a zinc finger protein in the classical sense.\nZinc finger proteins are a class of proteins that contain one or more zinc ions bound to cysteine residues, which form a structured domain that is involved in protein-protein interactions and DNA binding. Zinc finger proteins are typically involved in transcriptional regulation, DNA repair, and other cellular processes.\nNEMO, on the other hand, is a larger protein that contains multiple domains, including a zinc finger domain, a coiled-coil domain, and a proline-rich domain. The zinc finger domain of NEMO is responsible for binding to specific DNA sequences and mediating the interaction between NEMO and other proteins involved in nuclear transport.\nWhile NEMO does contain zinc finger motifs, its function is distinct from that of traditional zinc finger proteins. NEMO is primarily involved in the regulation of nuclear transport and the maintenance of nuclear shape, rather than in transcriptional regulation or DNA binding.\nIn summary, while NEMO does contain zinc finger motifs, it is not a zinc finger protein in the classical sense. It is a unique protein with a distinct function that plays a critical role in the regulation of nuclear transport and the maintenance of nuclear shape.",
    "llama-2-7b-chat-hf_fact_raw": "1. NEMO stands for Nuclear Envelope-Associated Matrix-Organizing protein.\n2. NEMO contains zinc finger motifs.\n3. Zinc finger proteins typically have zinc ions bound to cysteine residues.\n4. The zinc finger domain in NEMO is responsible for binding to specific DNA sequences.\n5. NEMO is involved in the regulation of nuclear transport and the maintenance of nuclear shape.",
    "llama-2-7b-chat-hf_fact": [
      "NEMO stands for Nuclear Envelope-Associated Matrix-Organizing protein.",
      "NEMO contains zinc finger motifs.",
      "Zinc finger proteins typically have zinc ions bound to cysteine residues.",
      "The zinc finger domain in NEMO is responsible for binding to specific DNA sequences.",
      "NEMO is involved in the regulation of nuclear transport and the maintenance of nuclear shape."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: NEMO stands for NF-kappa-B essential modulator.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: NEMO does not have a zinc finger domain responsible for binding to DNA sequences; it is involved in the NF-kappa-B signaling pathway.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "llama-2-7b-chat-hf_response": "TFIIS (Transcription Factor IIIS) is a transcriptional elongation factor that plays a crucial role in the regulation of gene expression by modulating the processivity of RNA polymerase II (RNAPII) during transcription. While TFIIS does not directly affect nucleosome positioning, it can indirectly influence nucleosome dynamics and gene expression by modulating the interaction between RNAPII and nucleosomes.\nNucleosomes are the basic units of chromatin, consisting of a segment of DNA wrapped around a core of eight histone proteins (two copies each of histones H2A, H2B, H3, and H4). Nucleosomes are positioned along the DNA molecule in a specific manner, with the histone proteins forming a barrier that can affect the accessibility of the DNA to the transcriptional machinery.\nTFIIS is a helicase-like protein that helps to unwind the DNA double helix and facilitates the processivity of RNAPII during transcription. TFIIS recognizes and binds to the RNAPII complex at the +1 position of the transcription start site, and then helps to recruit the RNAPII complex to the promoter region. Once the RNAPII complex is positioned at the promoter, TFIIS helps to displace the nucleosome at the transcription start site, allowing RNAPII to access the promoter region and initiate transcription.\nWhile TFIIS does not directly affect nucleosome positioning, its role in recruiting RNAPII to the promoter region and disrupting nucleosome barriers can indirectly influence nucleosome dynamics and gene expression. By facilitating the processivity of RNAPII, TFIIS can increase the amount of transcript produced from a gene, which can in turn affect the expression level of that gene. Additionally, the disruption of nucleosome barriers by TFIIS can allow for more efficient access to the promoter region, which can also influence gene expression.\nIn summary, while TFIIS does not directly affect nucleosome positioning, it can indirectly influence nucleosome dynamics and gene expression by modulating the interaction between RNAPII and nucleosomes",
    "llama-2-7b-chat-hf_fact_raw": "1. TFIIS is a transcriptional elongation factor that modulates the processivity of RNA polymerase II during transcription.\n2. Nucleosomes are composed of a segment of DNA wrapped around a core of eight histone proteins.\n3. TFIIS is a helicase-like protein that assists in unwinding the DNA double helix.\n4. TFIIS binds to the RNA polymerase II complex at the +1 position of the transcription start site.\n5. TFIIS helps to recruit the RNA polymerase II complex to the promoter region and displace the nucleosome at the transcription start site.",
    "llama-2-7b-chat-hf_fact": [
      "TFIIS is a transcriptional elongation factor that modulates the processivity of RNA polymerase II during transcription.",
      "Nucleosomes are composed of a segment of DNA wrapped around a core of eight histone proteins.",
      "TFIIS is a helicase-like protein that assists in unwinding the DNA double helix.",
      "TFIIS binds to the RNA polymerase II complex at the +1 position of the transcription start site.",
      "TFIIS helps to recruit the RNA polymerase II complex to the promoter region and displace the nucleosome at the transcription start site."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: TFIIS is not a helicase-like protein; it does not assist in unwinding the DNA double helix. It instead stimulates RNA polymerase II's intrinsic nuclease activity to clear transcriptional blockages.\n4. UNKNOWN\n5. FALSE [correction]: TFIIS does not help in recruiting the RNA polymerase II complex to the promoter region or in displacing the nucleosome. Its main role is to enhance the elongation phase of transcription by allowing RNA polymerase II to cleave the nascent RNA during backtracking.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "llama-2-7b-chat-hf_response": "The timing of origin firing during the yeast cell cycle is a complex process that involves multiple stages and regulatory factors. In budding yeast (Saccharomyces cerevisiae), there are two types of origins of replication: the early origin (E) and the late origin (L).\nThe early origin (E) is located near the centromere of the chromosome and fires around the G1/S transition, which is the beginning of the S phase of the cell cycle. This means that the E origin fires before the rest of the chromosomes and initiates the replication process. The early origin is thought to be regulated by the protein Mcm1, which binds to the origin and helps to recruit other proteins necessary for origin firing.\nOn the other hand, the late origin (L) is located further away from the centromere and fires around the G2/M transition, which is the end of the S phase and the beginning of the M phase of the cell cycle. This means that the L origin fires after the E origin and the rest of the chromosomes have already initiated replication. The late origin is regulated by a complex network of proteins, including the S-phase-specific protein Sld1 and the DNA-binding protein Mrc1.\nIt's worth noting that the timing of origin firing can vary depending on the specific conditions of the cell, such as the presence of certain nutrients or the level of DNA damage. Additionally, some studies have suggested that the timing of origin firing may be influenced by the expression of certain genes, although the exact mechanisms are not yet fully understood.\nIn summary, the origins of replication in yeast fire at different times during the cell cycle, with the early origin (E) firing before the rest of the chromosomes and the late origin (L) firing after. The timing of origin firing is regulated by a complex interplay of regulatory factors and cellular conditions.",
    "llama-2-7b-chat-hf_fact_raw": "1. In budding yeast (Saccharomyces cerevisiae), there are early origins (E) and late origins (L) of replication.\n2. The early origin (E) is located near the centromere of the chromosome and fires around the G1/S transition.\n3. The late origin (L) fires around the G2/M transition.\n4. The protein Mcm1 regulates the early origin by binding to it and recruiting other proteins necessary for origin firing.\n5. The late origin is regulated by proteins such as Sld1 and Mrc1.",
    "llama-2-7b-chat-hf_fact": [
      "In budding yeast (Saccharomyces cerevisiae), there are early origins (E) and late origins (L) of replication.",
      "The early origin (E) is located near the centromere of the chromosome and fires around the G1/S transition.",
      "The late origin (L) fires around the G2/M transition.",
      "The protein Mcm1 regulates the early origin by binding to it and recruiting other proteins necessary for origin firing.",
      "The late origin is regulated by proteins such as Sld1 and Mrc1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The late origin (L) generally fires later during S phase, not necessarily around the G2/M transition.\n4. TRUE \n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "llama-2-7b-chat-hf_response": "Mammalian GA-sequences, also known as microsatellites or simple repeat sequences, are short, repetitive DNA sequences found in the genomes of mammals. These sequences are composed of a small number of nucleotides (usually 2-5) that are repeated in a tandem array.\nHere are some of the key properties of mammalian GA-sequences:\n1. High variability: Mammalian GA-sequences are highly variable among individuals and species, which makes them useful for genetic studies. This variability is due to the random processes that occur during DNA replication and repair.\n2. Short repeat length: The repeat length of mammalian GA-sequences is typically short, ranging from 2-5 nucleotides. This is in contrast to longer repetitive sequences found in other organisms, such as the satellite DNA found in plants.\n3. Tandem repeat structure: Mammalian GA-sequences are organized in a tandem repeat structure, meaning that the repeat units are arranged head-to-tail in a linear fashion. This structure is thought to be the result of a process called imperfect palindromic repeats, which involves the unequal exchange of nucleotides during DNA replication.\n4. High GC content: Mammalian GA-sequences have a high GC content (greater than 50%), which is higher than many other types of repetitive DNA sequences. This high GC content may be due to the fact that these sequences are often located in regions of the genome that are rich in GC nucleotides.\n5. Lack of coding potential: Mammalian GA-sequences do not contain any coding potential, meaning that they do not encode any functional proteins or RNA molecules. This is in contrast to other types of repetitive DNA sequences, such as introns, which can encode functional RNA molecules.\n6. Widespread distribution: Mammalian GA-sequences are found throughout the genome, with the highest density of repeats located in the centromeric regions of chromosomes. They are also found in the telomeres, which are the repetitive DNA sequences that cap the ends of chromosomes.\n7. Age of the sequences: Mammalian GA-sequences are thought",
    "llama-2-7b-chat-hf_fact_raw": "1. Mammalian GA-sequences are composed of a small number of nucleotides (usually 2-5) that are repeated in a tandem array.\n2. They are highly variable among individuals and species, which makes them useful for genetic studies.\n3. The repeat length of mammalian GA-sequences typically ranges from 2-5 nucleotides.\n4. Mammalian GA-sequences have a high GC content (greater than 50%).\n5. Mammalian GA-sequences do not contain any coding potential, meaning they do not encode functional proteins or RNA molecules.",
    "llama-2-7b-chat-hf_fact": [
      "Mammalian GA-sequences are composed of a small number of nucleotides (usually 2-5) that are repeated in a tandem array.",
      "They are highly variable among individuals and species, which makes them useful for genetic studies.",
      "The repeat length of mammalian GA-sequences typically ranges from 2-5 nucleotides.",
      "Mammalian GA-sequences have a high GC content (greater than 50%).",
      "Mammalian GA-sequences do not contain any coding potential, meaning they do not encode functional proteins or RNA molecules."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Mammalian GA-sequences do not necessarily have a high GC content; the content can vary.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-2-7b-chat-hf_response": "Ah, a question about Groucho-related genes! *adjusts glasses*\nThe mouse genome contains a total of 19 Groucho-related genes (GRG), which are also known as Groucho-like genes or Grhl genes. These genes are involved in a variety of cellular processes, including transcriptional regulation, chromatin remodeling, and neuronal development.\nHere are the 19 GRGs found in the mouse genome:\n1. Grhl1 (Groucho-like 1)\n2. Grhl2 (Groucho-like 2)\n3. Grhl3 (Groucho-like 3)\n4. Grhl4 (Groucho-like 4)\n5. Grhl5 (Groucho-like 5)\n6. Grhl6 (Groucho-like 6)\n7. Grhl7 (Groucho-like 7)\n8. Grhl8 (Groucho-like 8)\n9. Grhl9 (Groucho-like 9)\n10. Grhl10 (Groucho-like 10)\n11. Grhl11 (Groucho-like 11)\n12. Grhl12 (Groucho-like 12)\n13. Grhl13 (Groucho-like 13)\n14. Grhl14 (Groucho-like 14)\n15. Grhl15 (Groucho-like 15)\n16. Grhl16 (Groucho-like 16)\n17. Grhl17 (Groucho-like 17)\n18. Grhl18 (Groucho-like 18)\n19. Grhl19 (Groucho-like 19)\nEach of these GRGs has a unique function and expression pattern in different cell types and tissues, although some of them show overlapping functions. For example, Grhl1 and Grhl2 are involved in the regulation of neural stem cell proliferation and differentiation, while Grhl3 and Grhl4 are involved in the control of muscle cell differentiation and muscle regeneration",
    "llama-2-7b-chat-hf_fact_raw": "1. The mouse genome contains a total of 19 Groucho-related genes (GRG).\n2. Groucho-related genes are also known as Groucho-like genes or Grhl genes.\n3. GRGs are involved in transcriptional regulation, chromatin remodeling, and neuronal development.\n4. Grhl1 and Grhl2 are involved in the regulation of neural stem cell proliferation and differentiation.\n5. Grhl3 and Grhl4 are involved in control of muscle cell differentiation and muscle regeneration.",
    "llama-2-7b-chat-hf_fact": [
      "The mouse genome contains a total of 19 Groucho-related genes (GRG).",
      "Groucho-related genes are also known as Groucho-like genes or Grhl genes.",
      "GRGs are involved in transcriptional regulation, chromatin remodeling, and neuronal development.",
      "Grhl1 and Grhl2 are involved in the regulation of neural stem cell proliferation and differentiation.",
      "Grhl3 and Grhl4 are involved in control of muscle cell differentiation and muscle regeneration."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The mouse genome contains a total of 4 Groucho-related genes (GRG).\n2. FALSE [correction]: Groucho-related genes are also known as Groucho/TLE genes or Gr genes.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: There is no Grhl4 gene, and Grhl3 is involved in the regulation of epithelial development and has a role in neural tube closure.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-2-7b-chat-hf_response": "RNA polymerase II (RNAPII) is the main enzyme responsible for transcribing DNA into RNA in eukaryotic cells. RNAPII is a complex of several subunits, including the core enzyme and additional factors that help to facilitate transcription. Of the subunits that make up RNAPII, only one carries RNA cleavage activity:\nThe RNA cleavage activity is carried out by the subunit known as RNA polymerase II (RNAP II) subunit B (also referred to as RPB1). RPB1 is one of the largest subunits of RNAPII and plays a crucial role in the transcription process. It is responsible for binding to the template DNA and initiating transcription by unwinding the DNA double helix. Once transcription is initiated, RPB1 helps to facilitate the elongation of the RNA transcript by recruiting and positioning the other subunits of RNAPII.\nRPB1 also contains a RNA cleavage domain called the \"RNAse H\" domain, which is responsible for cleaving the RNA transcript after transcription is complete. This cleavage activity is important for the proper regulation of gene expression, as it allows the cell to control the amount of RNA that is produced from a particular gene.\nIn summary, RNA polymerase II subunit B (RPB1) is the only subunit of RNAPII that carries RNA cleavage activity, and it plays a crucial role in the transcription process by initiating transcription, facilitating elongation, and cleaving the RNA transcript after transcription is complete.",
    "llama-2-7b-chat-hf_fact_raw": "1. RNA polymerase II (RNAPII) is responsible for transcribing DNA into RNA in eukaryotic cells.\n2. RNA polymerase II (RNAP II) subunit B, also known as RPB1, carries RNA cleavage activity.\n3. RPB1 is one of the largest subunits of RNAPII.\n4. RPB1 is responsible for binding to the template DNA and initiating transcription.\n5. RPB1 contains an RNA cleavage domain called the \"RNAse H\" domain, which cleaves the RNA transcript after transcription.",
    "llama-2-7b-chat-hf_fact": [
      "RNA polymerase II (RNAPII) is responsible for transcribing DNA into RNA in eukaryotic cells.",
      "RNA polymerase II (RNAP II) subunit B, also known as RPB1, carries RNA cleavage activity.",
      "RPB1 is one of the largest subunits of RNAPII.",
      "RPB1 is responsible for binding to the template DNA and initiating transcription.",
      "RPB1 contains an RNA cleavage domain called the \"RNAse H\" domain, which cleaves the RNA transcript after transcription."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: RNA polymerase II (RNAPII) subunit B, also known as RPB1, does not carry RNA cleavage activity. RNA cleavage activity in eukaryotic cells is typically associated with RNA processing enzymes, not with RNA polymerase itself.\n3. TRUE\n4. FALSE [correction]: RPB1 is not solely responsible for binding to the template DNA and initiating transcription; it is part of the RNAPII complex and contributes to the overall binding and initiation process but does not perform this function independently.\n5. FALSE [correction]: RPB1 does not contain an RNA cleavage domain called the \"RNAse H\" domain. RNAse H is a separate enzyme that removes RNA primers during DNA replication, not during transcription by RNAPII.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "llama-2-7b-chat-hf_response": "Ohdo syndrome, also known as Ohdo-Takahashi syndrome or X-linked mental retardation syndrome, is a rare genetic disorder that affects males almost exclusively. It is caused by mutations in the FMR1 gene, which codes for the protein fragile X mental retardation protein (FMRP). FMRP plays a critical role in the regulation of synaptic plasticity and neural circuit development, and mutations in the FMR1 gene lead to the characteristic cognitive and behavioral symptoms of Ohdo syndrome.\nThe FMR1 gene is located on the X chromosome and is one of the most commonly mutated genes in X-linked mental retardation disorders. Females, who have two X chromosomes, are less likely to be affected by Ohdo syndrome, as they have a second X chromosome that can compensate for the loss of function caused by a mutation in one of the X chromosomes. Males, on the other hand, have only one X chromosome and are therefore more susceptible to the effects of a mutation in the FMR1 gene.\nThe symptoms of Ohdo syndrome typically become apparent in early childhood and can include:\n1. Intellectual disability: Individuals with Ohdo syndrome often have significant cognitive impairments, including delays in language development, learning disabilities, and difficulties with problem-solving and executive function.\n2. Autism spectrum disorder: Many individuals with Ohdo syndrome also have a diagnosis of autism spectrum disorder (ASD), which can include difficulties with social interaction, communication, and repetitive behaviors.\n3. Speech and language impairments: Individuals with Ohdo syndrome may have difficulties with speech and language development, including articulation problems, stuttering, and difficulty with language comprehension.\n4. Behavioral problems: Ohdo syndrome can also be associated with a range of behavioral problems, including anxiety, hyperactivity, and mood disorders.\n5. Motor coordination impairments: Some individuals with Ohdo syndrome may have difficulties with motor coordination and balance, which can affect their ability to perform daily activities.\nThe genetic basis of Ohdo syndrome is complex and multifactorial, and the disorder is caused",
    "llama-2-7b-chat-hf_fact_raw": "1. Ohdo syndrome is caused by mutations in the FMR1 gene.\n2. The FMR1 gene codes for the protein fragile X mental retardation protein (FMRP).\n3. FMR1 gene is located on the X chromosome.\n4. Females are less likely to be affected by Ohdo syndrome due to having two X chromosomes.\n5. Symptoms of Ohdo syndrome typically become apparent in early childhood.",
    "llama-2-7b-chat-hf_fact": [
      "Ohdo syndrome is caused by mutations in the FMR1 gene.",
      "The FMR1 gene codes for the protein fragile X mental retardation protein (FMRP).",
      "FMR1 gene is located on the X chromosome.",
      "Females are less likely to be affected by Ohdo syndrome due to having two X chromosomes.",
      "Symptoms of Ohdo syndrome typically become apparent in early childhood."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ohdo syndrome is caused by mutations in the MED12 gene, not the FMR1 gene.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Females can still be affected by Ohdo syndrome, but the presence of a second X chromosome can result in a less severe phenotype.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-2-7b-chat-hf_response": "There are several R/Bioconductor packages that have been developed for the analysis of psychiatric disease genes. Here are some of the most popular ones:\n1. PsychGen: This package provides a comprehensive set of tools for the analysis of genetic data in psychiatric disorders. It includes functions for genome-wide association study (GWAS) analysis, gene-set enrichment analysis, and pathway analysis.\n2. PsychGWAS: This package provides a set of tools for GWAS analysis in psychiatric disorders. It includes functions for imputation, association mapping, and gene-set enrichment analysis.\n3. MentalHealth: This package provides a set of tools for the analysis of genetic data in mental health disorders. It includes functions for GWAS analysis, gene-set enrichment analysis, and pathway analysis.\n4. PsychiatricGenetics: This package provides a comprehensive set of tools for the analysis of genetic data in psychiatric disorders. It includes functions for GWAS analysis, gene-set enrichment analysis, and pathway analysis, as well as tools for visualizing and interpreting the results.\n5. RDoC: This package provides a set of tools for the analysis of genetic data in psychiatric disorders using a dimensionality reduction approach. It includes functions for principal component analysis (PCA), independent component analysis (ICA), and non-negative matrix factorization (NMF).\n6. PsychGenomics: This package provides a set of tools for the analysis of genetic data in psychiatric disorders using a genomic approach. It includes functions for genome-wide association study (GWAS) analysis, gene-set enrichment analysis, and pathway analysis.\n7. PsychiatricGenomicsDB: This package provides a comprehensive set of tools for the analysis of genetic data in psychiatric disorders using a genomic approach. It includes functions for GWAS analysis, gene-set enrichment analysis, and pathway analysis, as well as tools for visualizing and interpreting the results.\n8. PsychiatricGenomicsR: This package provides a set of tools for the analysis of genetic data in psychiatric disorders using a genomic approach. It includes functions for GWAS analysis, gene-set enrich",
    "llama-2-7b-chat-hf_fact_raw": "1. PsychGen is an R/Bioconductor package developed for the analysis of genetic data in psychiatric disorders.\n2. PsychGWAS is an R/Bioconductor package providing tools for GWAS analysis in psychiatric disorders.\n3. MentalHealth is an R/Bioconductor package with functions for GWAS analysis in mental health disorders.\n4. PsychiatricGenetics is an R/Bioconductor package offering tools for visualizing and interpreting results in psychiatric disorders genetic data analysis.\n5. RDoC is an R/Bioconductor package that uses a dimensionality reduction approach for the analysis of genetic data in psychiatric disorders.",
    "llama-2-7b-chat-hf_fact": [
      "PsychGen is an R/Bioconductor package developed for the analysis of genetic data in psychiatric disorders.",
      "PsychGWAS is an R/Bioconductor package providing tools for GWAS analysis in psychiatric disorders.",
      "MentalHealth is an R/Bioconductor package with functions for GWAS analysis in mental health disorders.",
      "PsychiatricGenetics is an R/Bioconductor package offering tools for visualizing and interpreting results in psychiatric disorders genetic data analysis.",
      "RDoC is an R/Bioconductor package that uses a dimensionality reduction approach for the analysis of genetic data in psychiatric disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: Without specific knowledge or context about these R/Bioconductor packages, it is not possible to determine the accuracy of these statements.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "llama-2-7b-chat-hf_response": "Certainly, I'd be happy to help!\nSwirl sign, also known as the \"whirlpool sign,\" is a clinical finding that can be observed in some patients with intracerebral hemorrhage (ICH). It is characterized by a swirling or whirlpool-like pattern of blood in the affected area of the brain, typically seen on computed tomography (CT) or magnetic resonance imaging (MRI) scans.\nThe swirl sign is caused by the movement of blood within the affected brain tissue due to the hemorrhage. When blood flows through the damaged blood vessels, it can create a swirling motion, which can be visualized on imaging studies. The size and shape of the swirl sign can vary depending on the location and severity of the hemorrhage.\nThe swirl sign can be an important diagnostic marker for ICH, as it can help identify the location and extent of the hemorrhage. For example, a swirl sign in the frontal lobe may indicate a hemorrhage in the frontal lobe, while a swirl sign in the temporal lobe may indicate a hemorrhage in the temporal lobe.\nIt is important to note that the swirl sign is not a definitive diagnostic marker for ICH, and other conditions, such as cerebral edema or mass effect, can also cause similar imaging findings. A thorough clinical evaluation and imaging studies, including CT or MRI with contrast, are necessary to accurately diagnose and manage ICH.\nIn summary, the swirl sign is a clinical finding observed on imaging studies in some patients with ICH, characterized by a swirling or whirlpool-like pattern of blood in the affected area of the brain. It can be an important diagnostic marker for ICH, but it should be interpreted in conjunction with other clinical and imaging findings to ensure accurate diagnosis and management.",
    "llama-2-7b-chat-hf_fact_raw": "1. Swirl sign, also known as the \"whirlpool sign,\" is a clinical finding observed in some patients with intracerebral hemorrhage (ICH).\n2. Swirl sign is characterized by a swirling pattern of blood in the brain, typically seen on CT or MRI scans.\n3. The swirl sign is caused by the movement of blood within the affected brain tissue due to hemorrhage.\n4. The swirl sign can vary in size and shape depending on the location and severity of the hemorrhage.\n5. The presence of a swirl sign can help identify the location and extent of the hemorrhage in ICH patients.",
    "llama-2-7b-chat-hf_fact": [
      "Swirl sign, also known as the \"whirlpool sign,\" is a clinical finding observed in some patients with intracerebral hemorrhage (ICH).",
      "Swirl sign is characterized by a swirling pattern of blood in the brain, typically seen on CT or MRI scans.",
      "The swirl sign is caused by the movement of blood within the affected brain tissue due to hemorrhage.",
      "The swirl sign can vary in size and shape depending on the location and severity of the hemorrhage.",
      "The presence of a swirl sign can help identify the location and extent of the hemorrhage in ICH patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "llama-2-7b-chat-hf_response": "Arabidopsis ROF1 (RNA-binding protein 1) is a transcription factor that plays a crucial role in regulating plant growth and development. The expression of ROF1 is induced in response to various environmental and developmental cues. Here are some of the key factors that induce Arabidopsis ROF1 expression:\n1. Light: ROF1 expression is induced by light, particularly blue light. This is because ROF1 plays a key role in the regulation of photomorphogenesis, the process by which plants respond to light. When exposed to blue light, ROF1 is activated and promotes the expression of genes involved in cell elongation and cell division, leading to the formation of new leaves and stems.\n2. Temperature: ROF1 expression is also temperature-sensitive, with higher expression levels observed at higher temperatures. For example, a study published in the journal Plant Cell found that ROF1 expression was higher in Arabidopsis plants grown at 25C than at 15C.\n3. Water availability: ROF1 expression can be induced by changes in water availability. For example, a study published in the journal The Plant Cell found that ROF1 expression was higher in Arabidopsis plants grown in a well-watered environment than in those grown in a water-stressed environment.\n4. Hormones: ROF1 expression can be induced by various hormones, including auxin, cytokinin, and ethylene. For example, a study published in the journal Plant Physiology found that ROF1 expression was higher in Arabidopsis plants treated with the auxin indole-3-acetic acid (IAA) than in untreated plants.\n5. Developmental cues: ROF1 expression can also be induced by developmental cues, such as the onset of flowering. For example, a study published in the journal Developmental Cell found that ROF1 expression was higher in Arabidopsis flowers than in rosette leaves.\n6. Abiotic stress: ROF1 expression can be induced by abiotic stress, such as drought, salt, and heat stress. For example, a study published in the journal Plant Cell Reports found that ROF1 expression was higher in Arabidopsis plants exposed to drought stress than in unexposed plants.\n7",
    "llama-2-7b-chat-hf_fact_raw": "1. Arabidopsis ROF1 expression is induced by light, especially blue light.\n2. Higher temperatures result in higher expression levels of Arabidopsis ROF1.\n3. Changes in water availability can induce Arabidopsis ROF1 expression.\n4. Various hormones such as auxin, cytokinin, and ethylene can induce Arabidopsis ROF1 expression.\n5. Developmental cues like the onset of flowering can induce Arabidopsis ROF1 expression.",
    "llama-2-7b-chat-hf_fact": [
      "Arabidopsis ROF1 expression is induced by light, especially blue light.",
      "Higher temperatures result in higher expression levels of Arabidopsis ROF1.",
      "Changes in water availability can induce Arabidopsis ROF1 expression.",
      "Various hormones such as auxin, cytokinin, and ethylene can induce Arabidopsis ROF1 expression.",
      "Developmental cues like the onset of flowering can induce Arabidopsis ROF1 expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific context or reference to a study or source confirming these statements about Arabidopsis ROF1 expression, it's impossible to determine the accuracy of these claims.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-2-7b-chat-hf_response": "Hereditary renal amyloidosis is a rare genetic disorder characterized by the accumulation of abnormal protein deposits in the kidneys, leading to progressive kidney damage and eventually kidney failure. The most common cause of hereditary renal amyloidosis is the accumulation of immunoglobulin light chain (AL) amyloid, which is derived from the immunoglobulin light chains produced by the body's immune system.\nAL amyloid is produced when the body's immune system produces excessive amounts of abnormal immunoglobulin light ch Chains, which are then deposited in the kidneys and other organs. This can occur due to various genetic mutations that affect the production or breakdown of immunoglobulin light chains.\nThe accumulation of AL amyloid in the kidneys can lead to a range of symptoms, including:\n1. Proteinuria (excess protein in the urine)\n2. Hematuria (blood in the urine)\n3. Decreased kidney function\n4. Kidney failure\n5. Hypertension (high blood pressure)\n6. Kidney stones\n7. Bone disease\nThe diagnosis of hereditary renal amyloidosis typically involves a combination of clinical evaluation, laboratory tests, and genetic analysis. Laboratory tests may include urine and blood tests to measure protein levels and kidney function, as well as genetic testing to identify the specific genetic mutation causing the disorder.\nTreatment for hereditary renal amyloidosis typically involves managing the symptoms and slowing the progression of the disease. This may include:\n1. Blood pressure control\n2. Protein restriction\n3. Diuretics to reduce fluid buildup in the body\n4. Dialysis to remove waste products from the blood when the kidneys are no longer able to do so\n5. In some cases, a kidney transplant may be necessary.\nIt is important to note that hereditary renal amyloidosis is a rare disorder, and the causes and symptoms can vary depending on the specific genetic mutation involved. If you have any concerns or questions about hereditary renal am",
    "llama-2-7b-chat-hf_fact_raw": "1. Hereditary renal amyloidosis is caused by the accumulation of immunoglobulin light chain (AL) amyloid.\n2. AL amyloid is derived from the immunoglobulin light chains produced by the body's immune system.\n3. Excess production of abnormal immunoglobulin light chains can lead to AL amyloid deposits in the kidneys.\n4. Symptoms of hereditary renal amyloidosis can include proteinuria, hematuria, and decreased kidney function.\n5. Treatment options for hereditary renal amyloidosis may include blood pressure control, protein restriction, diuretics, dialysis, and possibly a kidney transplant.",
    "llama-2-7b-chat-hf_fact": [
      "Hereditary renal amyloidosis is caused by the accumulation of immunoglobulin light chain (AL) amyloid.",
      "AL amyloid is derived from the immunoglobulin light chains produced by the body's immune system.",
      "Excess production of abnormal immunoglobulin light chains can lead to AL amyloid deposits in the kidneys.",
      "Symptoms of hereditary renal amyloidosis can include proteinuria, hematuria, and decreased kidney function.",
      "Treatment options for hereditary renal amyloidosis may include blood pressure control, protein restriction, diuretics, dialysis, and possibly a kidney transplant."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Hereditary renal amyloidosis is caused by the accumulation of amyloid A (AA) protein, not immunoglobulin light chain (AL) amyloid.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "llama-2-7b-chat-hf_response": "Yes, the proteome of the mouse hippocampus has been extensively analyzed through various studies using different techniques such as mass spectrometry, two-dimensional gel electrophoresis, and protein microarrays.\nThe hippocampus is a part of the brain that plays a critical role in memory formation, spatial navigation, and emotion regulation. As such, it has been a popular target for proteomic studies aimed at identifying and quantifying proteins in this region.\nOne of the earliest and most influential proteomic studies in the hippocampus was conducted by Koo et al. in 2001. Using two-dimensional gel electrophoresis (2DE), they identified and quantified over 100 proteins in the hippocampus of mice. These proteins included a variety of functional categories, such as structural proteins, enzymes, transport proteins, and signaling molecules.\nSubsequent studies have built upon these findings by using more advanced techniques such as mass spectrometry (MS) and protein microarrays. For example, a study by Li et al. (2010) used MS to identify and quantify over 1,000 proteins in the hippocampus of mice. They found that the hippocampus expressed a unique set of proteins that were not found in other brain regions, and that these proteins were involved in a variety of cellular processes, including synaptic plasticity, neurotransmission, and inflammation.\nOther studies have focused on specific aspects of hippocampal function, such as memory formation and retrieval. For example, a study by Nestler et al. (2001) used proteomics to identify proteins involved in the formation and retrieval of memories in the hippocampus. They found that the hippocampus expressed a variety of proteins involved in synaptic plasticity, including N-methyl-D-aspartate (NMDA) receptors, AMPA receptors, and synaptic scaffolding proteins.\nOverall, the proteome of the mouse hippocampus has been found to be complex and dynamic, with a wide range of proteins involved in various cellular processes. These studies have provided",
    "llama-2-7b-chat-hf_fact_raw": "1. The proteome of the mouse hippocampus has been analyzed using mass spectrometry, two-dimensional gel electrophoresis, and protein microarrays.\n2. The hippocampus plays a critical role in memory formation, spatial navigation, and emotion regulation.\n3. Koo et al. conducted a proteomic study in 2001 and identified and quantified over 100 proteins in the hippocampus of mice.\n4. Li et al. used mass spectrometry in 2010 to identify and quantify over 1,000 proteins in the mouse hippocampus.\n5. Nestler et al. identified proteins involved in memory formation and retrieval in the hippocampus in a proteomic study conducted in 2001.",
    "llama-2-7b-chat-hf_fact": [
      "The proteome of the mouse hippocampus has been analyzed using mass spectrometry, two-dimensional gel electrophoresis, and protein microarrays.",
      "The hippocampus plays a critical role in memory formation, spatial navigation, and emotion regulation.",
      "Koo et al. conducted a proteomic study in 2001 and identified and quantified over 100 proteins in the hippocampus of mice.",
      "Li et al. used mass spectrometry in 2010 to identify and quantify over 1,000 proteins in the mouse hippocampus.",
      "Nestler et al. identified proteins involved in memory formation and retrieval in the hippocampus in a proteomic study conducted in 2001."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "llama-2-7b-chat-hf_response": "Great question! As a helpful assistant, I'm here to provide you with accurate and informative answers.\nAcrocentric chromosomes are a type of chromosome where the centromere, the region where the chromosome is attached to the spindle fibers during cell division, is located near the center of the chromosome.\nIn the case of mouse chromosomes, they are actually metacentric, which means that the centromere is located near the middle of the chromosome. This is in contrast to acrocentric chromosomes, where the centromere is located closer to the ends of the chromosome.\nSo, to summarize: mouse chromosomes are not acrocentric, they are metacentric. I hope this helps clarify things for you! Let me know if you have any other questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Acrocentric chromosomes have the centromere located near the ends of the chromosome.\n2. Mouse chromosomes are metacentric, meaning the centromere is located near the middle of the chromosome.",
    "llama-2-7b-chat-hf_fact": [
      "Acrocentric chromosomes have the centromere located near the ends of the chromosome.",
      "Mouse chromosomes are metacentric, meaning the centromere is located near the middle of the chromosome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Mouse chromosomes are acrocentric, meaning the centromere is located near the ends of the chromosome.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-2-7b-chat-hf_response": "There are several siRNA-based drugs that are currently in clinical trials for the treatment of pancreatic cancer. Here are a few examples:\n1. Vitrakvi (larotrectinib): This is a first-in-class, oral TRK inhibitor that is being developed by Bayer and Loxo Oncology. Vitrakvi is designed to target the tropomyosin receptor kinase (TRK) gene, which is often mutated in pancreatic cancer. In November 2018, Vitrakvi was approved by the FDA for the treatment of adults and children with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. Clinical trials are ongoing to evaluate the safety and efficacy of Vitrakvi in patients with pancreatic cancer.\n2. Oncoprex-106: This is a lipid nanoparticle-formulated siRNA drug that is being developed by BioXcel Therapeutics. Oncoprex-106 is designed to target and silence the expression of the gene encoding the protein HMGA2, which is overexpressed in many types of cancer, including pancreatic cancer. In December 2018, BioXcel Therapeutics announced that it had initiated a Phase 1 clinical trial of Oncoprex-106 in patients with advanced solid tumors, including pancreatic cancer.\n3. AR-509: This is a small molecule inhibitor of the enzyme arginase-1, which is being developed by Argena Bioscience. Arginase-1 is overexpressed in many types of cancer, including pancreatic cancer, and is thought to play a role in the development and progression of cancer. In June 2019, Argena Bioscience announced that it had initiated a Phase 1 clinical trial of AR-509 in patients with advanced solid tumors, including pancreatic cancer.\n4. RX-0201: This is a small molecule inhibitor of the enzyme poly (ADP-ribose) polymerase (PARP), which is being developed by Rexahn Pharmaceuticals. PAR",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "llama-2-7b-chat-hf_response": "The HPG pore, also known as the hemoglobin-protein G pore, is a transmembrane protein complex found in the red blood cell membrane of mammals. It is a specialized pore that allows the passage of small molecules, such as oxygen, carbon dioxide, and other gases, across the red blood cell membrane.\nThe HPG pore is composed of several subunits, including hemoglobin and protein G, which are non-covalently linked to form a heterodimer. The pore is located in the red blood cell membrane and spans the cell's entire width, allowing the passage of molecules through the membrane.\nThe HPG pore plays a crucial role in the delivery of oxygen to the body's tissues and the removal of carbon dioxide from the tissues. When oxygen is inhaled, it binds to hemoglobin in the red blood cells, causing a conformational change in the protein that opens the HPG pore. This allows oxygen to pass through the pore and diffuse into the tissues, where it is used for cellular metabolism. Similarly, when carbon dioxide is inhaled, it binds to hemoglobin in the red blood cells, causing the HPG pore to close, preventing carbon dioxide from passing through the pore and entering the tissues.\nIn addition to its role in oxygen and carbon dioxide transport, the HPG pore has been implicated in the regulation of red blood cell membrane transport of other molecules, such as ions and nutrients. It has also been shown to play a role in the immune response, as it can act as a barrier to the entry of pathogens into the red blood cells.\nOverall, the HPG pore is a critical component of the red blood cell membrane that plays a vital role in maintaining the proper balance of oxygen and carbon dioxide in the body. Its unique structure and function allow it to selectively regulate the passage of specific molecules across the red blood cell membrane, ensuring that oxygen is delivered to the tissues and carbon dioxide is removed from the body.",
    "llama-2-7b-chat-hf_fact_raw": "1. The HPG pore, also known as the hemoglobin-protein G pore, is a transmembrane protein complex found in the red blood cell membrane of mammals.\n2. The HPG pore allows the passage of small molecules, such as oxygen, carbon dioxide, and other gases, across the red blood cell membrane.\n3. It is composed of several subunits, including hemoglobin and protein G, which form a heterodimer.\n4. The HPG pore plays a crucial role in the delivery of oxygen to the body's tissues and the removal of carbon dioxide from the tissues.\n5. The HPG pore has been implicated in the regulation of red blood cell membrane transport of other molecules, such as ions and nutrients.",
    "llama-2-7b-chat-hf_fact": [
      "The HPG pore, also known as the hemoglobin-protein G pore, is a transmembrane protein complex found in the red blood cell membrane of mammals.",
      "The HPG pore allows the passage of small molecules, such as oxygen, carbon dioxide, and other gases, across the red blood cell membrane.",
      "It is composed of several subunits, including hemoglobin and protein G, which form a heterodimer.",
      "The HPG pore plays a crucial role in the delivery of oxygen to the body's tissues and the removal of carbon dioxide from the tissues.",
      "The HPG pore has been implicated in the regulation of red blood cell membrane transport of other molecules, such as ions and nutrients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The HPG pore stands for \"hydrophobic gating pore\" not \"hemoglobin-protein G pore\".\n2. TRUE\n3. FALSE [correction]: The HPG pore is not composed of hemoglobin and protein G forming a heterodimer. It refers to a structural feature of certain proteins that allows passage of small molecules across a membrane.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "llama-2-7b-chat-hf_response": "The 959 Nematode Genomes initiative is a large-scale research project aimed at sequencing and analyzing the genomes of 959 species of nematodes, which are a group of microscopic worms that are found in almost every environment on Earth. Nematodes are important organisms in many ecosystems, and they play a crucial role in decomposing organic matter, fixing nitrogen, and serving as hosts for beneficial microorganisms.\nThe 959 Nematode Genomes initiative was launched in 2017 by the National Science Foundation (NSF) and the Department of Energy (DOE) to advance our understanding of nematode biology and ecology. The project brings together researchers from universities, government agencies, and private companies to study the genomes of nematodes from different environments, including soil, plants, and animals.\nThe goals of the 959 Nematode Genomes initiative are to:\n1. Sequence the genomes of 959 nematode species using cutting-edge sequencing technologies.\n2. Analyze the genomes of these nematodes to identify genes that are involved in important biological processes, such as nutrient cycling, pathogenesis, and symbiosis.\n3. Develop tools and methods for analyzing nematode genomes and for integrating data from multiple species.\n4. Use the knowledge gained from this project to improve our understanding of nematode ecology and to develop new strategies for controlling nematode populations that are harmful to crops and plants.\n5. Share the data and resources generated by this project with the scientific community to promote collaboration and to accelerate the discovery of new insights into nematode biology.\nThe 959 Nematode Genomes initiative is a major undertaking that will require several years to complete. The project is using a variety of cutting-edge sequencing technologies, including single-molecule real-time sequencing and nanopore sequencing, to generate high-quality genomic data for each of the 959 nematode species. The project is also developing new computational tools and methods for analyzing the large amounts of data generated by the project.\nSome of the key goals of the 9",
    "llama-2-7b-chat-hf_fact_raw": "1. The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of 959 species of nematodes.\n2. The initiative was launched in 2017 by the National Science Foundation and the Department of Energy.\n3. The goal of the project is to improve the understanding of nematode biology and ecology.\n4. The initiative uses cutting-edge sequencing technologies such as single-molecule real-time sequencing and nanopore sequencing.\n5. The project aims to develop new strategies for controlling nematode populations that are harmful to crops and plants.",
    "llama-2-7b-chat-hf_fact": [
      "The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of 959 species of nematodes.",
      "The initiative was launched in 2017 by the National Science Foundation and the Department of Energy.",
      "The goal of the project is to improve the understanding of nematode biology and ecology.",
      "The initiative uses cutting-edge sequencing technologies such as single-molecule real-time sequencing and nanopore sequencing.",
      "The project aims to develop new strategies for controlling nematode populations that are harmful to crops and plants."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-2-7b-chat-hf_response": "There are several R packages that have been developed for analyzing Non-invasive prenatal testing (NIPT) data. Here are some of the most popular ones:\n1. `niftyc`: This package provides a comprehensive set of tools for analyzing NIPT data, including data cleaning, quality control, and statistical analysis. It can handle various types of NIPT data, including DNA methylation, chromosomal abnormalities, and gene expression data.\n2. `niphtools`: This package provides a set of tools for analyzing NIPT data, including data cleaning, filtering, and statistical analysis. It can handle data from various NIPT platforms, including sequencing and PCR-based methods.\n3. `prenatals`: This package provides a set of tools for analyzing NIPT data, including data cleaning, quality control, and statistical analysis. It can handle various types of NIPT data, including DNA methylation, chromosomal abnormalities, and gene expression data.\n4. `pneuma`: This package provides a comprehensive set of tools for analyzing NIPT data, including data cleaning, quality control, and statistical analysis. It can handle various types of NIPT data, including DNA methylation, chromosomal abnormalities, and gene expression data.\n5. `niptech`: This package provides a set of tools for analyzing NIPT data, including data cleaning, filtering, and statistical analysis. It can handle data from various NIPT platforms, including sequencing and PCR-based methods.\n6. `NIPTAnalysis`: This package provides a comprehensive set of tools for analyzing NIPT data, including data cleaning, quality control, and statistical analysis. It can handle various types of NIPT data, including DNA methylation, chromosomal abnormalities, and gene expression data.\n7. `PrenatalGenomics`: This package provides a set of tools for analyzing NIPT data, including data cleaning, quality control, and statistical analysis. It can handle various types of NIPT data, including DNA methylation, chromosomal abnormalities, and gene expression data.\n8. `NIPTworkbench`: This package provides a comprehensive set of tools for",
    "llama-2-7b-chat-hf_fact_raw": "1. `niftyc` is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data.\n2. `niphtools` is an R package that can analyze NIPT data from various platforms, including sequencing and PCR-based methods.\n3. `prenatals` is an R package designed to handle various types of NIPT data for analysis.\n4. `pneuma` is an R package that provides a comprehensive set of tools for NIPT data analysis.\n5. `niptech` is an R package that includes tools for data cleaning and statistical analysis of NIPT data.",
    "llama-2-7b-chat-hf_fact": [
      "`niftyc` is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data.",
      "`niphtools` is an R package that can analyze NIPT data from various platforms, including sequencing and PCR-based methods.",
      "`prenatals` is an R package designed to handle various types of NIPT data for analysis.",
      "`pneuma` is an R package that provides a comprehensive set of tools for NIPT data analysis.",
      "`niptech` is an R package that includes tools for data cleaning and statistical analysis of NIPT data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: Without specific knowledge or reference to these R packages, it is not possible to verify the statements' accuracy.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbachs syndrome.",
    "llama-2-7b-chat-hf_response": "Achenbach's syndrome is a rare genetic disorder that affects the development of the brain and nervous system. It is characterized by a range of symptoms that can vary in severity and impact the individual's quality of life. Here are some of the key features of Achenbach's syndrome:\n1. Delayed development: Children with Achenbach's syndrome typically experience delays in reaching developmental milestones, such as sitting, standing, and walking. These delays can range from mild to severe.\n2. Intellectual disability: Individuals with Achenbach's syndrome often have intellectual disability, which can range from mild to severe. This can affect their ability to learn and adapt to new situations.\n3. Speech and language difficulties: Achenbach's syndrome can cause difficulties with speech and language development, including stuttering, slurred speech, and difficulty with word recognition.\n4. Motor skills challenges: The syndrome can also cause problems with motor skills, including coordination, balance, and fine motor skills. This can make it difficult for individuals to perform everyday tasks, such as dressing and grooming.\n5. Vision problems: Some individuals with Achenbach's syndrome may experience vision problems, including blurred vision, double vision, and difficulty with depth perception.\n6. Hearing loss: Hearing loss is a common feature of Achenbach's syndrome, and can range from mild to severe.\n7. Seizures: Some individuals with Achenbach's syndrome may experience seizures, which can be a result of the genetic mutation that causes the syndrome.\n8. Behavioral challenges: Achenbach's syndrome can also cause behavioral challenges, including anxiety, irritability, and difficulty with social interactions.\n9. Cognitive impairments: Individuals with Achenbach's syndrome may experience cognitive impairments, including difficulty with memory, attention, and problem-solving.\n10. Short stature: Achenbach's syndrome can also cause short stature, which can be a result of the genetic mutation that causes the syndrome.\nIt is important to note that the severity of Achenbach's syndrome can vary widely between",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "llama-2-7b-chat-hf_response": "Long repeat expansions are a type of genomic variation that can cause a range of genetic disorders, including those associated with neurological and psychiatric conditions. The detection of long repeat expansions is a complex task that requires specialized algorithms and computational methods. Here are some of the commonly used algorithms for detecting long repeat expansions:\n1. RepeatMasker: RepeatMasker is a widely used algorithm for detecting repeat elements in genomic sequences. It uses a combination of heuristics and statistical models to identify repeat sequences, including long repeat expansions. RepeatMasker can be used to identify both short and long repeat expansions, and it can be applied to both DNA and RNA sequences.\n2. GATK-Repeat: GATK-Repeat is a tool developed by the Broad Institute's Genome Analysis Toolkit (GATK) for detecting repeat elements in genomic sequences. It uses a combination of heuristics and machine learning algorithms to identify repeat sequences, including long repeat expansions. GATK-Repeat can be used to identify both short and long repeat expansions, and it can be applied to both DNA and RNA sequences.\n3. RepeatAnalyzer: RepeatAnalyzer is a tool developed by the University of California, Santa Cruz for detecting repeat elements in genomic sequences. It uses a combination of heuristics and statistical models to identify repeat sequences, including long repeat expansions. RepeatAnalyzer can be used to identify both short and long repeat expansions, and it can be applied to both DNA and RNA sequences.\n4. LRE-Cutter: LRE-Cutter is a tool developed by the University of California, Los Angeles for detecting long repeat expansions in genomic sequences. It uses a combination of heuristics and statistical models to identify long repeat sequences, and it can be used to identify both repetitive and non-repetitive regions of the genome.\n5. LongRepeats: LongRepeats is a tool developed by the University of California, San Diego for detecting long repeat expansions in genomic sequences. It uses a combination of heuristics and statistical models to identify long repeat sequences, and it can be used to identify both repetitive and non-repetitive regions of the genome.\n6. RepeatFinder",
    "llama-2-7b-chat-hf_fact_raw": "1. RepeatMasker is an algorithm used for detecting repeat elements, including long repeat expansions, in genomic sequences.\n2. GATK-Repeat is developed by the Broad Institute's Genome Analysis Toolkit for detecting repeat elements in genomic sequences.\n3. RepeatAnalyzer is developed by the University of California, Santa Cruz for detecting repeat elements in genomic sequences.\n4. LRE-Cutter is developed by the University of California, Los Angeles for detecting long repeat expansions in genomic sequences.\n5. LongRepeats is developed by the University of California, San Diego for detecting long repeat expansions in genomic sequences.",
    "llama-2-7b-chat-hf_fact": [
      "RepeatMasker is an algorithm used for detecting repeat elements, including long repeat expansions, in genomic sequences.",
      "GATK-Repeat is developed by the Broad Institute's Genome Analysis Toolkit for detecting repeat elements in genomic sequences.",
      "RepeatAnalyzer is developed by the University of California, Santa Cruz for detecting repeat elements in genomic sequences.",
      "LRE-Cutter is developed by the University of California, Los Angeles for detecting long repeat expansions in genomic sequences.",
      "LongRepeats is developed by the University of California, San Diego for detecting long repeat expansions in genomic sequences."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "llama-2-7b-chat-hf_response": "Neuroligin-3 is a protein that has been implicated in the development and progression of various types of brain tumors, including:\n1. Glioblastoma: Glioblastoma, also known as glioblastoma multiforme (GBM), is the most common and aggressive type of primary brain cancer. Neuroligin-3 has been shown to be overexpressed in glioblastoma cells, and high levels of neuroligin-3 expression have been associated with poorer prognosis.\n2. Medulloblastoma: Medulloblastoma is a type of pediatric brain cancer that arises in the cerebellum. Neuroligin-3 has been shown to be overexpressed in medulloblastoma cells, and high levels of neuroligin-3 expression have been associated with more aggressive tumor behavior.\n3. Meningioma: Meningioma is a type of non-cancerous brain tumor that arises in the meninges, the protective membranes that cover the brain and spinal cord. While meningioma is generally a slow-growing tumor, some cases can be more aggressive and may overexpress neuroligin-3.\n4. Pineal gland tumors: The pineal gland is a small endocrine gland located in the brain. Pineal gland tumors are rare, but they can be malignant or benign. Neuroligin-3 has been shown to be overexpressed in some pineal gland tumors, and high levels of neuroligin-3 expression have been associated with more aggressive tumor behavior.\n5. Astrocytoma: Astrocytoma is a type of brain tumor that arises from star-shaped glial cells called astrocytes. Neuroligin-3 has been shown to be overexpressed in some astrocytoma cells, and high levels of neuroligin-3 expression have been associated with more aggressive tumor behavior.\nIt is important to note that the expression of neuroligin-3 in these tumors can vary depending on the specific type of tumor and the individual patient. Additionally, while neuroligin-3 has been implicated in the development and progression of these tumors, it is",
    "llama-2-7b-chat-hf_fact_raw": "1. Neuroligin-3 is overexpressed in glioblastoma cells, and high levels are associated with poorer prognosis.\n2. Neuroligin-3 is overexpressed in medulloblastoma cells, and high levels are associated with more aggressive tumor behavior.\n3. Some cases of meningioma may overexpress neuroligin-3.\n4. Neuroligin-3 is overexpressed in some pineal gland tumors, and high levels are associated with more aggressive tumor behavior.\n5. Neuroligin-3 is overexpressed in some astrocytoma cells, and high levels are associated with more aggressive tumor behavior.",
    "llama-2-7b-chat-hf_fact": [
      "Neuroligin-3 is overexpressed in glioblastoma cells, and high levels are associated with poorer prognosis.",
      "Neuroligin-3 is overexpressed in medulloblastoma cells, and high levels are associated with more aggressive tumor behavior.",
      "Some cases of meningioma may overexpress neuroligin-3.",
      "Neuroligin-3 is overexpressed in some pineal gland tumors, and high levels are associated with more aggressive tumor behavior.",
      "Neuroligin-3 is overexpressed in some astrocytoma cells, and high levels are associated with more aggressive tumor behavior."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "llama-2-7b-chat-hf_response": "Gas vesicles are small, membrane-bound structures that are found in some bacteria and archaea. They are used to store and release gas, such as oxygen or nitrogen, which can be used for a variety of purposes, including buoyancy, motility, and protection from predators.\nThe size of gas vesicles can vary widely depending on the species of bacteria or archaea that produce them, as well as the specific function of the gas vesicle. Here are some approximate sizes of gas vesicles in different species:\n* In the bacterium Vibrio cholerae, gas vesicles are typically around 100-200 nanometers (nm) in diameter.\n* In the bacterium Escherichia coli, gas vesicles are around 50-100 nm in diameter.\n* In the archaeon Halorubrum sodomense, gas vesicles are around 200-400 nm in diameter.\n* In the bacterium Rhodopseudomonas palustris, gas vesicles can be as large as 1-2 micrometers (m) in diameter.\nIt's worth noting that these sizes are approximate, and the actual size of gas vesicles can vary depending on the specific conditions in which they are found. Additionally, some species of bacteria and archaea may produce gas vesicles that are larger or smaller than these approximate sizes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gas vesicles are membrane-bound structures found in bacteria and archaea.\n2. They are used to store and release gases such as oxygen and nitrogen.\n3. Vibrio cholerae gas vesicles are approximately 100-200 nanometers in diameter.\n4. Escherichia coli gas vesicles are approximately 50-100 nanometers in diameter.\n5. Halorubrum sodomense gas vesicles are approximately 200-400 nanometers in diameter.",
    "llama-2-7b-chat-hf_fact": [
      "Gas vesicles are membrane-bound structures found in bacteria and archaea.",
      "They are used to store and release gases such as oxygen and nitrogen.",
      "Vibrio cholerae gas vesicles are approximately 100-200 nanometers in diameter.",
      "Escherichia coli gas vesicles are approximately 50-100 nanometers in diameter.",
      "Halorubrum sodomense gas vesicles are approximately 200-400 nanometers in diameter."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Gas vesicles are used for buoyancy control in aquatic environments, not for storing and releasing gases such as oxygen and nitrogen.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "llama-2-7b-chat-hf_response": "BET (Bromodomain and Extra-Terminal) proteins are a family of proteins that play a crucial role in regulating gene expression by modifying chromatin structure. There are four known BET proteins in humans:\n1. BET1 (Bromodomain-Containing Protein 1): Also known as BRD1, this protein is the founding member of the BET family and is involved in the regulation of gene expression, cell proliferation, and differentiation. It binds to acetylated histone H3 and H4, and its overexpression has been implicated in various cancers.\n2. BET2 (Bromodomain-Containing Protein 2): BRD2 is another key member of the BET family and has been shown to play a role in the regulation of gene expression, cell fate determination, and the maintenance of stem cell self-renewal. It binds to both acetylated and methylated histone H3 and H4.\n3. BET3 (Bromodomain-Containing Protein 3): BRD3 is the third member of the BET family and is involved in the regulation of gene expression, cell fate determination, and the maintenance of stem cell self-renewal. It binds to both acetylated and methylated histone H3 and H4.\n4. BET4 (Bromodomain-Containing Protein 4): This is the most recently identified member of the BET family and is involved in the regulation of gene expression and cell fate determination. It binds to acetylated histone H3 and H4.\nAll BET proteins contain a bromodomain, a structural motif that is responsible for their ability to recognize and bind to acetylated histones. They also contain additional domains that allow them to interact with other proteins and modulate chromatin structure.\nOverall, the BET proteins play a crucial role in regulating gene expression by modifying chromatin structure and recruiting other proteins that are involved in transcriptional activation or repression. Dysregulation of BET protein expression or function has been implicated in various diseases, including cancer and neurological disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are four known BET proteins in humans: BET1, BET2, BET3, and BET4.\n2. BET1, also known as BRD1, binds to acetylated histone H3 and H4.\n3. BET2, or BRD2, plays a role in the regulation of gene expression and the maintenance of stem cell self-renewal.\n4. BET3, known as BRD3, is involved in regulating gene expression and cell fate determination.\n5. BET4 binds to acetylated histone H3 and H4 and is involved in gene expression and cell fate determination.",
    "llama-2-7b-chat-hf_fact": [
      "There are four known BET proteins in humans: BET1, BET2, BET3, and BET4.",
      "BET1, also known as BRD1, binds to acetylated histone H3 and H4.",
      "BET2, or BRD2, plays a role in the regulation of gene expression and the maintenance of stem cell self-renewal.",
      "BET3, known as BRD3, is involved in regulating gene expression and cell fate determination.",
      "BET4 binds to acetylated histone H3 and H4 and is involved in gene expression and cell fate determination."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: There are four known BET proteins in humans: BRD2, BRD3, BRD4, and BRDT.\n2. FALSE [correction]: BET1 is not a BET protein, BRD1 does not exist. BRD4 binds to acetylated histone H3 and H4.\n3. TRUE\n4. FALSE [correction]: BET3 is not a BET protein, BRD3 is involved in chromatin organization and transcriptional regulation.\n5. FALSE [correction]: There is no BET4, and BRD4 is the BET protein that binds to acetylated histone H3 and H4 and is involved in gene expression and cell fate determination.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-2-7b-chat-hf_response": "There have been several deep learning algorithms developed for protein subcellular localization prediction. Here are some of the most notable ones:\n1. DeepLoc: Developed by Zhang et al. in 2018, DeepLoc is a deep learning-based method for predicting protein subcellular localization. It uses a multi-task learning framework, where the model is trained to predict both the localization and the functional sites of a protein simultaneously. DeepLoc achieves state-of-the-art performance on several benchmark datasets, including the well-known LocPat dataset.\n2. LocNet: LocNet is another deep learning-based method for protein subcellular localization prediction, developed by Li et al. in 2018. LocNet uses a hierarchical convolutional neural network (CNN) to predict the localization of a protein. The model is trained on a large dataset of protein structures and their corresponding localizations, and achieves high accuracy on several benchmark datasets.\n3. PredictProteinLocalization: PredictProteinLocalization is a deep learning-based method developed by the PredictProtein team. It uses a combination of sequence-based and structure-based features to predict protein subcellular localization. The model is trained on a large dataset of protein sequences and structures, and achieves high accuracy on several benchmark datasets.\n4. DeepPLoc: DeepPLoc is a deep learning-based method for protein subcellular localization prediction, developed by Zhang et al. in 2020. It uses a combination of sequence-based and structure-based features, along with a novel attention mechanism to focus on the most important features. DeepPLoc achieves state-of-the-art performance on several benchmark datasets, including the LocPat dataset.\n5.ProteinLoc: ProteinLoc is a deep learning-based method for protein subcellular localization prediction, developed by the Google protein team. It uses a combination of sequence-based and structure-based features, along with a novel multi-task learning framework to predict both the localization and the functional sites of a protein simultaneously. ProteinLoc achieves high accuracy on several benchmark datasets, including the LocPat dataset.\nThese are some of the most notable deep learning-based methods for protein subcellular localization prediction. Each of these methods has its own strengths and weaknesses, and the",
    "llama-2-7b-chat-hf_fact_raw": "1. DeepLoc is a deep learning-based method for predicting protein subcellular localization, developed by Zhang et al. in 2018.\n2. LocNet is a deep learning-based method for protein subcellular localization prediction, developed by Li et al. in 2018.\n3. PredictProteinLocalization is a deep learning-based method for protein subcellular localization prediction, developed by the PredictProtein team.\n4. DeepPLoc is a deep learning-based method for protein subcellular localization prediction, developed by Zhang et al. in 2020.\n5. ProteinLoc is a deep learning-based method for protein subcellular localization prediction, developed by the Google protein team.",
    "llama-2-7b-chat-hf_fact": [
      "DeepLoc is a deep learning-based method for predicting protein subcellular localization, developed by Zhang et al. in 2018.",
      "LocNet is a deep learning-based method for protein subcellular localization prediction, developed by Li et al. in 2018.",
      "PredictProteinLocalization is a deep learning-based method for protein subcellular localization prediction, developed by the PredictProtein team.",
      "DeepPLoc is a deep learning-based method for protein subcellular localization prediction, developed by Zhang et al. in 2020.",
      "ProteinLoc is a deep learning-based method for protein subcellular localization prediction, developed by the Google protein team."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: DeepLoc is a deep learning-based method for predicting protein subcellular localization, developed by Almagro Armenteros et al. in 2017.\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. FALSE [correction]: ProteinLoc is not a known deep learning-based method for protein subcellular localization prediction developed by the Google protein team.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "llama-2-7b-chat-hf_response": "Hello! I'm here to help you with your question. Unfortunately, I couldn't find any information on a term called \"MULTOVL\". It's possible that it's a misspelling or a term that is not widely used. Can you please provide more context or details about where you encountered this term? This will help me better understand your question and provide a more accurate answer.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "llama-2-7b-chat-hf_response": "GDF15 (Growth Differentiation Factor 15) has been gaining attention as a potential biomarker for metformin treatment due to its role in regulating glucose metabolism and insulin sensitivity. Here are some key points to consider when evaluating the potential of GDF15 as a biomarker for metformin treatment:\n1. What is GDF15?\nGDF15 is a member of the TGF- (Transforming Growth Factor ) superfamily of proteins. It is primarily produced by the liver and plays a crucial role in regulating glucose metabolism, insulin sensitivity, and inflammation. GDF15 has been shown to promote the differentiation of adipocytes and inhibit the proliferation of hepatocytes, which can contribute to the regulation of glucose metabolism.\n2. The relationship between GDF15 and metformin\nMetformin is a widely used medication for type 2 diabetes that works by increasing insulin sensitivity and reducing glucose production in the liver. Studies have shown that GDF15 levels are altered in response to metformin treatment, suggesting a potential link between the two. For example, one study found that GDF15 levels were significantly increased in patients with type 2 diabetes treated with metformin compared to those not treated with the drug.\n3. Potential of GDF15 as a biomarker for metformin treatment\nGDF15 has been proposed as a potential biomarker for metformin treatment due to its altered levels in response to the medication. The use of GDF15 as a biomarker could potentially help identify patients who are most likely to benefit from metformin treatment and monitor their response to the medication. Additionally, GDF15 levels may be used to predict the risk of metformin-related adverse effects, such as lactic acidosis.\n4. Limitations and future directions\nWhile GDF15 has shown promise as a biomarker for metformin treatment, there are several limitations to its use. For example, GDF15 levels can be influenced by a variety of factors, including age, sex, and other",
    "llama-2-7b-chat-hf_fact_raw": "1. GDF15 is a member of the TGF- superfamily of proteins primarily produced by the liver.\n2. GDF15 plays a role in regulating glucose metabolism, insulin sensitivity, and inflammation.\n3. Metformin is a medication for type 2 diabetes that increases insulin sensitivity and reduces glucose production in the liver.\n4. Studies have shown that GDF15 levels are altered in response to metformin treatment.\n5. GDF15 has been proposed as a potential biomarker for identifying patients most likely to benefit from metformin treatment.",
    "llama-2-7b-chat-hf_fact": [
      "GDF15 is a member of the TGF- superfamily of proteins primarily produced by the liver.",
      "GDF15 plays a role in regulating glucose metabolism, insulin sensitivity, and inflammation.",
      "Metformin is a medication for type 2 diabetes that increases insulin sensitivity and reduces glucose production in the liver.",
      "Studies have shown that GDF15 levels are altered in response to metformin treatment.",
      "GDF15 has been proposed as a potential biomarker for identifying patients most likely to benefit from metformin treatment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: GDF15 is a member of the TGF- superfamily of proteins but is not primarily produced by the liver; it is expressed in various tissues.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "llama-2-7b-chat-hf_response": "Recursive splicing is a type of splicing event in which the same intron is spliced back into the RNA transcript at a different position than its original splicing site. This type of splicing is more common in short introns, which are introns that are shorter than 100 nucleotides in length.\nThere are several reasons why recursive splicing is more common in short introns:\n1. Short introns have a higher concentration of splice sites: Short introns have a higher concentration of splice sites compared to longer introns. This means that there are more potential sites for the spliceosome to recognize and splice, increasing the likelihood of recursive splicing.\n2. Short introns are more flexible: Short introns are more flexible than longer introns, which makes them more prone to recursive splicing. The spliceosome can more easily recognize and bind to the intron-exon junction in short introns, leading to recursive splicing.\n3. Short introns are more likely to be located near the 3' end of the gene: Short introns are more likely to be located near the 3' end of the gene, which can increase the likelihood of recursive splicing. The 3' end of the gene is the site where the spliceosome recognizes and splices the intron-exon junction, so short introns located near this end are more likely to be spliced recursively.\n4. Recursive splicing can be a mechanism for regulating gene expression: Recursive splicing can be a mechanism for regulating gene expression by creating different isoforms of the RNA transcript. By splicing the same intron back into the RNA transcript at different positions, the spliceosome can create different combinations of exons, leading to different isoforms of the RNA transcript.\n5. Recursive splicing can be a mechanism for creating alternative splicing events: Recursive splicing can be a mechanism for creating alternative splicing events, which are different splicing patterns that occur in different cells or tissues. By splicing the same intron back into the RNA transcript at different positions, the spliceosome can create different splicing patterns, leading to different isoforms of the RNA transcript.",
    "llama-2-7b-chat-hf_fact_raw": "1. Recursive splicing is more common in introns that are shorter than 100 nucleotides in length.\n2. Short introns have a higher concentration of splice sites compared to longer introns.\n3. Short introns are more flexible than longer introns.\n4. Short introns are more likely to be located near the 3' end of the gene.\n5. Recursive splicing can be a mechanism for regulating gene expression by creating different isoforms of the RNA transcript.",
    "llama-2-7b-chat-hf_fact": [
      "Recursive splicing is more common in introns that are shorter than 100 nucleotides in length.",
      "Short introns have a higher concentration of splice sites compared to longer introns.",
      "Short introns are more flexible than longer introns.",
      "Short introns are more likely to be located near the 3' end of the gene.",
      "Recursive splicing can be a mechanism for regulating gene expression by creating different isoforms of the RNA transcript."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "llama-2-7b-chat-hf_response": "The TALE-iD method is a gene editing technique that is used to modify specific genes in a genome. It is a type of transcription activator-like effector (TALE) gene editing system that is based on the CRISPR-Cas9 system.\nThe TALE-iD method works by using a TALE protein to recognize and bind to a specific DNA sequence in the genome, called a target site. The TALE protein is engineered to recognize a specific sequence of nucleotides, called a TALEnt, which is designed to be complementary to the target site. Once the TALE protein binds to the target site, it can be used to introduce a DNA break at that site, which can then be repaired by the cell's own repair machinery.\nThe TALE-iD method is used for a variety of applications, including:\n1. Gene knockout: By introducing a DNA break at a specific gene, the gene can be inactivated or \"knocked out.\" This can be useful for studying the function of a gene or for developing new therapies for diseases caused by mutations in that gene.\n2. Gene editing: The TALE-iD method can be used to introduce specific mutations into a gene, which can be used to study the function of the gene or to develop new therapies for diseases caused by mutations in that gene.\n3. Gene expression: The TALE-iD method can be used to activate or repress the expression of a specific gene by introducing a DNA break at a specific location in the gene.\n4. Genome engineering: The TALE-iD method can be used to introduce specific mutations or modifications into the genome at specific locations, which can be used to study the function of specific genes or to develop new therapies for diseases.\n5. Cancer treatment: The TALE-iD method can be used to selectively kill cancer cells by introducing a DNA break at a specific location in the genome that is only present in cancer cells.\n6. Gene therapy: The TALE-iD method can be used to introduce healthy copies of a gene into cells to replace a faulty or missing gene, which can be used to treat genetic diseases.\n7. Regener",
    "llama-2-7b-chat-hf_fact_raw": "1. The TALE-iD method is a gene editing technique used to modify specific genes in a genome.\n2. It is based on the CRISPR-Cas9 system and uses a TALE protein to recognize and bind to a specific DNA sequence.\n3. The TALE-iD method can be used for gene knockout, effectively inactivating a gene.\n4. It can also be used to introduce specific mutations or modifications into the genome.\n5. The TALE-iD method has applications in cancer treatment by selectively targeting cancer cells.",
    "llama-2-7b-chat-hf_fact": [
      "The TALE-iD method is a gene editing technique used to modify specific genes in a genome.",
      "It is based on the CRISPR-Cas9 system and uses a TALE protein to recognize and bind to a specific DNA sequence.",
      "The TALE-iD method can be used for gene knockout, effectively inactivating a gene.",
      "It can also be used to introduce specific mutations or modifications into the genome.",
      "The TALE-iD method has applications in cancer treatment by selectively targeting cancer cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The TALE-iD method is not based on the CRISPR-Cas9 system; it is based on transcription activator-like effector (TALE) proteins.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "llama-2-7b-chat-hf_response": "There are several Lisp frameworks that have been developed for image processing. Here are some of the most popular ones:\n1. CLISP Image Processing: CLISP is a Lisp image processing framework that provides a wide range of image processing functions, including image filtering, thresholding, segmentation, and feature extraction. It also includes a number of pre-built image processing tools and libraries.\n2. Lisp-Image: Lisp-Image is a Lisp framework specifically designed for image processing. It provides a simple and flexible interface for image processing, and includes a number of built-in image processing functions, such as convolution, thresholding, and edge detection.\n3. ImageCraft: ImageCraft is a Lisp framework for image processing that provides a comprehensive set of image processing functions, including image filtering, thresholding, segmentation, and feature extraction. It also includes a number of pre-built image processing tools and libraries.\n4. Lisp-based Image Processing Toolkit (LIPT): LIPT is a Lisp framework for image processing that provides a wide range of image processing functions, including image filtering, thresholding, segmentation, and feature extraction. It also includes a number of pre-built image processing tools and libraries.\n5. Lisp-based Image Processing Library (LIPL): LIPL is a Lisp library for image processing that provides a wide range of image processing functions, including image filtering, thresholding, segmentation, and feature extraction. It also includes a number of pre-built image processing tools and libraries.\n6. OpenLisp-Image: OpenLisp-Image is a Lisp framework for image processing that provides a wide range of image processing functions, including image filtering, thresholding, segmentation, and feature extraction. It also includes a number of pre-built image processing tools and libraries.\n7. Lisp-based Image Processing System (LIPS): LIPS is a Lisp framework for image processing that provides a wide range of image processing functions, including image filtering, thresholding, segmentation, and feature extraction. It also includes a number of pre-built image processing tools and libraries.\n8. Lisp-based Image Processing Toolkit (LIPTO): LIPTO is a Lisp framework for image processing that provides a wide range of image processing functions, including image filtering, thresholding, segmentation, and feature extra",
    "llama-2-7b-chat-hf_fact_raw": "1. CLISP Image Processing is a Lisp framework that provides image processing functions and pre-built tools and libraries.\n2. Lisp-Image is specifically designed for image processing with built-in functions like convolution and edge detection.\n3. ImageCraft offers a comprehensive set of image processing functions, including filtering and segmentation.\n4. Lisp-based Image Processing Toolkit (LIPT) offers a range of image processing functions and pre-built tools.\n5. OpenLisp-Image provides image processing functions and includes pre-built tools and libraries.",
    "llama-2-7b-chat-hf_fact": [
      "CLISP Image Processing is a Lisp framework that provides image processing functions and pre-built tools and libraries.",
      "Lisp-Image is specifically designed for image processing with built-in functions like convolution and edge detection.",
      "ImageCraft offers a comprehensive set of image processing functions, including filtering and segmentation.",
      "Lisp-based Image Processing Toolkit (LIPT) offers a range of image processing functions and pre-built tools.",
      "OpenLisp-Image provides image processing functions and includes pre-built tools and libraries."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: CLISP Image Processing is a Common Lisp framework, not specifically called \"CLISP Image Processing.\"\n2. TRUE\n3. UNKNOWN\n4. FALSE [correction]: There is no widely recognized toolkit called \"Lisp-based Image Processing Toolkit (LIPT).\"\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-2-7b-chat-hf_response": "Great, thank you for asking! The answer to your question is a bit complex, but I'll do my best to provide a detailed explanation.\nSaccharomyces cerevisiae, also known as baker's yeast, has a genome that is the result of several ancient whole genome duplications (WGDs). These WGDs occurred millions of years ago and resulted in the duplication of large segments of the yeast genome.\nThe most recent WGD in S. cerevisiae occurred around 100-150 million years ago, during the Cenozoic era. This event, known as the \"S. cerevisiae WGD,\" duplicated approximately 800-1000 genes, including many important genes involved in various cellular processes such as metabolism, stress response, and protein synthesis.\nTo give you an idea of the scale of gene duplication in S. cerevisiae, the genome of this organism contains approximately 6,000 protein-coding genes. Of these, around 300-400 genes are the result of the S. cerevisiae WGD.\nIt's worth noting that the number of genes duplicated in the S. cerevisiae WGD is relatively small compared to other organisms, such as the African clawed frog (Xenopus laevis), which underwent a much more extensive WGD around 300 million years ago. This event resulted in the duplication of around 20,000 genes, which is a much larger proportion of the frog genome compared to the S. cerevisiae WGD.\nIn summary, around 300-400 genes in the S. cerevisiae genome are the result of an ancient whole genome duplication that occurred around 100-150 million years ago. These genes are involved in various cellular processes and play important roles in the biology of this organism.",
    "llama-2-7b-chat-hf_fact_raw": "1. Saccharomyces cerevisiae, also known as baker's yeast, has a genome result of several ancient whole genome duplications.\n2. The most recent whole genome duplication in S. cerevisiae occurred around 100-150 million years ago during the Cenozoic era.\n3. The S. cerevisiae whole genome duplication duplicated approximately 800-1000 genes.\n4. The genome of Saccharomyces cerevisiae contains approximately 6,000 protein-coding genes.\n5. Around 300-400 genes in the S. cerevisiae genome are the result of the ancient whole genome duplication that occurred 100-150 million years ago.",
    "llama-2-7b-chat-hf_fact": [
      "Saccharomyces cerevisiae, also known as baker's yeast, has a genome result of several ancient whole genome duplications.",
      "The most recent whole genome duplication in S. cerevisiae occurred around 100-150 million years ago during the Cenozoic era.",
      "The S. cerevisiae whole genome duplication duplicated approximately 800-1000 genes.",
      "The genome of Saccharomyces cerevisiae contains approximately 6,000 protein-coding genes.",
      "Around 300-400 genes in the S. cerevisiae genome are the result of the ancient whole genome duplication that occurred 100-150 million years ago."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The most recent whole genome duplication in S. cerevisiae occurred around 100 million years ago, but it was during the Mesozoic era, not the Cenozoic era.\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor  (Esrrb)?",
    "llama-2-7b-chat-hf_response": "Estrogen-related receptor  (Esrrb) is a nuclear receptor that is bound by a variety of complexes, including:\n1. Estrogen: Esrrb is activated by estrogen, and it plays a crucial role in regulating gene expression in response to estrogen signaling.\n2. Coactivators: Esrrb can interact with coactivators, such as p300 and CBP (CREB-binding protein), to enhance the transcriptional activity of estrogen-responsive genes.\n3. Corepressors: Esrrb can also interact with corepressors, such as N-CoR (nuclear receptor corepressor) and SMRT (silencing mediator for retinoid and thyroid hormone receptors), to repress the transcription of genes that are inhibited by estrogen.\n4. Chromatin-modifying complexes: Esrrb can also interact with chromatin-modifying complexes, such as histone acetyltransferases (HATs) and histone deacetylases (HDACs), to regulate the chromatin structure and accessibility to estrogen-responsive genes.\n5. Non-coding RNAs: Esrrb can also interact with non-coding RNAs, such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), to regulate the expression of estrogen-responsive genes.\n6. Signaling pathways: Esrrb can also interact with signaling pathways, such as the PI3K/Akt pathway, the MAPK/ERK pathway, and the JNK pathway, to regulate the expression of estrogen-responsive genes.\n7. Other transcription factors: Esrrb can also interact with other transcription factors, such as E2F1, SP1, and SP3, to regulate the expression of estrogen-responsive genes.\n8. DNA damage response: Esrrb can also interact with the DNA damage response pathway, such as ATM and ATR, to regulate the expression of genes involved in DNA repair and checkpoint pathways.\n9. Stem cell maintenance:",
    "llama-2-7b-chat-hf_fact_raw": "1. Estrogen-related receptor  (Esrrb) is activated by estrogen.\n2. Esrrb interacts with coactivators like p300 and CBP to enhance transcriptional activity of estrogen-responsive genes.\n3. Esrrb interacts with corepressors like N-CoR and SMRT to repress transcription of genes inhibited by estrogen.\n4. Esrrb interacts with chromatin-modifying complexes such as HATs and HDACs.\n5. Esrrb can interact with non-coding RNAs including microRNAs and long non-coding RNAs.",
    "llama-2-7b-chat-hf_fact": [
      "Estrogen-related receptor  (Esrrb) is activated by estrogen.",
      "Esrrb interacts with coactivators like p300 and CBP to enhance transcriptional activity of estrogen-responsive genes.",
      "Esrrb interacts with corepressors like N-CoR and SMRT to repress transcription of genes inhibited by estrogen.",
      "Esrrb interacts with chromatin-modifying complexes such as HATs and HDACs.",
      "Esrrb can interact with non-coding RNAs including microRNAs and long non-coding RNAs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Estrogen-related receptor  (Esrrb) is not activated by estrogen; it is an orphan receptor, meaning it has no known natural ligand.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "llama-2-7b-chat-hf_response": "ZCCHC17 is a protein that plays a crucial role in various cellular processes, including cell signaling, differentiation, and survival. Here are some of the key functions of ZCCHC17:\n1. Cell signaling: ZCCHC17 is involved in the regulation of multiple signaling pathways, including the Wnt/-catenin pathway, the Notch pathway, and the PI3K/Akt pathway. It does this by modulating the activity of key signaling proteins, such as -catenin, Notch, and PI3K.\n2. Cell differentiation: ZCCHC17 has been shown to regulate the differentiation of various cell types, including neurons, muscle cells, and adipocytes. It does this by controlling the expression of genes involved in cell differentiation and by modulating the activity of transcription factors.\n3. Cell survival: ZCCHC17 has been implicated in the regulation of cell survival and apoptosis. It has been shown to inhibit the pro-apoptotic protein Bax and to promote the anti-apoptotic protein Bcl-2, thereby protecting cells from apoptosis.\n4. Cancer: ZCCHC17 has been implicated in the development and progression of various types of cancer, including breast, lung, and colon cancer. It is thought to promote cancer cell proliferation, migration, and invasion by modulating the activity of key signaling pathways.\n5. Neurodegeneration: ZCCHC17 has been linked to the regulation of neurodegeneration, with studies suggesting that it may play a role in the development of neurodegenerative diseases such as Alzheimer's and Parkinson's.\n6. Development: ZCCHC17 has been implicated in the regulation of embryonic development, with studies suggesting that it may play a role in the formation of various tissues and organs.\n7. Immune response: ZCCHC17 has been shown to be involved in the regulation of the immune response, with studies suggesting that it may play a role in the modulation of immune cell function and the regulation of inflammation.\n8. Metabol",
    "llama-2-7b-chat-hf_fact_raw": "1. ZCCHC17 is involved in the regulation of multiple signaling pathways, including the Wnt/-catenin pathway, the Notch pathway, and the PI3K/Akt pathway.\n2. ZCCHC17 regulates the differentiation of various cell types, including neurons, muscle cells, and adipocytes.\n3. ZCCHC17 has been shown to inhibit the pro-apoptotic protein Bax and to promote the anti-apoptotic protein Bcl-2.\n4. ZCCHC17 has been implicated in the development and progression of various types of cancer, including breast, lung, and colon cancer.\n5. ZCCHC17 has been linked to the regulation of neurodegeneration and may play a role in the development of neurodegenerative diseases such as Alzheimer's and Parkinson's.",
    "llama-2-7b-chat-hf_fact": [
      "ZCCHC17 is involved in the regulation of multiple signaling pathways, including the Wnt/-catenin pathway, the Notch pathway, and the PI3K/Akt pathway.",
      "ZCCHC17 regulates the differentiation of various cell types, including neurons, muscle cells, and adipocytes.",
      "ZCCHC17 has been shown to inhibit the pro-apoptotic protein Bax and to promote the anti-apoptotic protein Bcl-2.",
      "ZCCHC17 has been implicated in the development and progression of various types of cancer, including breast, lung, and colon cancer.",
      "ZCCHC17 has been linked to the regulation of neurodegeneration and may play a role in the development of neurodegenerative diseases such as Alzheimer's and Parkinson's."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout the specific passage or additional scientific context, it is impossible to determine the accuracy of these statements about ZCCHC17.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "llama-2-7b-chat-hf_response": "The nuclear pore basket, also known as the nuclear pore complex (NPC), is a large protein structure that spans the nuclear envelope in eukaryotic cells, including human cells. The NPC acts as a selective barrier between the nucleus and the cytoplasm, regulating the transport of molecules between these two compartments.\nThe proteins that form the NPC can be broadly categorized into three main groups:\n1. Fibrillar proteins: These proteins make up the majority of the NPC structure and provide the framework for the complex. The main fibrillar proteins involved in the NPC are:\n* Nucleoporin 1 (Nup1): This protein is the most abundant protein in the NPC and forms the central channel through which molecules pass.\n* Nucleoporin 2 (Nup2): This protein is involved in the formation of the nuclear pore basket and helps to regulate the transport of molecules through the NPC.\n* Nucleoporin 3 (Nup3): This protein is involved in the formation of the NPC and helps to regulate the transport of molecules through the complex.\n2. Perforin proteins: These proteins form the pores through which molecules pass through the NPC. The main perforin proteins involved in the NPC are:\n* Nucleoporin 4 (Nup4): This protein forms the peripheral channels through which molecules pass through the NPC.\n* Nucleoporin 5 (Nup5): This protein is involved in the formation of the NPC and helps to regulate the transport of molecules through the complex.\n3. Associated proteins: These proteins are involved in the regulation of the NPC and help to control the transport of molecules through the complex. The main associated proteins involved in the NPC are:\n* Importin alpha (Importin-): This protein is involved in the import of proteins and RNA molecules into the nucleus through the NPC.\n* Importin beta (Importin-): This protein is involved in the import of proteins and RNA molecules into the nucleus through the NPC.\n* Nucleoporin 6 (Nup6): This protein is involved in the",
    "llama-2-7b-chat-hf_fact_raw": "1. The nuclear pore basket is a large protein structure that spans the nuclear envelope in eukaryotic cells.\n2. Nucleoporin 1 (Nup1) forms the central channel of the nuclear pore complex.\n3. Nucleoporin 2 (Nup2) is involved in the formation of the nuclear pore basket.\n4. Nucleoporin 4 (Nup4) forms the peripheral channels of the nuclear pore complex.\n5. Importin alpha (Importin-) is involved in the import of proteins and RNA molecules into the nucleus through the nuclear pore complex.",
    "llama-2-7b-chat-hf_fact": [
      "The nuclear pore basket is a large protein structure that spans the nuclear envelope in eukaryotic cells.",
      "Nucleoporin 1 (Nup1) forms the central channel of the nuclear pore complex.",
      "Nucleoporin 2 (Nup2) is involved in the formation of the nuclear pore basket.",
      "Nucleoporin 4 (Nup4) forms the peripheral channels of the nuclear pore complex.",
      "Importin alpha (Importin-) is involved in the import of proteins and RNA molecules into the nucleus through the nuclear pore complex."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Nucleoporin 1 (Nup1) does not form the central channel, other nucleoporins such as Nup107, Nup160, and Nup133 are involved in the central channel formation of the nuclear pore complex.\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "llama-2-7b-chat-hf_response": "Gepotidacin is a novel, orally available topoisomerase inhibitor that is currently being investigated as a potential treatment for various types of cancer, including acute myeloid leukemia (AML) and bladder cancer.\nTopoisomerase inhibitors are a class of drugs that work by binding to and inhibiting the activity of topoisomerases, which are enzymes that play a crucial role in DNA replication, repair, and transcription. By inhibiting the activity of topoisomerases, these drugs can disrupt the normal functioning of cancer cells, leading to cell death and tumor regression.\nGepotidacin is a highly selective and potent inhibitor of topoisomerase II (TOP2), which is overexpressed in many types of cancer. TOP2 is a key enzyme involved in the repair of DNA double-strand breaks, and its overexpression can contribute to the development and progression of cancer. Gepotidacin has been shown to be effective in inhibiting the growth of cancer cells, both in vitro and in vivo, and it has been investigated as a potential treatment for a variety of different types of cancer, including AML, bladder cancer, and ovarian cancer.\nGepotidacin has several potential advantages over other topoisomerase inhibitors. For example, it is highly selective for TOP2, which reduces the risk of toxic side effects associated with non-specific inhibition of other topoisomerases. Additionally, it has been shown to be effective in combination with other chemotherapeutic agents, such as cisplatin, which may enhance its anti-tumor activity.\nHowever, it is important to note that gepotidacin is still an investigational drug, and further clinical trials are needed to fully evaluate its safety and efficacy in humans. Additionally, the use of topoisomerase inhibitors can have side effects, such as nausea, vomiting, and diarrhea, and long-term use of these drugs can lead to the development of resistance.\nIn summary, gepotidacin is a novel, orally available topoisomerase inhibitor that is being investigated as a potential treatment for various types of cancer. It is highly select",
    "llama-2-7b-chat-hf_fact_raw": "1. Gepotidacin is an orally available topoisomerase inhibitor being investigated as a treatment for cancer.\n2. Gepotidacin is being investigated as a potential treatment for acute myeloid leukemia (AML) and bladder cancer.\n3. Gepotidacin is a selective and potent inhibitor of topoisomerase II (TOP2).\n4. TOP2 is overexpressed in many types of cancer and is involved in the repair of DNA double-strand breaks.\n5. Gepotidacin is still an investigational drug and requires further clinical trials to evaluate its safety and efficacy in humans.",
    "llama-2-7b-chat-hf_fact": [
      "Gepotidacin is an orally available topoisomerase inhibitor being investigated as a treatment for cancer.",
      "Gepotidacin is being investigated as a potential treatment for acute myeloid leukemia (AML) and bladder cancer.",
      "Gepotidacin is a selective and potent inhibitor of topoisomerase II (TOP2).",
      "TOP2 is overexpressed in many types of cancer and is involved in the repair of DNA double-strand breaks.",
      "Gepotidacin is still an investigational drug and requires further clinical trials to evaluate its safety and efficacy in humans."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Gepotidacin is an orally available topoisomerase inhibitor being investigated as a treatment for bacterial infections, not cancer.\n2. FALSE [correction]: Gepotidacin is being investigated as a potential treatment for bacterial infections such as urinary tract infections and gonorrhea, not AML and bladder cancer.\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "llama-2-7b-chat-hf_response": "Canvas SPW (Software as a Service) is a cloud-based platform designed for businesses to manage their workforce and streamline their HR processes. It is a comprehensive solution that provides a range of tools and features to help organizations automate and optimize their HR functions, including recruitment, onboarding, time and attendance tracking, benefits management, performance management, and more.\nHere are some key features and benefits of Canvas SPW:\n1. Recruitment Management: Canvas SPW provides tools to help businesses manage their recruitment process, including job posting, resume screening, interview scheduling, and candidate tracking.\n2. Onboarding: The platform offers a streamlined onboarding process that includes electronic forms, document management, and compliance tracking.\n3. Time and Attendance Tracking: Canvas SPW provides a time and attendance tracking system that allows employees to clock in and out from any device, and provides managers with real-time visibility into employee attendance.\n4. Benefits Management: The platform offers a benefits management system that allows businesses to manage employee benefits, including health insurance, retirement plans, and other benefits.\n5. Performance Management: Canvas SPW provides tools for performance management, including goal setting, performance evaluations, and succession planning.\n6. Compliance: The platform offers compliance features to help businesses stay up-to-date with labor laws and regulations, including automatic updates and alerts.\n7. Reporting and Analytics: Canvas SPW provides a range of reporting and analytics tools that allow businesses to track HR metrics, including employee turnover, time off, and performance.\n8. Integration: The platform integrates with a wide range of HR systems, including payroll, talent management, and performance management systems.\n9. Security and Privacy: Canvas SPW is built on a secure and compliant infrastructure, with advanced security measures in place to protect sensitive employee data.\n10. Scalability: The platform is designed to grow with your business, with customizable workflows and a scalable architecture that can handle the needs of businesses of all sizes.\nBenefits of using Canvas SPW:\n1. Streamlined HR processes: Canvas SPW automates and streamlines many of the HR functions, freeing up HR staff",
    "llama-2-7b-chat-hf_fact_raw": "1. Canvas SPW is a cloud-based platform used for managing workforce and HR processes.\n2. The platform provides recruitment management tools for job posting, resume screening, and interview scheduling.\n3. Canvas SPW offers a time and attendance tracking system that is accessible from any device.\n4. The platform includes a benefits management system for managing employee benefits like health insurance and retirement plans.\n5. Canvas SPW has compliance features to help businesses adhere to labor laws and regulations.",
    "llama-2-7b-chat-hf_fact": [
      "Canvas SPW is a cloud-based platform used for managing workforce and HR processes.",
      "The platform provides recruitment management tools for job posting, resume screening, and interview scheduling.",
      "Canvas SPW offers a time and attendance tracking system that is accessible from any device.",
      "The platform includes a benefits management system for managing employee benefits like health insurance and retirement plans.",
      "Canvas SPW has compliance features to help businesses adhere to labor laws and regulations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Without additional context or information on \"Canvas SPW\", it is impossible to determine the accuracy of these statements.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I'd be happy to provide you with a list of STING agonists!\nSTING (Stimulator of Interferon Genes) is a protein found on the surface of cells that plays a crucial role in the innate immune response. STING agonists are compounds or molecules that activate STING, leading to the production of interferons and other immune molecules. Here are some examples of STING agonists:\n1. PolyICLC: PolyICLC (polyinosinic-polycytidylic acid-lysine-choline) is a synthetic analog of double-stranded RNA that activates STING and triggers an interferon response.\n2. CpG ODN: CpG oligonucleotides (ODNs) are synthetic DNA molecules that contain the characteristic CpG motif found in bacterial DNA. They activate STING and stimulate the production of interferons.\n3. Toll-like receptor (TLR) agonists: TLRs are pattern recognition receptors that recognize pathogen-associated molecular patterns (PAMPs). Some TLR agonists, such as flagellin and lipopolysaccharide, can activate STING and trigger an interferon response.\n4. RIG-I agonists: RIG-I (retinoic acid-inducible gene-I) is a protein that recognizes viral RNA and activates STING. Some RIG-I agonists, such as small molecule inhibitors of the viral RNA-binding protein, Vpas, can activate STING and stimulate an interferon response.\n5. STING itself: STING can also act as an agonist of itself, as it can bind to and activate its own protein. This process is known as autoactivation.\n6. R848: R848 is a synthetic agonist of the Toll-like receptor 7 (TLR7) that can activate STING and stimulate an interferon response.\n7. Vitamin D: Vitamin D has been shown to activate STING and stimulate the production of interferons in some studies.\n8. Resverat",
    "llama-2-7b-chat-hf_fact_raw": "1. PolyICLC is a synthetic analog of double-stranded RNA that activates STING.\n2. CpG ODNs are synthetic DNA molecules that activate STING and stimulate interferon production.\n3. Some TLR agonists can activate STING and trigger an interferon response.\n4. RIG-I agonists can activate STING and stimulate an interferon response.\n5. Vitamin D can activate STING and stimulate the production of interferons.",
    "llama-2-7b-chat-hf_fact": [
      "PolyICLC is a synthetic analog of double-stranded RNA that activates STING.",
      "CpG ODNs are synthetic DNA molecules that activate STING and stimulate interferon production.",
      "Some TLR agonists can activate STING and trigger an interferon response.",
      "RIG-I agonists can activate STING and stimulate an interferon response.",
      "Vitamin D can activate STING and stimulate the production of interferons."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: PolyICLC is a synthetic analog of double-stranded RNA that activates TLR3 and RIG-I/MDA5, not STING.\n2. FALSE [correction]: CpG ODNs are synthetic DNA molecules that activate TLR9, not STING.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Vitamin D does not activate STING; it modulates the immune response in other ways.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "llama-2-7b-chat-hf_response": "SLIC-CAGE is a widely used algorithm in bioinformatics and computational biology for the prediction of protein-ligand interactions. It stands for \"Sparse Linear Impulse Response-Cached Artificial Geometry Environment.\" The algorithm was developed by researchers at the University of California, San Diego and is designed to predict the binding affinity of a protein for a small molecule ligand.\nHere's a detailed explanation of how SLIC-CAGE works:\n1. Ligand representation: The ligand is represented as a set of atoms, each with a set of possible bond angles and distances. This representation is called the \"ligand fingerprint.\"\n2. Protein representation: The protein is represented as a three-dimensional structure, which is converted into a set of features that describe the protein's binding site. These features include the distances between the protein atoms and the ligand atoms, as well as the angles between the protein and ligand atoms.\n3. Sparse linear impulse response: The protein-ligand interactions are modeled using a sparse linear impulse response (SLIR) function. This function describes the response of the protein to a small perturbation in the ligand. The SLIR function is computed using a linear combination of basis functions, which are optimized to capture the essential features of the protein-ligand interactions.\n4. Cached artificial geometry environment: The protein-ligand interactions are modeled using a cached artificial geometry environment (CAGE). This environment is a set of pre-computed protein-ligand complexes, which are used to predict the binding affinity of the protein for the ligand. The CAGE is constructed by computing the protein-ligand complexes for a set of possible ligand conformations, and then caching the resulting complexes for future use.\n5. Machine learning: The predicted binding affinity is computed using a machine learning algorithm, such as support vector machines (SVM) or neural networks. The algorithm is trained on a set of known protein-ligand complexes, and then used to predict the binding affinity of the protein for the ligand.\n6. Prediction: The final prediction of the binding affinity is made by combining the results of the SLIR and CAGE computations. The predicted binding affinity is a measure of the strength of the interaction between the protein and ligand, and can be used to identify potential drug targets or to",
    "llama-2-7b-chat-hf_fact_raw": "1. SLIC-CAGE is an algorithm used for predicting protein-ligand interactions in bioinformatics and computational biology.\n2. The acronym SLIC-CAGE stands for \"Sparse Linear Impulse Response-Cached Artificial Geometry Environment.\"\n3. SLIC-CAGE was developed by researchers at the University of California, San Diego.\n4. The algorithm predicts the binding affinity of a protein for a small molecule ligand.\n5. SLIC-CAGE uses machine learning algorithms, like support vector machines or neural networks, to compute the predicted binding affinity.",
    "llama-2-7b-chat-hf_fact": [
      "SLIC-CAGE is an algorithm used for predicting protein-ligand interactions in bioinformatics and computational biology.",
      "The acronym SLIC-CAGE stands for \"Sparse Linear Impulse Response-Cached Artificial Geometry Environment.\"",
      "SLIC-CAGE was developed by researchers at the University of California, San Diego.",
      "The algorithm predicts the binding affinity of a protein for a small molecule ligand.",
      "SLIC-CAGE uses machine learning algorithms, like support vector machines or neural networks, to compute the predicted binding affinity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The acronym SLIC-CAGE stands for \"Structure-Based Ligand Interaction by Caching Aggregated Geometric Entities.\"\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "llama-2-7b-chat-hf_response": "LEM-3 (Lethal Midline Granule 3) is a protein that plays a crucial role in the regulation of cellular processes, including cell division, differentiation, and survival. Here are some of the key roles of LEM-3:\n1. Regulation of the cell cycle: LEM-3 is involved in the regulation of the G1/S checkpoint, which is a critical control point in the cell cycle. It helps to ensure that cells are ready to enter the S phase of the cell cycle and that they are not prematurely entered into the cycle.\n2. Modulation of protein kinase activity: LEM-3 can modulate the activity of protein kinases, which are enzymes that add phosphate groups to proteins to activate or inhibit their activity. LEM-3 can bind to and inhibit the activity of certain protein kinases, thereby regulating various cellular processes.\n3. Regulation of gene expression: LEM-3 can bind to specific DNA sequences and regulate the expression of nearby genes. It has been shown to bind to the promoter regions of certain genes and enhance or repress their transcription.\n4. Modulation of apoptosis: LEM-3 can modulate the process of programmed cell death (apoptosis), which is a critical mechanism for eliminating damaged or unwanted cells. LEM-3 can inhibit the activity of pro-apoptotic proteins, such as BAX and BAK, and promote the activity of anti-apoptotic proteins, such as BCL-2.\n5. Regulation of autophagy: LEM-3 has been shown to regulate the process of autophagy, which is the degradation of cellular components, such as proteins and organelles, during times of stress or nutrient deprivation. LEM-3 can modulate the activity of autophagy-related proteins, such as ATG5 and ATG12, and regulate the degradation of cellular components.\n6. Regulation of cellular stress responses: LEM-3 can regulate the response of cells to various forms of stress, including oxidative stress, heat shock, and endoplasmic reticulum stress. It can modulate the activity of stress-inducible proteins, such as heat",
    "llama-2-7b-chat-hf_fact_raw": "1. LEM-3 is involved in the regulation of the G1/S checkpoint in the cell cycle.\n2. LEM-3 can modulate the activity of protein kinases by binding and inhibiting them.\n3. LEM-3 can bind to specific DNA sequences and regulate the expression of nearby genes.\n4. LEM-3 can inhibit the activity of pro-apoptotic proteins and promote the activity of anti-apoptotic proteins.\n5. LEM-3 has been shown to regulate the process of autophagy by modulating the activity of autophagy-related proteins.",
    "llama-2-7b-chat-hf_fact": [
      "LEM-3 is involved in the regulation of the G1/S checkpoint in the cell cycle.",
      "LEM-3 can modulate the activity of protein kinases by binding and inhibiting them.",
      "LEM-3 can bind to specific DNA sequences and regulate the expression of nearby genes.",
      "LEM-3 can inhibit the activity of pro-apoptotic proteins and promote the activity of anti-apoptotic proteins.",
      "LEM-3 has been shown to regulate the process of autophagy by modulating the activity of autophagy-related proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Without context or a specific reference to which LEM-3 is being discussed (as there could be multiple interpretations of the acronym), it's unclear whether these statements are accurate descriptions of the functions of LEM-3. Additional information would be needed to verify these claims.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I'm happy to provide you with the releases of tmVar, a popular time series forecasting library. Here are the releases of tmVar, along with their release dates and notable features:\n1. tmVar 0.1.0 (2017-01-01)\n\t* Initial release of tmVar, which provides a simple and efficient way to forecast time series data using a variational autoencoder (VAE).\n2. tmVar 0.2.0 (2017-06-01)\n\t* Added support for forecasting multiple time series using a single VAE model.\n\t* Introduced the `forecast_Multi` function, which takes in a list of time series data and returns a list of forecasted values for each series.\n3. tmVar 0.3.0 (2017-10-01)\n\t* Improved the stability and performance of the model by using a more efficient optimizer.\n\t* Introduced the `utils` module, which provides utility functions for working with time series data.\n4. tmVar 0.4.0 (2018-03-01)\n\t* Added support for forecasting with multiple output variables.\n\t* Introduced the `forecast_MultiOutput` function, which takes in a list of time series data and returns a list of forecasted values for each output variable.\n5. tmVar 0.5.0 (2018-06-01)\n\t* Improved the documentation and added more examples to make it easier to use the library.\n\t* Introduced the `plot` function, which allows users to visualize the forecasted values and the learned latent space of the VAE model.\n6. tmVar 0.6.0 (2018-10-01)\n\t* Added support for forecasting with different types of time series data, including time series with multiple seasons and time series with non-linear trends.\n\t* Introduced the `forecast_MultiSeason` and `forecast_NonLinear` functions, which take in a list of time series data and return a list of forecasted values for each season and non-linear trend, respectively.\n7",
    "llama-2-7b-chat-hf_fact_raw": "1. tmVar 0.1.0 was released on January 1, 2017, and featured an initial release providing a way to forecast time series data using a VAE.\n2. tmVar 0.2.0 was released on June 1, 2017, and added support for forecasting multiple time series with a single VAE model.\n3. tmVar 0.3.0 was released on October 1, 2017, and introduced the `utils` module for utility functions related to time series data.\n4. tmVar 0.4.0 was released on March 1, 2018, and added the ability to forecast with multiple output variables.\n5. tmVar 0.5.0 was released on June 1, 2018, and introduced the `plot` function for visualizing forecasted values and the VAE model's learned latent space.",
    "llama-2-7b-chat-hf_fact": [
      "tmVar 0.1.0 was released on January 1, 2017, and featured an initial release providing a way to forecast time series data using a VAE.",
      "tmVar 0.2.0 was released on June 1, 2017, and added support for forecasting multiple time series with a single VAE model.",
      "tmVar 0.3.0 was released on October 1, 2017, and introduced the `utils` module for utility functions related to time series data.",
      "tmVar 0.4.0 was released on March 1, 2018, and added the ability to forecast with multiple output variables.",
      "tmVar 0.5.0 was released on June 1, 2018, and introduced the `plot` function for visualizing forecasted values and the VAE model's learned latent space."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: The validity of these statements cannot be determined without additional context or reference to the specific release notes and features of the tmVar software/tool.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "llama-2-7b-chat-hf_response": "There are several databases of somatic mutations in normal cells that have been identified through various research studies and projects. Here are some of the most notable ones:\n1. The Cancer Genome Atlas (TCGA): TCGA is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) that aims to catalogue the genomic changes in various types of cancer. As part of this effort, TCGA has also collected data on somatic mutations in normal tissues, including those from the blood, brain, and other organs. The TCGA database contains RNA sequencing data, DNA methylation data, and other types of genomic data for over 10,000 samples from various cancer types and normal tissues.\n2. The 1000 Genomes Project: The 1000 Genomes Project is an international collaboration that aimed to sequence the genomes of 1,000 individuals from around the world. As part of this project, the researchers also collected DNA samples from normal tissues, including blood, saliva, and other tissues. The resulting dataset contains information on millions of single nucleotide polymorphisms (SNPs), insertions, deletions, and other types of genomic variations.\n3. The ExAC database: The ExAC database is a collection of genomic data from over 60,000 individuals, including both cancer cases and normal controls. The database contains RNA sequencing data, DNA methylation data, and other types of genomic data, as well as information on the genetic variants associated with various diseases.\n4. The GTEx database: The GTEx database is a collection of genomic data from over 450 normal tissues from various organs and tissues, including the brain, blood, and other organs. The database contains RNA sequencing data, DNA methylation data, and other types of genomic data, as well as information on the genetic variants associated with various diseases.\n5. The Roadmap Epigenomics Project: The Roadmap Epigenomics Project is an international collaboration that aimed to map the epigenetic landscape of various tissues and cell types. As part of this project, the researchers collected DNA methylation data from over 1",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cancer Genome Atlas (TCGA) is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).\n2. The 1000 Genomes Project aimed to sequence the genomes of 1,000 individuals from around the world.\n3. The ExAC database contains genomic data from over 60,000 individuals, including both cancer cases and normal controls.\n4. The GTEx database contains genomic data from over 450 normal tissues from various organs and tissues.\n5. The Roadmap Epigenomics Project aimed to map the epigenetic landscape of various tissues and cell types.",
    "llama-2-7b-chat-hf_fact": [
      "The Cancer Genome Atlas (TCGA) is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).",
      "The 1000 Genomes Project aimed to sequence the genomes of 1,000 individuals from around the world.",
      "The ExAC database contains genomic data from over 60,000 individuals, including both cancer cases and normal controls.",
      "The GTEx database contains genomic data from over 450 normal tissues from various organs and tissues.",
      "The Roadmap Epigenomics Project aimed to map the epigenetic landscape of various tissues and cell types."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The ExAC database contains genomic data from over 60,000 individuals, but it specifically excludes cancer cases.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "llama-2-7b-chat-hf_response": "Yes, there are several graph kernel libraries available that have been implemented in Java. Here are some of them:\n1. JGraphT: JGraphT is a Java library for graph theory. It provides a simple and efficient way to create, manipulate, and analyze graphs in Java. It supports a wide range of graph algorithms and data structures, including graphs, trees, and networks. JGraphT is actively maintained and has a large user community.\n2. GraphCompute: GraphCompute is a Java library for graph processing. It provides a simple and efficient way to perform graph computations, including graph traversal, graph clustering, and graph optimization. GraphCompute supports a variety of graph algorithms and data structures, including directed and undirected graphs, weighted and unweighted graphs, and graph networks.\n3. Graphical Models and Inference: Graphical Models and Inference is a Java library for graphical models and inference. It provides a simple and efficient way to perform graphical model inference, including Bayesian networks, Markov random fields, and graphical models. Graphical Models and Inference supports a variety of inference algorithms, including belief propagation, junction tree, and loopy belief propagation.\n4. Weave: Weave is a Java library for graph processing. It provides a simple and efficient way to perform graph computations, including graph traversal, graph clustering, and graph optimization. Weave supports a variety of graph algorithms and data structures, including directed and undirected graphs, weighted and unweighted graphs, and graph networks.\n5. GraphMol: GraphMol is a Java library for molecular graph processing. It provides a simple and efficient way to perform graph computations, including molecular graph clustering, molecular graph optimization, and molecular graph analysis. GraphMol supports a variety of graph algorithms and data structures, including molecular graphs, protein structures, and chemical compounds.\n6. Graphistry: Graphistry is a Java library for graph visualization and analysis. It provides a simple and efficient way to create, manipulate, and analyze graphs in 2D and 3D. Graphistry supports a variety of graph algorithms and data structures, including directed and undirected graphs, weighted and unweighted graphs, and graph networks.\n7. GraphFlow: GraphFlow is a Java library for graph processing. It provides a simple and efficient way to perform graph computations",
    "llama-2-7b-chat-hf_fact_raw": "1. JGraphT is a Java library for graph theory that is actively maintained with a large user community.\n2. GraphCompute is a Java library that performs graph computations, including graph traversal, clustering, and optimization.\n3. Graphical Models and Inference is a Java library for graphical model inference, supporting Bayesian networks, Markov random fields, and more.\n4. Weave is a Java library for graph processing that supports directed and undirected graphs, among other data structures.\n5. GraphMol is a Java library that performs computations on molecular graphs, including analysis and optimization.",
    "llama-2-7b-chat-hf_fact": [
      "JGraphT is a Java library for graph theory that is actively maintained with a large user community.",
      "GraphCompute is a Java library that performs graph computations, including graph traversal, clustering, and optimization.",
      "Graphical Models and Inference is a Java library for graphical model inference, supporting Bayesian networks, Markov random fields, and more.",
      "Weave is a Java library for graph processing that supports directed and undirected graphs, among other data structures.",
      "GraphMol is a Java library that performs computations on molecular graphs, including analysis and optimization."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I'm glad to provide you with the information you're seeking! The SHERLOCKv2 platform is a next-generation diagnostic tool that integrates four advanced technologies to provide fast, accurate, and cost-effective pathogen detection. Here are the four advances integrated into the SHERLOCKv2 platform:\n1. CRISPR-Cas13 Gene Editing: SHERLOCKv2 uses CRISPR-Cas13 gene editing to detect pathogens by specifically targeting and cleaving the DNA of the pathogen of interest. This approach allows for highly specific and sensitive detection of pathogens, even at very low concentrations.\n2. Single-Molecule Real-Time (SMRT) Sequencing: The SHERLOCKv2 platform utilizes SMRT sequencing to generate long-read DNA sequences, which are essential for detecting rare or low-abundance pathogens. SMRT sequencing provides high accuracy and resolution, enabling the detection of subtle changes in the DNA sequence that may indicate the presence of a pathogen.\n3. Digital PCR (dPCR): SHERLOCKv2 employs dPCR to quantify the number of pathogen cells in a sample. dPCR is a highly sensitive technique that can detect very small amounts of pathogens, making it ideal for detecting low-abundance pathogens in complex samples.\n4. Machine Learning (ML) and Artificial Intelligence (AI): The SHERLOCKv2 platform incorporates ML and AI algorithms to analyze the data generated by the CRISPR-Cas13 gene editing and SMRT sequencing steps. These algorithms enable the platform to identify and classify pathogens based on their unique genetic signatures, providing accurate and rapid detection of pathogens.\nBy integrating these four advanced technologies, the SHERLOCKv2 platform offers a highly sensitive and accurate diagnostic tool for pathogen detection, enabling rapid and effective response to outbreaks and improving public health outcomes.",
    "llama-2-7b-chat-hf_fact_raw": "1. The SHERLOCKv2 platform uses CRISPR-Cas13 gene editing for pathogen detection.\n2. Single-Molecule Real-Time (SMRT) Sequencing is utilized in the SHERLOCKv2 platform for long-read DNA sequences.\n3. Digital PCR (dPCR) is employed by the SHERLOCKv2 platform to quantify pathogen cells in a sample.\n4. Machine Learning (ML) and Artificial Intelligence (AI) algorithms are incorporated into the SHERLOCKv2 platform for data analysis.\n5. The SHERLOCKv2 platform is designed to detect pathogens rapidly and effectively.",
    "llama-2-7b-chat-hf_fact": [
      "The SHERLOCKv2 platform uses CRISPR-Cas13 gene editing for pathogen detection.",
      "Single-Molecule Real-Time (SMRT) Sequencing is utilized in the SHERLOCKv2 platform for long-read DNA sequences.",
      "Digital PCR (dPCR) is employed by the SHERLOCKv2 platform to quantify pathogen cells in a sample.",
      "Machine Learning (ML) and Artificial Intelligence (AI) algorithms are incorporated into the SHERLOCKv2 platform for data analysis.",
      "The SHERLOCKv2 platform is designed to detect pathogens rapidly and effectively."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The SHERLOCKv2 platform does not utilize Single-Molecule Real-Time (SMRT) Sequencing; it relies on CRISPR-Cas technology for pathogen detection.\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "llama-2-7b-chat-hf_response": "The Bartender Algorithm is a machine learning algorithm used for solving the Traveling Salesman Problem (TSP), which is a classic problem in computer science and operations research. The algorithm was first introduced by John H. Holland in 1960 and is named after the bartender who mixes drinks at a bar.\nThe Bartender Algorithm is a heuristic algorithm, meaning it is not guaranteed to find the optimal solution to the TSP, but it can provide a good approximation in a reasonable amount of time. The algorithm works by starting with an initial solution and iteratively improving it through a series of operations called \"mixed drinks.\"\nHere is a high-level overview of how the Bartender Algorithm works:\n1. Initialize the solution: The algorithm starts with an initial solution, which is typically a random solution.\n2. Evaluate the solution: The algorithm evaluates the current solution using a fitness function, which assigns a score based on how good the solution is.\n3. Mix drinks: If the current solution is not the best, the algorithm selects a \"drink\" (i.e., a subset of the original solution) and applies a series of operations to create a new solution. These operations include:\na. Swap two edges: The algorithm swaps two edges in the solution to create a new solution.\nb. Add an edge: The algorithm adds a new edge to the solution to create a new solution.\nc. Remove an edge: The algorithm removes an edge from the solution to create a new solution.\nd. Flip an edge: The algorithm flips an edge in the solution, which means that the edge is reversed.\n4. Repeat steps 3a-3d: The algorithm repeats steps 3a-3d until a stopping criterion is reached, such as a maximum number of iterations or a minimum fitness score.\n5. Output the solution: The algorithm outputs the final solution after the stopping criterion is reached.\nThe Bartender Algorithm is a simple and efficient algorithm for solving the Traveling Salesman Problem, but it is not guaranteed to find the optimal solution. However, it can provide a good approximation in a reasonable amount of time, making it a useful tool for solving real-world TSP instances.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Bartender Algorithm is used for solving the Traveling Salesman Problem (TSP).\n2. John H. Holland introduced the Bartender Algorithm in 1960.\n3. The Bartender Algorithm is a heuristic algorithm.\n4. The Bartender Algorithm includes operations such as swapping two edges, adding an edge, removing an edge, and flipping an edge.\n5. The Bartender Algorithm iteratively improves an initial solution through a series of operations called \"mixed drinks.\"",
    "llama-2-7b-chat-hf_fact": [
      "The Bartender Algorithm is used for solving the Traveling Salesman Problem (TSP).",
      "John H. Holland introduced the Bartender Algorithm in 1960.",
      "The Bartender Algorithm is a heuristic algorithm.",
      "The Bartender Algorithm includes operations such as swapping two edges, adding an edge, removing an edge, and flipping an edge.",
      "The Bartender Algorithm iteratively improves an initial solution through a series of operations called \"mixed drinks.\""
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Bartender Algorithm is not a known algorithm for solving the Traveling Salesman Problem (TSP). The correct algorithm might be the Nearest Neighbor or the Christofides algorithm.\n2. FALSE [correction]: John H. Holland did not introduce the Bartender Algorithm in 1960. He is known for genetic algorithms.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I'm glad to provide you with a list of web-based pedigree editors that are available. Here are some of the most popular and widely used options:\n1. Pedigree Manager: Pedigree Manager is a web-based genealogy software that allows users to create, edit, and share their family trees. It offers a user-friendly interface and supports a wide range of data sources, including GEDCOM files, family photos, and historical records.\n2. Family Tree Builder: Family Tree Builder is a free online genealogy tool that allows users to create and edit their family trees. It offers a simple and intuitive interface, and users can easily add and manage their ancestors, relatives, and other important family members.\n3. GenoPro: GenoPro is a web-based genealogy software that offers a range of features for creating and managing family trees. It supports GEDCOM files, photos, and other media, and users can easily share their trees with others.\n4. Legacy Family Tree: Legacy Family Tree is a popular web-based genealogy software that offers a range of features for creating and managing family trees. It supports GEDCOM files, photos, and other media, and users can easily share their trees with others.\n5. Family Tree Maker: Family Tree Maker is a web-based genealogy software that offers a range of features for creating and managing family trees. It supports GEDCOM files, photos, and other media, and users can easily share their trees with others.\n6. MyHeritage: MyHeritage is a web-based genealogy platform that offers a range of features for creating and managing family trees. It supports GEDCOM files, photos, and other media, and users can easily share their trees with others.\n7. WeRelate: WeRelate is a web-based genealogy platform that allows users to create and edit their family trees. It offers a simple and intuitive interface, and users can easily add and manage their ancestors, relatives, and other important family members.\n8. WikiTree: WikiTree is a web-based genealogy platform that allows users to create and edit their family trees. It offers a simple and intuitive interface, and users can easily add and manage their ancestors, relatives, and other important family members.\n9.",
    "llama-2-7b-chat-hf_fact_raw": "1. Pedigree Manager is a web-based genealogy software.\n2. Family Tree Builder is a free online genealogy tool.\n3. GenoPro supports GEDCOM files, photos, and other media for creating family trees.\n4. Legacy Family Tree is a web-based genealogy software that allows sharing of family trees.\n5. MyHeritage is a web-based genealogy platform that offers features for managing family trees.",
    "llama-2-7b-chat-hf_fact": [
      "Pedigree Manager is a web-based genealogy software.",
      "Family Tree Builder is a free online genealogy tool.",
      "GenoPro supports GEDCOM files, photos, and other media for creating family trees.",
      "Legacy Family Tree is a web-based genealogy software that allows sharing of family trees.",
      "MyHeritage is a web-based genealogy platform that offers features for managing family trees."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Pedigree Manager is not a commonly known genealogy software, and without further context, it's unclear whether it is web-based.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Legacy Family Tree is not exclusively web-based; it is primarily a downloadable desktop software that also offers some online functionality.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "llama-2-7b-chat-hf_response": "There are several curated databases available for spider-venom toxins, which are compiled and maintained by various research groups and organizations. Here are some of the most well-known and widely used databases for spider-venom toxins:\n1. ToxinDB: ToxinDB is a comprehensive database of toxins from various sources, including spider venom. It contains information on the structure, function, and biological activity of toxins, as well as their distribution and taxonomy. ToxinDB is maintained by the University of California, San Diego.\n2. Spider Toxin Database (STD): The Spider Toxin Database is a curated database of spider-venom toxins, including peptides, proteins, and other compounds. It contains information on the structure, function, and biological activity of these toxins, as well as their pharmacological and toxicological properties. STD is maintained by the University of Queensland, Australia.\n3. Venom-DB: Venom-DB is a database of venom peptides and proteins from various animals, including spiders. It contains information on the structure, function, and biological activity of these peptides and proteins, as well as their distribution and taxonomy. Venom-DB is maintained by the University of California, Berkeley.\n4. Spider Venom Toxin Database (SVTD): The Spider Venom Toxin Database is a curated database of spider-venom toxins, including peptides, proteins, and other compounds. It contains information on the structure, function, and biological activity of these toxins, as well as their pharmacological and toxicological properties. SVTD is maintained by the University of Florida.\n5. Natural Products Module (NPM): The Natural Products Module is a database of natural products, including spider-venom toxins. It contains information on the structure, function, and biological activity of these compounds, as well as their distribution and taxonomy. NPM is maintained by the University of California, San Diego.\n6. Venom-Vipera: Venom-Vipera is a database of venom peptides and proteins from various animals, including spiders. It contains information on the structure, function, and biological activity",
    "llama-2-7b-chat-hf_fact_raw": "1. ToxinDB is a database that includes information on toxins from various sources, including spider venom.\n2. The Spider Toxin Database (STD) is curated specifically for spider-venom toxins and is maintained by the University of Queensland, Australia.\n3. Venom-DB contains information on venom peptides and proteins from various animals, including spiders, and is maintained by the University of California, Berkeley.\n4. The Spider Venom Toxin Database (SVTD) is a curated database for spider-venom toxins, maintained by the University of Florida.\n5. The Natural Products Module (NPM) is a database that contains information on natural products, including spider-venom toxins, and is maintained by the University of California, San Diego.",
    "llama-2-7b-chat-hf_fact": [
      "ToxinDB is a database that includes information on toxins from various sources, including spider venom.",
      "The Spider Toxin Database (STD) is curated specifically for spider-venom toxins and is maintained by the University of Queensland, Australia.",
      "Venom-DB contains information on venom peptides and proteins from various animals, including spiders, and is maintained by the University of California, Berkeley.",
      "The Spider Venom Toxin Database (SVTD) is a curated database for spider-venom toxins, maintained by the University of Florida.",
      "The Natural Products Module (NPM) is a database that contains information on natural products, including spider-venom toxins, and is maintained by the University of California, San Diego."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-2-7b-chat-hf_response": "Axitinib is a tyrosine kinase inhibitor that has been investigated for its potential in treating various types of cancer, including pancreatic cancer. While the available evidence suggests that Axitinib may have some activity against pancreatic cancer, it is important to note that the current data are limited and more research is needed to fully understand its effectiveness in this context.\nSeveral studies have suggested that Axitinib may have antitumor activity against pancreatic cancer cells, both in vitro and in vivo. For example, one study published in the journal Cancer Research found that Axitinib inhibited the growth of pancreatic cancer cells and induced cell death by blocking the activation of the MEK/ERK signaling pathway (1). Another study published in the journal Clinical Cancer Research found that Axitinib was effective in reducing the growth of pancreatic tumors in mice (2).\nHowever, it is important to note that these studies were small and had limited sample sizes, so more research is needed to confirm these findings and establish the safety and efficacy of Axitinib in pancreatic cancer patients. Additionally, the current data do not suggest that Axitinib prolongs survival in pancreatic cancer patients.\nA systematic review and meta-analysis published in the journal Gut in 2019 analyzed the available data from randomized controlled trials on the use of Axitinib in pancreatic cancer. The review found that Axitinib was associated with a modest improvement in progression-free survival (PFS) compared to standard chemotherapy, but the overall survival (OS) benefit was not significant (3).\nAnother recent study published in the journal Cancer found that Axitinib was associated with improved PFS and OS in patients with advanced pancreatic cancer who had progressed after previous treatment with gemcitabine and nab-paclitaxel (4).\nIn summary, while the available evidence suggests that Axitinib may have some activity against pancreatic cancer, more research is needed to fully understand its effectiveness and safety in this context. Currently, the data do not support the conclusion that Axitinib prolongs survival in pancreatic cancer patients.\nReferences:\n1. Lee J, et al. (2017). Inhib",
    "llama-2-7b-chat-hf_fact_raw": "1. Axitinib is a tyrosine kinase inhibitor investigated for treating pancreatic cancer.\n2. One study found Axitinib inhibited the growth of pancreatic cancer cells by blocking the MEK/ERK signaling pathway.\n3. Another study found Axitinib was effective in reducing the growth of pancreatic tumors in mice.\n4. A systematic review and meta-analysis in the journal Gut in 2019 found that Axitinib was associated with a modest improvement in progression-free survival in pancreatic cancer patients but did not significantly benefit overall survival.\n5. A study in the journal Cancer found improved progression-free survival and overall survival in patients with advanced pancreatic cancer treated with Axitinib after progressing on previous treatments.",
    "llama-2-7b-chat-hf_fact": [
      "Axitinib is a tyrosine kinase inhibitor investigated for treating pancreatic cancer.",
      "One study found Axitinib inhibited the growth of pancreatic cancer cells by blocking the MEK/ERK signaling pathway.",
      "Another study found Axitinib was effective in reducing the growth of pancreatic tumors in mice.",
      "A systematic review and meta-analysis in the journal Gut in 2019 found that Axitinib was associated with a modest improvement in progression-free survival in pancreatic cancer patients but did not significantly benefit overall survival.",
      "A study in the journal Cancer found improved progression-free survival and overall survival in patients with advanced pancreatic cancer treated with Axitinib after progressing on previous treatments."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: A systematic review and meta-analysis in the journal Gut in 2019 would not have found results related to Axitinib and pancreatic cancer as Axitinib is primarily indicated for renal cell carcinoma, not pancreatic cancer.\n5. FALSE [correction]: The journal Cancer may have published a study regarding Axitinib, but it would not be focused on advanced pancreatic cancer treatment as Axitinib is not primarily used for this type of cancer.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-2-7b-chat-hf_response": "MLP (Microtubule-associated protein) regulates F-actin dynamics through several protein interactions. Here are some of the key interactions:\n1. MLP interacts with the F-actin severing protein, Spire: MLP has been shown to bind to the F-actin severing protein, Spire, and this interaction regulates the severing of F-actin filaments. Spire is a crucial regulator of F-actin dynamics, and MLP's interaction with Spire helps to modulate its activity.\nReference: Kornberg, E., & Pollard, T. D. (2010). MLP: a novel regulator of F-actin dynamics. Journal of Cell Science, 123(Pt 14), 2341-2349.\n2. MLP interacts with the actin-related protein 2/3 complex (ARP2/3 complex): MLP has been shown to interact with the ARP2/3 complex, which is a key regulator of F-actin dynamics. The ARP2/3 complex is composed of actin-related protein 2 (ARP2) and actin-related protein 3 (ARP3), and it plays a crucial role in the regulation of F-actin dynamics, particularly during cell migration and cell signaling. MLP's interaction with the ARP2/3 complex helps to modulate its activity and regulate F-actin dynamics.\nReference: Wang, Y., et al. (2012). MLP regulates F-actin dynamics by modulating the ARP2/3 complex. Journal of Biological Chemistry, 287(24), 20432-20440.\n3. MLP interacts with the formin protein, FN3: FN3 is a formin protein that is involved in the regulation of F-actin dynamics. MLP has been shown to interact with FN3, and this interaction helps to regulate F-actin dynamics by modulating the activity of FN3.\nReference: Liu, Y., et al. (2014). MLP regulates F-actin dynamics by modulating the activity of the formin protein, FN3. Journal of",
    "llama-2-7b-chat-hf_fact_raw": "1. MLP binds to the F-actin severing protein, Spire, to regulate the severing of F-actin filaments.\n2. MLP interacts with the ARP2/3 complex, which is composed of actin-related protein 2 (ARP2) and actin-related protein 3 (ARP3).\n3. The interaction between MLP and the ARP2/3 complex plays a role in the regulation of F-actin dynamics, especially during cell migration and signaling.\n4. MLP has been shown to interact with the formin protein, FN3, which is involved in the regulation of F-actin dynamics.\n5. The interaction between MLP and FN3 modulates the activity of FN3 to regulate F-actin dynamics.",
    "llama-2-7b-chat-hf_fact": [
      "MLP binds to the F-actin severing protein, Spire, to regulate the severing of F-actin filaments.",
      "MLP interacts with the ARP2/3 complex, which is composed of actin-related protein 2 (ARP2) and actin-related protein 3 (ARP3).",
      "The interaction between MLP and the ARP2/3 complex plays a role in the regulation of F-actin dynamics, especially during cell migration and signaling.",
      "MLP has been shown to interact with the formin protein, FN3, which is involved in the regulation of F-actin dynamics.",
      "The interaction between MLP and FN3 modulates the activity of FN3 to regulate F-actin dynamics."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout the specific context or passage these statements are referring to, it's impossible to determine their accuracy.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "llama-2-7b-chat-hf_response": "Great question! The human kinome, which refers to the collection of protein kinases present in the human genome, contains a total of 519 pseudokinases, according to a study published in the journal Nature Communications in 2018.\nPseudokinases are proteins that have some characteristics of kinases, but do not have the full range of kinase activity. They are often involved in signaling pathways, but their exact functions can vary depending on the specific protein.\nTo give you a better idea of the numbers, the study identified 519 pseudokinases in the human kinome, which is approximately 20% of the total number of protein kinases present in the genome. Of these, 240 were classified as \"full-length\" pseudokinases, which have the typical structural features of kinases, including an ATP binding site and a catalytic domain. The remaining 279 pseudokinases were classified as \"non-full-length\" pseudokinases, which lack some or all of these structural features.\nIt's worth noting that the number of pseudokinases can vary depending on the specific organism being studied, and different studies may define pseudokinases differently. However, the general trend is that pseudokinases are a significant proportion of the protein kinase repertoire in many organisms, and they play important roles in cellular signaling and regulation.",
    "llama-2-7b-chat-hf_fact_raw": "1. The human kinome contains a total of 519 pseudokinases according to a study published in Nature Communications in 2018.\n2. Pseudokinases are proteins that have characteristics of kinases, but lack the full range of kinase activity.\n3. Pseudokinases are involved in signaling pathways.\n4. 240 pseudokinases in the human kinome were classified as \"full-length\" with typical structural features of kinases.\n5. 279 pseudokinases in the human kinome were classified as \"non-full-length\" and lack some or all of the typical structural features of kinases.",
    "llama-2-7b-chat-hf_fact": [
      "The human kinome contains a total of 519 pseudokinases according to a study published in Nature Communications in 2018.",
      "Pseudokinases are proteins that have characteristics of kinases, but lack the full range of kinase activity.",
      "Pseudokinases are involved in signaling pathways.",
      "240 pseudokinases in the human kinome were classified as \"full-length\" with typical structural features of kinases.",
      "279 pseudokinases in the human kinome were classified as \"non-full-length\" and lack some or all of the typical structural features of kinases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The human kinome contains a total of 539 kinases, not pseudokinases, according to a study published in Nature Communications in 2018.\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "llama-2-7b-chat-hf_response": "Certainly! ApoE mimetics are compounds that mimic the structure and function of apolipoprotein E (apoE), a protein that plays a crucial role in lipid metabolism and is associated with various diseases, including cardiovascular disease and Alzheimer's disease. Here are three apoE mimetics that have been studied:\n1. ApoE-mimetic peptides: These are short peptides that mimic the structure of apoE and have been shown to have anti-inflammatory and anti-atherosclerotic effects. One example of an apoE-mimetic peptide is the peptide Gly-Thr-Gly-Gly-Ala-Gly-Ser-Gly-Gly-Ala (GTS-011). Studies have shown that GTS-011 can reduce liver inflammation and improve insulin sensitivity in mice with non-alcoholic fatty liver disease (NAFLD).\n2. ApoE-mimetic small molecules: These are small molecules that mimic the structure of apoE and have been shown to have cholesterol-lowering and anti-inflammatory effects. One example of an apoE-mimetic small molecule is the compound 3-[5-(4-Chlorophenyl)-3-methyl-1,2,4-triazol-1-yl]-butyric acid (LXR-101). Studies have shown that LXR-101 can reduce cholesterol levels and improve insulin sensitivity in mice with high cholesterol diet-induced hypercholesterolemia.\n3. ApoE-mimetic nanoparticles: These are nanoparticles that mimic the structure of apoE and have been shown to have anti-inflammatory and anti-atherosclerotic effects. One example of an apoE-mimetic nanoparticle is the nanoparticle composed of a polyethylene glycol (PEG) shell and a hydrophobic core (PEG-POP). Studies have shown that PEG-POP can reduce inflammation and improve cardiovasc",
    "llama-2-7b-chat-hf_fact_raw": "1. ApoE-mimetic peptides are short peptides designed to mimic the structure of apolipoprotein E.\n2. The apoE-mimetic peptide Gly-Thr-Gly-Gly-Ala-Gly-Ser-Gly-Gly-Ala (GTS-011) has been shown to reduce liver inflammation and improve insulin sensitivity in mice with non-alcoholic fatty liver disease.\n3. ApoE-mimetic small molecules are designed to mimic the structure of apolipoprotein E and have cholesterol-lowering and anti-inflammatory effects.\n4. The apoE-mimetic small molecule 3-[5-(4-Chlorophenyl)-3-methyl-1,2,4-triazol-1-yl]-butyric acid (LXR-101) can reduce cholesterol levels and improve insulin sensitivity in mice with a high cholesterol diet-induced hypercholesterolemia.\n5. ApoE-mimetic nanoparticles have a polyethylene glycol shell and a hydrophobic core, and have shown anti-inflammatory and anti-atherosclerotic effects.",
    "llama-2-7b-chat-hf_fact": [
      "ApoE-mimetic peptides are short peptides designed to mimic the structure of apolipoprotein E.",
      "The apoE-mimetic peptide Gly-Thr-Gly-Gly-Ala-Gly-Ser-Gly-Gly-Ala (GTS-011) has been shown to reduce liver inflammation and improve insulin sensitivity in mice with non-alcoholic fatty liver disease.",
      "ApoE-mimetic small molecules are designed to mimic the structure of apolipoprotein E and have cholesterol-lowering and anti-inflammatory effects.",
      "The apoE-mimetic small molecule 3-[5-(4-Chlorophenyl)-3-methyl-1,2,4-triazol-1-yl]-butyric acid (LXR-101) can reduce cholesterol levels and improve insulin sensitivity in mice with a high cholesterol diet-induced hypercholesterolemia.",
      "ApoE-mimetic nanoparticles have a polyethylene glycol shell and a hydrophobic core, and have shown anti-inflammatory and anti-atherosclerotic effects."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "llama-2-7b-chat-hf_response": "SAMHD1 (Sterile alpha and TIR domain-containing protein HD1) is a protein that plays a crucial role in regulating the innate immune response to viral infections. Recent studies have shown that there are sex differences in SAMHD1 activity, which can impact the immune response to viral infections. Here are some key findings:\n1. SAMHD1 expression: Studies have shown that SAMHD1 expression is higher in females than in males, particularly in the brain and liver. This higher expression may contribute to the observed sex differences in SAMHD1 activity.\n2. Enzymatic activity: SAMHD1 has been shown to have higher enzymatic activity in females than in males, which may also contribute to the observed sex differences in immune response.\n3. Viral infection: Females have been shown to be more susceptible to certain viral infections, such as HIV and HCV, than males. This may be due in part to sex differences in SAMHD1 activity, as SAMHD1 has been shown to play a role in restricting viral replication.\n4. Inflammation: Sex differences in SAMHD1 activity may also impact the inflammatory response to viral infections. For example, females have been shown to have higher levels of pro-inflammatory cytokines, such as TNF-alpha, in response to viral infection, which may contribute to the observed sex differences in immune response.\n5. Hormonal regulation: Sex hormones, such as estrogen and testosterone, have been shown to regulate SAMHD1 expression and activity. For example, estrogen has been shown to increase SAMHD1 expression and activity, while testosterone has been shown to decrease SAMHD1 expression and activity.\n6. Tissue distribution: SAMHD1 is expressed in a variety of tissues, including the brain, liver, and immune cells. Sex differences in SAMHD1 expression and activity may vary depending on the tissue and the type of viral infection.\n7. Genetic variation: Genetic variation within the SAMHD1 gene itself may also contribute to sex differences in SAMHD1 activity. For example, some studies have identified genetic variants that are more common in one",
    "llama-2-7b-chat-hf_fact_raw": "1. Studies have shown that SAMHD1 expression is higher in females than in males, especially in the brain and liver.\n2. Females have higher enzymatic activity of SAMHD1 than males.\n3. Females are more susceptible to certain viral infections, such as HIV and HCV, than males.\n4. Females have higher levels of pro-inflammatory cytokines, such as TNF-alpha, in response to viral infection compared to males.\n5. Sex hormones like estrogen and testosterone regulate SAMHD1 expression and activity, with estrogen increasing and testosterone decreasing it.",
    "llama-2-7b-chat-hf_fact": [
      "Studies have shown that SAMHD1 expression is higher in females than in males, especially in the brain and liver.",
      "Females have higher enzymatic activity of SAMHD1 than males.",
      "Females are more susceptible to certain viral infections, such as HIV and HCV, than males.",
      "Females have higher levels of pro-inflammatory cytokines, such as TNF-alpha, in response to viral infection compared to males.",
      "Sex hormones like estrogen and testosterone regulate SAMHD1 expression and activity, with estrogen increasing and testosterone decreasing it."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: Males are generally more susceptible to certain viral infections, such as HIV and HCV, than females.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "llama-2-7b-chat-hf_response": "Thank you for your question! RUNX2 (RUNX2 gene) is a transcription factor that plays a crucial role in the regulation of cellular processes, including cell proliferation, differentiation, and survival. While there is limited direct evidence on the effect of RUNX2 on astrocyte differentiation, there are some studies that provide insights into its potential role in this process.\nAstrocytes are a type of glial cell that play a crucial role in the central nervous system (CNS), and their differentiation is a complex process that involves the coordinated action of multiple transcription factors. RUNX2 has been shown to be involved in the regulation of astrocyte differentiation, although the exact mechanisms are not fully understood.\nStudies have shown that RUNX2 can inhibit the differentiation of astrocytes in certain contexts. For example, one study found that RUNX2 overexpression inhibited the differentiation of astrocytes in the developing CNS (1). Another study found that RUNX2 knockdown in astrocytes led to an increase in their differentiation (2). These findings suggest that RUNX2 may play a negative role in astrocyte differentiation, although the exact mechanisms are still being elucidated.\nHowever, it is important to note that the role of RUNX2 in astrocyte differentiation is context-dependent. For example, in some studies, RUNX2 has been shown to promote the differentiation of astrocytes in certain conditions, such as in the regulation of astrocyte maturation and function in the adult CNS (3, 4).\nIn summary, while there is limited direct evidence on the effect of RUNX2 on astrocyte differentiation, studies suggest that it may play a negative role in this process, although the mechanisms are still being elucidated and are context-dependent. Further research is needed to fully understand the role of RUNX2 in astrocyte differentiation and its implications for CNS development and function.\nReferences:\n1. Kim, J. et al. (2010). Overexpression of Runx2 inhibits the differentiation of astrocytes in the developing central nervous system. Developmental Dynamics, 239(10), 2",
    "llama-2-7b-chat-hf_fact_raw": "1. RUNX2 is a transcription factor that regulates cellular processes such as proliferation, differentiation, and survival.\n2. Astrocytes are a type of glial cell in the central nervous system.\n3. RUNX2 has been shown to be involved in the regulation of astrocyte differentiation.\n4. One study found that RUNX2 overexpression inhibited the differentiation of astrocytes in the developing CNS.\n5. Another study found that RUNX2 knockdown in astrocytes led to an increase in their differentiation.",
    "llama-2-7b-chat-hf_fact": [
      "RUNX2 is a transcription factor that regulates cellular processes such as proliferation, differentiation, and survival.",
      "Astrocytes are a type of glial cell in the central nervous system.",
      "RUNX2 has been shown to be involved in the regulation of astrocyte differentiation.",
      "One study found that RUNX2 overexpression inhibited the differentiation of astrocytes in the developing CNS.",
      "Another study found that RUNX2 knockdown in astrocytes led to an increase in their differentiation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-2-7b-chat-hf_response": "Thank you for asking! The Cobb-Stainsby excision arthroplasty is a surgical procedure that is typically performed to treat a condition called osteoarthritis of the knee.\nThe procedure involves removing a portion of the bone from the affected knee joint and replacing it with an artificial joint component. The specific location where the procedure is performed in the body depends on the severity and location of the osteoarthritis.\nIn general, the Cobb-Stainsby excision arthroplasty is performed through a posterior incision, which means an incision is made on the back of the knee. This approach allows the surgeon to access the affected joint without disrupting any important nerves or blood vessels.\nThe specific steps of the procedure may vary depending on the individual case, but generally involve the following steps:\n1. Preparation: The patient is given general anesthesia and is positioned on their back on the operating table.\n2. Incision: An incision is made on the back of the knee, usually starting at the top of the knee and extending down to the bottom.\n3. Removal of the damaged bone: The surgeon will remove the damaged or arthritic bone from the affected knee joint using specialized instruments.\n4. Insertion of the artificial joint component: The surgeon will then insert an artificial joint component, such as a prosthetic implant, into the space where the damaged bone was removed. This component is designed to replicate the natural movement of the knee joint and provide pain relief.\n5. Closure: The incision is then closed with sutures or staples, and the knee is immobilized in a brace to allow the new joint to heal properly.\nIt's important to note that the Cobb-Stainsby excision arthroplasty is a complex surgical procedure that requires a skilled and experienced orthopedic surgeon. The procedure can be performed in an outpatient setting, but may require several days of recovery time before the patient can return to their normal activities.\nI hope this information helps answer your question! If you have any further questions or concerns, please don't hesitate to ask.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cobb-Stainsby excision arthroplasty is a surgical procedure typically used to treat osteoarthritis of the knee.\n2. The procedure involves removing bone from the affected knee joint and replacing it with an artificial joint component.\n3. The Cobb-Stainsby excision arthroplasty is generally performed through a posterior incision on the back of the knee.\n4. The procedure requires general anesthesia and positioning of the patient on their back on the operating table.\n5. Recovery from the Cobb-Stainsby excision arthroplasty may require several days before the patient can return to normal activities.",
    "llama-2-7b-chat-hf_fact": [
      "The Cobb-Stainsby excision arthroplasty is a surgical procedure typically used to treat osteoarthritis of the knee.",
      "The procedure involves removing bone from the affected knee joint and replacing it with an artificial joint component.",
      "The Cobb-Stainsby excision arthroplasty is generally performed through a posterior incision on the back of the knee.",
      "The procedure requires general anesthesia and positioning of the patient on their back on the operating table.",
      "Recovery from the Cobb-Stainsby excision arthroplasty may require several days before the patient can return to normal activities."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Cobb-Stainsby excision arthroplasty is a surgical procedure typically used to treat severe hallux valgus (bunion deformity), not osteoarthritis of the knee.\n2. TRUE\n3. FALSE [correction]: The Cobb-Stainsby excision arthroplasty is generally performed through a dorsal incision on the top of the foot, not a posterior incision on the back of the knee.\n4. TRUE\n5. FALSE [correction]: Recovery from the Cobb-Stainsby excision arthroplasty may require several weeks before the patient can return to normal activities.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "llama-2-7b-chat-hf_response": "GRHL2 (Growth Hormone Releasing Hormone 2) is a protein that plays a crucial role in regulating various cellular processes, including cell proliferation, differentiation, and survival. Over-expression of GRHL2 has been implicated in various cancers, including breast, lung, and colon cancer, and has been shown to promote tumorigenesis and cancer progression.\nEMT (Epithelial-to-Mesenchymal Transition) is a process by which epithelial cells undergo a transformation to become mesenchymal cells, which are characterized by increased migratory and invasive properties. EMT is a crucial step in cancer progression and metastasis, and has been implicated in the development of resistance to chemotherapy and radiation therapy.\nWhile GRHL2 over-expression does not directly cause EMT, there is evidence to suggest that GRHL2 can promote EMT in certain contexts. For example, one study found that GRHL2 over-expression in breast cancer cells led to increased expression of mesenchymal markers, such as vimentin and N-cadherin, and decreased expression of epithelial markers, such as E-cadherin. Another study found that GRHL2 over-expression in lung cancer cells led to increased migration and invasion, which are hallmarks of EMT.\nThe mechanisms by which GRHL2 promotes EMT are not fully understood, but it is thought to involve the regulation of key transcription factors, such as ZEB1 and Snail, which are critical regulators of EMT. GRHL2 has been shown to bind to and activate the transcriptional activity of these factors, leading to the upregulation of mesenchymal genes and the downregulation of epithelial genes.\nIn summary, while GRHL2 over-expression does not directly cause EMT, it can promote EMT by regulating key transcription factors involved in this process. Further research is needed to fully understand the mechanisms by which GRHL2 regulates EMT and to identify potential therapeutic targets for cancer treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. GRHL2 (Growth Hormone Releasing Hormone 2) plays a crucial role in regulating cell proliferation, differentiation, and survival.\n2. Over-expression of GRHL2 has been implicated in various cancers, such as breast, lung, and colon cancer.\n3. EMT (Epithelial-to-Mesenchymal Transition) is characterized by increased migratory and invasive properties of cells.\n4. GRHL2 over-expression has been shown to increase the expression of mesenchymal markers and decrease the expression of epithelial markers in breast cancer cells.\n5. Studies suggest that GRHL2 over-expression can lead to increased migration and invasion in lung cancer cells.",
    "llama-2-7b-chat-hf_fact": [
      "GRHL2 (Growth Hormone Releasing Hormone 2) plays a crucial role in regulating cell proliferation, differentiation, and survival.",
      "Over-expression of GRHL2 has been implicated in various cancers, such as breast, lung, and colon cancer.",
      "EMT (Epithelial-to-Mesenchymal Transition) is characterized by increased migratory and invasive properties of cells.",
      "GRHL2 over-expression has been shown to increase the expression of mesenchymal markers and decrease the expression of epithelial markers in breast cancer cells.",
      "Studies suggest that GRHL2 over-expression can lead to increased migration and invasion in lung cancer cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I'm glad to provide you with information on T-UCRs (tumor-associated circulating cells) and their implication in lung cancer.\nT-UCRs are a subtype of circulating tumor cells (CTCs) that are found in the bloodstream of cancer patients. These cells are thought to be involved in the progression and metastasis of various types of cancer, including lung cancer.\nSeveral studies have identified T-UCRs in the bloodstream of lung cancer patients. For example, a study published in the journal Cancer Research found that 75% of lung cancer patients had T-UCRs in their bloodstream. Another study published in the journal Clinical Cancer Research found that T-UCRs were more common in non-small cell lung cancer (NSCLC) than in other types of lung cancer.\nSeveral T-UCRs have been implicated in lung cancer, including:\n1. Lung cancer-associated cells (LUACs): These cells are derived from the primary tumor and have been found to have increased expression of genes involved in cell migration and invasion.\n2. Circulating tumor cells (CTCs): These cells are found in the bloodstream and are thought to be involved in the metastasis of lung cancer to other parts of the body.\n3. Cancer stem cells (CSCs): These cells are thought to be responsible for the initiation and progression of cancer, including lung cancer.\n4. Tumor-associated macrophages (TAMs): These cells are found in the bloodstream and are thought to play a role in the progression of lung cancer.\n5. Tumor-associated endothelial cells (TECs): These cells are found in the bloodstream and are thought to be involved in the formation of new blood vessels in the tumor.\nIt is important to note that the presence of T-UCRs in the bloodstream of lung cancer patients does not necessarily mean that the cancer has spread to other parts of the body. However, the presence of these cells may indicate a higher risk of metastasis and recurrence of the disease.\nIn summary, several T-UCRs have been implicated in lung cancer, including LUACs, CTCs, CSCs, TAMs",
    "llama-2-7b-chat-hf_fact_raw": "1. T-UCRs are a subtype of circulating tumor cells found in the bloodstream of cancer patients.\n2. Studies have identified T-UCRs in 75% of lung cancer patients' bloodstream.\n3. T-UCRs are more common in non-small cell lung cancer than in other types of lung cancer.\n4. Lung cancer-associated cells (LUACs) have increased expression of genes involved in cell migration and invasion.\n5. The presence of T-UCRs in the bloodstream may indicate a higher risk of metastasis and recurrence of lung cancer.",
    "llama-2-7b-chat-hf_fact": [
      "T-UCRs are a subtype of circulating tumor cells found in the bloodstream of cancer patients.",
      "Studies have identified T-UCRs in 75% of lung cancer patients' bloodstream.",
      "T-UCRs are more common in non-small cell lung cancer than in other types of lung cancer.",
      "Lung cancer-associated cells (LUACs) have increased expression of genes involved in cell migration and invasion.",
      "The presence of T-UCRs in the bloodstream may indicate a higher risk of metastasis and recurrence of lung cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "llama-2-7b-chat-hf_response": "GPR151 (G protein-coupled receptor 151) is an orphan receptor, meaning that it does not have a well-defined endogenous ligand or a clear physiological function. Despite its designation as an orphan receptor, GPR151 has been found to be involved in a variety of physiological processes, including regulation of inflammation, immune response, and cardiovascular function.\nHere are some key aspects of what is known about GPR151:\n1. Structure: GPR151 is a member of the G protein-coupled receptor (GPCR) superfamily, which consists of seven transmembrane alpha helices (TMHs) and an extracellular N-terminus. The receptor is approximately 400 amino acids in length and contains a characteristic GPCR signature sequence.\n2. Expression: GPR151 is expressed in a wide range of tissues, including the brain, heart, liver, and immune cells. Its expression is particularly high in the brain, where it is found in regions involved in regulation of emotion, motivation, and cognitive function.\n3. Ligands: Despite its designation as an orphan receptor, GPR151 has been found to be activated by a variety of ligands, including fatty acids, bile acids, and neurosteroids. For example, the fatty acid 22(R)-hydroxycholesterol has been shown to activate GPR151 in a dose-dependent manner, leading to activation of downstream signaling pathways.\n4. Signaling pathways: Activation of GPR151 leads to activation of G alpha subunits, which in turn activate downstream signaling pathways involving beta-arrestins, phospholipase C, and protein kinase C. These pathways can lead to a variety of cellular responses, including activation of mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK), and cAMP response element-binding protein (CREB).\n5. Physiological functions: GPR151 has been implicated in a variety of physiological processes, including regulation of infl",
    "llama-2-7b-chat-hf_fact_raw": "1. GPR151 is classified as an orphan receptor without a well-defined endogenous ligand or clear physiological function.\n2. GPR151 is part of the G protein-coupled receptor superfamily and has seven transmembrane alpha helices.\n3. GPR151 is highly expressed in the brain as well as in the heart, liver, and immune cells.\n4. GPR151 can be activated by various ligands such as fatty acids, bile acids, and neurosteroids.\n5. The activation of GPR151 leads to the activation of downstream signaling pathways involving beta-arrestins, phospholipase C, and protein kinase C.",
    "llama-2-7b-chat-hf_fact": [
      "GPR151 is classified as an orphan receptor without a well-defined endogenous ligand or clear physiological function.",
      "GPR151 is part of the G protein-coupled receptor superfamily and has seven transmembrane alpha helices.",
      "GPR151 is highly expressed in the brain as well as in the heart, liver, and immune cells.",
      "GPR151 can be activated by various ligands such as fatty acids, bile acids, and neurosteroids.",
      "The activation of GPR151 leads to the activation of downstream signaling pathways involving beta-arrestins, phospholipase C, and protein kinase C."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: GPR151 is primarily expressed in the brain, particularly in the basal ganglia and the limbic system, and is not highly expressed in the heart, liver, or immune cells.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-2-7b-chat-hf_response": "The Fluzone Intradermal Quadrivalent vaccine is a vaccine that contains four different live attenuated viruses:\n1. FluB: The FluB virus is an attenuated strain of the influenza B virus. It is grown in eggs and has been weakened so that it cannot cause the full-blown flu in humans.\n2. FluA/H1N1: The FluA/H1N1 virus is an attenuated strain of the influenza A virus subtype H1N1. It is also grown in eggs and has been weakened so that it cannot cause the full-blown flu in humans.\n3. FluA/H3N2: The FluA/H3N2 virus is an attenuated strain of the influenza A virus subtype H3N2. It is also grown in eggs and has been weakened so that it cannot cause the full-blown flu in humans.\n4. FluA/H1N2: The FluA/H1N2 virus is an attenuated strain of the influenza A virus subtype H1N2. It is also grown in eggs and has been weakened so that it cannot cause the full-blown flu in humans.\nIt is important to note that while these viruses are attenuated, they are still capable of causing mild flu-like symptoms in some individuals, such as soreness at the injection site, fatigue, and low-grade fever. However, these symptoms are generally mild and short-lived, and they do not progress to the full-blown flu.\nIt is also worth noting that the Fluzone Intradermal Quadrivalent vaccine is approved for use in individuals aged 18 years and older, and it is not recommended for use in individuals with a history of anaphylaxis or other severe allergic reactions to egg products, as it contains egg protein.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Fluzone Intradermal Quadrivalent vaccine contains an attenuated strain of the influenza B virus known as FluB.\n2. The Fluzone Intradermal Quadrivalent vaccine contains an attenuated strain of the influenza A virus subtype H1N1 known as FluA/H1N1.\n3. The Fluzone Intradermal Quadrivalent vaccine contains an attenuated strain of the influenza A virus subtype H3N2 known as FluA/H3N2.\n4. The Fluzone Intradermal Quadrivalent vaccine contains an attenuated strain of the influenza A virus subtype H1N2 known as FluA/H1N2.\n5. The Fluzone Intradermal Quadrivalent vaccine is approved for use in individuals aged 18 years and older.",
    "llama-2-7b-chat-hf_fact": [
      "The Fluzone Intradermal Quadrivalent vaccine contains an attenuated strain of the influenza B virus known as FluB.",
      "The Fluzone Intradermal Quadrivalent vaccine contains an attenuated strain of the influenza A virus subtype H1N1 known as FluA/H1N1.",
      "The Fluzone Intradermal Quadrivalent vaccine contains an attenuated strain of the influenza A virus subtype H3N2 known as FluA/H3N2.",
      "The Fluzone Intradermal Quadrivalent vaccine contains an attenuated strain of the influenza A virus subtype H1N2 known as FluA/H1N2.",
      "The Fluzone Intradermal Quadrivalent vaccine is approved for use in individuals aged 18 years and older."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Fluzone Intradermal Quadrivalent vaccine does not contain live attenuated influenza viruses, but rather inactivated (killed) ones.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The Fluzone Intradermal Quadrivalent vaccine does not contain a strain for influenza A virus subtype H1N2. It typically contains two influenza A strains (H1N1 and H3N2) and two influenza B strains.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-2-7b-chat-hf_response": "Systemic Lupus Erythematosus (SLE) is a complex and multifactorial autoimmune disease that affects various organs and tissues in the body. While the exact genetic causes of SLE are still not fully understood, several genetic variants have been identified as risk factors for the development of the disease. One of these genes is the Tumor Necrosis Factor Receptor 2 (TNFR2) gene.\nThe TNFR2 gene is located on chromosome 6q23 and encodes a protein called TNFR2, which is a key player in the regulation of immune responses. TNFR2 is a member of the TNF (tumor necrosis factor) receptor superfamily and is primarily involved in the regulation of inflammation and immune homeostasis.\nSeveral genetic variants in the TNFR2 gene have been associated with an increased risk of developing SLE. These variants are found in the promoter region of the TNFR2 gene, which is responsible for regulating the expression of the gene. Specifically, two common genetic variants in the TNFR2 gene have been identified as risk factors for SLE:\n1. -173G>C polymorphism: This variant is located in the promoter region of the TNFR2 gene and is associated with increased TNFR2 expression. Studies have shown that individuals with the -173G>C variant have a higher risk of developing SLE compared to those with the -173C>G variant.\n2. -248A>G polymorphism: This variant is also located in the promoter region of the TNFR2 gene and is associated with decreased TNFR2 expression. Studies have found that individuals with the -248A>G variant have a lower risk of developing SLE compared to those with the -248G>A variant.\nIt's important to note that the genetic variants in the TNFR2 gene are not the only risk factors for SLE, and other genetic and environmental factors also play a role in the development of the disease. However, these genetic variants have been consistently associated with an increased risk of SLE in multiple studies, and may help to explain the underlying genetic basis of the disease.\nIn summary, the TN",
    "llama-2-7b-chat-hf_fact_raw": "1. The TNFR2 gene is located on chromosome 6q23.\n2. The TNFR2 gene encodes a protein called TNFR2, which is involved in the regulation of immune responses.\n3. Genetic variants in the promoter region of the TNFR2 gene have been associated with an increased risk of developing Systemic Lupus Erythematosus (SLE).\n4. The -173G>C polymorphism in the TNFR2 gene is associated with increased TNFR2 expression and a higher risk of developing SLE.\n5. The -248A>G polymorphism in the TNFR2 gene is associated with decreased TNFR2 expression and a lower risk of developing SLE.",
    "llama-2-7b-chat-hf_fact": [
      "The TNFR2 gene is located on chromosome 6q23.",
      "The TNFR2 gene encodes a protein called TNFR2, which is involved in the regulation of immune responses.",
      "Genetic variants in the promoter region of the TNFR2 gene have been associated with an increased risk of developing Systemic Lupus Erythematosus (SLE).",
      "The -173G>C polymorphism in the TNFR2 gene is associated with increased TNFR2 expression and a higher risk of developing SLE.",
      "The -248A>G polymorphism in the TNFR2 gene is associated with decreased TNFR2 expression and a lower risk of developing SLE."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "llama-2-7b-chat-hf_response": "Thank you for reaching out with your question! I'm glad you're interested in learning more about peanut allergy and potential treatments.\nUnfortunately, there is currently no widely available vaccine for peanut allergy. Peanut allergy is an immune-mediated reaction, meaning it is caused by the immune system mistakenly identifying peanut proteins as harmful. Developing a vaccine for peanut allergy has been challenging due to the complexity of the allergen and the need for a highly specific and personalized approach.\nHowever, researchers are actively working on developing new treatments for peanut allergy, including vaccines, sublingual immunotherapy, and oral immunotherapy. These approaches aim to gradually desensitize the immune system to peanut proteins, reducing the risk of an allergic reaction.\nSublingual immunotherapy involves placing small amounts of peanut protein under the tongue, where it is absorbed by the immune system. This approach has shown promise in clinical trials, with some participants experiencing a significant reduction in peanut allergy symptoms.\nOral immunotherapy is similar to sublingual immunotherapy but involves consuming small amounts of peanut protein in a controlled manner. This approach can also help desensitize the immune system to peanut proteins, potentially leading to a reduction in allergy symptoms.\nWhile these new treatments show promise, it's important to note that they are still in the experimental phase and have not yet been widely adopted. If you or someone you know has a peanut allergy, it's essential to consult with a healthcare professional for proper diagnosis and treatment.\nIn summary, while there is currently no vaccine for peanut allergy, researchers are actively working on developing new treatments that may help desensitize the immune system to peanut proteins. If you have a peanut allergy, it's crucial to consult with a healthcare professional for proper diagnosis and treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is currently no widely available vaccine for peanut allergy.\n2. Peanut allergy is caused by the immune system mistakenly identifying peanut proteins as harmful.\n3. Researchers are actively working on developing new treatments for peanut allergy, including vaccines.\n4. Sublingual immunotherapy involves placing small amounts of peanut protein under the tongue.\n5. Oral immunotherapy involves consuming small amounts of peanut protein in a controlled manner.",
    "llama-2-7b-chat-hf_fact": [
      "There is currently no widely available vaccine for peanut allergy.",
      "Peanut allergy is caused by the immune system mistakenly identifying peanut proteins as harmful.",
      "Researchers are actively working on developing new treatments for peanut allergy, including vaccines.",
      "Sublingual immunotherapy involves placing small amounts of peanut protein under the tongue.",
      "Oral immunotherapy involves consuming small amounts of peanut protein in a controlled manner."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-2-7b-chat-hf_response": "The mouse Fxy gene, also known as the Forkhead box C (FoxC) gene, is located on chromosome 12 in mice. Specifically, it is situated on the distal part of chromosome 12, near the centromere region. The chromosomal position of the Fxy gene is important because it can affect the expression of the gene and its role in various biological processes.\nThe Fxy gene is a transcription factor gene that plays a crucial role in regulating the expression of other genes involved in embryonic development, tissue patterning, and cell fate determination. It is a member of the forkhead box (Fox) gene family, which consists of 11 members in mice. The Fxy gene is specifically expressed in the developing embryo, particularly in the mesoderm and neuroectoderm lineages, and it is important for the proper formation of these tissues.\nThe chromosomal position of the Fxy gene can affect its expression levels and its interactions with other genes on the same chromosome. For example, the Fxy gene is located near the centromere region of chromosome 12, which is a region that is involved in the regulation of chromosome segregation during cell division. This proximity to the centromere can affect the stability of the Fxy gene and its expression levels, particularly during cell division.\nIn addition, the chromosomal position of the Fxy gene can also affect its interactions with other genes on the same chromosome. For example, the Fxy gene is located near the Hoxa13 gene, which is involved in the regulation of limb development. The proximity of the Fxy gene to the Hoxa13 gene can affect the expression of these genes and their role in limb development.\nOverall, the chromosomal position of the Fxy gene is an important factor that can affect its expression levels, interactions with other genes, and its role in various biological processes.",
    "llama-2-7b-chat-hf_fact_raw": "1. The mouse Fxy gene, also known as the Forkhead box C (FoxC) gene, is located on chromosome 12 in mice.\n2. The Fxy gene is situated on the distal part of chromosome 12 near the centromere region.\n3. The Fxy gene is a transcription factor gene that regulates the expression of other genes involved in embryonic development, tissue patterning, and cell fate determination.\n4. The Fxy gene is a member of the forkhead box (Fox) gene family, which consists of 11 members in mice.\n5. The Fxy gene is specifically expressed in the developing embryo, particularly in the mesoderm and neuroectoderm lineages.",
    "llama-2-7b-chat-hf_fact": [
      "The mouse Fxy gene, also known as the Forkhead box C (FoxC) gene, is located on chromosome 12 in mice.",
      "The Fxy gene is situated on the distal part of chromosome 12 near the centromere region.",
      "The Fxy gene is a transcription factor gene that regulates the expression of other genes involved in embryonic development, tissue patterning, and cell fate determination.",
      "The Fxy gene is a member of the forkhead box (Fox) gene family, which consists of 11 members in mice.",
      "The Fxy gene is specifically expressed in the developing embryo, particularly in the mesoderm and neuroectoderm lineages."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. FALSE [correction]: The forkhead box (Fox) gene family consists of numerous members, with over 50 identified in mammals, not just 11 in mice.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-2-7b-chat-hf_response": "MPE-seq, or methylation-profiling by sequencing, is a method used to analyze the epigenetic modification of DNA methylation. The method is based on the following principles:\n1. Sample Preparation: The sample is first prepared by isolating DNA from the cells or tissues of interest. This is typically done using standard molecular biology techniques such as phenol-chloroform extraction or using commercial DNA isolation kits.\n2. Bisulfite Conversion: The isolated DNA is then treated with bisulfite, which is a reagent that deaminates unmethylated cytosine residues, but not methylated ones. This step is important because it allows researchers to distinguish between methylated and unmethylated cytosine residues in the DNA sequence.\n3. PCR Amplification: The bisulfite-treated DNA is then amplified using PCR (polymerase chain reaction) with primers that are specific to the region of interest. This step allows researchers to generate enough DNA for sequencing.\n4. Sequencing: The amplified DNA is then sequenced using Next-Generation Sequencing (NGS) technologies, such as Illumina or PacBio. The resulting sequencing data contains information about the methylation status of the cytosine residues in the sample.\n5. Data Analysis: The sequencing data is then analyzed using specialized software that can identify the methylation status of the cytosine residues in the sample. The software can also identify other epigenetic marks, such as histone modifications, and can provide information about the distribution of these marks throughout the genome.\n6. Data Interpretation: The final step is to interpret the results of the analysis in the context of the research question. This may involve comparing the methylation patterns in the sample to those in other samples, or to known references, such as the human genome. The results can also be used to identify specific genes or regions of the genome that are associated with specific diseases or conditions.\nThe basis of MPE-seq is the use of bisulfite treatment to deaminate unmethylated cytosine residues, allowing researchers to distinguish between methylated and unmethylated",
    "llama-2-7b-chat-hf_fact_raw": "1. MPE-seq is used to analyze the epigenetic modification of DNA methylation.\n2. Sample preparation involves isolating DNA using techniques like phenol-chloroform extraction or commercial DNA isolation kits.\n3. Bisulfite treatment deaminates unmethylated cytosine residues but not methylated ones.\n4. PCR amplification with specific primers generates enough DNA for sequencing.\n5. Sequencing data is analyzed using software to identify methylation status and other epigenetic marks.",
    "llama-2-7b-chat-hf_fact": [
      "MPE-seq is used to analyze the epigenetic modification of DNA methylation.",
      "Sample preparation involves isolating DNA using techniques like phenol-chloroform extraction or commercial DNA isolation kits.",
      "Bisulfite treatment deaminates unmethylated cytosine residues but not methylated ones.",
      "PCR amplification with specific primers generates enough DNA for sequencing.",
      "Sequencing data is analyzed using software to identify methylation status and other epigenetic marks."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "llama-2-7b-chat-hf_response": "GWAR is a complex and ambitious project that has involved a wide range of technologies and programming languages. While I cannot provide a definitive answer to your question, I can offer some insights based on available information.\nGWAR is a large-scale, open-source, distributed simulation platform that is designed to support the development and execution of complex simulations across a wide range of domains, including military, civilian, and academic applications. As such, it is unlikely that any single programming language has been used exclusively for implementing GWAR.\nInstead, GWAR is likely to have been built using a combination of programming languages, each of which serves a specific purpose. Here are some of the programming languages that may have been used in the development of GWAR:\n1. Python: Python is a popular programming language that is widely used in scientific computing, data analysis, and machine learning. It is likely that Python has been used extensively in the development of GWAR's simulation engine, data models, and visualization tools.\n2. C++: C++ is a high-performance programming language that is commonly used in the development of large-scale simulations, including those that require real-time processing and high-speed data transfer. C++ may have been used for developing GWAR's core simulation engine, as well as for optimizing the performance of the platform.\n3. Java: Java is a popular programming language that is widely used in the development of distributed applications, including those that require multi-threading and multi-processing capabilities. Java may have been used for developing GWAR's distributed simulation architecture, as well as for creating the platform's graphical user interface.\n4. MATLAB: MATLAB is a high-level programming language that is commonly used in scientific computing, data analysis, and modeling. MATLAB may have been used for developing GWAR's mathematical models and simulations, as well as for creating visualizations and interactive tools.\n5. JavaScript: JavaScript is a popular programming language that is widely used in web development, including the creation of interactive web applications and simulations. JavaScript may have been used for developing GWAR's web-based interfaces and visualization tools, as well as for creating interactive simulations that can be run in a web browser.\nIn summary, while I cannot provide a definitive answer to your question, it is likely that a combination of programming",
    "llama-2-7b-chat-hf_fact_raw": "1. Python may have been used extensively in the development of GWAR's simulation engine, data models, and visualization tools.\n2. C++ may have been used for developing GWAR's core simulation engine and for optimizing platform performance.\n3. Java may have been used for developing GWAR's distributed simulation architecture and graphical user interface.\n4. MATLAB may have been used for developing GWAR's mathematical models and simulations, as well as creating visualizations and interactive tools.\n5. JavaScript may have been used for developing GWAR's web-based interfaces and visualization tools.",
    "llama-2-7b-chat-hf_fact": [
      "Python may have been used extensively in the development of GWAR's simulation engine, data models, and visualization tools.",
      "C++ may have been used for developing GWAR's core simulation engine and for optimizing platform performance.",
      "Java may have been used for developing GWAR's distributed simulation architecture and graphical user interface.",
      "MATLAB may have been used for developing GWAR's mathematical models and simulations, as well as creating visualizations and interactive tools.",
      "JavaScript may have been used for developing GWAR's web-based interfaces and visualization tools."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-2-7b-chat-hf_response": "Xaliproden (also known as remacemide) is a small molecule that has been investigated for its potential to improve the prognosis of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. While the current evidence is limited, there are some studies that suggest that xaliproden may have a beneficial effect on the progression of ALS.\nXaliproden is a selective activator of the cellular pathway known as the cAMP-dependent protein kinase (PKA) pathway. This pathway plays a crucial role in regulating various cellular processes, including neuronal survival and function. In the context of ALS, PKA activation has been shown to promote the survival of motor neurons and reduce the levels of toxic proteins that are characteristic of the disease.\nSeveral studies have investigated the effectiveness of xaliproden in ALS models, including animal studies and clinical trials. For example, a study published in the journal Nature Medicine in 2018 found that xaliproden treatment improved motor function and reduced the progression of ALS in a mouse model of the disease. Another study published in the journal Neurology in 2019 found that xaliproden was safe and well-tolerated in a small group of people with ALS.\nWhile these findings are promising, it is important to note that the current evidence for the effectiveness of xaliproden in ALS is based on early-stage studies, and more research is needed to confirm these findings and establish the long-term safety and efficacy of the drug. Additionally, xaliproden is not yet approved by regulatory authorities for the treatment of ALS, and it is not clear when or if it will become available for use in patients.\nIn summary, while the current evidence suggests that xaliproden may have a beneficial effect on the progression of ALS, more research is needed to confirm these findings and establish the drug's safety and efficacy in larger, longer-term studies. If you have ALS and are interested in learning more about xaliproden or other potential treatments, it is best to speak with your healthcare provider or a reputable ALS organization for the most up",
    "llama-2-7b-chat-hf_fact_raw": "1. Xaliproden is a small molecule that has been investigated for its potential to improve the prognosis of amyotrophic lateral sclerosis (ALS).\n2. Xaliproden acts as a selective activator of the cAMP-dependent protein kinase (PKA) pathway.\n3. Studies suggest that the PKA pathway's activation by xaliproden promotes the survival of motor neurons and reduces levels of toxic proteins in ALS.\n4. A study published in Nature Medicine in 2018 found xaliproden treatment improved motor function and reduced progression of ALS in a mouse model.\n5. A study published in Neurology in 2019 reported that xaliproden was safe and well-tolerated in a small group of people with ALS.",
    "llama-2-7b-chat-hf_fact": [
      "Xaliproden is a small molecule that has been investigated for its potential to improve the prognosis of amyotrophic lateral sclerosis (ALS).",
      "Xaliproden acts as a selective activator of the cAMP-dependent protein kinase (PKA) pathway.",
      "Studies suggest that the PKA pathway's activation by xaliproden promotes the survival of motor neurons and reduces levels of toxic proteins in ALS.",
      "A study published in Nature Medicine in 2018 found xaliproden treatment improved motor function and reduced progression of ALS in a mouse model.",
      "A study published in Neurology in 2019 reported that xaliproden was safe and well-tolerated in a small group of people with ALS."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Xaliproden acts as an agonist at the serotonin (5-HT1A) receptors.\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-2-7b-chat-hf_response": "Thank you for your question! The LiPS-A3S line is a popular transgenic mouse line used in scientific research, particularly in the field of genetics and genomics.\nTo answer your question, transgenes in the LiPS-A3S line are inserted into chromosome 16. Specifically, the transgene encoding the fluorescent protein GFP (green fluorescent protein) is located on chromosome 16, specifically at the locus 16:12.3. This means that the GFP gene is inserted into the genome at position 12.3 on chromosome 16.\nIt's worth noting that the LiPS-A3S line is a BAC (bacterial artificial chromosome) transgenic line, which means that the transgene is inserted into a bacterial artificial chromosome (BAC) that has been modified to contain the GFP gene. The BAC is then introduced into mouse embryonic stem cells, where it integrates into the genome and the GFP gene is expressed.\nI hope this information helps! Let me know if you have any further questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The LiPS-A3S line is a transgenic mouse line used in scientific research.\n2. Transgenes in the LiPS-A3S line are inserted into chromosome 16.\n3. The transgene encoding the fluorescent protein GFP is located at locus 16:12.3 on chromosome 16.\n4. The LiPS-A3S line is a BAC transgenic line.\n5. The BAC containing the GFP gene is introduced into mouse embryonic stem cells for integration into the genome.",
    "llama-2-7b-chat-hf_fact": [
      "The LiPS-A3S line is a transgenic mouse line used in scientific research.",
      "Transgenes in the LiPS-A3S line are inserted into chromosome 16.",
      "The transgene encoding the fluorescent protein GFP is located at locus 16:12.3 on chromosome 16.",
      "The LiPS-A3S line is a BAC transgenic line.",
      "The BAC containing the GFP gene is introduced into mouse embryonic stem cells for integration into the genome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "llama-2-7b-chat-hf_response": "There are several deep learning tools and models that have been developed for predicting drug synergy, also known as drug combination or drug interaction. Here are some of the most notable ones:\n1. DeepSynth: Developed by the University of California, DeepSynth is a deep learning framework for predicting drug synergy. It uses a combination of convolutional neural networks (CNNs) and recurrent neural networks (RNNs) to analyze the chemical structures of drugs and predict their interactions.\n2. Drug2Drug: This is a web server developed by the University of California, Los Angeles (UCLA) that uses deep learning to predict drug synergy. Drug2Drug uses a combination of CNNs and RNNs to analyze the chemical structures of drugs and predict their interactions.\n3. DrugComb: Developed by the University of Texas Southwestern Medical Center, DrugComb is a deep learning model that predicts drug synergy by analyzing the chemical structures of drugs and their targets. DrugComb uses a combination of CNNs and RNNs to predict drug interactions.\n4. Drugan: This is a deep learning model developed by the University of California, San Diego that predicts drug synergy by analyzing the chemical structures of drugs and their targets. Drugan uses a combination of CNNs and RNNs to predict drug interactions.\n5. Synergizer: Developed by the University of Michigan, Synergizer is a deep learning model that predicts drug synergy by analyzing the chemical structures of drugs and their targets. Synergizer uses a combination of CNNs and RNNs to predict drug interactions.\n6. Drug-Drug Interaction Predictor (DDIP): This is a deep learning model developed by the University of California, San Francisco that predicts drug synergy by analyzing the chemical structures of drugs and their targets. DDIP uses a combination of CNNs and RNNs to predict drug interactions.\n7. MultiDrug: Developed by the University of Groningen, MultiDrug is a deep learning model that predicts drug synergy by analyzing the chemical structures of drugs and their targets. MultiDrug uses a combination of CNNs and RNNs to predict drug interactions.\n8. Drug-Drug Interaction Predictor (DDII): This",
    "llama-2-7b-chat-hf_fact_raw": "1. DeepSynth is a deep learning framework developed by the University of California for predicting drug synergy.\n2. Drug2Drug is a web server developed by the University of California, Los Angeles that predicts drug synergy using deep learning.\n3. DrugComb is a deep learning model developed by the University of Texas Southwestern Medical Center that predicts drug synergy.\n4. Drugan is a deep learning model developed by the University of California, San Diego that predicts drug synergy.\n5. Synergizer is a deep learning model developed by the University of Michigan that predicts drug synergy.",
    "llama-2-7b-chat-hf_fact": [
      "DeepSynth is a deep learning framework developed by the University of California for predicting drug synergy.",
      "Drug2Drug is a web server developed by the University of California, Los Angeles that predicts drug synergy using deep learning.",
      "DrugComb is a deep learning model developed by the University of Texas Southwestern Medical Center that predicts drug synergy.",
      "Drugan is a deep learning model developed by the University of California, San Diego that predicts drug synergy.",
      "Synergizer is a deep learning model developed by the University of Michigan that predicts drug synergy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "llama-2-7b-chat-hf_response": "There are several cloud-based platforms that have been developed for comparing Genome-Wide Association Studies (GWAS). Here are some of the most popular ones:\n1. WORDI (Web-based Open Resource for Disease Investigation): WORDI is a cloud-based platform designed for analyzing and interpreting GWAS data. It provides tools for imputation, gene-level association testing, and pathway-level analysis. WORDI also integrates with other bioinformatics resources, such as the National Center for Biotechnology Information's (NCBI) dbGaP database.\n2. GWAScore: GWAScore is a cloud-based platform that provides tools for GWAS analysis, including imputation, association testing, and gene-set analysis. It also includes a database of pre-computed genotype data for over 100,000 individuals from multiple populations.\n3. GTEx-Cloud: GTEx-Cloud is a cloud-based platform for analyzing GWAS data from the Genotype-Tissue Expression (GTEx) project. It provides tools for imputation, gene-level association testing, and gene expression analysis.\n4. BioMart: BioMart is a cloud-based platform that provides tools for analyzing GWAS data, including imputation, association testing, and gene-set analysis. It also includes a database of pre-computed genotype data for over 100,000 individuals from multiple populations.\n5. Cloud-GWAS: Cloud-GWAS is a cloud-based platform that provides tools for GWAS analysis, including imputation, association testing, and gene-set analysis. It also includes a database of pre-computed genotype data for over 100,000 individuals from multiple populations.\n6. GWASworkflow: GWASworkflow is a cloud-based platform that provides tools for GWAS analysis, including imputation, association testing, and gene-set analysis. It also includes a database of pre-computed genotype data for over 100,000 individuals from multiple populations.\n7. OpenGWAS: OpenGWAS is a cloud-based platform that provides tools for GWAS analysis, including imputation, association testing, and gene-set analysis. It also includes a",
    "llama-2-7b-chat-hf_fact_raw": "1. WORDI is a cloud-based platform designed for analyzing and interpreting GWAS data.\n2. GWAScore is a cloud-based platform that includes a database of pre-computed genotype data for over 100,000 individuals from multiple populations.\n3. GTEx-Cloud is a cloud-based platform for analyzing GWAS data from the Genotype-Tissue Expression project.\n4. BioMart is a cloud-based platform that provides tools for analyzing GWAS data.\n5. Cloud-GWAS is a cloud-based platform that provides tools for GWAS analysis and includes a database of pre-computed genotype data for over 100,000 individuals from multiple populations.",
    "llama-2-7b-chat-hf_fact": [
      "WORDI is a cloud-based platform designed for analyzing and interpreting GWAS data.",
      "GWAScore is a cloud-based platform that includes a database of pre-computed genotype data for over 100,000 individuals from multiple populations.",
      "GTEx-Cloud is a cloud-based platform for analyzing GWAS data from the Genotype-Tissue Expression project.",
      "BioMart is a cloud-based platform that provides tools for analyzing GWAS data.",
      "Cloud-GWAS is a cloud-based platform that provides tools for GWAS analysis and includes a database of pre-computed genotype data for over 100,000 individuals from multiple populations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: BioMart is not specifically a cloud-based platform, it is a data management system that provides tools for data mining and analysis.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "llama-2-7b-chat-hf_response": "CMB305 is a first-in-class, orally available, small molecule inhibitor of the enzyme DNA-dependent protein kinase (DNA-PK). DNA-PK is a key player in the DNA damage response pathway, which is activated in response to DNA double-strand breaks (DSBs). DSBs are a type of DNA damage that can occur as a result of various factors, including genetic mutations, environmental exposures, and cancer treatment.\nWhile CMB305 has shown promise in preclinical studies as a potential treatment for various cancers, including breast, lung, and colon cancers, its efficacy against sarcomas is less clear.\nSarcomas are a type of cancer that originates in the connective tissue of the body, including bone, cartilage, fat, muscle, nerves, and blood vessels. There are several subtypes of sarcomas, including osteosarcoma, chondrosarcoma, leiomyosarcoma, and liposarcoma.\nPreclinical studies have suggested that CMB305 may be effective against some subtypes of sarcomas, particularly those that are characterized by high levels of DNA damage. For example, one study published in the journal Cancer Research found that CMB305 inhibited the growth of osteosarcoma cells and induced apoptosis (cell death) in these cells, suggesting that it may be a potential treatment option for this type of sarcoma.\nHowever, other subtypes of sarcomas may be less sensitive to CMB305, and more research is needed to determine its efficacy in these cases. Additionally, CMB305 is currently being studied in clinical trials for the treatment of various cancers, including breast, lung, and colon cancers, but it has not yet been tested in clinical trials for the treatment of sarcomas.\nIn summary, while CMB305 has shown promise in preclinical studies as a potential treatment for some subtypes of sarcomas, more research is needed to determine its efficacy against this type of cancer. It is important to note that CMB305 is currently being studied in clinical trials for the treatment of other cancers, and its potential use in the treatment of sar",
    "llama-2-7b-chat-hf_fact_raw": "1. CMB305 is an inhibitor of the enzyme DNA-dependent protein kinase (DNA-PK).\n2. DNA-PK is involved in the DNA damage response pathway, which is activated in response to DNA double-strand breaks.\n3. Sarcomas are cancers that originate in the connective tissue of the body.\n4. Preclinical studies have suggested CMB305 may be effective against some subtypes of sarcomas.\n5. CMB305 is currently being studied in clinical trials for the treatment of breast, lung, and colon cancers but has not yet been tested in clinical trials for the treatment of sarcomas.",
    "llama-2-7b-chat-hf_fact": [
      "CMB305 is an inhibitor of the enzyme DNA-dependent protein kinase (DNA-PK).",
      "DNA-PK is involved in the DNA damage response pathway, which is activated in response to DNA double-strand breaks.",
      "Sarcomas are cancers that originate in the connective tissue of the body.",
      "Preclinical studies have suggested CMB305 may be effective against some subtypes of sarcomas.",
      "CMB305 is currently being studied in clinical trials for the treatment of breast, lung, and colon cancers but has not yet been tested in clinical trials for the treatment of sarcomas."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: CMB305 is currently being studied in clinical trials for the treatment of sarcomas, not breast, lung, and colon cancers.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "llama-2-7b-chat-hf_response": "The Saint's Triad, also known as the Trinity of Saint Patrick, is a symbol of the Holy Trinity in Christianity, particularly in the Catholic and Anglican traditions. It consists of three interconnected elements: the Cross, the Circle, and the Celtic Cross. Here are some manifestations of the Saint's Triad:\n1. The Cross: The Cross is the most obvious element of the Saint's Triad, representing the crucifixion of Jesus Christ and his sacrifice for humanity's sins. The Cross is often depicted as a plain cross or as a cross with a rounded top, and it is often surrounded by the other two elements of the Triad.\n2. The Circle: The Circle represents the unity and wholeness of the Holy Trinity, symbolizing the Father, Son, and Holy Spirit as one God in three persons. The Circle is often depicted as a circle with a small cross at its center, representing the connection between the Father, Son, and Holy Spirit.\n3. The Celtic Cross: The Celtic Cross is a variation of the Cross that combines the Cross with a circle at the intersection of the arms. This design is thought to have originated in Ireland and Scotland, where it was used to mark graves and churches. The Celtic Cross is often seen as a symbol of the connection between the earthly and spiritual realms, as well as the connection between the living and the dead.\n4. The Shamrock: The Shamrock is a three-leafed plant that is often associated with Saint Patrick, the patron saint of Ireland. According to legend, Saint Patrick used the Shamrock to explain the concept of the Holy Trinity to the pagan Irish, showing how the three leaves of the plant could represent the Father, Son, and Holy Spirit. The Shamrock is often used as a symbol of the Saint's Triad, particularly in Irish and Scottish contexts.\n5. The Triquetra: The Triquetra is a symbol that combines three interconnected circles, representing the three aspects of the Holy Trinity: the Father, Son, and Holy Spirit. The Triquetra is often used in place of the Celtic Cross in some contexts, particularly in Irish and Scottish art.\n6. The Triskelion: The Triskelion is a symbol that consists of three interconnected spirals,",
    "llama-2-7b-chat-hf_fact_raw": "1. The Saint's Triad is a symbol of the Holy Trinity in Christianity, particularly in Catholic and Anglican traditions.\n2. The Saint's Triad consists of the Cross, the Circle, and the Celtic Cross.\n3. The Cross represents the crucifixion of Jesus Christ and his sacrifice for humanity's sins.\n4. The Circle represents the unity and wholeness of the Holy Trinity, symbolizing the Father, Son, and Holy Spirit as one God in three persons.\n5. The Celtic Cross is thought to have originated in Ireland and Scotland and is used to mark graves and churches.",
    "llama-2-7b-chat-hf_fact": [
      "The Saint's Triad is a symbol of the Holy Trinity in Christianity, particularly in Catholic and Anglican traditions.",
      "The Saint's Triad consists of the Cross, the Circle, and the Celtic Cross.",
      "The Cross represents the crucifixion of Jesus Christ and his sacrifice for humanity's sins.",
      "The Circle represents the unity and wholeness of the Holy Trinity, symbolizing the Father, Son, and Holy Spirit as one God in three persons.",
      "The Celtic Cross is thought to have originated in Ireland and Scotland and is used to mark graves and churches."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: The Saint's Triad is not a commonly known or recognized symbol in Christianity. The terms used to describe the Holy Trinity are typically just the Father, Son, and Holy Spirit.\n3. TRUE\n4. FALSE [correction]: While the circle can symbolize unity and eternity, it is not exclusively associated with the Holy Trinity in Christian symbolism.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-2-7b-chat-hf_response": "LY6K is a protein that has been found to be overexpressed in various types of cancer, including non-small cell lung cancer (NSCLC). Overexpression of LY6K has been associated with poor prognosis in some cancer types, but the prognostic significance of LY6K in NSCLC is not well established.\nStudies have shown that LY6K is overexpressed in a significant proportion of NSCLC cases, and this overexpression is often associated with aggressive tumor phenotypes, such as high tumor grade, nodal metastasis, and poor differentiation. However, the relationship between LY6K overexpression and patient outcomes in NSCLC is complex and may depend on various factors, including the stage and histological subtype of the disease.\nSome studies have suggested that high levels of LY6K expression are associated with improved prognosis in NSCLC patients. For example, a study published in the journal Cancer Research found that high LY6K expression was associated with longer overall survival and disease-free survival in patients with stage III NSCLC. Another study published in the journal Clinical Cancer Research found that high LY6K expression was associated with improved overall survival in patients with adenocarcinoma, the most common histological subtype of NSCLC.\nHowever, other studies have found conflicting results. For example, a study published in the journal Lung Cancer found that high LY6K expression was associated with poorer overall survival in patients with stage III NSCLC. Another study published in the journal Thoracic Cancer found that high LY6K expression was associated with increased risk of disease recurrence in patients with NSCLC.\nThe discrepant results may be due to differences in study populations, sample sizes, and methodologies. For example, some studies have focused on specific subgroups of NSCLC patients, such as those with adenocarcinoma or those with high levels of tumor mutational burden, which may have different prognostic implications for LY6K expression.\nIn summary, the prognostic significance of LY6K overexpression in NSCLC is not well established and may depend on various factors, including the stage and histological subtype of the disease. While some studies have suggested that high levels of LY6K expression are associated with improved prognosis",
    "llama-2-7b-chat-hf_fact_raw": "1. LY6K is a protein that is overexpressed in various types of cancer, including non-small cell lung cancer (NSCLC).\n2. Studies have shown that LY6K overexpression in NSCLC is often associated with aggressive tumor phenotypes like high tumor grade, nodal metastasis, and poor differentiation.\n3. A study published in Cancer Research found that high LY6K expression was associated with longer overall survival and disease-free survival in patients with stage III NSCLC.\n4. Another study published in Clinical Cancer Research found that high LY6K expression was associated with improved overall survival in patients with adenocarcinoma, a subtype of NSCLC.\n5. A study published in Lung Cancer found that high LY6K expression was associated with poorer overall survival in patients with stage III NSCLC.",
    "llama-2-7b-chat-hf_fact": [
      "LY6K is a protein that is overexpressed in various types of cancer, including non-small cell lung cancer (NSCLC).",
      "Studies have shown that LY6K overexpression in NSCLC is often associated with aggressive tumor phenotypes like high tumor grade, nodal metastasis, and poor differentiation.",
      "A study published in Cancer Research found that high LY6K expression was associated with longer overall survival and disease-free survival in patients with stage III NSCLC.",
      "Another study published in Clinical Cancer Research found that high LY6K expression was associated with improved overall survival in patients with adenocarcinoma, a subtype of NSCLC.",
      "A study published in Lung Cancer found that high LY6K expression was associated with poorer overall survival in patients with stage III NSCLC."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: A study published in Cancer Research found that high LY6K expression was associated with shorter overall survival and disease-free survival in patients with stage III NSCLC.\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-2-7b-chat-hf_response": "CDK (Cyclin-Dependent Kinase) targets that are dephosphorylated during cytokinesis include:\n1. Cyclin-dependent kinase 1 (CDK1): CDK1 is a key regulator of the cell cycle and is involved in the progression from G2 phase to M phase. During cytokinesis, CDK1 is dephosphorylated by the protein phosphatase PP1, leading to its activation and the promotion of cell separation.\n2. Cyclin-dependent kinase 2 (CDK2): CDK2 is another important regulator of the cell cycle and is involved in the G1/S transition. During cytokinesis, CDK2 is dephosphorylated by PP1, leading to its activation and the promotion of cell separation.\n3. Cyclin-dependent kinase 5 (CDK5): CDK5 is primarily involved in the regulation of the G1 phase of the cell cycle. During cytokinesis, CDK5 is dephosphorylated by PP1, leading to its activation and the promotion of cell separation.\n4. Cyclin-dependent kinase 6 (CDK6): CDK6 is involved in the regulation of the G1 phase of the cell cycle. During cytokinesis, CDK6 is dephosphorylated by PP1, leading to its activation and the promotion of cell separation.\n5. Cyclin-dependent kinase 7 (CDK7): CDK7 is primarily involved in the regulation of the G1 phase of the cell cycle. During cytokinesis, CDK7 is dephosphorylated by PP1, leading to its activation and the promotion of cell separation.\n6. Polo-like kinase 1 (PLK1): PLK1 is involved in the regulation of the cell cycle and is particularly important during cytokinesis. During cytokinesis, PLK1 is dephosphorylated by PP1, leading to its activation and the promotion of cell separation.\n7. Polo-like kinase 4 (PLK4): PLK4 is involved in the regulation of the cell cycle and is particularly important during cytokinesis. During cytokinesis, PLK4 is dephosph",
    "llama-2-7b-chat-hf_fact_raw": "1. Cyclin-dependent kinase 1 (CDK1) is dephosphorylated by the protein phosphatase PP1 during cytokinesis.\n2. Cyclin-dependent kinase 2 (CDK2) is dephosphorylated by PP1 during cytokinesis.\n3. Cyclin-dependent kinase 5 (CDK5) is dephosphorylated by PP1 during cytokinesis.\n4. Cyclin-dependent kinase 6 (CDK6) is dephosphorylated by PP1 during cytokinesis.\n5. Cyclyn-dependent kinase 7 (CDK7) is dephosphorylated by PP1 during cytokinesis.",
    "llama-2-7b-chat-hf_fact": [
      "Cyclin-dependent kinase 1 (CDK1) is dephosphorylated by the protein phosphatase PP1 during cytokinesis.",
      "Cyclin-dependent kinase 2 (CDK2) is dephosphorylated by PP1 during cytokinesis.",
      "Cyclin-dependent kinase 5 (CDK5) is dephosphorylated by PP1 during cytokinesis.",
      "Cyclin-dependent kinase 6 (CDK6) is dephosphorylated by PP1 during cytokinesis.",
      "Cyclyn-dependent kinase 7 (CDK7) is dephosphorylated by PP1 during cytokinesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Cyclin-dependent kinase 2 (CDK2) is not dephosphorylated by PP1 during cytokinesis; it's primarily involved in controlling the progression of the cell cycle at the G1/S transition.\n3. FALSE [correction]: Cyclin-dependent kinase 5 (CDK5) is not dephosphorylated by PP1 during cytokinesis; it's predominantly involved in regulating the nervous system and is not directly involved in cell division.\n4. UNKNOWN\n5. FALSE [correction]: The statement contains a typo; it should be \"Cyclin-dependent kinase\" not \"Cyclyn-dependent kinase\", and CDK7 is not dephosphorylated by PP1 during cytokinesis; it's involved in controlling the cell cycle at various points and also in transcription regulation.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "llama-2-7b-chat-hf_response": "Xanamem is a term that has gained popularity in recent years, particularly in the realm of mental health and wellness. It refers to a state of being where an individual's memories, thoughts, and emotions are disconnected or fragmented, making it difficult for them to recall specific events or experiences from their past.\nThe term \"Xanamem\" is a combination of the words \"xanax,\" a brand name for the prescription drug alprazolam, and \"amnesia,\" which refers to the loss of memory. It is often used to describe a condition where an individual's memories are affected by the use of benzodiazepines, such as alprazolam, which are commonly prescribed to treat anxiety and other mental health conditions.\nXanamem can manifest in different ways, depending on the individual and the circumstances. Some common symptoms of Xanamem include:\n1. Memory loss: Individuals with Xanamem may struggle to recall specific events or experiences from their past, including important dates, events, or conversations.\n2. Dissociation: Xanamem can lead to a feeling of disconnection from oneself or from the world around them, making it difficult to feel grounded or centered.\n3. Emotional numbing: Individuals with Xanamem may experience a lack of emotional response to situations or events, which can make it difficult to connect with others or to feel empathy.\n4. Confusion: Xanamem can cause confusion and difficulty concentrating, making it challenging to perform daily tasks or to focus on complex tasks.\n5. Depersonalization: Individuals with Xanamem may feel detached from their body or their identity, which can lead to feelings of alienation or disconnection from oneself.\nIt is important to note that Xanamem is not a formal medical diagnosis, but rather a colloquial term used to describe a range of symptoms that can be caused by the use of benzodiazepines or other factors. If you are experiencing any of these symptoms, it is important to consult with a mental health professional for proper diagnosis and treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. \"Xanamem\" refers to a state where an individual's memories, thoughts, and emotions are disconnected or fragmented.\n2. The term \"Xanamem\" is a combination of the words \"xanax\" and \"amnesia.\"\n3. Benzodiazepines, such as alprazolam, can affect an individual's memories, leading to Xanamem.\n4. Common symptoms of Xanamem include memory loss, dissociation, emotional numbing, confusion, and depersonalization.\n5. Xanamem is not a formal medical diagnosis but a colloquial term.",
    "llama-2-7b-chat-hf_fact": [
      "\"Xanamem\" refers to a state where an individual's memories, thoughts, and emotions are disconnected or fragmented.",
      "The term \"Xanamem\" is a combination of the words \"xanax\" and \"amnesia.\"",
      "Benzodiazepines, such as alprazolam, can affect an individual's memories, leading to Xanamem.",
      "Common symptoms of Xanamem include memory loss, dissociation, emotional numbing, confusion, and depersonalization.",
      "Xanamem is not a formal medical diagnosis but a colloquial term."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-2-7b-chat-hf_response": "Hof1-Cyk3 is a protein complex involved in various cellular processes in yeast, including cell cycle regulation, DNA damage response, and protein degradation. The interaction between Hof1 and Cyk3 plays a crucial role in these processes. Here's a detailed answer to your question:\nThe Hof1 protein is a transcriptional repressor that regulates the expression of genes involved in various cellular processes, including cell cycle progression, DNA damage response, and protein degradation. Hof1 is a key regulator of the G1/S checkpoint, which ensures that cells are ready to enter the S phase of the cell cycle. Cyk3, on the other hand, is a protein kinase that regulates the activity of Hof1.\nThe interaction between Hof1 and Cyk3 is essential for the proper regulation of cellular processes in yeast. Here are some of the key functions of the Hof1-Cyk3 interaction:\n1. Regulation of G1/S checkpoint: Hof1 is a key regulator of the G1/S checkpoint, which ensures that cells are ready to enter the S phase of the cell cycle. Cyk3 phosphorylates Hof1, leading to its dissociation from the DNA-binding complex and activation of the S phase.\n2. Regulation of DNA damage response: Hof1-Cyk3 interaction is also involved in the regulation of the DNA damage response. When DNA damage is detected, Cyk3 phosphorylates Hof1, leading to its association with the DNA damage response complex and activation of the checkpoint.\n3. Regulation of protein degradation: Hof1-Cyk3 interaction also plays a role in the regulation of protein degradation. Cyk3 phosphorylates Hof1, leading to its ubiquitination and subsequent degradation, which is important for maintaining cellular homeostasis.\n4. Regulation of cell cycle progression: Hof1-Cyk3 interaction also regulates cell cycle progression. Cyk3 phosphorylates Hof1, leading to its association with the cyclin-dependent kinase (CDK) complex and activation of the CDK/cyclin complex, which promotes cell cycle progression.\nIn summary, the Hof1-Cyk3 interaction plays a crucial role in various cellular processes in ye",
    "llama-2-7b-chat-hf_fact_raw": "1. Hof1-Cyk3 is a protein complex that regulates cell cycle, DNA damage response, and protein degradation in yeast.\n2. Hof1 is a transcriptional repressor regulating genes related to cell cycle progression, DNA damage response, and protein degradation.\n3. Cyk3 is a protein kinase that regulates the activity of Hof1.\n4. The interaction between Hof1 and Cyk3 is essential for the regulation of the G1/S checkpoint in the cell cycle.\n5. Cyk3 phosphorylates Hof1, leading to its dissociation from the DNA-binding complex and activation of the S phase.",
    "llama-2-7b-chat-hf_fact": [
      "Hof1-Cyk3 is a protein complex that regulates cell cycle, DNA damage response, and protein degradation in yeast.",
      "Hof1 is a transcriptional repressor regulating genes related to cell cycle progression, DNA damage response, and protein degradation.",
      "Cyk3 is a protein kinase that regulates the activity of Hof1.",
      "The interaction between Hof1 and Cyk3 is essential for the regulation of the G1/S checkpoint in the cell cycle.",
      "Cyk3 phosphorylates Hof1, leading to its dissociation from the DNA-binding complex and activation of the S phase."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "llama-2-7b-chat-hf_response": "Gastric cancer, also known as stomach cancer, is a common type of cancer worldwide, and it is estimated that approximately 952,000 people will die from gastric cancer in 2020 alone. The etiology of gastric cancer is complex and involves multiple factors, including genetic mutations, environmental factors, and lifestyle habits.\nTumor suppressor genes (TSGs) are critical for maintaining genomic stability and preventing cancer. TSGs can be inactivated by mutations, deletions, or epigenetic silencing, leading to the development of cancer. Over the years, several TSGs have been implicated in gastric cancer, including:\n1. TP53: TP53 is a tumor suppressor gene that encodes a transcription factor involved in cell cycle regulation, apoptosis, and DNA repair. TP53 mutations are present in approximately 70-80% of gastric cancers and are associated with poor prognosis.\n2. CDKN2A: CDKN2A is a TSG that encodes a protein involved in cell cycle regulation and DNA repair. CDKN2A mutations are present in approximately 10-20% of gastric cancers and are associated with poor prognosis.\n3. MSH2: MSH2 is a TSG that encodes a protein involved in DNA mismatch repair. MSH2 mutations are present in approximately 5-10% of gastric cancers and are associated with poor prognosis.\n4. MLH1: MLH1 is a TSG that encodes a protein involved in DNA mismatch repair. MLH1 mutations are present in approximately 5-10% of gastric cancers and are associated with poor prognosis.\n5. PTEN: PTEN is a TSG that encodes a protein involved in cell signaling pathways. PTEN mutations are present in approximately 10-20% of gastric cancers and are associated with poor prognosis.\n6. STK11: STK11 is a TSG that encodes a protein involved in cell signaling pathways. STK11 mutations are present in approximately 5-10%",
    "llama-2-7b-chat-hf_fact_raw": "1. Gastric cancer is estimated to cause approximately 952,000 deaths in 2020.\n2. TP53 mutations are present in approximately 70-80% of gastric cancers.\n3. CDKN2A mutations are present in approximately 10-20% of gastric cancers.\n4. MSH2 mutations are present in approximately 5-10% of gastric cancers.\n5. MLH1 mutations are present in approximately 5-10% of gastric cancers.",
    "llama-2-7b-chat-hf_fact": [
      "Gastric cancer is estimated to cause approximately 952,000 deaths in 2020.",
      "TP53 mutations are present in approximately 70-80% of gastric cancers.",
      "CDKN2A mutations are present in approximately 10-20% of gastric cancers.",
      "MSH2 mutations are present in approximately 5-10% of gastric cancers.",
      "MLH1 mutations are present in approximately 5-10% of gastric cancers."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Gastric cancer is estimated to have caused approximately 768,793 deaths in 2020.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "llama-2-7b-chat-hf_response": "The Lupus Severity Index (LSI) is a tool used to assess the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disease that affects various parts of the body, including the skin, joints, and organs. The LSI is a standardized measure that takes into account the patient's symptoms, laboratory test results, and organ damage to provide a comprehensive assessment of the disease severity.\nThe LSI was developed by a team of researchers led by Dr. Daniel J. Wallace in the 1980s and has been widely used in clinical practice and research studies since then. The index is based on a combination of six variables:\n1. Skin involvement: The presence and severity of skin rashes, lesions, or photosensitivity.\n2. Joint involvement: The presence and severity of joint pain, swelling, or deformity.\n3. Renal involvement: The presence and severity of kidney inflammation or damage, as measured by laboratory tests or imaging studies.\n4. Neuropsychiatric involvement: The presence and severity of neurological symptoms such as headaches, confusion, or mood changes.\n5. Haematological involvement: The presence and severity of blood abnormalities such as anemia, leukopenia, or thrombocytopenia.\n6. Serosal involvement: The presence and severity of inflammation in the lining of the heart, lungs, or abdomen.\nEach of these variables is assigned a score of 0 to 4, based on the severity of the symptoms or abnormalities. The scores are then added up to give a total LSI score, which can range from 0 to 24.\nThe LSI has been shown to be a useful tool for assessing the severity of SLE and monitoring the response to treatment. A higher LSI score indicates more severe disease, and the score can help clinicians to identify patients who may require more intensive treatment or closer monitoring. However, it is important to note that the LSI is not a perfect measure, and other factors such as patient quality of life and disease activity may also need to be considered when assessing the severity of SLE.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Lupus Severity Index (LSI) is a tool used to assess the severity of systemic lupus erythematosus (SLE).\n2. The LSI takes into account the patient's symptoms, laboratory test results, and organ damage.\n3. Dr. Daniel J. Wallace led the team that developed the LSI in the 1980s.\n4. The LSI includes six variables: skin involvement, joint involvement, renal involvement, neuropsychiatric involvement, haematological involvement, and serosal involvement.\n5. The LSI score ranges from 0 to 24, with higher scores indicating more severe disease.",
    "llama-2-7b-chat-hf_fact": [
      "The Lupus Severity Index (LSI) is a tool used to assess the severity of systemic lupus erythematosus (SLE).",
      "The LSI takes into account the patient's symptoms, laboratory test results, and organ damage.",
      "Dr. Daniel J. Wallace led the team that developed the LSI in the 1980s.",
      "The LSI includes six variables: skin involvement, joint involvement, renal involvement, neuropsychiatric involvement, haematological involvement, and serosal involvement.",
      "The LSI score ranges from 0 to 24, with higher scores indicating more severe disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. FALSE [correction]: The LSI score ranges from 0 to 10, with higher scores indicating more severe disease.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-2-7b-chat-hf_response": "ZSWIM6 is a gene that has been associated with several neurodevelopmental disorders, including:\n1. Autism Spectrum Disorder (ASD): Studies have identified de novo mutations in ZSWIM6 in individuals with ASD, and these mutations have been found to be more common in individuals with more severe symptoms.\n2. Intellectual Disability (ID): ZSWIM6 mutations have been identified in individuals with ID, and these mutations are often found in combination with other genetic changes.\n3. Epilepsy: Some studies have found an increased risk of epilepsy in individuals with ZSWIM6 mutations, particularly those with de novo mutations.\n4. Schizophrenia: While the evidence is not yet conclusive, some studies have suggested a potential association between ZSWIM6 mutations and an increased risk of schizophrenia.\n5. ADHD: Attention Deficit Hyperactivity Disorder (ADHD) has also been linked to ZSWIM6 mutations, although the evidence is still emerging.\nIt is important to note that the relationship between ZSWIM6 mutations and these disorders is complex and not fully understood, and more research is needed to determine the exact mechanisms by which these mutations contribute to disease. Additionally, not all individuals with ZSWIM6 mutations will develop these disorders, and other factors such as environmental and genetic factors can also play a role.\nIn summary, ZSWIM6 mutations have been implicated in several neurodevelopmental disorders, including autism spectrum disorder, intellectual disability, epilepsy, schizophrenia, and ADHD. However, the relationship between these mutations and these disorders is complex and not fully understood, and more research is needed to determine the exact mechanisms by which these mutations contribute to disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. De novo mutations in ZSWIM6 have been identified in individuals with Autism Spectrum Disorder (ASD).\n2. ZSWIM6 mutations have been found in individuals with Intellectual Disability (ID).\n3. An increased risk of epilepsy has been observed in individuals with de novo mutations in ZSWIM6.\n4. Some studies suggest a potential association between ZSWIM6 mutations and schizophrenia.\n5. Attention Deficit Hyperactivity Disorder (ADHD) has been linked to ZSWIM6 mutations.",
    "llama-2-7b-chat-hf_fact": [
      "De novo mutations in ZSWIM6 have been identified in individuals with Autism Spectrum Disorder (ASD).",
      "ZSWIM6 mutations have been found in individuals with Intellectual Disability (ID).",
      "An increased risk of epilepsy has been observed in individuals with de novo mutations in ZSWIM6.",
      "Some studies suggest a potential association between ZSWIM6 mutations and schizophrenia.",
      "Attention Deficit Hyperactivity Disorder (ADHD) has been linked to ZSWIM6 mutations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "llama-2-7b-chat-hf_response": "The Koos Classification is a system used to classify and categorize diseases based on their underlying pathological processes. The classification system was developed by Dr. A.M. Koos, a Dutch pathologist, and it is widely used in pathology and medicine.\nAccording to the Koos Classification, diseases can be classified into one of the following categories:\n1. Inflammatory diseases: These are diseases that are characterized by an inflammatory response, which is a complex biological response to tissue damage or infection. Examples of inflammatory diseases include rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.\n2. Neoplastic diseases: These are diseases that are characterized by the growth and proliferation of abnormal cells, which can invade and damage surrounding tissues. Examples of neoplastic diseases include cancer, benign tumors, and precancerous lesions.\n3. Congenital and developmental diseases: These are diseases that are present at birth or develop during fetal development. Examples of congenital and developmental diseases include Down syndrome, cerebral palsy, and congenital heart disease.\n4. Metabolic diseases: These are diseases that are caused by abnormalities in metabolic processes, such as the breakdown or synthesis of nutrients. Examples of metabolic diseases include diabetes, thyroid disorders, and metabolic syndrome.\n5. Endocrine diseases: These are diseases that are caused by abnormalities in the endocrine system, which produces hormones that regulate various bodily functions. Examples of endocrine diseases include diabetes, thyroid disorders, and adrenal insufficiency.\n6. Immunological diseases: These are diseases that are caused by abnormalities in the immune system, which is responsible for protecting the body against infection and disease. Examples of immunological diseases include autoimmune disorders, such as rheumatoid arthritis and lupus, and infectious diseases, such as HIV/AIDS and tuberculosis.\n7. Neurological dise",
    "llama-2-7b-chat-hf_fact_raw": "1. The Koos Classification is a system used to classify diseases based on their underlying pathological processes.\n2. The classification system was developed by Dr. A.M. Koos, a Dutch pathologist.\n3. Inflammatory diseases are included in the Koos Classification and are characterized by an inflammatory response to tissue damage or infection.\n4. Neoplastic diseases are categorized in the Koos Classification and involve the growth of abnormal cells that can invade surrounding tissues.\n5. Congenital and developmental diseases present at birth or develop during fetal development are part of the Koos Classification.",
    "llama-2-7b-chat-hf_fact": [
      "The Koos Classification is a system used to classify diseases based on their underlying pathological processes.",
      "The classification system was developed by Dr. A.M. Koos, a Dutch pathologist.",
      "Inflammatory diseases are included in the Koos Classification and are characterized by an inflammatory response to tissue damage or infection.",
      "Neoplastic diseases are categorized in the Koos Classification and involve the growth of abnormal cells that can invade surrounding tissues.",
      "Congenital and developmental diseases present at birth or develop during fetal development are part of the Koos Classification."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Koos Classification is a system used to classify brain tumors in pediatric patients based on their location and the likelihood of neurofibromatosis.\n2. FALSE [correction]: The classification system was developed by Dr. Eugene Koos.\n3. UNKNOWN\n4. FALSE [correction]: Neoplastic diseases involve the growth of abnormal cells that can form tumors, but they are not specifically categorized in the Koos Classification which is specific to brain tumors in pediatric patients.\n5. FALSE [correction]: While congenital and developmental diseases may be present at birth or develop during fetal development, the Koos Classification is specifically for brain tumors in children and does not encompass all congenital and developmental diseases.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "llama-2-7b-chat-hf_response": "AZD8601 is a potent and selective inhibitor of the enzyme soluble guanylyl cyclase (sGC), which plays a crucial role in the regulation of cyclic guanosine monophosphate (cGMP) levels in various cell types. cGMP is an important second messenger that regulates a wide range of physiological processes, including smooth muscle relaxation, platelet aggregation, and vasodilation.\nIn vivo, AZD8601 has been shown to have a variety of effects on different physiological systems, including:\n1. Cardiovascular system: AZD8601 has been shown to lower blood pressure in both hypertensive and normotensive animals. This is thought to be due to the inhibition of sGC, which leads to decreased cGMP levels and relaxation of smooth muscle in blood vessels, resulting in vasodilation.\n2. Pulmonary system: AZD8601 has been shown to improve lung function in animals with chronic obstructive pulmonary disease (COPD) by increasing cGMP levels in the lungs. This leads to relaxation of airway smooth muscle and improved lung compliance.\n3. Neurological system: AZD8601 has been shown to have neuroprotective effects in animal models of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. This is thought to be due to the inhibition of sGC, which leads to increased cGMP levels in the brain, which in turn can protect against oxidative stress and inflammation.\n4. Immune system: AZD8601 has been shown to have immunomodulatory effects in animals, including the suppression of T cell activation and the reduction of inflammation in various tissues.\n5. Cancer: AZD8601 has been shown to have antitumor effects in various animal models of cancer, including the inhibition of tumor growth and the induction of apoptosis (cell death) in cancer cells. This is thought to be due to the inhibition of sGC, which leads to decreased cGMP levels in cancer cells, resulting in the inhibition of cell",
    "llama-2-7b-chat-hf_fact_raw": "1. AZD8601 is a selective inhibitor of the enzyme soluble guanylyl cyclase (sGC).\n2. AZD8601 has been shown to lower blood pressure in hypertensive and normotensive animals.\n3. The drug improves lung function in animals with chronic obstructive pulmonary disease (COPD) by increasing cGMP levels in the lungs.\n4. AZD8601 has neuroprotective effects in animal models of neurodegenerative diseases such as Alzheimer's and Parkinson's.\n5. AZD8601 has antitumor effects in various animal models of cancer, including the inhibition of tumor growth and the induction of apoptosis in cancer cells.",
    "llama-2-7b-chat-hf_fact": [
      "AZD8601 is a selective inhibitor of the enzyme soluble guanylyl cyclase (sGC).",
      "AZD8601 has been shown to lower blood pressure in hypertensive and normotensive animals.",
      "The drug improves lung function in animals with chronic obstructive pulmonary disease (COPD) by increasing cGMP levels in the lungs.",
      "AZD8601 has neuroprotective effects in animal models of neurodegenerative diseases such as Alzheimer's and Parkinson's.",
      "AZD8601 has antitumor effects in various animal models of cancer, including the inhibition of tumor growth and the induction of apoptosis in cancer cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: AZD8601 is not a selective inhibitor of sGC; it is actually mRNA therapy that encodes for VEGF-A, which is being developed as a treatment for heart disease.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "llama-2-7b-chat-hf_response": "SAHFS, or Super Absorbent Hydrophilic Fiber Systems, are created through a process called electrospinning. Electrospinning is a technique used to produce fibers with unique properties by using an electric field to draw out and align polymeric solutions.\nHere's a step-by-step explanation of how SAHFS are created:\n1. Polymer Selection: The first step in creating SAHFS is to select the appropriate polymer. The polymer should have good hydrophilicity and the ability to form a gel in water. Common polymers used for SAHFS include polyvinyl alcohol (PVA), polyethylene oxide (PEO), and polyacrylic acid (PAA).\n2. Solution Preparation: Once the polymer has been selected, the next step is to prepare the polymer solution. The polymer is dissolved in a solvent, such as water or a mixture of water and organic solvents, to create a polymer solution. The concentration of the polymer solution can vary depending on the desired properties of the SAHFS.\n3. Electrospinning: The polymer solution is then fed into an electrospinning apparatus, which consists of a syringe and a collector. The syringe is used to draw out the polymer solution, and the collector is used to align the fibers. An electric field is applied to the syringe and collector, which causes the polymer solution to be drawn out and aligned into fibers.\n4. Fiber Formation: As the polymer solution is drawn out and aligned, the fibers begin to form. The fibers are typically several micrometers in diameter and can range in length from a few millimeters to several centimeters. The length of the fibers can be controlled by adjusting the flow rate of the polymer solution and the distance between the syringe and collector.\n5. Cross-Linking: After the fibers have been formed, they may undergo cross-linking to improve their stability and mechanical properties. Cross-linking can be achieved through various methods, including thermal cross-linking, chemical cross-linking, or radiation cross-linking.\n6. Washing and Drying: Finally, the SAHFS are washed and dried to remove any impur",
    "llama-2-7b-chat-hf_fact_raw": "1. SAHFS, or Super Absorbent Hydrophilic Fiber Systems, are created through a process called electrospinning.\n2. Electrospinning uses an electric field to draw out and align polymeric solutions to produce fibers with unique properties.\n3. Common polymers used for SAHFS include polyvinyl alcohol (PVA), polyethylene oxide (PEO), and polyacrylic acid (PAA).\n4. The polymer solution is fed into an electrospinning apparatus, which consists of a syringe and a collector, to align the fibers.\n5. The fibers formed through electrospinning are typically several micrometers in diameter and can range in length from a few millimeters to several centimeters.",
    "llama-2-7b-chat-hf_fact": [
      "SAHFS, or Super Absorbent Hydrophilic Fiber Systems, are created through a process called electrospinning.",
      "Electrospinning uses an electric field to draw out and align polymeric solutions to produce fibers with unique properties.",
      "Common polymers used for SAHFS include polyvinyl alcohol (PVA), polyethylene oxide (PEO), and polyacrylic acid (PAA).",
      "The polymer solution is fed into an electrospinning apparatus, which consists of a syringe and a collector, to align the fibers.",
      "The fibers formed through electrospinning are typically several micrometers in diameter and can range in length from a few millimeters to several centimeters."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "llama-2-7b-chat-hf_response": "The PDZ (PSD-95/DZF/ZO-1) domain is a protein-binding domain found in the SATB1 (Sonic/Spatial Analysis Thyroid and Brain 1) transcription factor. SATB1 is a transcriptional regulator that plays a crucial role in the development and maintenance of various tissues, including the nervous system, pancreas, and immune system. The PDZ domain of SATB1 is involved in protein-protein interactions and plays a key role in regulating the activity of SATB1.\nThe PDZ domain of SATB1 is composed of approximately 100 amino acids and is located at the C-terminal end of the protein. It is a relatively small domain, but it has a high binding affinity for a variety of proteins, including other transcription factors, cytoskeleton components, and signaling molecules. The PDZ domain of SATB1 can bind to these proteins through hydrophobic and ionic interactions, leading to the formation of protein complexes.\nThe function of the PDZ domain of SATB1 can be summarized as follows:\n1. Protein-protein interactions: The PDZ domain of SATB1 can interact with other transcription factors, cytoskeleton components, and signaling molecules, leading to the formation of protein complexes that regulate transcriptional activity.\n2. Subcellular localization: The PDZ domain of SATB1 can also influence the subcellular localization of the protein. For example, the PDZ domain can direct SATB1 to the nucleus or other subcellular compartments, where it can interact with other proteins and regulate transcription.\n3. Protein degradation: The PDZ domain of SATB1 can also participate in the ubiquitination and degradation of other proteins. For example, the PDZ domain of SATB1 can bind to the ubiquitin-protein ligase complex, which can ubiquitinate and degrade other proteins.\n4. Transcriptional regulation: The PDZ domain of SATB1 can also regulate transcriptional activity by interacting with other transcription factors and cof",
    "llama-2-7b-chat-hf_fact_raw": "1. The PDZ domain of SATB1 is involved in protein-protein interactions.\n2. SATB1 plays a crucial role in the development and maintenance of various tissues including the nervous system, pancreas, and immune system.\n3. The PDZ domain of SATB1 has a high binding affinity for a variety of proteins.\n4. The PDZ domain can influence the subcellular localization of SATB1, possibly directing it to the nucleus or other compartments.\n5. The PDZ domain of SATB1 can participate in the ubiquitination and degradation of other proteins.",
    "llama-2-7b-chat-hf_fact": [
      "The PDZ domain of SATB1 is involved in protein-protein interactions.",
      "SATB1 plays a crucial role in the development and maintenance of various tissues including the nervous system, pancreas, and immune system.",
      "The PDZ domain of SATB1 has a high binding affinity for a variety of proteins.",
      "The PDZ domain can influence the subcellular localization of SATB1, possibly directing it to the nucleus or other compartments.",
      "The PDZ domain of SATB1 can participate in the ubiquitination and degradation of other proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "llama-2-7b-chat-hf_response": "The BLISS technique is a method for managing anxiety and stress that was developed by Dr. David A. Clark and Dr. Aaron T. Beck. BLISS stands for \"Breathing, Loving-kindness, Imagery, and Sensory focus,\" and it is based on the principles of cognitive-behavioral therapy (CBT).\nThe BLISS technique is designed to help individuals manage their anxiety and stress by teaching them how to focus their attention on the present moment, rather than getting caught up in negative thoughts and emotions. The technique involves four main components:\n1. Breathing: The first step in the BLISS technique is to focus on your breath. Pay attention to the sensation of the air moving in and out of your body, and try to let go of any thoughts or distractions.\n2. Loving-kindness: The second step is to cultivate feelings of loving-kindness towards yourself and others. This involves repeating phrases such as \"May I be happy, may I be healthy, may I be at peace\" to yourself and others.\n3. Imagery: The third step is to use imagery to create a peaceful and relaxing environment. This can involve visualizing a calm and peaceful place, or imagining a scenario that makes you feel safe and relaxed.\n4. Sensory focus: The final step is to focus on your senses, paying attention to the sights, sounds, smells, tastes, and textures around you. This can help you become more grounded in the present moment and less focused on negative thoughts and emotions.\nBy using the BLISS technique, individuals can learn how to manage their anxiety and stress in a more mindful and intentional way. It can be a helpful tool for anyone looking to reduce their stress and improve their overall well-being.",
    "llama-2-7b-chat-hf_fact_raw": "1. The BLISS technique was developed by Dr. David A. Clark and Dr. Aaron T. Beck.\n2. BLISS stands for \"Breathing, Loving-kindness, Imagery, and Sensory focus.\"\n3. The technique is based on the principles of cognitive-behavioral therapy (CBT).\n4. Breathing, as a part of the BLISS technique, involves focusing on the sensation of air moving in and out of the body.\n5. The Loving-kindness step of the BLISS technique includes repeating phrases such as \"May I be happy, may I be healthy, may I be at peace.\"",
    "llama-2-7b-chat-hf_fact": [
      "The BLISS technique was developed by Dr. David A. Clark and Dr. Aaron T. Beck.",
      "BLISS stands for \"Breathing, Loving-kindness, Imagery, and Sensory focus.\"",
      "The technique is based on the principles of cognitive-behavioral therapy (CBT).",
      "Breathing, as a part of the BLISS technique, involves focusing on the sensation of air moving in and out of the body.",
      "The Loving-kindness step of the BLISS technique includes repeating phrases such as \"May I be happy, may I be healthy, may I be at peace.\""
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I'm happy to provide you with information on NK3R antagonists. NK3R (Nuclear receptor subfamily 4, group F, member 1) is a G protein-coupled receptor that plays a crucial role in regulating various physiological processes, including glucose and lipid metabolism, inflammation, and cardiovascular health. Here are three NK3R antagonists that have been identified and studied:\n1. RX-0201: RX-0201 is a potent and selective NK3R antagonist that has been shown to reduce food intake and body weight in preclinical studies. It has also been shown to improve glucose tolerance and insulin sensitivity, making it a potential therapeutic agent for the treatment of obesity-related metabolic disorders.\n2. BMS-986177: BMS-986177 is a highly selective NK3R antagonist that has been shown to reduce food intake and body weight in preclinical studies. It has also been shown to improve insulin sensitivity and glucose tolerance, making it a potential therapeutic agent for the treatment of type 2 diabetes.\n3. MK-0677: MK-0677 is a potent and selective NK3R antagonist that has been shown to reduce food intake and body weight in preclinical studies. It has also been shown to improve insulin sensitivity and glucose tolerance, making it a potential therapeutic agent for the treatment of obesity-related metabolic disorders.\nIt's important to note that these are just a few examples of NK3R antagonists, and there are many other compounds that have been identified and studied for their potential as therapeutic agents. Additionally, while these compounds have shown promise in preclinical studies, further research is needed to determine their safety and efficacy in humans.",
    "llama-2-7b-chat-hf_fact_raw": "1. RX-0201 is a potent and selective NK3R antagonist.\n2. BMS-986177 is a highly selective NK3R antagonist.\n3. MK-0677 is a potent and selective NK3R antagonist.\n4. RX-0201 has been shown to reduce food intake and body weight in preclinical studies.\n5. BMS-986177 has been shown to improve insulin sensitivity and glucose tolerance in preclinical studies.",
    "llama-2-7b-chat-hf_fact": [
      "RX-0201 is a potent and selective NK3R antagonist.",
      "BMS-986177 is a highly selective NK3R antagonist.",
      "MK-0677 is a potent and selective NK3R antagonist.",
      "RX-0201 has been shown to reduce food intake and body weight in preclinical studies.",
      "BMS-986177 has been shown to improve insulin sensitivity and glucose tolerance in preclinical studies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout additional context or information on these specific compounds, it is not possible to determine the accuracy of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-2-7b-chat-hf_response": "The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is called BMS-986177.\nGhrelin is a hormone that regulates appetite and metabolism, and its receptor, GHS-R, is a key player in the regulation of these processes. Inverse agonists of the GHS-R are drugs that bind to the receptor and prevent it from activating its normal signaling pathways, leading to decreased appetite and increased fat burning.\nBMS-986177 is a potent and selective inverse agonist of the GHS-R, developed by Bristol-Myers Squibb (BMS). It was the first oral GHS-R inverse agonist to be evaluated in healthy subjects in a clinical trial. The trial, conducted in 2011, evaluated the safety, pharmacokinetics, and pharmacodynamics of BMS-986177 in 48 healthy male subjects.\nThe results of the trial showed that BMS-986177 was well-tolerated and had a predictable pharmacokinetic profile, with a mean terminal half-life of approximately 12 hours. Importantly, the trial also demonstrated that BMS-986177 produced significant reductions in ghrelin levels and increases in peptide YY (PYY) levels, which are associated with feelings of fullness and satiety.\nWhile BMS-986177 showed promise as a potential treatment for obesity, it was later abandoned by BMS due to concerns about its potential to cause muscle wasting and other adverse effects. However, the development of GHS-R inverse agonists has continued, and several other compounds are currently in various stages of clinical development for the treatment of obesity and related metabolic disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. BMS-986177 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.\n2. Ghrelin is a hormone that regulates appetite and metabolism.\n3. BMS-986177 was developed by Bristol-Myers Squibb (BMS).\n4. A clinical trial conducted in 2011 evaluated the safety, pharmacokinetics, and pharmacodynamics of BMS-986177 in 48 healthy male subjects.\n5. The trial demonstrated that BMS-986177 produced significant reductions in ghrelin levels and increases in PYY levels.",
    "llama-2-7b-chat-hf_fact": [
      "BMS-986177 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.",
      "Ghrelin is a hormone that regulates appetite and metabolism.",
      "BMS-986177 was developed by Bristol-Myers Squibb (BMS).",
      "A clinical trial conducted in 2011 evaluated the safety, pharmacokinetics, and pharmacodynamics of BMS-986177 in 48 healthy male subjects.",
      "The trial demonstrated that BMS-986177 produced significant reductions in ghrelin levels and increases in PYY levels."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-2-7b-chat-hf_response": "Vaxchora is a cholera vaccine that has been shown to be highly effective in preventing moderate to severe cholera in individuals. The protective efficacy of Vaxchora against moderate to severe cholera has been demonstrated in several clinical trials.\nIn a phase 3 clinical trial conducted in Bangladesh, Vaxchora was shown to provide 86% protection against moderate to severe cholera in individuals who received a single dose of the vaccine. The trial involved 2,570 participants, aged 18-60 years, who were randomly assigned to receive either Vaxchora or a placebo. The participants were then monitored for 12 months for the development of cholera.\nAnother clinical trial conducted in Africa found that Vaxchora provided 77% protection against moderate to severe cholera in individuals who received a two-dose regimen of the vaccine. The trial involved 1,050 participants, aged 18-60 years, who were randomly assigned to receive either Vaxchora or a placebo.\nThe protective efficacy of Vaxchora has also been demonstrated in a meta-analysis of six clinical trials conducted in Africa and Asia. The meta-analysis found that Vaxchora provided 74% protection against moderate to severe cholera in individuals who received a single dose of the vaccine.\nIt is important to note that the protective efficacy of Vaxchora may vary depending on several factors, including the strain of the cholera bacteria, the individual's age and health status, and the timing and route of vaccine administration. However, the available data suggest that Vaxchora is highly effective in preventing moderate to severe cholera in individuals.\nIt is important to consult with a healthcare professional for advice on the use of Vaxchora and other cholera vaccines. They can provide information on the specific strain of cholera in the area, the individual's risk factors, and the appropriate vaccination schedule.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vaxchora is a vaccine that prevents moderate to severe cholera.\n2. A phase 3 clinical trial in Bangladesh demonstrated Vaxchora's 86% protection against moderate to severe cholera with a single dose.\n3. The Bangladesh trial included 2,570 participants aged 18-60 years who were monitored for 12 months.\n4. Another clinical trial in Africa showed Vaxchora offering 77% protection with a two-dose regimen.\n5. A meta-analysis of six clinical trials found that Vaxchora provided 74% protection against moderate to severe cholera with a single dose.",
    "llama-2-7b-chat-hf_fact": [
      "Vaxchora is a vaccine that prevents moderate to severe cholera.",
      "A phase 3 clinical trial in Bangladesh demonstrated Vaxchora's 86% protection against moderate to severe cholera with a single dose.",
      "The Bangladesh trial included 2,570 participants aged 18-60 years who were monitored for 12 months.",
      "Another clinical trial in Africa showed Vaxchora offering 77% protection with a two-dose regimen.",
      "A meta-analysis of six clinical trials found that Vaxchora provided 74% protection against moderate to severe cholera with a single dose."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "llama-2-7b-chat-hf_response": "The first cholera vaccine approved in the US was the Shanchol vaccine, which was approved by the Food and Drug Administration (FDA) in 2007. The Shanchol vaccine is a live, oral vaccine that is given in two doses, spaced one month apart. It is recommended for adults aged 18 years or older who are traveling to areas where cholera is common, such as parts of Asia, Africa, and Latin America.\nThe Shanchol vaccine was developed by the biotechnology company, Sanofi Pasteur, and has been shown to be highly effective in preventing cholera in clinical trials. In a large clinical trial conducted in Bangladesh, the vaccine was found to be 86% effective in preventing cholera in individuals who received two doses of the vaccine.\nIt is important to note that the Shanchol vaccine is not 100% effective, and it does not provide lifelong immunity against cholera. Therefore, it is still important to take other precautions to prevent cholera, such as drinking safe water and food, and practicing good hygiene.\nIt is also important to note that the Shanchol vaccine is not recommended for everyone, especially for individuals with certain medical conditions, such as a weakened immune system, or for pregnant or breastfeeding women. It is important to consult with a healthcare provider before receiving the vaccine to determine if it is safe for you.\nIn summary, the first cholera vaccine approved in the US is the Shanchol vaccine, which was approved in 2007 and is recommended for adults traveling to areas where cholera is common. It is a live, oral vaccine that is given in two doses, spaced one month apart, and has been shown to be highly effective in preventing cholera in clinical trials. However, it is not 100% effective and does not provide lifelong immunity, and it is not recommended for everyone, especially for individuals with certain medical conditions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The first cholera vaccine approved in the US was the Shanchol vaccine.\n2. Shanchol vaccine was approved by the Food and Drug Administration (FDA) in 2007.\n3. The vaccine is recommended for adults aged 18 years or older who are traveling to areas where cholera is common.\n4. In a clinical trial conducted in Bangladesh, the Shanchol vaccine was found to be 86% effective in preventing cholera.\n5. The Shanchol vaccine is a live, oral vaccine that is administered in two doses, spaced one month apart.",
    "llama-2-7b-chat-hf_fact": [
      "The first cholera vaccine approved in the US was the Shanchol vaccine.",
      "Shanchol vaccine was approved by the Food and Drug Administration (FDA) in 2007.",
      "The vaccine is recommended for adults aged 18 years or older who are traveling to areas where cholera is common.",
      "In a clinical trial conducted in Bangladesh, the Shanchol vaccine was found to be 86% effective in preventing cholera.",
      "The Shanchol vaccine is a live, oral vaccine that is administered in two doses, spaced one month apart."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The first cholera vaccine approved in the US was the Vaxchora vaccine.\n2. FALSE [correction]: The Shanchol vaccine was not approved by the FDA; Vaxchora was approved by the FDA in 2016.\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-2-7b-chat-hf_response": "Common variable immunodeficiency (CVID) is a primary immunodeficiency disorder that affects the immune system's ability to function properly, leading to recurrent infections and other immune-related problems. Monogenic causes of CVID refer to genetic mutations that occur in a single gene, leading to the development of the disorder.\nAmong Europeans, the most common monogenic cause of CVID is mutations in the X-linked lymphoproliferative disease (XLP) gene. XLP is a genetic disorder that affects the immune system, particularly the B cells, and is characterized by recurrent infections, lymphadenopathy, and a high risk of developing autoimmune disorders.\nThe XLP gene is located on the X chromosome and codes for a protein called CD40 ligand (CD40L). CD40L is involved in the activation and proliferation of B cells, and mutations in the XLP gene can lead to a deficiency in CD40L, resulting in impaired B cell function and the development of CVID.\nStudies have shown that approximately 70% of CVID patients of European descent have a mutation in the XLP gene, making it the most common monogenic cause of CVID in this population. Other genetic mutations that can cause CVID in Europeans include mutations in the genes encoding the proteins CD19, CD21, and CD79A, among others.\nIt's important to note that CVID can also be caused by a combination of genetic and environmental factors, such as infections, medications, and exposure to toxins. A thorough evaluation by a healthcare provider is necessary to determine the underlying cause of CVID in any given individual.",
    "llama-2-7b-chat-hf_fact_raw": "1. Common variable immunodeficiency (CVID) is a primary immunodeficiency disorder.\n2. The most common monogenic cause of CVID among Europeans is mutations in the X-linked lymphoproliferative disease (XLP) gene.\n3. The XLP gene mutation leads to a deficiency in the protein CD40 ligand (CD40L).\n4. Approximately 70% of CVID patients of European descent have a mutation in the XLP gene.\n5. Other genetic mutations that can cause CVID in Europeans include those in the genes encoding proteins CD19, CD21, and CD79A.",
    "llama-2-7b-chat-hf_fact": [
      "Common variable immunodeficiency (CVID) is a primary immunodeficiency disorder.",
      "The most common monogenic cause of CVID among Europeans is mutations in the X-linked lymphoproliferative disease (XLP) gene.",
      "The XLP gene mutation leads to a deficiency in the protein CD40 ligand (CD40L).",
      "Approximately 70% of CVID patients of European descent have a mutation in the XLP gene.",
      "Other genetic mutations that can cause CVID in Europeans include those in the genes encoding proteins CD19, CD21, and CD79A."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The most common monogenic cause of CVID among Europeans is mutations in the TNFRSF13B (TACI) gene.\n3. FALSE [correction]: The XLP gene mutation leads to a deficiency in the protein SAP (SLAM-associated protein).\n4. FALSE [correction]: It is not accurate that 70% of CVID patients of European descent have a mutation in the XLP gene; the percentage is much lower.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-2-7b-chat-hf_response": "The IFIT1 gene is a key player in the development and progression of Systemic Lupus Erythematosus (SLE), a complex and multifactorial autoimmune disease. Here's a detailed explanation of the role of the IFIT1 gene in SLE:\n1. Autoantigen presentation: The IFIT1 gene encodes for a protein called IFIT1, which is involved in the presentation of self-antigens to T cells. In SLE, the IFIT1 gene is mutated, leading to the production of abnormal self-antigens that can trigger an immune response and contribute to the development of autoantibodies.\n2. T cell activation and proliferation: IFIT1 also plays a role in the activation and proliferation of T cells, which are central to the immune response. In SLE, the IFIT1 gene is overexpressed, leading to an imbalance in the T cell response and contributing to the development of autoimmune phenomena.\n3. Cytokine production: The IFIT1 gene is also involved in the production of cytokines, which are signaling molecules that help coordinate the immune response. In SLE, the IFIT1 gene is overexpressed, leading to an excessive production of pro-inflammatory cytokines, such as TNF-alpha and IL-1 beta, which can exacerbate inflammation and tissue damage.\n4. Nuclear factor kappa B (NF-B) activation: The IFIT1 gene can also activate the transcription factor NF-B, which regulates the expression of genes involved in inflammation and immune response. In SLE, the IFIT1 gene is overexpressed, leading to excessive NF-B activation, which can contribute to the development of autoimmune phenomena.\n5. Epigenetic regulation: The IFIT1 gene is also subject to epigenetic regulation, which can affect its expression and activity. In SLE, the IFIT1 gene is known to be subject to epigenetic modifications, such as DNA methylation and histone modification, which can lead to changes in its expression and activity.\n6. Genetic susceptibility: The IFIT1 gene has been identified as a genetic susceptibility gene for",
    "llama-2-7b-chat-hf_fact_raw": "1. The IFIT1 gene encodes for a protein involved in the presentation of self-antigens to T cells.\n2. In SLE, the IFIT1 gene is mutated, leading to the production of abnormal self-antigens.\n3. The IFIT1 gene is overexpressed in SLE, causing an imbalance in T cell response.\n4. Overexpression of the IFIT1 gene in SLE leads to an excessive production of pro-inflammatory cytokines like TNF-alpha and IL-1 beta.\n5. The IFIT1 gene can activate the transcription factor NF-B, which regulates genes involved in inflammation and immune response.",
    "llama-2-7b-chat-hf_fact": [
      "The IFIT1 gene encodes for a protein involved in the presentation of self-antigens to T cells.",
      "In SLE, the IFIT1 gene is mutated, leading to the production of abnormal self-antigens.",
      "The IFIT1 gene is overexpressed in SLE, causing an imbalance in T cell response.",
      "Overexpression of the IFIT1 gene in SLE leads to an excessive production of pro-inflammatory cytokines like TNF-alpha and IL-1 beta.",
      "The IFIT1 gene can activate the transcription factor NF-B, which regulates genes involved in inflammation and immune response."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The IFIT1 gene encodes for an interferon-induced protein with tetratricopeptide repeats, which is involved in antiviral defense mechanisms.\n2. FALSE [correction]: In SLE (Systemic Lupus Erythematosus), it is not specifically the IFIT1 gene that is mutated. Instead, a complex combination of genetic and environmental factors are involved in the disease.\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: The IFIT1 gene does not directly activate the transcription factor NF-B. However, IFIT1 can play a role in pathways that ultimately lead to NF-B activation.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "llama-2-7b-chat-hf_response": "The Liverpool Elbow Score (LES) is a clinical assessment tool used to evaluate the severity of elbow pain and disability in patients. It is a simple and reliable method that assesses the degree of elbow pain, stiffness, and limited mobility, and helps healthcare providers determine the most appropriate course of treatment.\nThe LES is based on a 10-point scale, with higher scores indicating greater severity of symptoms. The assessment includes questions on the following:\n1. Pain (0-3): The patient is asked to rate their elbow pain on a numerical scale from 0 (no pain) to 3 (severe pain).\n2. Stiffness (0-2): The patient is asked to rate the stiffness of their elbow on a numerical scale from 0 (no stiffness) to 2 (severe stiffness).\n3. Functional limitation (0-3): The patient is asked to rate the limitation of their elbow function on a numerical scale from 0 (no limitation) to 3 (severe limitation).\n4. Grip strength (0-2): The patient is asked to squeeze a dynamometer to measure the strength of their grip.\n5. Palpation (0-2): The examiner palpates the elbow to assess for any tenderness or pain.\n6. Range of motion (0-2): The examiner measures the range of motion of the elbow through flexion, extension, abduction, and adduction.\nThe total score on the LES ranges from 0 to 30, with higher scores indicating greater severity of symptoms. A score of 0-6 indicates mild symptoms, 7-12 indicates moderate symptoms, and 13-30 indicates severe symptoms.\nThe LES is commonly used in clinical settings to evaluate patients with elbow pain or disability, such as those with tennis elbow, golfer's elbow, or fractures. It is also used to monitor the effectiveness of treatment interventions and to evaluate the progression of the condition over time.\nIn conclusion, the Liverpool Elbow Score is a useful tool for healthcare providers to assess the severity of elbow pain and disability in patients. It is simple to administer, reliable",
    "llama-2-7b-chat-hf_fact_raw": "1. The Liverpool Elbow Score (LES) is used to evaluate the severity of elbow pain and disability in patients.\n2. The LES uses a 10-point scale, where higher scores indicate greater severity of symptoms.\n3. The assessment includes ratings for pain, stiffness, functional limitation, grip strength, palpation, and range of motion.\n4. The total score on the LES ranges from 0 to 30, with 0-6 indicating mild symptoms, 7-12 moderate symptoms, and 13-30 severe symptoms.\n5. The LES is used to monitor treatment effectiveness and evaluate the progression of elbow conditions over time.",
    "llama-2-7b-chat-hf_fact": [
      "The Liverpool Elbow Score (LES) is used to evaluate the severity of elbow pain and disability in patients.",
      "The LES uses a 10-point scale, where higher scores indicate greater severity of symptoms.",
      "The assessment includes ratings for pain, stiffness, functional limitation, grip strength, palpation, and range of motion.",
      "The total score on the LES ranges from 0 to 30, with 0-6 indicating mild symptoms, 7-12 moderate symptoms, and 13-30 severe symptoms.",
      "The LES is used to monitor treatment effectiveness and evaluate the progression of elbow conditions over time."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The LES uses a 10-point scale for each section, resulting in a total score ranging from 0 to 100.\n3. TRUE\n4. FALSE [correction]: The total score on the LES ranges from 0 to 100, with the scoring for severity levels unclear in the statement provided.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-2-7b-chat-hf_response": "The 100,000 Genomes Project is a groundbreaking initiative launched in 2015 by the National Health Service (NHS) in the United Kingdom to analyze the genomes of 100,000 patients with rare and common diseases, including sarcoma. The project aims to provide better diagnoses, treatments, and care for patients with rare and complex diseases, including sarcoma.\nSarcoma is a rare and complex cancer that affects the connective tissue of the body, including bone, cartilage, fat, muscle, nerves, and blood vessels. It accounts for approximately 1% of all adult cancers and 15% of all pediatric cancers. The 100,000 Genomes Project has focused on improving the understanding of sarcoma and developing new treatments for this disease.\nEfforts on sarcoma from the 100,000 Genomes Project include:\n1. Whole-genome sequencing: The project has performed whole-genome sequencing on a large number of sarcoma samples to identify genetic mutations and variations that may be associated with the disease. This has helped researchers to better understand the genetic basis of sarcoma and to identify potential targets for therapy.\n2. Translational research: The project has enabled researchers to translate genetic findings into clinical practice by developing new diagnostic tests and treatments for sarcoma. This has included the development of liquid biopsy tests, which can detect genetic mutations in blood samples, and the use of targeted therapies, such as imatinib, which can be used to treat certain types of sarcoma.\n3. Collaboration with clinicians: The project has collaborated closely with clinicians to ensure that genetic findings are translated into clinical practice. This has included working with clinicians to develop new diagnostic criteria and treatment protocols for sarcoma.\n4. Development of data resources: The project has developed a range of data resources, including the UK Sarcoma Cytogenetics Database, which contains genetic information on over 1,000 sarcoma samples, and the Cancer Genome Project, which provides access to genomic data on a wide range of cancers, including",
    "llama-2-7b-chat-hf_fact_raw": "1. The 100,000 Genomes Project was launched in 2015 by the National Health Service in the United Kingdom.\n2. The project's goal is to analyze the genomes of 100,000 patients with rare and common diseases, including sarcoma.\n3. Sarcoma accounts for approximately 1% of all adult cancers and 15% of all pediatric cancers.\n4. Whole-genome sequencing on sarcoma samples has been performed to identify genetic mutations and variations.\n5. The UK Sarcoma Cytogenetics Database contains genetic information on over 1,000 sarcoma samples.",
    "llama-2-7b-chat-hf_fact": [
      "The 100,000 Genomes Project was launched in 2015 by the National Health Service in the United Kingdom.",
      "The project's goal is to analyze the genomes of 100,000 patients with rare and common diseases, including sarcoma.",
      "Sarcoma accounts for approximately 1% of all adult cancers and 15% of all pediatric cancers.",
      "Whole-genome sequencing on sarcoma samples has been performed to identify genetic mutations and variations.",
      "The UK Sarcoma Cytogenetics Database contains genetic information on over 1,000 sarcoma samples."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "llama-2-7b-chat-hf_response": "Protein ALEX1 is a transcriptional repressor that was first identified in Drosophila melanogaster (the fruit fly) and is named after the Alexian Brothers, a group of Catholic brothers who were involved in the discovery of the protein. ALEX1 is composed of multiple domains, including an N-terminal transcriptional repression domain, a DNA-binding domain, and several armadillo repeats.\nArmadillo repeats are a type of structural motif found in proteins that are involved in protein-protein interactions. They are named after the armadillo animal, which has a distinctive protective shell made up of small, repetitive plates. Armadillo repeats are composed of a repeating pattern of amino acids that form a beta-sheet structure, which is stabilized by hydrogen bonds.\nIn the case of ALEX1, the protein contains multiple armadillo repeats, specifically four to six repeats, depending on the isoform. These repeats are located in the N-terminal region of the protein and are thought to play a role in the protein's ability to bind to DNA and regulate transcription.\nThe armadillo repeats in ALEX1 are important for its function as a transcriptional repressor, as they allow the protein to recognize and bind to specific DNA sequences. The repeats also contribute to the protein's stability and folding, as they help to form a stable structure that can interact with DNA.\nIt is worth noting that ALEX1 is a complex protein that contains multiple domains and interacts with a variety of other proteins and molecules. While the armadillo repeats are an important component of ALEX1, they are just one of several structural motifs that are found in the protein.",
    "llama-2-7b-chat-hf_fact_raw": "1. Protein ALEX1 contains multiple domains including an N-terminal transcriptional repression domain, a DNA-binding domain, and several armadillo repeats.\n2. Armadillo repeats are structural motifs involved in protein-protein interactions.\n3. ALEX1 contains four to six armadillo repeats depending on the isoform.\n4. Armadillo repeats in ALEX1 play a role in binding to DNA and regulating transcription.\n5. Armadillo repeats contribute to the stability and folding of ALEX1.",
    "llama-2-7b-chat-hf_fact": [
      "Protein ALEX1 contains multiple domains including an N-terminal transcriptional repression domain, a DNA-binding domain, and several armadillo repeats.",
      "Armadillo repeats are structural motifs involved in protein-protein interactions.",
      "ALEX1 contains four to six armadillo repeats depending on the isoform.",
      "Armadillo repeats in ALEX1 play a role in binding to DNA and regulating transcription.",
      "Armadillo repeats contribute to the stability and folding of ALEX1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. FALSE [correction]: Armadillo repeats in ALEX1 play a role in protein-protein interactions, not directly in DNA binding and regulating transcription.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "llama-2-7b-chat-hf_response": "Histone modifications are chemical modifications to the histone proteins that make up the chromatin structure of DNA in eukaryotic cells. These modifications can play a crucial role in regulating gene expression, DNA repair, and other cellular processes. Enzymes that remove histone modifications are called histone demethylases, and they are involved in the removal of methyl groups from histone proteins. Here are some examples of histone demethylases:\n1. Histone demethylase (KDM) family: This family of enzymes is responsible for removing methyl groups from histone H3 and H4. There are several subtypes of KDMs, each with a specific substrate specificity.\n2. JMJD2 family: This family of enzymes is involved in the removal of methyl groups from histone H3 lysine 9 (H3K9). JMJD2A and JMJD2B are the two main isoforms of this enzyme.\n3. JMJD3 family: This family of enzymes is involved in the removal of methyl groups from histone H3 lysine 27 (H3K27). JMJD3 is the only member of this family.\n4. EZH2 family: This family of enzymes is involved in the removal of methyl groups from histone H3 lysine 27 (H3K27) and histone H4 lysine 20 (H4K20). EZH2 is the only member of this family.\n5. SUV39H1 family: This family of enzymes is involved in the removal of methyl groups from histone H3 lysine 9 (H3K9) and histone H4 lysine 5 (H4K5). SUV39H1 is the only member of this family.\n6. KMT1 family: This family of enzymes is involved in the methylation of histone H3 and H4. KMT1A, KMT1B, and KMT1E are the three main isoforms of this family.\n7. KMT5 family: This family of enzymes is involved in the methylation of histone H3 and",
    "llama-2-7b-chat-hf_fact_raw": "1. Histone demethylases are enzymes that remove methyl groups from histone proteins.\n2. The Histone demethylase (KDM) family is responsible for removing methyl groups from histone H3 and H4.\n3. The JMJD2 family of enzymes removes methyl groups from histone H3 lysine 9 (H3K9).\n4. JMJD3 is the only member of the JMJD3 family, which removes methyl groups from histone H3 lysine 27 (H3K27).\n5. EZH2 is the only member of the EZH2 family, and it is involved in the removal of methyl groups from histone H3 lysine 27 (H3K27) and histone H4 lysine 20 (H4K20).",
    "llama-2-7b-chat-hf_fact": [
      "Histone demethylases are enzymes that remove methyl groups from histone proteins.",
      "The Histone demethylase (KDM) family is responsible for removing methyl groups from histone H3 and H4.",
      "The JMJD2 family of enzymes removes methyl groups from histone H3 lysine 9 (H3K9).",
      "JMJD3 is the only member of the JMJD3 family, which removes methyl groups from histone H3 lysine 27 (H3K27).",
      "EZH2 is the only member of the EZH2 family, and it is involved in the removal of methyl groups from histone H3 lysine 27 (H3K27) and histone H4 lysine 20 (H4K20)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: JMJD3 is a member of the Jumonji domain-containing (JMJD) family of enzymes, not the only one, that removes methyl groups from histone H3 lysine 27 (H3K27).\n5. FALSE [correction]: EZH2 is a member of the Polycomb group (PcG) protein family, and it is involved in the addition of methyl groups to histone H3 lysine 27 (H3K27), not the removal.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "llama-2-7b-chat-hf_response": "Thank you for reaching out with your question! I'm here to help you understand the potential risks associated with head CT scans and brain tumors.\nFirstly, it's important to understand that head CT scans are a diagnostic tool used to identify a variety of conditions, including brain tumors. A head CT scan uses X-rays to produce detailed images of the brain, which can help doctors identify any abnormalities or lesions within the brain tissue.\nNow, to answer your question directly, there is some evidence to suggest that head CT scans may increase the risk of developing a brain tumor, particularly in children and young adults. However, it's important to note that the risk is still relatively low, and the benefits of a head CT scan in diagnosing and treating a potential brain tumor far outweigh the potential risks.\nStudies have shown that exposure to ionizing radiation from CT scans can increase the risk of developing a brain tumor by a small amount. The risk is thought to be higher in children and young adults due to their developing brains being more sensitive to radiation. However, the risk is still relatively low, and the benefits of a head CT scan in diagnosing and treating a potential brain tumor far outweigh the potential risks.\nIt's important to keep in mind that the risk of developing a brain tumor from a head CT scan is still much lower than the risk of not getting a CT scan when one is needed. In many cases, a head CT scan can help doctors diagnose and treat a potential brain tumor before it becomes more serious.\nIf you have any concerns about the potential risks of a head CT scan, it's important to discuss them with your doctor. They can help you understand the potential risks and benefits of the scan and make an informed decision about whether it's right for you.\nIn summary, while there is some evidence to suggest that head CT scans may increase the risk of developing a brain tumor, the risk is still relatively low. The benefits of a head CT scan in diagnosing and treating a potential brain tumor far outweigh the potential risks, and it's important to discuss any concerns with your doctor.",
    "llama-2-7b-chat-hf_fact_raw": "1. Head CT scans use X-rays to produce detailed images of the brain.\n2. Some evidence suggests that head CT scans may increase the risk of developing a brain tumor, particularly in children and young adults.\n3. Exposure to ionizing radiation from CT scans can increase the risk of developing a brain tumor by a small amount.\n4. The risk of developing a brain tumor from a head CT scan is higher in children and young adults due to their developing brains being more sensitive to radiation.\n5. The risk of not getting a CT scan when one is needed is higher than the risk of developing a brain tumor from the scan.",
    "llama-2-7b-chat-hf_fact": [
      "Head CT scans use X-rays to produce detailed images of the brain.",
      "Some evidence suggests that head CT scans may increase the risk of developing a brain tumor, particularly in children and young adults.",
      "Exposure to ionizing radiation from CT scans can increase the risk of developing a brain tumor by a small amount.",
      "The risk of developing a brain tumor from a head CT scan is higher in children and young adults due to their developing brains being more sensitive to radiation.",
      "The risk of not getting a CT scan when one is needed is higher than the risk of developing a brain tumor from the scan."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "llama-2-7b-chat-hf_response": "Otx2 is a transcription factor that is associated with neural pluripotency. Specifically, Otx2 is a marker of mesencephalic-Rathke's (M-R) plate-derived progenitors, which are a type of neural progenitor cell that is involved in the development of the central nervous system (CNS). These progenitors are thought to be responsible for the generation of midbrain and hindbrain neurons, as well as the formation of the cerebral aqueduct and the pons.\nOtx2 is expressed in these progenitors throughout embryonic development, and it continues to be expressed in adult neural stem cells and progenitors, including those found in the subventricular zone (SVZ) and the subgranular zone (SGZ) of the cerebral cortex.\nIn addition to its role in neural development and maintenance, Otx2 has been implicated in a number of neurological disorders, including Parkinson's disease, Alzheimer's disease, and cancer. For example, studies have shown that Otx2 is downregulated in the brains of individuals with Parkinson's disease, and that restoring Otx2 expression can improve motor function in animal models of the disease.\nOverall, Otx2 is an important transcription factor that plays a critical role in the development and maintenance of the nervous system, and its dysregulation has been implicated in a number of neurological disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. Otx2 is a transcription factor associated with neural pluripotency.\n2. Otx2 is a marker of mesencephalic-Rathke's (M-R) plate-derived progenitors involved in developing the central nervous system (CNS).\n3. Otx2 is expressed in neural progenitors throughout embryonic development and in adult neural stem cells and progenitors.\n4. Otx2 expression continues in adult progenitors found in the subventricular zone (SVZ) and the subgranular zone (SGZ) of the cerebral cortex.\n5. Dysregulation of Otx2 has been implicated in neurological disorders such as Parkinson's disease, Alzheimer's disease, and cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Otx2 is a transcription factor associated with neural pluripotency.",
      "Otx2 is a marker of mesencephalic-Rathke's (M-R) plate-derived progenitors involved in developing the central nervous system (CNS).",
      "Otx2 is expressed in neural progenitors throughout embryonic development and in adult neural stem cells and progenitors.",
      "Otx2 expression continues in adult progenitors found in the subventricular zone (SVZ) and the subgranular zone (SGZ) of the cerebral cortex.",
      "Dysregulation of Otx2 has been implicated in neurological disorders such as Parkinson's disease, Alzheimer's disease, and cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-2-7b-chat-hf_response": "The murine beta globin locus region, also known as the beta-globin gene cluster, spans approximately 110 kb of genomic DNA on chromosome 7 in mice. The beta globin gene cluster consists of five genes (Beta-1, Beta-2, Beta-3, Beta-4, and Beta-5) that encode the beta-chain subunits of hemoglobin.\nThere are several DNaseI hypersensitive sites (DHS) located throughout the beta globin locus region. These DHS are specific regions of DNA where the enzyme DNaseI is more active and can be used as markers to identify the boundaries of gene promoters, enhancers, and other regulatory elements.\nAccording to a study published in the journal Genomics in 2001, there are at least 17 DHS markers located in the beta globin locus region. These markers are spaced approximately 1-2 kb apart and cover the entire length of the beta globin gene cluster.\nHere are the locations and characteristics of the 17 DHS markers identified in the study:\n1. DHS-1: Located upstream of the Beta-1 gene, approximately 1 kb upstream of the transcription start site.\n2. DHS-2: Located downstream of the Beta-1 gene, approximately 1 kb downstream of the transcription termination site.\n3. DHS-3: Located upstream of the Beta-2 gene, approximately 2 kb upstream of the transcription start site.\n4. DHS-4: Located downstream of the Beta-2 gene, approximately 2 kb downstream of the transcription termination site.\n5. DHS-5: Located upstream of the Beta-3 gene, approximately 3 kb upstream of the transcription start site.\n6. DHS-6: Located downstream of the Beta-3 gene, approximately 3 kb downstream of the transcription termination site.\n7. DHS-7: Located upstream of the Beta-4 gene, approximately 4 kb upstream of the transcription start site.\n8. DHS-8: Located downstream of",
    "llama-2-7b-chat-hf_fact_raw": "1. The murine beta globin locus region spans approximately 110 kb of genomic DNA on chromosome 7 in mice.\n2. The beta globin gene cluster consists of five genes that encode the beta-chain subunits of hemoglobin.\n3. There are at least 17 DNaseI hypersensitive sites (DHS) markers located in the beta globin locus region according to a study published in the journal Genomics in 2001.\n4. The 17 DHS markers are spaced approximately 1-2 kb apart and cover the entire length of the beta globin gene cluster.\n5. Each of the 17 DHS markers has a specific location relative to the beta globin genes, such as upstream or downstream of the transcription start or termination sites.",
    "llama-2-7b-chat-hf_fact": [
      "The murine beta globin locus region spans approximately 110 kb of genomic DNA on chromosome 7 in mice.",
      "The beta globin gene cluster consists of five genes that encode the beta-chain subunits of hemoglobin.",
      "There are at least 17 DNaseI hypersensitive sites (DHS) markers located in the beta globin locus region according to a study published in the journal Genomics in 2001.",
      "The 17 DHS markers are spaced approximately 1-2 kb apart and cover the entire length of the beta globin gene cluster.",
      "Each of the 17 DHS markers has a specific location relative to the beta globin genes, such as upstream or downstream of the transcription start or termination sites."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "llama-2-7b-chat-hf_response": "Certainly! Here are some of the most commonly used European influenza vaccines:\n1. Fluvirin (AstraZeneca): This is a trivalent influenza vaccine (TIV) that protects against three strains of the influenza virus: two A strains and one B strain. It is approved for use in individuals 6 months of age and older.\n2. FluMist (GlaxoSmithKline): This is a quadrivalent influenza vaccine (QIV) that protects against four strains of the influenza virus: two A strains and two B strains. It is approved for use in individuals 2-49 years of age.\n3. Fluad (GlaxoSmithKline): This is a TIV that contains an adjuvanted formulation of the influenza virus. Adjuvants are substances that help stimulate the immune system to produce a stronger response to the vaccine. Fluad is approved for use in individuals 65 years of age and older.\n4. Focetria (Sanofi Pasteur): This is a QIV that protects against four strains of the influenza virus: two A strains and two B strains. It is approved for use in individuals 18-49 years of age.\n5. Afluria (CSL Limited): This is a TIV that protects against three strains of the influenza virus: two A strains and one B strain. It is approved for use in individuals 18-64 years of age.\n6. Fluarix (GlaxoSmithKline): This is a TIV that protects against three strains of the influenza virus: two A strains and one B strain. It is approved for use in individuals 6 months of age and older.\n7. Vaxigrip (Sanofi Pasteur): This is a TIV that protects against three strains of the influenza virus: two A strains and one B strain. It is approved for use in individuals 6 months of age and older.\n8. Influvac (Bio-Medica): This is a QIV that protects against four strains of the influenza virus: two A strains and two B strains. It is approved for use",
    "llama-2-7b-chat-hf_fact_raw": "1. Fluvirin is a trivalent influenza vaccine approved for use in individuals 6 months of age and older.\n2. FluMist is a quadrivalent influenza vaccine approved for use in individuals 2-49 years of age.\n3. Fluad contains an adjuvanted formulation and is approved for use in individuals 65 years of age and older.\n4. Focetria is a quadrivalent influenza vaccine approved for use in individuals 18-49 years of age.\n5. Afluria is a trivalent influenza vaccine approved for use in individuals 18-64 years of age.",
    "llama-2-7b-chat-hf_fact": [
      "Fluvirin is a trivalent influenza vaccine approved for use in individuals 6 months of age and older.",
      "FluMist is a quadrivalent influenza vaccine approved for use in individuals 2-49 years of age.",
      "Fluad contains an adjuvanted formulation and is approved for use in individuals 65 years of age and older.",
      "Focetria is a quadrivalent influenza vaccine approved for use in individuals 18-49 years of age.",
      "Afluria is a trivalent influenza vaccine approved for use in individuals 18-64 years of age."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Focetria is a trivalent influenza vaccine, not quadrivalent, and it was approved for use in individuals 18 years of age and older, not just 18-49.\n5. FALSE [correction]: Afluria is a trivalent influenza vaccine approved for use in individuals 5 years of age and older, not just 18-64.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-2-7b-chat-hf_response": "Yes, the Paramyxovirus geneome is segmented, negative-sense RNA.\nParamyxoviruses are a family of viruses that include several important pathogens, such as the measles virus, mumps virus, and Nipah virus. The genome of these viruses is composed of a single-stranded RNA molecule that is segmented into several smaller segments, known as genes. Each gene encodes a specific protein or function necessary for the virus's replication and survival.\nThe RNA of Paramyxoviruses is negative-sense, meaning that the RNA sequence is complementary to the messenger RNA (mRNA) that is transcribed from it. This means that the RNA sequence is the complement of the mRNA sequence, and the two strands are antiparallel to each other.\nThe segmented nature of the Paramyxovirus genome means that each gene is encoded on a separate segment of the RNA molecule. This allows for the efficient replication and transcription of the virus, as each gene can be transcribed and translated independently of the others.\nIn addition, the negative-sense RNA of Paramyxoviruses can be translated into protein using a process called \"cap-independent translation.\" This means that the RNA can be translated into protein without the presence of a polyribosome, which is typically required for protein synthesis. This allows the virus to quickly produce large amounts of protein in response to changes in its environment.\nOverall, the segmented, negative-sense RNA genome of Paramyxoviruses is a key feature that allows these viruses to efficiently replicate and evolve in response to changing environments.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Paramyxovirus genome is composed of single-stranded RNA.\n2. The RNA molecule of Paramyxoviruses is segmented into several smaller segments known as genes.\n3. Each gene of the Paramyxovirus encodes a specific protein or function necessary for the virus's replication and survival.\n4. The RNA of Paramyxoviruses is negative-sense, meaning it is complementary to the mRNA transcribed from it.\n5. The negative-sense RNA of Paramyxoviruses can undergo cap-independent translation.",
    "llama-2-7b-chat-hf_fact": [
      "The Paramyxovirus genome is composed of single-stranded RNA.",
      "The RNA molecule of Paramyxoviruses is segmented into several smaller segments known as genes.",
      "Each gene of the Paramyxovirus encodes a specific protein or function necessary for the virus's replication and survival.",
      "The RNA of Paramyxoviruses is negative-sense, meaning it is complementary to the mRNA transcribed from it.",
      "The negative-sense RNA of Paramyxoviruses can undergo cap-independent translation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The RNA molecule of Paramyxoviruses is non-segmented and consists of a single continuous strand.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The negative-sense RNA of Paramyxoviruses cannot undergo translation directly; it must first be transcribed into a positive-sense mRNA by the viral RNA-dependent RNA polymerase.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "llama-2-7b-chat-hf_response": "Roflumilast cream is a topical medication that is used to treat a specific type of skin condition called psoriasis. Specifically, it is approved for the treatment of plaque psoriasis, which is a chronic skin condition characterized by red, scaly patches on the skin.\nRoflumilast cream works by reducing inflammation in the skin, which can help to slow down the growth of skin cells and improve the appearance of the skin. It is applied directly to the affected area of the skin, usually once or twice a day, depending on the severity of the condition.\nStudies have shown that roflumilast cream can be effective in improving symptoms of psoriasis, including reducing the size and number of skin lesions, improving skin thickness and texture, and reducing the itching and scaling associated with the condition. However, it may take several weeks to see the full effects of the medication.\nIt's important to note that roflumilast cream is not a cure for psoriasis, and it may not be effective for everyone. It's also important to use the medication as directed and to follow up with your healthcare provider to monitor your progress and adjust your treatment plan as needed.\nIn summary, roflumilast cream is an effective treatment option for plaque psoriasis, a chronic skin condition characterized by red, scaly patches on the skin. It works by reducing inflammation in the skin and can help to improve symptoms and appearance of the skin. However, it may not be effective for everyone and it's important to use the medication as directed and to follow up with your healthcare provider.",
    "llama-2-7b-chat-hf_fact_raw": "1. Roflumilast cream is used to treat plaque psoriasis.\n2. Plaque psoriasis is characterized by red, scaly patches on the skin.\n3. Roflumilast cream works by reducing inflammation in the skin.\n4. It is usually applied once or twice a day to the affected area.\n5. Roflumilast cream is not a cure for psoriasis.",
    "llama-2-7b-chat-hf_fact": [
      "Roflumilast cream is used to treat plaque psoriasis.",
      "Plaque psoriasis is characterized by red, scaly patches on the skin.",
      "Roflumilast cream works by reducing inflammation in the skin.",
      "It is usually applied once or twice a day to the affected area.",
      "Roflumilast cream is not a cure for psoriasis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-2-7b-chat-hf_response": "There are several tools that have been developed for identifying and visualizing non-coding RNA (ncRNA) promoters. Here are some of the most popular ones:\n1. CpG Island Finder: This tool identifies regions of the genome that are enriched in cytosine and guanine nucleotides (CpG dinucleotides), which are commonly found near ncRNA promoters. CpG Island Finder can be used to identify potential ncRNA promoters in a genome.\n2. Cis-Acting Regulatory Element (CRE) Finder: This tool identifies potential transcriptional regulatory elements, including ncRNA promoters, in a genome. CRE Finder uses a combination of machine learning algorithms and known transcription factor binding sites to predict the location of ncRNA promoters.\n3. RNApromoter: This tool uses a combination of sequence and structural features to predict the location of ncRNA promoters in a genome. RNApromoter can also be used to predict the strength of ncRNA promoters based on their sequence and structural properties.\n4. Prognosticate: This tool uses a combination of machine learning algorithms and known transcription factor binding sites to predict the location of ncRNA promoters in a genome. Prognosticate can also be used to predict the strength of ncRNA promoters based on their sequence and structural properties.\n5. ncRNApromoter: This tool uses a combination of sequence and structural features to predict the location of ncRNA promoters in a genome. ncRNApromoter can also be used to predict the strength of ncRNA promoters based on their sequence and structural properties.\n6. RNApredict: This tool uses a combination of machine learning algorithms and known transcription factor binding sites to predict the location of ncRNA promoters in a genome. RNApredict can also be used to predict the strength of ncRNA promoters based on their sequence and structural properties.\n7. NCRNApromoter: This tool uses a combination of sequence and structural features to predict the location of ncRNA promoters in a genome. NCRNApromoter can",
    "llama-2-7b-chat-hf_fact_raw": "1. CpG Island Finder is a tool that identifies regions enriched in cytosine and guanine nucleotides near ncRNA promoters.\n2. Cis-Acting Regulatory Element (CRE) Finder is a tool that identifies potential transcriptional regulatory elements, including ncRNA promoters, using machine learning algorithms and known transcription factor binding sites.\n3. RNApromoter is a tool that predicts the location and strength of ncRNA promoters based on sequence and structural features.\n4. Prognosticate is a tool that predicts the location and strength of ncRNA promoters using machine learning algorithms and known transcription factor binding sites.\n5. ncRNApromoter is a tool that predicts the location and strength of ncRNA promoters based on sequence and structural properties.",
    "llama-2-7b-chat-hf_fact": [
      "CpG Island Finder is a tool that identifies regions enriched in cytosine and guanine nucleotides near ncRNA promoters.",
      "Cis-Acting Regulatory Element (CRE) Finder is a tool that identifies potential transcriptional regulatory elements, including ncRNA promoters, using machine learning algorithms and known transcription factor binding sites.",
      "RNApromoter is a tool that predicts the location and strength of ncRNA promoters based on sequence and structural features.",
      "Prognosticate is a tool that predicts the location and strength of ncRNA promoters using machine learning algorithms and known transcription factor binding sites.",
      "ncRNApromoter is a tool that predicts the location and strength of ncRNA promoters based on sequence and structural properties."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Prognosticate is not a known tool for predicting ncRNA promoters. No correction can be provided without the correct tool name.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I can provide you with some examples of genes that the SWIM tool has identified as down-regulated in glioblastoma using publicly available data. Please note that the accuracy of these results may vary depending on the quality and quantity of the data used, and that SWIM is just one of many tools that can be used to analyze gene expression data.\nGlioblastoma is a type of brain cancer that is aggressive and malignant, and it is the most common type of primary brain cancer. The following are some examples of genes that have been identified as down-regulated in glioblastoma using SWIM:\n1. TP53: TP53 is a tumor suppressor gene that is commonly mutated in glioblastoma. SWIM analysis has shown that TP53 is down-regulated in glioblastoma tissues compared to normal brain tissues.\n2. CDKN2A: CDKN2A is a gene that encodes a protein that regulates the cell cycle and is involved in tumor suppression. SWIM analysis has shown that CDKN2A is down-regulated in glioblastoma tissues compared to normal brain tissues.\n3. BRCA1: BRCA1 is a gene that is involved in DNA repair and is mutated in some glioblastomas. SWIM analysis has shown that BRCA1 is down-regulated in glioblastoma tissues compared to normal brain tissues.\n4. PTEN: PTEN is a gene that encodes a protein that regulates cell growth and survival. SWIM analysis has shown that PTEN is down-regulated in glioblastoma tissues compared to normal brain tissues.\n5. STK11: STK11 is a gene that encodes a protein that regulates cell growth and survival. SWIM analysis has shown that STK11 is down-regulated in glioblastoma tissues compared to normal brain tissues.\n6. APC: APC is a gene that encodes a protein that regulates cell growth and differentiation. SWIM analysis has shown that APC is down-regulated in glioblastoma tissues compared to normal brain tissues.\n7. PML: PML is a gene that encodes a protein that regulates cell growth and surv",
    "llama-2-7b-chat-hf_fact_raw": "1. TP53 is a tumor suppressor gene that is commonly mutated in glioblastoma.\n2. CDKN2A regulates the cell cycle and is involved in tumor suppression.\n3. BRCA1 is involved in DNA repair and is mutated in some glioblastomas.\n4. PTEN regulates cell growth and survival.\n5. STK11 encodes a protein that regulates cell growth and survival.",
    "llama-2-7b-chat-hf_fact": [
      "TP53 is a tumor suppressor gene that is commonly mutated in glioblastoma.",
      "CDKN2A regulates the cell cycle and is involved in tumor suppression.",
      "BRCA1 is involved in DNA repair and is mutated in some glioblastomas.",
      "PTEN regulates cell growth and survival.",
      "STK11 encodes a protein that regulates cell growth and survival."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "llama-2-7b-chat-hf_response": "There are several R packages that have been developed for studying Transcriptional Activation Domains (TADs). Here are some of the most popular ones:\n1. TADbit: TADbit is a package for identifying and visualizing TADs in ChIP-seq data. It uses a probabilistic model to identify TADs and can also be used to predict the functional impact of TADs on gene expression.\n2. TA DinR: TA DinR is a package for identifying TADs in ChIP-seq data using a dynamic programming approach. It can also be used to predict the functional impact of TADs on gene expression.\n3. TADhunter: TADhunter is a package for identifying TADs in ChIP-seq data using a machine learning approach. It can also be used to predict the functional impact of TADs on gene expression.\n4. ChIPseek: ChIPseek is a package for identifying TADs in ChIP-seq data using a probabilistic model. It can also be used to predict the functional impact of TADs on gene expression.\n5. TADtrack: TADtrack is a package for identifying TADs in ChIP-seq data using a machine learning approach. It can also be used to predict the functional impact of TADs on gene expression.\n6. HISAT2: HISAT2 is a spliced aligner that can also be used to identify TADs in ChIP-seq data. It uses a probabilistic model to identify TADs and can also be used to predict the functional impact of TADs on gene expression.\n7. STAR: STAR is a high-performance spliced aligner that can also be used to identify TADs in ChIP-seq data. It uses a probabilistic model to identify TADs and can also be used to predict the functional impact of TADs on gene expression.\n8. TopHat2: TopHat2 is a spliced aligner that can also be used to identify TADs in ChIP-seq data. It uses a probabilistic model to identify TADs and can also be used to predict the functional impact of TADs on gene expression.\n9. Cufflinks: Cufflinks is a package for quantifying gene expression from RNA-seq data",
    "llama-2-7b-chat-hf_fact_raw": "1. TADbit is an R package used for identifying and visualizing Transcriptional Activation Domains (TADs) in ChIP-seq data.\n2. TA DinR is an R package that identifies TADs in ChIP-seq data using a dynamic programming approach.\n3. TADhunter is an R package that uses a machine learning approach to identify TADs in ChIP-seq data.\n4. HISAT2 is a spliced aligner that can identify TADs in ChIP-seq data with a probabilistic model.\n5. STAR is a high-performance spliced aligner that can be used to identify TADs in ChIP-seq data using a probabilistic model.",
    "llama-2-7b-chat-hf_fact": [
      "TADbit is an R package used for identifying and visualizing Transcriptional Activation Domains (TADs) in ChIP-seq data.",
      "TA DinR is an R package that identifies TADs in ChIP-seq data using a dynamic programming approach.",
      "TADhunter is an R package that uses a machine learning approach to identify TADs in ChIP-seq data.",
      "HISAT2 is a spliced aligner that can identify TADs in ChIP-seq data with a probabilistic model.",
      "STAR is a high-performance spliced aligner that can be used to identify TADs in ChIP-seq data using a probabilistic model."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TADbit is a Python library used for the analysis and visual representation of the 3D structure of chromosomes from Hi-C data.\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: HISAT2 is a fast and sensitive spliced aligner for RNA-Seq data, not specifically designed to identify TADs in ChIP-seq data.\n5. FALSE [correction]: STAR is a spliced aligner for RNA-Seq data and is not specifically used to identify TADs in ChIP-seq data.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-2-7b-chat-hf_response": "There are several bioconductor tools that have been developed for accessing bacterial regulatory networks. Here are some of the most popular ones:\n1. BioCyc: BioCyc is a comprehensive collection of biochemical pathway and genomic information for over 1,000 microbial species, including bacteria. It contains a wealth of information on bacterial regulatory networks, including pathway maps, reaction maps, and gene regulatory networks. BioCyc also provides tools for analyzing and visualizing the data, such as the Pathway Tools software.\n2. KEGG: The Kyoto Encyclopedia of Genes and Genomes (KEGG) is a comprehensive database of biological pathways and genomic information. It contains a large collection of bacterial genomes, and provides tools for analyzing and visualizing the regulatory networks of these organisms. KEGG also includes a variety of tools for analyzing gene expression data, such as the KEGG Pathway Analysis Tool.\n3. RegulonDB: RegulonDB is a database of gene regulation in bacteria, containing information on the regulatory interactions between transcription factors and their target genes. It also includes tools for analyzing and visualizing the data, such as the RegulonDB Analyzer.\n4. TRANSFAC: TRANSFAC is a database of transcription factor binding sites in bacteria, containing information on the binding sites of over 100 transcription factors. It also includes tools for analyzing and visualizing the data, such as the TRANSFAC Predictor.\n5. BactoCyc: BactoCyc is a database of genomic and metabolic information for over 100 bacterial species, including information on gene regulation and metabolic pathways. It includes tools for analyzing and visualizing the data, such as the BactoCyc Analyzer.\n6. MG-RAST: MG-RAST is a comprehensive genome annotation platform for bacteria, including information on gene regulation, metabolic pathways, and genomic context. It includes tools for analyzing and visualizing the data, such as the MG-RAST Annotator.\n7. Rhea: Rhea is a bioconductor package for analyzing",
    "llama-2-7b-chat-hf_fact_raw": "1. BioCyc is a collection of biochemical pathway and genomic information for over 1,000 microbial species, including bacteria.\n2. KEGG is a comprehensive database that contains a large collection of bacterial genomes and biological pathways.\n3. RegulonDB contains information on regulatory interactions between transcription factors and their target genes in bacteria.\n4. TRANSFAC contains information on transcription factor binding sites in bacteria for over 100 transcription factors.\n5. BactoCyc is a database with genomic and metabolic information for over 100 bacterial species.",
    "llama-2-7b-chat-hf_fact": [
      "BioCyc is a collection of biochemical pathway and genomic information for over 1,000 microbial species, including bacteria.",
      "KEGG is a comprehensive database that contains a large collection of bacterial genomes and biological pathways.",
      "RegulonDB contains information on regulatory interactions between transcription factors and their target genes in bacteria.",
      "TRANSFAC contains information on transcription factor binding sites in bacteria for over 100 transcription factors.",
      "BactoCyc is a database with genomic and metabolic information for over 100 bacterial species."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: TRANSFAC contains information on transcription factor binding sites in eukaryotes for over 100 transcription factors.\n5. FALSE [correction]: BactoCyc is a database with genomic and metabolic information for E. coli and its close relatives.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "llama-2-7b-chat-hf_response": "The shikimate pathway is a metabolic pathway that plays a crucial role in the biosynthesis of aromatic amino acids, phenylalanine, tyrosine, and tryptophan, as well as other aromatic compounds in cells. The end products of the shikimate pathway are:\n1. Aromatic amino acids: The shikimate pathway produces three aromatic amino acids, phenylalanine, tyrosine, and tryptophan, which are essential for various cellular processes, including protein synthesis and signal transduction.\n2. Quinates: Quinates are a class of compounds that are produced through the oxidation of the shikimate pathway. They are involved in the biosynthesis of various aromatic compounds, including flavonoids, stilbenes, and lignins.\n3. Coenzyme Q: Coenzyme Q is a vitamin-like compound that is produced through the shikimate pathway. It plays a crucial role in the electron transport chain, particularly in the mitochondria, and is involved in the production of ATP, the primary energy currency of the cell.\n4. Ergothioneine: Ergothioneine is a unique amino acid that is produced through the shikimate pathway. It is involved in the detoxification of oxidants and acts as an antioxidant in cells.\n5. Tryptophan: Tryptophan is an aromatic amino acid that is produced through the shikimate pathway. It is involved in the biosynthesis of various neurotransmitters, including serotonin, dopamine, and melatonin, which are important for mood regulation, appetite, and sleep.\n6. Kynurenine: Kynurenine is a metabolite of tryptophan that is produced through the shikimate pathway. It is involved in the biosynthesis of various neurotransmitters and has been implicated in the pathogenesis of various neurological disorders, including depression, anxiety, and neurodegenerative diseases.\n7. Anthranilates: Anthranilates are a class of compounds that are produced through the shik",
    "llama-2-7b-chat-hf_fact_raw": "1. The shikimate pathway produces three aromatic amino acids: phenylalanine, tyrosine, and tryptophan.\n2. Quinates are produced through the oxidation of the shikimate pathway.\n3. Coenzyme Q is a vitamin-like compound produced through the shikimate pathway.\n4. Ergothioneine, a unique amino acid, is produced through the shikimate pathway.\n5. Kynurenine is a metabolite of tryptophan produced through the shikimate pathway.",
    "llama-2-7b-chat-hf_fact": [
      "The shikimate pathway produces three aromatic amino acids: phenylalanine, tyrosine, and tryptophan.",
      "Quinates are produced through the oxidation of the shikimate pathway.",
      "Coenzyme Q is a vitamin-like compound produced through the shikimate pathway.",
      "Ergothioneine, a unique amino acid, is produced through the shikimate pathway.",
      "Kynurenine is a metabolite of tryptophan produced through the shikimate pathway."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. FALSE [correction]: Coenzyme Q is not produced through the shikimate pathway; it is synthesized in a separate pathway in the body.\n4. FALSE [correction]: Ergothioneine is synthesized from histidine, not through the shikimate pathway.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-2-7b-chat-hf_response": "Yes, cabergoline is sometimes used to treat Nelson's syndrome, which is a rare and potentially life-threatening condition that can occur after treatment with dopamine agonists, such as bromocriptine or ropinirole.\nNelson's syndrome is characterized by the rapid growth of a tumor in the pituitary gland, which can lead to a range of symptoms including headaches, vision problems, and hormonal imbalances. If left untreated, Nelson's syndrome can be fatal.\nCabergoline is a dopamine receptor agonist that is specifically used to treat hyperprolactinemia, which is an excess of prolactin in the blood. However, it has also been shown to be effective in treating Nelson's syndrome. Cabergoline works by reducing the levels of prolactin in the blood, which can help to slow the growth of the tumor in the pituitary gland and alleviate symptoms.\nStudies have shown that cabergoline can be effective in controlling the growth of pituitary tumors in patients with Nelson's syndrome. In a study published in the Journal of Clinical Endocrinology and Metabolism, researchers found that cabergoline significantly reduced the levels of prolactin in the blood and slowed the growth of the tumor in the pituitary gland in patients with Nelson's syndrome.\nHowever, it is important to note that cabergoline is not a cure for Nelson's syndrome, and it may not be effective in all patients. In addition, cabergoline can have side effects, including dizziness, headache, and nausea, and it may interact with other medications. Therefore, it is important to discuss the potential benefits and risks of cabergoline with a healthcare provider before starting treatment.\nIn summary, cabergoline is sometimes used to treat Nelson's syndrome, a rare and potentially life-threatening condition that can occur after treatment with dopamine agonists. While cabergoline can be effective in controlling the growth of pituitary tumors, it may not be effective in all patients and can have side effects. It is important to discuss the potential benefits and risks of cabergoline with a",
    "llama-2-7b-chat-hf_fact_raw": "1. Cabergoline is sometimes used to treat Nelson's syndrome.\n2. Nelson's syndrome is a rare condition that can occur after treatment with dopamine agonists.\n3. Cabergoline is a dopamine receptor agonist used to treat hyperprolactinemia.\n4. In a study published in the Journal of Clinical Endocrinology and Metabolism, cabergoline was found to reduce levels of prolactin and slow tumor growth in patients with Nelson's syndrome.\n5. Cabergoline can have side effects, including dizziness, headache, and nausea.",
    "llama-2-7b-chat-hf_fact": [
      "Cabergoline is sometimes used to treat Nelson's syndrome.",
      "Nelson's syndrome is a rare condition that can occur after treatment with dopamine agonists.",
      "Cabergoline is a dopamine receptor agonist used to treat hyperprolactinemia.",
      "In a study published in the Journal of Clinical Endocrinology and Metabolism, cabergoline was found to reduce levels of prolactin and slow tumor growth in patients with Nelson's syndrome.",
      "Cabergoline can have side effects, including dizziness, headache, and nausea."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cabergoline is not typically used to treat Nelson's syndrome; it is used to treat hyperprolactinemia and Parkinson's disease.\n2. FALSE [correction]: Nelson's syndrome is a rare condition that can occur after surgical removal of the pituitary gland, not after treatment with dopamine agonists.\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "llama-2-7b-chat-hf_response": "Liebenberg syndrome is a rare and complex neurological disorder that is characterized by a range of symptoms affecting the nervous system. The main manifestations of Liebenberg syndrome include:\n1. Spasticity: Liebenberg syndrome is characterized by increased muscle tone and stiffness, which can lead to difficulty moving or controlling muscles. This can cause spasms, cramps, and muscle weakness.\n2. Sensory loss: People with Liebenberg syndrome may experience loss of sensation, numbness, or tingling in their limbs, particularly in the hands and feet.\n3. Weakness of the muscles of mastication: Liebenberg syndrome can cause weakness or paralysis of the muscles used for chewing, which can make it difficult to eat and speak.\n4. Difficulty with coordination and balance: Liebenberg syndrome can cause problems with coordination, balance, and gait, which can increase the risk of falls and injuries.\n5. Seizures: Some people with Liebenberg syndrome may experience seizures, which can be caused by the disorder itself or as a result of other underlying conditions.\n6. Cognitive impairment: Liebenberg syndrome can also cause cognitive impairment, including problems with memory, attention, and decision-making.\n7. Emotional changes: People with Liebenberg syndrome may experience emotional changes, such as depression, anxiety, and mood swings, which can be related to the physical symptoms of the disorder or to the impact of the disorder on their daily life.\n8. Sleep disturbances: Liebenberg syndrome can cause sleep disturbances, including insomnia, sleep apnea, and restless leg syndrome.\n9. Gastrointestinal problems: Some people with Liebenberg syndrome may experience gastrointestinal problems, such as constipation, diarrhea, and abdominal pain.\n10. Eye problems: Liebenberg syndrome can cause eye problems, including blurred vision, double vision, and eye pain.\nIt is important to note that the symptoms of Liebenberg syndrome can vary in severity and frequency from person to person, and may progress over time.",
    "llama-2-7b-chat-hf_fact_raw": "1. Liebenberg syndrome is a neurological disorder.\n2. Liebenberg syndrome is characterized by increased muscle tone and stiffness, known as spasticity.\n3. People with Liebenberg syndrome may experience loss of sensation in their limbs.\n4. Weakness or paralysis of the muscles used for chewing is a manifestation of Liebenberg syndrome.\n5. Seizures can occur in some individuals with Liebenberg syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Liebenberg syndrome is a neurological disorder.",
      "Liebenberg syndrome is characterized by increased muscle tone and stiffness, known as spasticity.",
      "People with Liebenberg syndrome may experience loss of sensation in their limbs.",
      "Weakness or paralysis of the muscles used for chewing is a manifestation of Liebenberg syndrome.",
      "Seizures can occur in some individuals with Liebenberg syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Liebenberg syndrome is not a neurological disorder, it is a musculoskeletal condition.\n2. FALSE [correction]: Liebenberg syndrome is characterized by the abnormal development of the elbow joint and other upper limb abnormalities, not spasticity.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I'm glad to provide you with a list of orally bioavailable MPS1 kinase inhibitors. MPS1 (Microtubule-associated protein 1) kinase is an enzyme that plays a crucial role in various cellular processes, including cell division, migration, and signaling. Inhibition of MPS1 kinase has been shown to be a promising therapeutic approach for treating various diseases, including cancer, neurodegenerative disorders, and inflammatory conditions. Here are some orally bioavailable MPS1 kinase inhibitors that have been identified or developed:\n1. Berberine: Berberine is a natural compound found in the Berberis genus of plants. It has been shown to inhibit MPS1 kinase activity in vitro and in vivo, and has been investigated as a potential treatment for various cancers, including breast, lung, and colon cancer.\n2. Quercetin: Quercetin is a flavonoid found in a variety of plant-based foods, such as fruits, vegetables, and herbs. It has been shown to inhibit MPS1 kinase activity and has been investigated as a potential treatment for cancer and other diseases.\n3. Curcumin: Curcumin is a compound found in turmeric (Curcuma longa) that has been used for centuries in traditional medicine. It has been shown to inhibit MPS1 kinase activity and has been investigated as a potential treatment for various diseases, including cancer and neurodegenerative disorders.\n4. Resveratrol: Resveratrol is a polyphenol found in grapes, berries, and other plant-based foods. It has been shown to inhibit MPS1 kinase activity and has been investigated as a potential treatment for various diseases, including cancer and neurodegenerative disorders.\n5. Epigallocatechin gallate (EGCG): EGCG is a catechin found in green tea that has been shown to inhibit MPS1 kinase activity. It has been investigated as a potential treatment for various diseases, including cancer and neurodegenerative disorders.\n6. Indole-3-carbinol (",
    "llama-2-7b-chat-hf_fact_raw": "1. Berberine is a natural compound found in the Berberis genus of plants.\n2. Quercetin is a flavonoid found in various plant-based foods.\n3. Curcumin is a compound found in turmeric (Curcuma longa).\n4. Resveratrol is a polyphenol found in grapes, berries, and other plant-based foods.\n5. Epigallocatechin gallate (EGCG) is a catechin found in green tea.",
    "llama-2-7b-chat-hf_fact": [
      "Berberine is a natural compound found in the Berberis genus of plants.",
      "Quercetin is a flavonoid found in various plant-based foods.",
      "Curcumin is a compound found in turmeric (Curcuma longa).",
      "Resveratrol is a polyphenol found in grapes, berries, and other plant-based foods.",
      "Epigallocatechin gallate (EGCG) is a catechin found in green tea."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "llama-2-7b-chat-hf_response": "Thank you for reaching out with your question! I'm here to help you.\nGolimumab is a medication that is used to treat certain autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. It is not approved by the US Food and Drug Administration (FDA) for the treatment of diabetes.\nThere are several clinical trials that have investigated the use of golimumab in patients with type 1 and type 2 diabetes, but these trials have not shown significant improvements in glycemic control or other outcomes compared to placebo or standard of care treatments. Therefore, golimumab is not currently recommended for the treatment of diabetes.\nIt's important to note that diabetes is a complex disease that requires a comprehensive treatment plan, including lifestyle modifications, medications, and insulin therapy. If you have diabetes and are interested in learning more about treatment options, I recommend consulting with a healthcare provider who can provide personalized advice and guidance.\nI hope this information is helpful. If you have any further questions, please don't hesitate to ask!",
    "llama-2-7b-chat-hf_fact_raw": "1. Golimumab is used to treat autoimmune diseases like rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.\n2. The US Food and Drug Administration (FDA) has not approved golimumab for the treatment of diabetes.\n3. Clinical trials have been conducted to investigate the use of golimumab in patients with type 1 and type 2 diabetes.\n4. The clinical trials did not show significant improvements in glycemic control or other outcomes compared to placebo or standard of care treatments for diabetes patients.\n5. Golimumab is not currently recommended for the treatment of diabetes.",
    "llama-2-7b-chat-hf_fact": [
      "Golimumab is used to treat autoimmune diseases like rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.",
      "The US Food and Drug Administration (FDA) has not approved golimumab for the treatment of diabetes.",
      "Clinical trials have been conducted to investigate the use of golimumab in patients with type 1 and type 2 diabetes.",
      "The clinical trials did not show significant improvements in glycemic control or other outcomes compared to placebo or standard of care treatments for diabetes patients.",
      "Golimumab is not currently recommended for the treatment of diabetes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "llama-2-7b-chat-hf_response": "Progeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), is a rare genetic disorder that causes accelerated aging in children. While the exact cause of progeria is still not fully understood, research has shown that it is caused by a mutation in the LMNA gene, which is responsible for producing a protein called lamin A.\nThe LMNA gene is located on chromosome 1 and is one of the most highly conserved genes in the human genome. It plays a critical role in maintaining the structure and function of the nucleus in cells, particularly in the production of lamin A, which is a key component of the nuclear lamina. The nuclear lamina is a network of filaments that provides structural support to the nucleus and regulates various cellular processes, including cell division and differentiation.\nIn progeria, the mutation in the LMNA gene leads to the production of a truncated form of lamin A, known as progerin, which is toxic to cells and disrupts the normal function of the nuclear lamina. This disruption leads to a wide range of symptoms, including accelerated aging, skin fragility, hair loss, and cardiovascular disease.\nProgeria is an autosomal recessive disorder, which means that a child must inherit two copies of the mutated LMNA gene, one from each parent, in order to develop the condition. The parents of a child with progeria typically do not show any symptoms themselves, as they carry a single copy of the mutated gene and are carriers of the disorder.\nWhile the exact mechanism by which the mutated LMNA gene leads to progeria is still being studied, research has shown that the disruption of the nuclear lamina and the production of progerin are key factors in the development of the condition. Understanding the genetic basis of progeria has important implications for the development of new treatments and therapies for the condition, and may also provide insights into the aging process in general.",
    "llama-2-7b-chat-hf_fact_raw": "1. Progeria is caused by a mutation in the LMNA gene.\n2. The LMNA gene is located on chromosome 1.\n3. The mutation in the LMNA gene leads to the production of a truncated form of lamin A called progerin.\n4. Progeria is an autosomal recessive disorder, requiring two copies of the mutated gene to develop the condition.\n5. Parents of a child with progeria are typically carriers of a single copy of the mutated gene.",
    "llama-2-7b-chat-hf_fact": [
      "Progeria is caused by a mutation in the LMNA gene.",
      "The LMNA gene is located on chromosome 1.",
      "The mutation in the LMNA gene leads to the production of a truncated form of lamin A called progerin.",
      "Progeria is an autosomal recessive disorder, requiring two copies of the mutated gene to develop the condition.",
      "Parents of a child with progeria are typically carriers of a single copy of the mutated gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The LMNA gene is located on chromosome 19.\n3. TRUE\n4. FALSE [correction]: Progeria is an autosomal dominant disorder, meaning that only one copy of the mutated gene is required to develop the condition.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "llama-2-7b-chat-hf_response": "The chromosome 12q14 and 12q24 regions are known to be associated with various genetic variants that have been implicated in different diseases and conditions. Here are some of the common variants found at these locations:\n12q14:\n* HLA-B*57: This variant is associated with an increased risk of developing certain autoimmune diseases, such as rheumatoid arthritis, lupus, and multiple sclerosis.\n* HLA-A*31: This variant is associated with an increased risk of developing certain infectious diseases, such as hepatitis B and C, and HIV.\n* ITGA2: This variant is associated with an increased risk of developing certain cardiovascular diseases, such as atherosclerosis and coronary artery disease.\n* TCF7L1: This variant is associated with an increased risk of developing certain metabolic disorders, such as type 2 diabetes and obesity.\n* KCNQ1: This variant is associated with an increased risk of developing certain cardiac arrhythmias, such as long QT syndrome.\n12q24:\n* CDKN2A: This variant is associated with an increased risk of developing certain types of cancer, including melanoma, breast cancer, and colorectal cancer.\n* CDKN2B: This variant is associated with an increased risk of developing certain types of cancer, including breast cancer and prostate cancer.\n* MSH2: This variant is associated with an increased risk of developing certain types of cancer, including colorectal cancer and ovarian cancer.\n* MLH1: This variant is associated with an increased risk of developing certain types of cancer, including colorectal cancer and endometrial cancer.\n* MSH6: This variant is associated with an increased risk of developing certain types of cancer, including colorectal cancer and ovarian cancer.\nIt's important to note that the presence of these variants does not guarantee the development of the associated disease, and many people with these variants will never develop the disease. Additionally, the risk of developing a disease associated with a particular variant can vary depending on a variety of factors, including genetic and environmental influences.\nIt's also worth noting that gen",
    "llama-2-7b-chat-hf_fact_raw": "1. HLA-B*57 variant at 12q14 is associated with an increased risk of autoimmune diseases such as rheumatoid arthritis, lupus, and multiple sclerosis.\n2. HLA-A*31 variant at 12q14 is associated with an increased risk of infectious diseases such as hepatitis B and C, and HIV.\n3. ITGA2 variant at 12q14 is associated with an increased risk of cardiovascular diseases such as atherosclerosis and coronary artery disease.\n4. CDKN2A variant at 12q24 is associated with an increased risk of cancers including melanoma, breast cancer, and colorectal cancer.\n5. MSH2 variant at 12q24 is associated with an increased risk of cancers including colorectal cancer and ovarian cancer.",
    "llama-2-7b-chat-hf_fact": [
      "HLA-B*57 variant at 12q14 is associated with an increased risk of autoimmune diseases such as rheumatoid arthritis, lupus, and multiple sclerosis.",
      "HLA-A*31 variant at 12q14 is associated with an increased risk of infectious diseases such as hepatitis B and C, and HIV.",
      "ITGA2 variant at 12q14 is associated with an increased risk of cardiovascular diseases such as atherosclerosis and coronary artery disease.",
      "CDKN2A variant at 12q24 is associated with an increased risk of cancers including melanoma, breast cancer, and colorectal cancer.",
      "MSH2 variant at 12q24 is associated with an increased risk of cancers including colorectal cancer and ovarian cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-2-7b-chat-hf_response": "The Roundabout (Robo) receptors are a family of transmembrane receptors that play a crucial role in regulating cellular behavior, including cell migration, differentiation, and survival. There are four known members of the Roundabout receptor family: Robo1, Robo2, Robo3, and Robo4. Each of these receptors has its own distinct ligands, which are responsible for mediating their signaling activities. Here are the known ligands of each Roundabout receptor:\n1. Robo1:\nRobo1 is primarily activated by the ligand epidermal growth factor (EGF), which is a potent mitogen that promotes cell proliferation and differentiation. EGF binds to the extracellular domain of Robo1, leading to the activation of downstream signaling pathways that regulate cell behavior.\n2. Robo2:\nRobo2 is primarily activated by the ligand fibroblast growth factor (FGF), which is a family of growth factors that promote cell proliferation and differentiation. FGF binds to the extracellular domain of Robo2, leading to the activation of downstream signaling pathways that regulate cell behavior.\n3. Robo3:\nRobo3 is primarily activated by the ligand Wnt3a, which is a member of the Wnt family of secreted signaling molecules. Wnt3a binds to the extracellular domain of Robo3, leading to the activation of downstream signaling pathways that regulate cell behavior.\n4. Robo4:\nRobo4 is primarily activated by the ligand Hedgehog (Hh), which is a family of secreted signaling molecules that regulate cell growth, differentiation, and tissue patterning. Hh binds to the extracellular domain of Robo4, leading to the activation of downstream signaling pathways that regulate cell behavior.\nIn addition to these specific ligands, Robo receptors can also be activated by other ligands, such as BMPs (bone morphogenetic proteins) and VEGFs (vascular endothelial growth factors), which can also modulate their signaling activities.\nOverall, the Roundabout receptors play a cru",
    "llama-2-7b-chat-hf_fact_raw": "1. The Roundabout receptor family consists of Robo1, Robo2, Robo3, and Robo4.\n2. Epidermal Growth Factor (EGF) activates Robo1 by binding to its extracellular domain.\n3. Fibroblast Growth Factor (FGF) activates Robo2 by binding to its extracellular domain.\n4. Wnt3a, a member of the Wnt family, activates Robo3 by binding to its extracellular domain.\n5. Hedgehog (Hh) activates Robo4 by binding to its extracellular domain.",
    "llama-2-7b-chat-hf_fact": [
      "The Roundabout receptor family consists of Robo1, Robo2, Robo3, and Robo4.",
      "Epidermal Growth Factor (EGF) activates Robo1 by binding to its extracellular domain.",
      "Fibroblast Growth Factor (FGF) activates Robo2 by binding to its extracellular domain.",
      "Wnt3a, a member of the Wnt family, activates Robo3 by binding to its extracellular domain.",
      "Hedgehog (Hh) activates Robo4 by binding to its extracellular domain."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: It is Slit proteins, not Epidermal Growth Factor (EGF), that activate Robo1 by binding to its extracellular domain.\n3. FALSE [correction]: It is not Fibroblast Growth Factor (FGF) but Netrin-1 protein that activates Robo2 by binding to its extracellular domain.\n4. UNKNOWN\n5. FALSE [correction]: Hedgehog (Hh) does not activate Robo4 by binding to its extracellular domain, it is the Slit proteins that activate Robo4.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "llama-2-7b-chat-hf_response": "TFII-I (Transcription Factor II-I) is a general transcription factor that plays a crucial role in the regulation of gene expression, particularly in the context of hematopoiesis, the process by which blood cells are produced. While TFII-I has been shown to have some involvement in megakaryopoiesis, the process by which platelets are produced, its role is not as clear-cut as that of other transcription factors.\nMegakaryopoiesis is a complex process that involves the coordinated regulation of multiple transcription factors, including TFII-I. TFII-I has been shown to play a role in the regulation of genes involved in platelet production, including the platelet-specific genes GATA1 and GATA2. However, the role of TFII-I in megakaryopoiesis is not limited to these genes, and it has been shown to regulate a wide range of genes involved in various cellular processes, including cell proliferation, differentiation, and survival.\nStudies have shown that TFII-I is required for the proper differentiation of megakaryocytes, the precursor cells that give rise to platelets. TFII-I deficiency in mice leads to a reduction in the number of megakaryocytes in the bone marrow, which in turn leads to a decrease in the number of platelets produced. This suggests that TFII-I plays a critical role in the regulation of megakaryocyte differentiation and platelet production.\nIn addition to its role in megakaryopoiesis, TFII-I has been implicated in the regulation of other hematopoietic lineages, including lymphocytes and monocytes. However, its role in these processes is less well understood than its role in megakaryopoiesis.\nOverall, while the role of TFII-I in megakaryopoiesis is not fully understood, it is clear that it plays a critical role in the regulation of platelet production and the proper differentiation of megakaryocytes. Further research is needed to fully elucidate the mechanisms by which TFII-I regulates these processes and to identify potential therapeutic targets for the treatment of platelet dis",
    "llama-2-7b-chat-hf_fact_raw": "1. TFII-I (Transcription Factor II-I) is involved in the regulation of gene expression in hematopoiesis.\n2. TFII-I has some involvement in megakaryopoiesis, the process by which platelets are produced.\n3. TFII-I has been shown to play a role in the regulation of genes, including GATA1 and GATA2, involved in platelet production.\n4. TFII-I deficiency in mice leads to a reduced number of megakaryocytes in the bone marrow and a decrease in platelet production.\n5. TFII-I is required for the proper differentiation of megakaryocytes, the precursor cells that give rise to platelets.",
    "llama-2-7b-chat-hf_fact": [
      "TFII-I (Transcription Factor II-I) is involved in the regulation of gene expression in hematopoiesis.",
      "TFII-I has some involvement in megakaryopoiesis, the process by which platelets are produced.",
      "TFII-I has been shown to play a role in the regulation of genes, including GATA1 and GATA2, involved in platelet production.",
      "TFII-I deficiency in mice leads to a reduced number of megakaryocytes in the bone marrow and a decrease in platelet production.",
      "TFII-I is required for the proper differentiation of megakaryocytes, the precursor cells that give rise to platelets."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "llama-2-7b-chat-hf_response": "Thank you for asking! Atenolol, a beta-blocker medication, is metabolized by the cytochrome P450 (CYP) enzyme system, specifically by CYP2D6.\nCYP2D6 is one of the most important enzymes involved in the metabolism of drugs in the human body. It is responsible for metabolizing a wide range of drugs, including beta-blockers like atenolol.\nAtenolol is primarily metabolized by CYP2D6 to form its active metabolite, beta-hydroxyatenolol. This metabolite is responsible for the majority of the drug's therapeutic effects. The activity of CYP2D6 can vary greatly among individuals, leading to inter-individual differences in drug metabolism and response.\nApproximately 20-30% of the population is poor metabolizers of CYP2D6, meaning they have reduced activity of this enzyme. These individuals may have reduced efficacy or increased side effects of drugs metabolized by CYP2D6, including atenolol.\nIn addition, genetic variations in the CYP2D6 gene can affect the metabolism of atenolol. For example, the CYP2D6*4 variant is associated with reduced enzyme activity and may lead to reduced efficacy of atenolol.\nIt's important to note that the metabolism of atenolol can also be influenced by other factors, such as liver function, kidney function, and the use of other medications that can inhibit or induce CYP2D6 activity.\nIn summary, atenolol is metabolized by CYP2D6, and the activity of this enzyme can vary greatly among individuals. Understanding the metabolism of atenolol and other drugs is crucial for optimal drug therapy and for minimizing the risk of adverse drug reactions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Atenolol is metabolized by the cytochrome P450 enzyme system, specifically by CYP2D6.\n2. CYP2D6 is responsible for metabolizing a wide range of drugs, including beta-blockers like atenolol.\n3. Atenolol is primarily metabolized by CYP2D6 to form its active metabolite, beta-hydroxyatenolol.\n4. Approximately 20-30% of the population is poor metabolizers of CYP2D6, which can lead to reduced efficacy or increased side effects of drugs metabolized by this enzyme.\n5. Genetic variations in the CYP2D6 gene, such as the CYP2D6*4 variant, can affect the metabolism of atenolol.",
    "llama-2-7b-chat-hf_fact": [
      "Atenolol is metabolized by the cytochrome P450 enzyme system, specifically by CYP2D6.",
      "CYP2D6 is responsible for metabolizing a wide range of drugs, including beta-blockers like atenolol.",
      "Atenolol is primarily metabolized by CYP2D6 to form its active metabolite, beta-hydroxyatenolol.",
      "Approximately 20-30% of the population is poor metabolizers of CYP2D6, which can lead to reduced efficacy or increased side effects of drugs metabolized by this enzyme.",
      "Genetic variations in the CYP2D6 gene, such as the CYP2D6*4 variant, can affect the metabolism of atenolol."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Atenolol is not primarily metabolized by the cytochrome P450 enzyme system; it is excreted mostly unchanged in the urine.\n2. TRUE\n3. FALSE [correction]: Atenolol does not have an active metabolite; it is excreted mostly unchanged.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I'm glad to provide you with information on the different versions of ExpansionHunter, a popular software tool used for finding and managing software updates. Here are some of the versions of ExpansionHunter:\n1. ExpansionHunter 1.0: This was the initial version of ExpansionHunter, released in 2016. It provided basic features such as automatic updates, update management, and a simple user interface.\n2. ExpansionHunter 2.0: Released in 2017, this version introduced several new features, including the ability to schedule updates, manage multiple software versions, and provide detailed update information.\n3. ExpansionHunter 3.0: In 2018, the software was updated with a new version that included improved update management capabilities, a more user-friendly interface, and enhanced compatibility with various software platforms.\n4. ExpansionHunter 4.0: This version, released in 2019, introduced advanced features such as automatic patch management, real-time update monitoring, and improved compatibility with cloud-based software platforms.\n5. ExpansionHunter 5.0: The latest version of ExpansionHunter, released in 2020, includes several new features such as improved update speed, enhanced security features, and support for multiple operating systems.\n6. ExpansionHunter Pro: This is a premium version of ExpansionHunter that offers additional features such as advanced update management capabilities, customizable update scheduling, and priority support.\n7. ExpansionHunter Enterprise: This is a customized version of ExpansionHunter designed for large organizations, providing advanced features such as centralized update management, multi-user access, and customizable branding.\n8. ExpansionHunter Ultimate: This is the top-of-the-line version of ExpansionHunter, offering all the features of the previous versions, as well as additional advanced features such as automated patch management, vulnerability scanning, and customizable reporting.\nI hope this information helps you in your search for the version of ExpansionHunter that best suits your needs. If you have any further questions or concerns, please feel free to ask!",
    "llama-2-7b-chat-hf_fact_raw": "1. ExpansionHunter 1.0 was released in 2016.\n2. ExpansionHunter 2.0 was released in 2017 and introduced the ability to schedule updates.\n3. ExpansionHunter 3.0 was released in 2018 with a more user-friendly interface.\n4. ExpansionHunter 4.0 was released in 2019 and included automatic patch management.\n5. ExpansionHunter 5.0 was released in 2020 with support for multiple operating systems.",
    "llama-2-7b-chat-hf_fact": [
      "ExpansionHunter 1.0 was released in 2016.",
      "ExpansionHunter 2.0 was released in 2017 and introduced the ability to schedule updates.",
      "ExpansionHunter 3.0 was released in 2018 with a more user-friendly interface.",
      "ExpansionHunter 4.0 was released in 2019 and included automatic patch management.",
      "ExpansionHunter 5.0 was released in 2020 with support for multiple operating systems."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ExpansionHunter 1.0 was released in 2017.\n2. FALSE [correction]: ExpansionHunter does not have the capability to schedule updates, this feature is not mentioned in any version release.\n3. TRUE\n4. FALSE [correction]: ExpansionHunter does not include automatic patch management, this feature is not mentioned in any version release.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "llama-2-7b-chat-hf_response": "Adamts18 is a protein that plays a crucial role in hormone receptor signaling, specifically in the regulation of estrogen receptor (ER) signaling. Here are some key points to understand the role of Adamts18 in hormone receptor signaling:\n1. Adamts18 is a member of the a disintegrin and metalloproteinase (ADAM) family of proteins, which are involved in various cellular processes, including cell adhesion, migration, and signaling.\n2. Adamts18 is specifically expressed in ER-positive breast cancer cells and plays a crucial role in ER signaling. ER is a nuclear receptor that is activated by estrogens and regulates various cellular processes, including cell proliferation, differentiation, and survival.\n3. Adamts18 interacts with the ER and modulates its activity by cleaving and inhibiting the activity of the ER. Specifically, Adamts18 cleaves the ER protein at specific sites, leading to its inactivation and reducing its ability to transactivate its target genes.\n4. Adamts18 also interacts with other signaling proteins, including the coactivator protein p300, which is involved in transcriptional activation. Adamts18 regulates the interaction between p300 and ER, and this interaction is important for ER signaling.\n5. Adamts18 has been shown to play a role in both the development and progression of ER-positive breast cancer. In breast cancer cells, Adamts18 is overexpressed, which leads to increased ER activity and promotes cell proliferation and survival.\n6. Adamts18 also regulates the expression of other genes involved in hormone signaling, including genes involved in the synthesis and metabolism of estrogens.\n7. Adamts18 has been shown to be a potential therapeutic target for the treatment of ER-positive breast cancer. Inhibition of Adamts18 has been shown to reduce the growth and survival of ER-positive breast cancer cells, both in vitro and in vivo.\n8. Overall, Adamts18 plays a crucial role in regulating ER signaling and is a potential therapeutic target for the treatment of",
    "llama-2-7b-chat-hf_fact_raw": "1. Adamts18 is a protein that is part of the ADAM family and is involved in cellular processes like cell adhesion, migration, and signaling.\n2. Adamts18 is expressed in ER-positive breast cancer cells and influences estrogen receptor signaling.\n3. Adamts18 cleaves the estrogen receptor protein at specific sites, leading to its inactivation.\n4. The interaction between Adamts18 and the coactivator protein p300 is important for ER signaling.\n5. Adamts18 has been identified as a potential therapeutic target for treating ER-positive breast cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Adamts18 is a protein that is part of the ADAM family and is involved in cellular processes like cell adhesion, migration, and signaling.",
      "Adamts18 is expressed in ER-positive breast cancer cells and influences estrogen receptor signaling.",
      "Adamts18 cleaves the estrogen receptor protein at specific sites, leading to its inactivation.",
      "The interaction between Adamts18 and the coactivator protein p300 is important for ER signaling.",
      "Adamts18 has been identified as a potential therapeutic target for treating ER-positive breast cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "llama-2-7b-chat-hf_response": "Thiazovivin is a small molecule inhibitor of the enzyme p38 alpha (MAPK14) that plays a crucial role in the signaling pathway of multiple cellular processes, including inflammation, immune response, and cell proliferation. The mode of action of thiazovivin involves its ability to selectively and irreversibly bind to the active site of p38 alpha, thereby inhibiting its activity.\np38 alpha is a member of the mitogen-activated protein kinase (MAPK) family, which plays a key role in transmitting signals from extracellular stimuli to intracellular responses. p38 alpha is activated in response to various stimuli, including pro-inflammatory cytokines, growth factors, and stress signals. Once activated, p38 alpha phosphorylates and activates a variety of downstream targets, including gene transcription factors, signaling proteins, and cytoskeleton components, leading to changes in cellular behavior and function.\nThiazovivin works by blocking the activity of p38 alpha, thereby inhibiting the downstream signaling cascade. Thiazovivin binds to the active site of p38 alpha with high affinity and specificity, preventing the enzyme from phosphorylating and activating its downstream targets. This results in a reduction of the inflammatory response, immune activation, and cell proliferation, making thiazovivin a potential therapeutic agent for a variety of diseases, including inflammatory disorders, cancer, and neurodegenerative diseases.\nIn addition to its direct inhibition of p38 alpha, thiazovivin has also been shown to modulate the activity of other signaling pathways, including the NF-B pathway, which is involved in the regulation of inflammation and immune response. Thiazovivin has also been shown to induce the expression of anti-inflammatory genes and to inhibit the production of pro-inflammatory cytokines, further supporting its potential as a therapeutic agent for inflammatory disorders.\nOverall, the mode of action of thiaz",
    "llama-2-7b-chat-hf_fact_raw": "1. Thiazovivin is a small molecule inhibitor of the enzyme p38 alpha (MAPK14).\n2. Thiazovivin binds selectively and irreversibly to the active site of p38 alpha, inhibiting its activity.\n3. p38 alpha is a member of the mitogen-activated protein kinase (MAPK) family.\n4. Activation of p38 alpha leads to the phosphorylation and activation of a variety of downstream targets.\n5. Thiazovivin has the potential to reduce the inflammatory response, immune activation, and cell proliferation.",
    "llama-2-7b-chat-hf_fact": [
      "Thiazovivin is a small molecule inhibitor of the enzyme p38 alpha (MAPK14).",
      "Thiazovivin binds selectively and irreversibly to the active site of p38 alpha, inhibiting its activity.",
      "p38 alpha is a member of the mitogen-activated protein kinase (MAPK) family.",
      "Activation of p38 alpha leads to the phosphorylation and activation of a variety of downstream targets.",
      "Thiazovivin has the potential to reduce the inflammatory response, immune activation, and cell proliferation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Thiazovivin is a small molecule inhibitor of Rho-associated kinase (ROCK), not p38 alpha.\n2. FALSE [correction]: Thiazovivin does not bind to p38 alpha as it is not its target.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "unknown"
    ]
  }
]